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Background and Importance: There has been much debate recently over rapidly growing 
drug expenditures. Cancer medicines, in particular, have driven new brand spending 
over recent years, and US oncological expenditures have risen faster than for many other 
disease areas, in part because of rapidly growing drug prices, as well as increased rates of 
use.  
Objective: In the face of ongoing debates on how to reasonably control growth in 
pharmaceutical spending, while also providing patients with the best possible care, this 
thesis sets out to help address the question of whether growing pharmaceutical 
expenditures are providing value-for-money to patients and society.  
Novelty and Empirical Contributions: This thesis is based in part on a systematic review 
with narrative synthesis of English-language HTA appraisals of the comparative clinical 
risks and benefits of new cancer medicines, as well as on the novel use of 
 methods to generate comparative evidence on their use and cost. Adapting 
established methods, these data are then used to examine existing questions over 
whether growing expenditures are worth the cost to patients and society. This thesis 
makes five major contributions to the literature on value-based spending on cancer 
medicines: 1) approximately one in three newly licensed cancer medicines provide no 
known overall survival benefit, while one in five provide no known overall survival, 
quality of life, or safety benefit; 2) novel use of methodologies to model treatment course 
and duration reveals that cancer drug use and costs vary greatly between individual 
medicines, and across Australia, France, the UK, and the US; 3) the monetized value of 





spending, varies across individual medicines, and, at a country-level, remains 
unambiguously positive in Australia, France, and the UK, but negative in the US; 4) 
spending on new cancer medicines is often only weakly associated with their clinical 
benefits; and 5) the strength of this association nevertheless varies across countries, with 
the UK demonstrating the strongest evidence of value-based spending on new cancer 
medicines.   
Clinical and Policy Implications: Findings from this thesis provide a resource for value-
based clinical decision-making by patients and physicians. Moreover, growing 
expenditures on cancer medicines may only weakly be associated with meaningful 
clinical benefits, though the extent to which this is true differs across countries. These 
findings highlight the important role that health policy can have in encouraging value-
based cancer drug spending. In particular, it is argued that managed access schemes 
promoting access and evidence development, as well as the use of value-based spending 
policies, can help expedite access to new treatments, incentivize the development of 
clinically meaningful medicines, and rationalize growing cancer drug expenditures.  
Future Research Directions: The comparative clinical risks and benefits from new cancer 
medicines using real-world data, and how they compare with trial-based results; how 
evidence on the comparative impact from new treatments is measured, weighted, and 
rewarded in decision-making by regulators and payers; and how it is effectively linked 
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1  Introduction 
 
 
There has been much debate recently over spending on medicines, with discussions over 
their clinical toxicity often giving way to discussions over their “financial toxicity”.(1) On 
a net price basis, total spending on medicines in the US reached $315 billion in 2015, an 
increase of 8.5% from 2014.(2) Of this, $121 billion was spent on high-cost, specialty 
medicines, a figure that was 15% higher than that spent one year prior.(2) Growing 
expenditures on medicines may be explained by growing prescription drug volumes, but 
also by rapid increases in prescription drug prices.(2)  
 
Western governments have launched new efforts aimed at bending the cost curve for 
prescription medicines downwards.(3) These developments come alongside recent 
controversies related to pharmaceutical pricing,(4,5) as well as growing budgetary 
pressures. For their part, pharmaceutical companies have expressed concern over what 
they perceive to be “growing political pressure on drug prices,”(6) with the suggestion 
being that cost-containment measures may be insensitive to the clinical benefits from 
pharmaceutical innovation. Caught in the middle are providers and patients, who may 
prefer and indeed benefit from new treatments, but who may also be burdened by 




In the face of ongoing debates on how to reasonably control growth in healthcare 
spending, while also providing patients with the best possible care, some have turned to 
the question of whether growing expenditures are worth it to both patients and 
society.(8,9)  
 
This question may help frame the positions that are taken on the issue of pharmaceutical 
spending. Regulatory concerns over drug price escalation may be based in part on the 
belief that drug-related expenditures exceed their worth to patients and payers. Indeed, 
as recent discussions show,(10) it may be difficult for governments or payers to decide 
against paying for new medicines that have a large budgetary impact if they are also 
associated with demonstrable improvements to health. Industry may defend 
pharmaceutical price increases by pointing to the argument that they incentivize 
pharmaceutical R&D and clinical breakthroughs.(11) During clinical decision-making, 
physicians and patients may also consider drug costs, clinical impact, and tradeoffs 
between the two.(12)  
 
Empirical evidence on the worth of added pharmaceutical spending—its value—may 
therefore provide an opportunity to move away from interest-driven debates and 
towards evidence-based policy and practice that promotes cost-efficient care. With this 
as a backdrop, this thesis focuses on the issue of value-based spending on medicines, and 





Before going any further, it is necessary to provide a few definitions. Michael Porter in 
2010 defined value in healthcare as the outcomes relative to costs from treatment.(13) 
This definition takes the value of healthcare interventions as a function of their cost and 
impact on clinical outcomes: 
 
 
According to Porter’s definition, higher value can be achieved if new treatments improve 
outcomes at lower cost; improve outcomes with no increase in cost; worsen outcomes, 
though with proportionally larger decreases in cost; lower costs, while having no effect 
on outcomes; or indeed raise costs, though with proportionally larger improvements in 
outcomes. The relationship between costs, clinical outcomes, and value from treatments 
can therefore be represented through the following formula:   
 
 
To provide some context to the use of this concept in healthcare, a brief overview of 
governmental, payer, industry, and clinical perspectives is now given on how to define, 




𝑉𝑎𝑙𝑢𝑒 = 𝑓(𝑐𝑜𝑠𝑡, 𝑐𝑙𝑖𝑛𝑖𝑐𝑎𝑙 𝑜𝑢𝑡𝑐𝑜𝑚𝑒𝑠) 
 














Regulatory authorities focus on the clinical dimension to value in healthcare spending 
when considering whether to authorize new treatments. That is, licensing decisions in 
the US, EU, and Australia, by the FDA, EMA, and TGA, respectively, focus on ensuring 
that safety, efficacy, and quality criteria are met. Regulatory authorities are generally not 
expected to assess the economic impact from new treatments. Discrepancies may 
therefore exist between regulatory assessment and any respective HTA process that may 
occur in these countries. 
 
At the same time, legislative and regulatory action has often focused on the economic 
dimension to value in healthcare spending. Recent examples of this include 
congressional investigations into drug pricing, regulatory backlogs, the generics 
industry, and price competition.(3) Indeed, of the healthcare-related bills that were 
introduced during the 114th US Congress, a majority focused on mechanisms for cost 
mitigation (Appendix 1.1). 
 
There nevertheless appears to be interest in the development of value-based policy that 
cuts across the issues of treatment costs and clinical impact. The Medicare Access and 
CHIP Reauthorization Act of 2015, for instance, amended the Social Security Act by 
replacing Medicare’s Sustainable Growth Rate Formula with a merit-based payment 
system that links spending on physician services with performance.(14) Elsewhere, the 
Patient Protection and Affordable Care Act of 2010 added Sec. 1115A to the Social Security 
Act to establish a Center for Medicare and Medicaid Innovation, whose purpose is to 
develop and test innovative payment and service delivery models that reduce healthcare 
spending while preserving or improving the quality of care.(15) While both pieces of 
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legislation directly or indirectly attempt to control costs, they also take into 
consideration the impact to patients from the therapies that are provided.  
 
Industry/Payer Perspective 
Value-based spending initiatives have also been adopted by industry in recent years. 
Aetna and Cigna, two private insurers in the US, recently negotiated an innovative, 
value-based payment mechanism with Novartis for its new heart failure medicine, 
Entresto.(16) Under this payment model, Cigna has agreed to scale its payments to 
Novartis based on how well treatment with Entresto improves the relative health of 
Cigna enrollees.(16) While the long-term cost and clinical implications of this innovative 
payment model remain unclear, it establishes a framework in which growth in spending 
is linked to clinically meaningful drug innovation. 
 
Clinical Perspective 
Clinicians have also pointed to the need to consider both the cost and clinical impact 
from treatments, and the AMA has recently expressed its support for value-based pricing 
of medicines. At an Interim Meeting of the AMA in November 2016, physicians adopted a 
policy outlining principles to change the “fundamentals of prescription drug pricing 
without compromising patient outcomes and access.”(17) As AMA President Gurman 
explains, this policy represents the belief that the “carte blanche approach to drug 
pricing” needs to change so that high-quality care is also based on value. He explains 
that this change should “support drug prices based on overall benefits to patients,”(17) so 
that growth in pharmaceutical spending is slowed and costs balance with clinical 




Disease Area of Focus: Cancer 
Value-based initiatives that target healthcare spending may be particularly helpful in the 
case of cancer. 
 
Spending 
Cancer treatment is often associated with significant expense. The US alone spent close 
to $125 billion in 2010 on cancer care; this is expected to rise by more than one quarter to 
a real total value of $158 billion by 2020 (2010 dollars).(18) It is in fact the most expensive 
disease area to treat on a per capita basis,(19,20) and has been one of the leading drivers 
of growth in healthcare expenditure.(21,22) New anticancer medicines, in particular, 
have driven recent increases in spending,(23) and projections estimate that they will 
contribute the most to global pharmaceutical spending growth through 2021, particularly 
in developed countries.(24) One-third of US cancer patients go into debt as a result of 
cancer treatment, and approximately 3 percent file for bankruptcy.(25) The economic 
impact from cancer treatment is also higher than that of other disease areas, with US 
cancer patients being 2.65 times more likely than age-matched controls to declare 
personal bankruptcy.(26)  
 
There is evidence to suggest that the high-cost of cancer care may also influence patient 
care and outcomes: most cancer patients apply for copayment assistance, and a large 
proportion of those patients take less than the prescribed amount of medicine, partially 
fill prescriptions, or avoid filling prescriptions altogether.(27) From a clinical perspective, 
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therefore, it is particularly important to consider potential tradeoffs between the cost 
and NHB of new therapies in the field of cancer.  
 
Cancer research is also the largest recipient of R&D spending. Moses and colleagues 
(2015) report that in 2010 the US NIH allocated $5.621 billion to cancer research, which, 
at 32.7% of its total research funding, was the highest figure among 27 conditions 
evaluated by the study.(28) Proportional to cancer-related DALYs, a measure of disease 
burden, cancer is in fact the most well-funded disease area for research in the US.(29) 
Public expenditure on cancer R&D has also trended upwards over recent years, both in 
the US and around the world.(30) Likely as a result of these investments, there has been 
a significant amount of innovation in cancer medicines over the last decade: as a few 
examples, this has included the first anti-angiogenic medicine for cancer (bevacizumab 
licensed in 2004), the first new kidney cancer drug in over a decade (sorafenib, 2005), the 
first treatment for peripheral T-cell lymphoma (pralatrexate, 2009), and two new 
medicines for melanoma in which treatment is personalized to the genetic profile of the 
patient (dabrafenib, trametinib, 2013).(31) Despite comparatively high rates of spending, 
and the emergence of many new anticancer medicines, little attention has been paid to 
the costs and patient outcomes from new cancer treatments.(22,32–35)    
 
In the face of scarce resources, high levels of spending on cancer may in part reflect the 
notion that societies deem it ‘fair’ to prioritize the development and use of cancer 
treatments. As Nord and colleagues explain,(36) ethical theory and public opinion in 
industrialized nations suggest that people often attribute greater utility to interventions 
that treat more severe disease. Indeed, regulators and HTA agencies, including England’s 
NICE, may give additional weight to the survival benefits associated with medicines that 
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are indicated for patients with terminal disease and short life expectancies.(37) To the 
extent that societies prioritize cancer drug development and use, this may therefore 
suggest that spending relative to the clinical impact of new therapies differs across 
countries and exceeds that observed in other disease areas.  
 
Burden of Disease 
Cancer is also associated with a high, and growing, burden of disease. In the US, cancer 
accounted for 12,363,000 DALYs lost in 2010.(29) At 21.6% of total DALYs lost from 27 
conditions provided with NIH research funding, cancer was associated with the largest 
burden of disease. Proportional to total DALYs lost, there are reasons to believe that the 
burden of disease from cancer will continue to increase due to several factors: a rise in 
the incidence and prevalence of cancer due to population growth and the aging of the 
population, and better control of competing sources of mortality.(12) With the escalation 
in treatment costs for cancer, as well as greater cost-sharing, health systems owe it to 
their patients to assess the value from spending on new cancer medicines.  
 
Value-Based Healthcare: The Case of Cancer Medicines 
As cancer-related treatment costs and disease burdens grow, regulators and clinicians 
have proposed value-based initiatives to link expenditures on cancer treatments with 
their clinical benefit.  
 
The US Department of Health and Human Services, for instance, recently proposed a 
plan to introduce a two-stage Part B Payment Model that would help reduce expenditure 
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on medicines that are administered in outpatient settings—typically high-cost, and 
encompassing cancer medicines—while maintaining or improving health outcomes.(38)  
 
The UK government established a dedicated cancer drugs funding program, the CDF, in 
2011. As is explained in the government’s White Paper on the matter,(39) this effort was 
driven by concerns regarding access to new cancer medicines in the UK, where there was 
often a lower likelihood of survival from cancer than in other Western European states. 
However, with expenditures on the CDF rising from £38 million in 2010/2011 to £416 
million in 2015/2016,(40) and with little evidence demonstrating improved clinical 
outcomes from prescription drug use,(41) lawmakers in the UK recently reformed the 
CDF into a managed access fund with the aim of ensuring sustainability, “genuine 
[therapeutic] promise,” and stronger value-for-money in drug spending.(42,43)   
 
For their part, oncologists may be uncertain of how economics should influence clinical 
care.(12) Clinical experts in the treatment of CML have argued that current rates of 
growth in cancer drug prices are unsustainable and may be clinically 
counterproductive,(44) particularly if growing costs hinder patient access.(45) However, 
reflecting the AMA’s position on the need to develop VBP mechanisms, these same 
medical oncologists acknowledge that “if drug price reflects value, then it should be 
proportional to the benefit to patients in objective measures.”(44) This perspective is 
widely shared. Lin and colleagues (2016), for instance, argue that the value of cancer care 
should ideally be measured not in terms of only price, but rather in terms of the 
outcomes achieved per unit of cost incurred.(22) Mailankody makes a similar argument, 
contending that high costs for medicines may be justified if they bring equally large 
clinical benefits to patients.(46) To date, however, there have been few systematic 
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attempts at comparing cancer drug spending and its clinical impact, and examining the 
degree to which this is the case.  
 
Approaches to Measuring Value 
Health care systems may employ HTA to perform, and respond to, pharmaceutical value 
assessments. The following section provides an overview of how value is appraised in 
Australia, France, the UK, and the US, and used to reward clinical innovation. 
 
Australia 
In Australia, once a new medicine has received market licensure, sponsors may apply to 
request that their product be made available for public subsidy through the nation’s PBS. 
Australia’s Pharmaceutical Benefits Advisory Committee (PBAC) is an independent 
expert body that is appointed by the Australian Government and tasked with 
determining whether it is in the social interest for medicines to be publicly reimbursed. 
To inform its decisions, PBAC considers the medicine’s indication for use, its clinical 
effectiveness, safety and cost-effectiveness (‘value-for-money’) compared with other 
treatments.(47,48) PBAC recommendations also consider the clinical need underlying 
drug use; estimates of the annual cost that would be incurred from public subsidization; 
and concerns over drug prescribing that could create challenges for subsidy limits.(48) 
 
The PBAC is composed of two sub-committees that advise on economic matters related 
to new medicines, the PBAC DUSC and the PBAC ESC. The DUSC is responsible for 
generating estimates of the expected use of new medicines, as well as the financial 
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impact to public purchasers from their subsidization. The ESC is responsible for advising 
the PBAC on the clinical and health economic data submitted to the agency through 
drug dossiers. 
 
Prior to 2014, a non-statutory body, the PBPA, was then tasked with advising Australia’s 
Department of Health and Ageing on appropriate drug pricing. The organization utilized 
a variety of methods to suggest pricing for new treatments, including: 1) the cost-plus 
method (used predominately since 2007 PBS reforms); 2) reference pricing (used 
predominantly before 2007 PBS reforms); 3) weighted Average Monthly Treatment Cost; 
and 4) statutory price arrangements. As of 2014, price negotiations are undertaken by the 
Pricing Section on behalf of the Minister following a positive PBAC recommendation, 
and relies on cost-plus, reference pricing, and weighted pricing methods.(49) To 
negotiate the price of new treatments, the Pricing Section considers: PBAC advice on 
their clinical and cost-effectiveness; prices of alternative brands; comparative prices of 
items containing drugs in the same Anatomical Therapeutic Chemical (ATC) groups; 
cost information; prescription volumes, economies of scale, special storage 
requirements, product stability, special arrangements; prices of items containing the 
drug in reasonably comparable overseas countries; other factors the applicant may wish 
the Pricing Section to consider; and directions from the Minister.(49) 
 
France 
The main HTA body in France is the Haute Autorité de Santé (HAS). A scientific group of 
experts within HAS called the Commission de la Transparence is responsible for 
evaluating submissions for reimbursement for drugs that have been issued market 
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authorization, and using the clinical evidence to assess the absolute (SMR) and relative 
therapeutic benefit (ASMR) provided by new treatments. This information is then fed 
into drug reimbursement and pricing decisions. 
 
SMR is assessed on the basis of five criteria: 1) efficacy and safety; 2) position of the 
medicine in the therapeutic strategy, and the existence or absence of therapeutic 
alternatives; 3) severity of the disease; 4) type of treatment, i.e., preventive, curative or 
symptomatic; and 5) public health impact.(50) In a process that is coordinated by 
UNCAM, SMR assessments are then used to set pharmaceutical reimbursement levels 
across the nation’s three major health insurance schemes. “Irreplaceable” drugs, as well 
as those that are indicated for 30 severe chronic diseases (e.g., HIV/AIDS, diabetes), are 
reimbursed at 100% of their price. Those that are indicated for severe conditions, but not 
deemed “irreplaceable”, are reimbursed at 65%; those indicated for acute, less serious 
conditions are reimbursed at 35%; and those that are being transitioned to non-
reimbursable status are reimbursed at 15%.(51) Therefore, medicines that do not provide 
any clinical benefit to patients may not be reimbursed, while those that provide 
substantial clinical benefit to patients may be reimbursed at higher levels.(50) 
 
When classifying a drug’s relative medical benefit, the Commission de la Transparence 
evaluates comparative clinical data that is available for applicant drugs and assigns each 
an ASMR (“improvement in actual benefit”) score, which represents the drug’s supposed 
therapeutic improvement over existing, comparable treatments. ASMR scores fall within 
one of five levels, listed in order of decreasing therapeutic improvement: ASMR I 
(“significant”), ASMR II (“important”), ASMR III (“moderate”), ASMR IV (“minor”), and 
ASMR V (“nonexistent”). ASMR ratings are then used by CEPS to internally assess the 
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value of new treatments, and help set pharmaceutical pricing. Drug pricing decisions are 
based on: ASMR scores; the price of the local comparators; prices of the product in other 
European markets (mainly UK, Germany, Italy, Spain); sales forecasts for the next three 
years; predictable or real conditions for use; and size of the target population.(50) 
 
United Kingdom 
In the UK, HTA falls within the remit of the National Institute for Health and Care 
Excellence (NICE), a non-departmental public body that operates independently of the 
government. Among other responsibilities, NICE is tasked with developing evidence-
based guidance and advice for health, public health, and social care practitioners. This 
guidance consists of: NICE guidelines, providing recommendations on the use of 
treatments and clinical services; and technology appraisal guidance, which assess the 
clinical and cost-effectiveness of health technologies, such as new pharmaceutical 
products. Several units within NICE carry out the function of guidance development, 
including IPAC, TAC, and academic centers (‘technology assessment groups’).(52)  
 
NICE technology assessment groups generate new drug assessment reports; these are 
then used by TAC to develop recommendations on whether the English NHS should 
cover those treatments. TAC recommendations are based on both clinical and economic 
evidence, and consider patient perspectives of risks and benefits, estimates of cost-
effectiveness, and the quality of the evidence. TAC uses cost-effectiveness analyses—
which may include incremental cost-effectiveness ratios—as the main tool to assess the 
value of new treatments. NICE typically adheres to a value cap of £20,000-£30,000/QALY 
gained when deciding whether to recommend the adoption of new technologies. 
38 
 
However, the agency can recommend reimbursement of treatments that exceed this 
cost-effectiveness threshold, and the agency may be particularly inclined to do so when 
drug therapeutic benefits coincide with social preferences (e.g. cancer treatment).(53) 
Since 2002, the NHS has been required to fund treatments that are recommended by 
NICE’s technology appraisal guidance.(54) Local commissioners may however adopt 
technologies that have not been appraised, not yet been issued a recommendation for 
coverage, or which may not have been deemed cost-effective by NICE.(54)  
 
Managed entry agreements, otherwise known as PAS, are an important part of the 
technology appraisal process for medicines. PAS are an arrangement between the 
manufacturer and the Department of Health that are designed to improve the cost-
effectiveness of a drug. There are two types of PAS: financially-based PAS involve the 
pharmaceutical company providing a discount on a new drug, depending on the number 
of patients who are expected to use the medication or other factors, such as patient 
group characteristics, clinical response, or dosing regimens.(55) The second type of PAS 
is outcome-based. Under this scheme, future discounts or rebates may be linked to the 
results from ongoing clinical trials, helping to ensure an association between long-term 
costing trends and clinical impact.(55)  
 
In the UK, pricing of all licensed, branded drugs is not directly regulated, but is often 
managed through the voluntary PPRS, which institutes mechanisms for price cuts, as 
well as profit controls—typically defined via return on capital—that weigh price and 
volume. Reserve statutory powers to control pharmaceutical prices also exist for 
medicines that are not regulated through the PPRS.(56) The PPRS is a voluntary 
arrangement between the Department of Health and the Association of British 
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Pharmaceutical Industry that is designed to give both industry and regulators additional 
certainty over pharmaceutical pricing and market entry in the UK. The latest version of 
the PPRS (2014) failed to incorporate VBP mechanisms linking national health 
technology assessments to price setting due to “technical problems and uncertainty,”(57) 
it may offer a platform to directly negotiate VBP of medicines in the future. However, in 
response to calls for value-based pricing, PPRS 2009 nevertheless implemented a flexible 
pricing arrangement that, among other stipulations, allowed companies to increase or 
decrease their original list price once by up to 30% in light of new evidence.(56) 
 
United States 
The US is a major producer of HTA evidence. CMS and private insurers commission HTA 
reports on new medical technologies to inform coverage decisions at national and local 
levels; AHRQ provides significant support for HTA research; the VHA performs 
pharmaceutical HTA through its Pharmacy Benefits Management Strategic Healthcare 
Group; and the NIH also develops evidence reviews to inform clinical practice. More 
recently, the PPACA of 2010 created PCORI, an agency whose mission is to fund and 
encourage the development of CER.  
 
Yet, public use of HTA in the US is modest compared with Australia, France, and the UK. 
In accordance with its enabling legislation, the US FDA only requires that new 
treatments be safe and efficacious for the agency to grant them licensing authorization. 
The agency does not mandate that efficacy be demonstrated against active comparators: 
comparative efficacy data is optional, except when ethical considerations would bar the 
use of non-active comparators in patient trials. Cost-effectiveness is not considered 
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during pre-authorization reviews. CMS’s Medicare Coverage Division may commission 
HTAs to support national decision-making on treatment coverage, and the agency uses 
public fora to weigh the evidence from HTA.(58) By law, however, the Coverage Division 
is barred from considering the cost or cost-effectiveness of new treatments when making 
coverage determinations.(58)  
 
High-level policies or regulations to control pharmaceutical spending are not used in the 
US. The social insurance programs Medicare and Medicaid are not allowed to directly 
negotiate pharmaceutical pricing once new medicines have entered the market,(59) may 
not consider costs within the drug reimbursement decision-making process, and yet may 
be required to cover new medicines.(60) Medicare PDPs are required to cover “all or 
substantially all” medications within six protected classes of medicines, including 
antineoplastics and immunosuppressants, under various regulations, including the 
MIPPA of 2008 and PPACA of 2010.(61) Bach and Pearson (2015) argue that Medicare’s 
ability to apply a VBP system is hindered by policies that require Part D private drug 
plans to cover all drugs of certain protected classes, while a flat co-insurance rate 
without an upper limit has put highly effective but expensive medicines out of reach for 
Medicare beneficiaries without supplemental health insurance.(59) For their part, 
private insurers are required to provide coverage for most new medicines, and may be 
unable to obtain significant price concessions from manufacturers, especially for drugs 
offering clinical advantages or using novel mechanisms of action.(59) While insurers 
may in theory negotiate lower prices for drugs that have therapeutic substitutes or 
questionable benefits by excluding them from formularies,(62) the extent to which this 




Empirical Challenges in Measuring Value 
Although value-based healthcare is not a new concept,(63) there is relatively little 
empirical evidence examining the extent to which spending on new cancer medicines is 
‘worth it.’(22,32–35) As Lee and colleagues (2016) state (34): 
 
“Few large health care organizations have accurately measured total care 
costs at the individual patient level and have related costs to quality.”  
 
This may be explained by several factors, including: the historical lack of a framework to 
define and measure the value generated from use of cancer medicines; and a dearth of 
comparative evidence on their use or cost. 
 
Conceptual Framework on Value of Cancer Medicines 
Patient perception of value is highly individualized in the case of cancer.(12) Although 
overall survival is generally taken as the gold standard for clinical efficacy, several 
surrogate markers of efficacy have emerged over recent decades to minimize delays in 
marketing of new cancer medicines. When making treatment decisions, however, 
patients often consider efficacy alongside other clinically-relevant parameters, including 
quality of life and toxicity.(12) In part owing to a multiplicity of clinical outcome 
measures,(64) there has historically been no evidence-based framework that could be 
used to weight across clinically-pertinent endpoints, measure the clinical impact from 
new cancer treatments, and therefore be used to rigorously assess the value from 




There has been progress in this regard, with the recent publication of frameworks to 
assess the value of tools and treatments in healthcare.(65–68) Neumann & Cohen (2015) 
offered an early review of five of them,(65) of which four were developed in 2015 and 
could be applied to oncology. Just as “value” may be interpreted differently by different 
people, all value frameworks vary in their goals and methods.(65–68) Of the four 
frameworks that could be used in oncology, ASCO’s Value Framework is specific to 
cancer; was designed through a deliberative consensus process; is rules-based; weights 
clinical measures according to their perceived value to patients; explicitly synthesizes 
clinical benefits; and incorporates direct costs from treatment (Table 1). It is therefore 
used in this thesis as a conceptual framework to assess the value from spending on 
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ASCO published its draft framework for assessing the value from cancer treatments in 
2015 (“ASCO Value Framework”)(Figure 1).(12) Based on consensus among oncologists, 
patients, payers, and manufacturers, the ASCO Value Framework identifies key clinical 
outcome measures that represent tangible harms and benefits to cancer patients, 
including efficacy, quality of life, and toxicity (Figure 1), while also proposing a set of 
weights for clinical endpoints. Clinical benefits and toxicity are combined to generate an 
NHB score, which is then juxtaposed against the direct cost of the treatment, to inform 
shared clinical decision-making. As the authors of this framework explain, this effort is 
based on the assumption that (12): 
 
“the cost of a given intervention should bear a relationship to the beneficial 





Adapted from Schnipper et al.,(12) ASCO Value Framework. 
Figure 1. Conceptual Framework to Assess the Value from Cancer Drug Expenditures 
Value 






Quality of Life 
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Without a conceptual framework in place to identify the key clinical outcome measures 
that represent tangible harms and benefits to cancer patients, it would otherwise be 
difficult to: assess the value associated with cancer drug spending by comparing the 
costs and clinical impact from new cancer medicines, and test whether the hypothesis 
that drug spending is indeed associated with their clinical benefits.  
 
Comparative Data on Cancer Drug Use and Cost 
There is as well a dearth of publicly available and comparable evidence on the use and 
cost associated with new cancer medicines. Even if evidence on the clinical risks and 
benefits from cancer medicines were available, this lack of data makes it difficult to 
examine whether spending is associated with the beneficial impact that new treatments 
provide to patients. 
  
First, there is often a significant amount of uncertainty in the total cost that will be 
incurred from treatment with cancer medicines. This owes in part to an often-
unpredictable length of treatment, which may be defined by progression-free survival, 
incidence of unacceptable toxicities, or death.[e.g. (69–71)] Unlike in other disease areas, 
response to cancer treatment is often highly variable, and associated with a wide 
distribution in length of treatment. To overcome this issue, cancer drug costs may be 
annualized,(72) or evaluated as monthly DAC or the ETP, both of which refer to the 
monthly cost for acquisition of cancer medicines based on list prices.(12,73)  This 
approach however does not adjust for potential differences in treatment duration across 
cancer medicines, and thus may reflect biased estimates of total treatment-related costs. 
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The lack of globally comparable costing data also makes it difficult to examine the value 
from cancer drug spending in any one context. 
 
Spending on cancer medicines however is defined by price, as well as use. From a 
societal perspective, the economic impact, and indeed relevance, of high cancer drug 
prices may be mitigated by value-based mechanisms that shift demand towards cheaper 
alternatives, ceteris paribus. On this however, comparative studies into cancer drug 
utilization are complicated by a lack of comparative information on cancer drug 
usage.(74–76) To add to this issue, methodological challenges, such as the lack of DDDs 
from the WHO for cancer medicines, makes it difficult to reliably compare usage purely 
in terms of drug volumes.(74,75) This adds another obstacle to studies that wish to 
examine the association between spending and drug-related clinical benefits.  
 
Thesis Overview 
Theory, Empirical Gaps, and Thesis Outline 
This thesis collects data on the clinical impact, use, and cost associated with new cancer 
medicines, before then examining whether cancer drug spending is providing patients 
and society with value-for-money. As is shown in Figure 3, these efforts are framed 
around ASCO’s Value Framework, and are designed to reflect its approach for assessing 




Chapter 2: Clinical Risks and Benefits of New Cancer Medicines 
Developed through consensus among oncologists, patients, payers, and manufacturers,  
ASCO’s recently published Value Framework identifies the clinical outcome measures 
that represent tangible harms and benefits to patients from cancer treatments.(12) 
Chapter 2 of this thesis uses it within the context of a systematic review with narrative 
synthesis of English-language HTA appraisals from Australia, France, and the UK to 
assess the clinical impact from treatment with new cancer medicines. These countries 
were selected because they publish English-language HTA appraisals, and also have 
comparable economic conditions and pharmaceutical systems.(77) Public bodies within 
each of these countries may utilize their own frameworks to inform value assessments, 
but may ultimately be held to the same standard with regards to ensuring that cancer 
drug expenditures reflect value-for-money. 
 
Chapter 3: Spending on New Cancer Medicines 
Moreover, there is a dearth of reliable and comparable evidence on the use and cost of 
cancer medicines, creating a second obstacle in assessing their value to health.(12) This 
owes in part to a lack of standardized units for comparing cancer drug use, as well as a 
dearth of publicly available, patient-level data on the factors that influence total 
prescribable drug dosage, including anthropometrics and DoT, cancer drug use, and 
cost. To address this challenge, Chapter 3 uses , 
and incorporates recent methodological advances,(78,79) to generate comparative 
evidence on the expected use and cost of new cancer medicines in Australia, France, the 





Given data on the clinical impact from new treatments, and their use and cost, the 
literature has generally taken two approaches to examine whether healthcare spending 
provides value-for-money. The first approach assesses whether spending on new 
treatments results in net positive economic returns to patients and society.(22,33,35,80–
82) The second assesses whether and to what extent spending is associated with 
measures of clinical benefit from use of those treatments.(73,83–87) 
 
Chapters 4 & 5: Assessing the Value of New Cancer Medicines 
Using data on the clinical impact from new cancer medicines (Chapter 2), and their use 
and cost (Chapter 3), Chapters 4 and 5 adopt both empirical approaches to examine 
whether cancer drug spending is providing patients and society with value-for-money. 
Chapter 4 adapts the methods from previous studies within the context of a cost-benefit 
analysis to analyze whether the monetized value of survival gains attributable to cancer 
drug innovation exceeds growth in drug spending, both at a societal- and drug-level. 
Chapter 5 then incorporates evidence from prior chapters within a regression-based 
framework to test the value-based hypothesis that spending on new cancer medicines is 
associated with their beneficial impact to patients. An overview of the conceptual 
framework and empirical gaps that underlie these efforts, as well as thesis research 
questions and outline is provided in Figure 3.  
 
Chapter 6: Synthesis & Conclusion 
This thesis ends with Chapter 6, which synthesizes research findings, and provides a 





By providing and evaluating evidence on the clinical impact, use, and cost of new cancer 
medicines, this thesis may provide policymakers and clinical practitioners with insights 
on the issue of value-for-money in cancer drug spending. However, by helping to address 
the research questions described above, this thesis is expected to primarily make 










Overarching Research Question: Is cancer drug spending providing patients 
and society with value-for-money? 
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Chapters 4 & 5: 
Empirical Gap: In the absence of information on the clinical impact (Ch 2), utilization or cost 
(Ch 3), associated with new cancer medicines, it is difficult to assess whether cancer drug 
spending provides patients and society with value-for-money. 
 
Research Question (Ch 4): Building on data collected from earlier chapters, is the net 
monetized value of survival gains that can be attributed to cancer drug innovation positive, 
both at a societal- and drug-level? 
Research Question (Ch 5): Building on data collected from earlier chapters, is spending on 
new cancer medicines associated with measures of their beneficial clinical impact to patients? 
Chapter 3: 
Empirical Gap: There is a dearth of publicly 
available and comparable evidence on the 
use and cost associated with new cancer 
medicines. 
 
Research Question: What is the utilization 
and cost (spending) associated with new 
cancer medicines?  
Chapter 2: 
Empirical Gap: Without a conceptual 
framework in place, it is difficult to 
systematically assess the clinical impact to 
cancer patients from new medicines. 
 
Research Question: What are the relative 
clinical risks and benefits (clinical impact) 
associated with new cancer medicines?  
Conceptual Framework (12): 




2  Clinical Risks and Benefits from 




There is growing debate about the value of drug expenditures in the US and around the 
world. Cancer drug prices in particular are growing rapidly, and now may result in 
annualized treatment costs that exceed $100,000.(44) In response to escalating drug 
costs, US policymakers have recently launched investigations into drug pricing and price 
competition.(3) UK policymakers have also recently implemented cutbacks and reforms 
to a national cancer drug access program, the CDF, over questions of its impact on 
patient health and concerns of value.(88,89) For their part, clinicians have criticized 
current cancer drug prices as excessive and unsustainable,(44) and have pointed to 
evidence suggesting that escalating costs may make it difficult for patients to access, or 
remain compliant with, life-extending therapies.(44,90) 
 
Discussions of the implications from escalating cancer drug costs however become more 
nuanced when clinical benefits are considered. Some have argued that high costs may be 
justified if new cancer treatments are also associated with significant benefits to 
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patients.(44,46) Even as recent studies point to marginal OS gains from new cancer 
medicines,(91) efforts to examine the value from related expenditures remain stymied by 
a dearth of systematic evidence on their clinical risks and benefits. This lack of evidence 
makes it difficult for the public to demand more from innovation,(92) and, where costs 
factor into value-based clinical decision-making, for clinicians and patients to balance 
preferences for the expected impact of treatment against rising drug costs.  
 
Measuring Clinical Benefits 
One issue that makes it difficult to systematically assess the value from spending on new 
cancer medicines is the multiplicity of clinical endpoints that may be used to inform 
assessments of their clinical impact.  
 
Overall Survival and Surrogate Efficacy Endpoints 
OS is generally taken as the gold standard among endpoints that can be used to measure 
the clinical effectiveness of new cancer medicines.(64,93,94) The US FDA in fact takes 
OS as a “universally accepted direct measure of benefit” in oncology drug trials.(95) 
Whereas surrogate clinical endpoints such as PFS may be subject to assessment bias or 
variability from measurement of radiologic or clinical measures and assessment 
schedules,(96,97) the interpretation of OS is objective and not prone to investigator 
bias.(98) This has led some to claim that OS is the “most objective end point to measure 





In line with these positions, ASCO’s Value Framework indicates that OS should be used, 
if it is reported, to assess the clinical benefit of treatments for advanced or metastatic 
disease. Only in cases where it is not should assessments of clinical benefit be informed 
by evidence on treatment-related improvements in PFS or, where also unavailable, RRs. 
Accordingly, ASCO’s Value Framework assigns OS benefits the greatest efficacy weight, 
and gives drug-related effects on efficacy the most weight—maximum of 80/100 possible 
points—in NHB scores measuring the overall therapeutic benefit from new cancer 
treatments. Memorial Sloan Kettering Cancer Center’s DrugAbacus Framework adopts a 
similar approach for assessing the value of cancer therapeutics.(66) Leading value 
frameworks, including ASCO’s Value Framework, reflect the importance that is generally 
ascribed to OS in measuring treatment efficacy.  
 
There is however a growing body of literature that discusses the potential use of 
surrogate measures in assessing the impact from cancer treatments on clinical efficacy. 
This in part owes to the FDA’s adoption of Accelerated Approval regulations in 1992,(100) 
which created a fast-track procedure for the evaluation of medicines that treat serious 
conditions or fill an unmet medical need.(101) To shorten the time required for 
regulatory evaluation, this procedure allows for the approval of new cancer medicines on 
the basis of surrogate endpoints, such as PFS and ORRs, that are “reasonably likely to 
predict clinical benefit”.(101) The adoption of this policy has been associated with 
licensing and coverage decisions for new medicines that increasingly rely on surrogate 
endpoints: about 16 drugs were approved by the FDA on the basis of surrogate evidence 




The use of surrogate efficacy endpoints is supported by one stream of evidence 
indicating that they may predict clinical benefits.(103–106) Oncologists and patients may 
for instance take PFS, one major surrogate efficacy marker, as prognostic of patient 
outcomes.(107) Where this is the case, surrogate efficacy endpoints may represent 
unique dimensions of clinical benefit that could be considered independently of OS.  
 
There are however several challenges in using surrogate endpoints to assess drug-related 
efficacy benefits to patients.  
 
First, while FDA accelerated approvals provide the manufacturer with full licensing 
rights, they do not guarantee clinical benefits. Drugs licensed through an accelerated 
approval procedure are in fact required to complete phase 4 post-marketing trials to 
confirm clinical benefits.(101) If confirmatory trials are not conducted, or if they fail to 
demonstrate effectiveness, the FDA can act to remove the drug from the market,(108) as 
recently happened for bevacizumab’s approved use in breast cancer.(73) Fast-track 
procedures have more recently been supported with the passage of accelerated approval 
provisions in Sec. 902 of the Food and Drug Administration Safety and Innovation Act of 
2012 (FDASIA), which permits the FDA to fast-track approval of high-need molecules 
that it considers to be a breakthrough in therapy,(109) as well as the 21st Century Cures 
Act of 2016, which allows the FDA to consider previously submitted data in its 
evaluations of precision medicines for serious or rare conditions.(110) Therefore, while 
accelerated approval procedures may allow for surrogate endpoints, they do not ensure 
efficacy benefits. By requiring phase 4 post-marketing confirmatory trials, accelerated 
approvals implicitly suggest that surrogate efficacy data may only unreliably predict 




Second, the evidence supporting an association between OS and PFS varies considerably 
by cancer type, and may even vary within cancer types.(111) The quality of evidence 
supporting the existence of an association between surrogate endpoints and OS may also 
be questionable.(111) For instance, in their review of the evidence examining the 
relationship between PFS/TTP and OS in advanced or metastatic cancer, Davis and 
colleagues (2012) find three papers indicating a positive association between PFS and OS 
in colorectal cancer. The magnitude of this association varied substantially between 
studies (0.481 to 0.79), and was also inconsistent with the reported association between 
OS and TTP, with just one of two studies finding a significant association between both 
outcome variables.(111) Reports of a positive association between individual PFS/TTP and 
OS outcomes in breast and non-small cell lung cancers also came from a single study for 
each cancer type.(111) Reviewed studies also lacked a standardized empirical approach 
that would otherwise make it easier to definitively claim the existence of an association 
between PFS/TTP and OS.(111) The authors conclude by arguing that studies making 
strong assumptions regarding the relationship between PFS and OS should therefore be 
“treated with caution.”(111) 
 
Bognar and colleagues (2017) cite growing discomfort among clinicians and payers over 
the impact from growing use of surrogate endpoints by regulators on the quality of 
evidence supporting the use of new medical technologies.(102) Surrogates are 
“imperfectly correlated with the final outcomes of interest” and “imperfectly predict 
clinical benefits,” the authors charge.(102) They therefore provide “weaker evidence of 
the benefit value than ... ‘hard’ or final outcome evidence.”(102) With respect to clinical 
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practice, PFS may be correlated with survival in oncology, but it “might not [reflect] 
intrinsically valuable” benefits to patients.(102) 
 
There is in fact a lack of consensus on whether PFS is indeed a “true measure of outcome 
due to treatment,”(112) and similar arguments may apply to other surrogate efficacy 
markers. While this may simply reflect limitations in the available evidence, it remains 
the case that consensus has not been reached on whether surrogate measures of efficacy, 
including PFS, are valid indicators of clinical benefit. This may be why the FDA states 
that surrogate efficacy endpoints are potentially “[predictive of] clinical benefit, but [are 
not themselves] a measure of clinical benefit”.(108)  
 
Second, while the use of surrogate endpoints has recently increased, they continue to be 
used as a primary endpoint in a minority of cancer drug evaluations.(113) Even if clinical 
efficacy is established through surrogate measures in accelerated approvals,(64) the FDA 
states that “overall survival should be evaluated in randomized controlled trials”,(95) 
indicating that this parameter should be collected during the oncology drug 
development process. In contrast, FDA guidance documentation for industry does not 
explicitly recommend that manufacturers collect data on particular surrogate endpoints 
for all new cancer drugs.(95) Therefore, even if surrogate efficacy measures were 
indicative of objective clinical benefits, the non-systematic nature of their collection and 
evaluation during drug evaluations prevents researchers from using them to measure 




Quality of Life and Safety 
Finally, regulators also often examine the impact from treatment on QoL and safety to 
evaluate the clinical risks and benefits from treatment.(114,115)  
 
The FDA’s enabling legislation—the Federal Food, Drug, and Cosmetic Act of 1938, and 
the Kefauver-Harris Amendments of 1962—requires that the agency evaluate both the 
safety and efficacy of new medical products in the Unites States.(114,116) In particular, for 
an oncology approval to occur, there must be “substantial evidence of efficacy from 
adequate and well-controlled trials,” and drugs must also be “safe for their intended 
use.”(114) These requirements have since been informally broadened to include 
considerations of QoL. Coordinating with internal experts from the Oncologic Drugs 
Advisory Committee, the FDA determined in the 1980s that cancer drug approvals 
should also be based on direct evidence of clinical benefits, which was defined in terms 
of improvements in survival, physical functioning, symptoms, as well as in QoL.(95) 
Though this is not codified, regular oncology approvals may therefore consider drug-
related effects on QoL alongside OS and safety.  
 
In other countries, HTA agencies—including England’s NICE, France’s HAS, and 
Australia’s PBAC—may consider clinical efficacy, QoL and safety when evaluating new 
medicines prior to decision-making on coverage, pricing, and reimbursement.(117–119) 
One key distinction, however, is that FDA approvals do not require an evaluation of 
comparative benefits from treatment,(120) or late-stage clinical trial evidence under 
accelerated licensing procedures.(109) HTA agencies—including NICE, HAS, and the 
PBAC—may however require the submission of clinical evidence comparing the clinical 
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performance of new medicines with that of main therapeutic comparators, defined as the 
therapy that would most likely be replaced by the new intervention.(121–123)  
 
Context and Empirical Gaps 
As healthcare debates focus on the issue of rising drug costs, there is a growing need to 
systematically evaluate how new cancer medicines have impacted patient health. A 
handful of recent studies have started to address this gap by measuring the survival 
benefits associated with newly licensed cancer medicines.(46,73) However, this evidence 
should be evaluated alongside other clinical features that are known to impact the well-
being of patients, including QoL and safety. Such an exercise is particularly timely given 
the recent emergence of evidence-based value frameworks for cancer that identify the 
outcome measures—efficacy, toxicity, and QoL—that matter to patients, and, when 
considered alongside convenience and cost, help patients define the value to them from 
new therapies.(12) The current lack of evidence on these outcome measures otherwise 
makes it difficult for the public to demand more from innovation,(92) and, where costs 
factor into the decision-making process, for clinicians and patients to balance personal 
preferences on the expected impact of treatment against rising drug costs.  
 
Summary of Research 
To shed light on the clinical risks and benefits from new cancer medicines, a narrative 
synthesis approach was taken within the context of a systematic review of health 
technology assessments. All NMEs approved by regulatory authorities in the US (FDA) 
and Europe (EMA) between 2003-2013 with a primary indication for oncology were 
considered. Since US licensing decisions do not require proof of comparative efficacy and 
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may not consider OS benefits under accelerated licensing procedures,(109,124) summary 
conclusions of drug-related effects on OS, QoL, and safety were extracted and analyzed 
from appraisals that had been published by leading HTA agencies in Australia (PBAC), 
England (NICE), and France (HAS). These countries were selected because they publish 
English-language HTA appraisals, and also have comparable economic conditions and 
pharmaceutical systems.(77) 
 
This analysis finds that the magnitude of clinical benefits varies widely across all newly 
licensed cancer medicines and indications, improvements in OS and QoL often come at 
the cost of safety, and there are reasons to doubt whether clinical efficacy has been 
matched by effectiveness in real-world clinical settings. This study provides additional 
clarity on the potential risks and benefits of new cancer medicines, and therefore 
provides an additional resource for clinical decision-making by patients and physicians. 
It also raises questions about how clinical impact is measured by regulators as part of the 
drug review process, how the scientific evidence is used to inform clinical practice, and 




The methods used by Roberts and colleagues (125) were adapted to this study to identify 
all initial cancer drug approvals by the US FDA and EU EMA occurring between 2003-
2013. All NMEs approved by the FDA or EMA over this period with a primary indication 
for oncology were eligible for inclusion. Primary indication is defined within this context 
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as the first FDA- or EMA-approved indication for new NMEs (initial approvals).(125) 
EMA-approved indications were used only if an FDA approval was not available. Any 
molecule that did not receive licensure by either of the FDA or EMA between 2003-2013, 
and which did not have an initial, primary anticancer indication was therefore excluded. 
This analysis also focused on primary indications exclusively, which are likely to reflect 
their main intended use after initial licensure. Drugs that could be prescribed to cancer 
patients, but which were indicated for uses other than to actively treat the disease—e.g. 
to manage symptoms or side effects from active treatment—were excluded.  
 
Initial approvals for oncology medicines that met these selection criteria and which were 
approved by the FDA between 2003-2010 were obtained from Roberts and 
colleagues,(125) while those that were approved by the FDA between 2011-2013 were 
identified through the FDA’s annual lists of novel drug approvals and its Drugs@FDA 
registry.(126–129) EMA initial anti-cancer drug approvals occurring between 2003-2013 
were identified by applying the above selection criteria to the EMA’s EPAR search 
engine.(130) Of those medicines that were identified by Roberts and colleagues,(125) this 
analysis excluded plerixafor and palifermin—both are indicated for use in cancer 
patients, but they have no direct anticancer effect (Table 2). Medicinal inclusion was 
confirmed by an anonymous medical reviewer at the US FDA. A flow diagram depicting 













1∘ indication is 
not for anticancer 
therapy. 
“Mozobil™, a hematopoietic stem cell 
mobilizer, is indicated in combination with 
granulocyte-colony stimulating factor (G-CSF) 
to mobilize hematopoietic stem cells to the 
peripheral blood for collection and 
subsequent autologous transplantation in 




1∘ indication is 
not for anticancer 
therapy. 
“Kepivance™ is indicated to decrease the 
incidence and duration of severe oral 
mucositis in patients with hemtologic 
malignancies receiving myelotoxic therapy 









#1: Neither used in oncology, nor indicated as 
active, anti-cancer medicine. 
 
aflibercept; clobazam; deferiprone; icatibant; 
ticagrelor; rivaroxaban; indacaterol inhalation 
powder; belatacept; ezogabine; fidaxomicin; 
telaprevir; rilpivirine; boceprevir; linagliptin; 
gabapentin enacarbil; gadobutrol; belimumab; 
roflumilast; azilsartan medoxomil; vilazodone 
hydrochloride; spinosad; ioflupane i-123; 
glucarpidase; ingenol mebutate; ivacaftor; tafluprost; 
lucinactant; peginesatide; Florbetapir F 18; avanafil; 
taliglucerase alfa; lorcaserin hydrochloride; 
mirabegron; sodium picosulfate, magnesium oxide 
and citric acid; aclidinium bromide; elvitegravir, 
cobicistat, emtricitabine, tenofovir disoproxil 
fumarate; linaclotide; teriflunomide; ocriplasmin; 
perampanel; tofacitinib; raxibacumab; pasereotide; 
teduglutide; lomitapide; apixaban; bedaquiline; 
crofelemer; alogliptin; mipomersen sodium; 
ospemifene; gadoterate meglumine; dimethyl 
fumarate; canagliflozin; fluticasone furoate and 
vilanterol inhalation powder; dolutegravir; 
vortioxetine; conjugated estrogens/bazedoxifene; 
riociguat; macitentan; flutemetamol F 18 injection; 
eslicarbazepine acetate; luliconozole; simeprevir; 
sofosbuvir; umeclidinium and vilanterol inhalation 
powder 
#2: Used in oncology, but not indicated as 
active, anti-cancer medicine. 
 
plerixafor; palifermin; tbo-filgrastim; choline C 11 








(n = 133 drug-indications) 
Criteria: 
       Primary oncology; initial approval (NME); active anticancer treatment 
Sources: 
       1) Roberts et al. 2011 (drugs approved between 2003-2010) 
2) FDA Drugs@FDA database (drugs approved between 2011-2013) 
3) EMA EPAR database (drugs approved between 2003-2013) 
Included: Treatment use and cost 
(n = 62 drugs; n = 63 drug-indications) 
 
Figure 4. Drug Sample Inclusion/Exclusion Criteria 
Source: 




This study based its analysis of the comparative clinical risks and benefits of new cancer 
medicines on regulatory summaries of the impact from new treatments, as reported in 
Australian, English, and French HTA agency appraisals. This approach was taken for 
three reasons: 
 
First, it is often difficult to systematically assess the comparative harms and benefits of 
new cancer medicines based solely on FDA drug reviews. While the agency publishes an 
extensive amount of information in its medical, statistical, chemistry, pharmacology, 
microbiology, clinical pharmacology biopharmaceutics, risk assessment and risk 
mitigation reviews of new medicines, they are often published with non-rendered or 
scanned text. FDA reviews may also often be structured differently, which may make it 
difficult to systematically assess the clinical risks and benefits of new treatments. Finally, 
FDA reviews may sometimes be heavily redacted, even where non-economic information 
(e.g. comparative effectiveness and harms) is discussed (e.g. (131)). 
 
Second, the FDA’s enabling legislation—the Federal Food, Drug, and Cosmetic Act of 
1938, and the Kefauver-Harris Amendments of 1962—requires that the agency evaluate 
the safety and efficacy of new medical products in the US.(114,116) New approvals are not 
required to prove comparative effectiveness, resulting in “relatively few serious attempts 
[at its] assessment”.(120) However, under certain circumstances—for example, if it would 
ethically unacceptable to use placebo controls to seriously ill patients (132)—it may only 
be possible to prove efficacy and safety in relation to an active comparator. As a 
consequence, although many clinical trials submitted in support of a new drug 
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application include both active and placebo controls, the “FDA’s experience with 
comparative effectiveness claims is relatively limited.”(120) 
 
Third, this approach helps eliminate any bias that could occur from the independent 
review and interpretation of the primary clinical evidence. There is no large-scale, 
patient-level registry that provides information on patient characteristics, treatment and 
outcomes before and after entry of new cancer medicines. There are indications that this 
may change in the near future with, for instance, the emergence of the US National 
Cancer Institute’s National Cancer Knowledge System, a component of the US Precision 
Medicine Initiative® that will integrate genomic information with clinical response data 
and outcomes information. Future studies may be able to leverage data from this system 
to assess the real-world clinical impact from newly developed cancer medicines. 
 
Nevertheless, since this information is not available today, this study used a systematic 
process to assess the expected clinical impact on therapy from recent cancer drug 
innovations. This involved reviewing and extracting trial-based HTA agency summary 
evaluations of new medicines. One alternative might have been to evaluate the primary 
clinical evidence directly. However, results from clinical trials may go unpublished,(133) 
and primary clinical trial data is often not available for secondary analysis by 
independent researchers.  
 
HTA agencies, in contrast, may have the authority to require submission of all applicable 
clinical data, published and unpublished,(121,134,135) in theory minimizing the level of 
bias that could occur in their evaluations of treatment-related clinical risks and benefits. 
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By drawing from HTA agency evaluations, this study synthesizes regulatory evaluations 
of all relevant scientific evidence, and expert opinions regarding the expected clinical 
impact from new cancer medicines. 
 
Fourth, even if access to all of primary scientific data were not an issue, it is unclear 
whether an independent evaluation of the drug-related clinical risks and benefits would 
consistently correspond with those of regulators and other public authorities. Regulatory 
conclusions of drug-related clinical benefits are often used to define value-based 
decision-making on issues such as drug coverage, pricing and reimbursement. For 
instance, assessments of the absolute (SMR) and comparative (ASMR) clinical benefit 
from France’s HAS are used to determine whether to publicly reimburse for new health 
technologies (SMR), what the level of reimbursement should be (SMR), and in the 
pricing of new therapies (ASMR). Therefore, by relying on these sources of information 
rather independent evaluations of the primary evidence, subsequent chapters can test 
the value-based proposition that (12): 
 
“the cost of a given intervention [based on accepted pricing] … bears a 
relationship to the beneficial impact it has for patients who receive that 
treatment.”  
 
Finally, although OS has traditionally been taken as a universal marker of clinical 
efficacy in oncology drug trials, licensing approvals are increasingly based on surrogate 
measures.(136) This is reflected most prominently by the FDA’s accelerated approval 
pathway for serious or life-threatening diseases, which is designed to help expedite drug 
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development and availability in cases where few alternative treatment options exist. To 
do so, accelerated approvals may be based on surrogate measures of efficacy from Phase 
II trials.(64) Surrogate efficacy markers can be measured sooner than OS,(137) may be 
used to justify reimbursement, and may be “reasonably likely” to predict longer-term 
clinical benefits in certain circumstances.(95,138) 
 
Molecules that are approved under an accelerated procedure are nevertheless required to 
conduct post-marketing confirmatory clinical trials to verify the effect on IMM. As a 
result, the purpose of early phase clinical trials is often to “evaluate safety and identify 
evidence of biological drug activity, such as tumor shrinkage”, while later phase, 
confirmatory efficacy studies may instead “evaluate whether a drug provides a clinical 
benefit such as prolongation of survival or an improvement in symptoms.”(136) 
Reflecting this, Johnson and colleagues (2003) find that, unlike regular approvals, 
assessments of clinical effectiveness of oncology medicines approved under an 
accelerated pathway are often not based on OS benefits, but on surrogate measures, 
including objective response rates.(114) 
 
Perhaps particularly where there is an outstanding medical need, it is therefore unlikely 
for FDA reviews underlying initial cancer drug approvals to systematically evaluate the 
full clinical impact of new cancer medicines. At the same time, high failure rates of Phase 
III clinical trials in oncology may indicate that Phase II clinical trials alone are 
insufficiently informative on the clinical effectiveness of new medicines,(139) at least in 





Appraisals from English (NICE), French (HAS), and Australian (PBAC) HTA agencies 
published through May 2015 were therefore used to assess the clinical impact from 
cancer drug treatment. These organizations are required to evaluate the clinical risks 
and benefits of new medicines in relation to existing clinical standards that are used for 
the same indication,(121–123) and their assessments are often used in value-based 
decision-making on issues including coverage, pricing, and reimbursement.  
 
Although new cancer drug molecules are often first approved in the US,(125) they often 
gain licensure in other settings. Any delay in market entry may make it more likely for 
evidence from confirmatory clinical trials to be incorporated into the evaluation by 
international HTA agencies. These agencies also operate within countries that are similar 
to the US in terms of their populations and degree of economic development, and they 
regularly publish comprehensive, and consistently structured, HTA reports in the 
English language.  
 
From a clinical perspective, the available comparative evidence suggests that clinical 
practice guidelines for cancer treatment often coincide across developed healthcare 
settings.(140–142) At least within the case of metastatic breast cancer, this may reflect 
the notion that there are relatively few differences in individual and tumor 
characteristics across independently selected patients in industrialized nations.(143)  
 
Where a HAS appraisal could not be found using the agency website’s native search 
engine, an additional search was performed for HAS reports using an online search 
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engine (Google) that included the drug’s active ingredient and “HAS Santé” (e.g. 
“Bortezomib HAS Santé”). In the few cases where French TAs were not available in 
English, the documents were translated. Discussions of drug costs were not considered 
in this chapter. EU orphan drug status were obtained for each FDA-approved cancer 
drug indication from www.orpha.net. 
 
Selection Process 
HTA appraisals were selected for review if they pertained to the same target condition 
(e.g. colorectal cancer) as of the first FDA-approved indication. If multiple reports 
evaluated the same target condition, this analysis selected the latest report that most 
closely matched the first FDA-approved indication with respect to any treatment 
restrictions (e.g. cancer staging). In ambiguous cases, determinations were made in 
consultation with a medical expert. If the FDA approved two indications in its first 
evaluation of a new cancer drug (e.g. sunitinib), appraisals for both primary indications 
were extracted. Initial EMA-approved indications were used if the drug had not been 
approved by the US FDA through May 2015. 
 
Data Extraction 
The patient, intervention, comparator, outcomes process was used as a structured 
approach to review technological appraisals and evaluate the clinical benefits from new 
interventions.(144) For this, information on recommended patient populations and novel 
interventions were extracted from each drug appraisal. Therapeutic comparators were 
also extracted alongside data pertaining to outcome measures. This approach was used 
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to systematically identify trial design parameters that could influence regulatory 
assessments of treatment-related clinical outcome measures.  
 
Systematic Review with Narrative Synthesis 
Two reviewers independently adopted the patient, intervention, comparator, outcomes 
process within the context of a systematic review with narrative synthesis of HTA 
assessments of the clinical impact from new cancer medicines. Two reviewers were 
needed to minimize any bias from the qualitative synthesis of HTA assessments. 
Summary HTA assessments of clinical impact were typically characterized by explicit 
value judgments of the supporting evidence or an acknowledgement of the significance 
of clinical trial results.2 Accepted gains in OS were typically given as discrete, one-sided 
directional, or a range of values.3 Manufacturer-submitted data was not considered 
unless it had been accepted by the HTA agency in its summary assessment. For an 
overview of narrative syntheses, and how the procedure was used in this study, please 
refer to Box 1. 
                                                     
2 For example, England’s NICE accepted that sunitinib was associated with a more than 3-month increase in 
overall survival for its first-line RCC indication, specifically acknowledging an increase of 10 months 
according to the model that reflected the “Committee’s preferred assumptions.” 
3 England’s NICE, for instance, determined that bevacizumab was associated with a 4.7-month increase in 
median OS compared to IFL (irinotecan, bolus 5-FU and leucovorin), but no significant difference in OS 





Information on recommended patient populations (treatment indications, usage 
restrictions), novel interventions [ATC code, therapeutic target], and therapeutic 
comparators were extracted from each drug appraisal, as were evaluations of the impact 
on OS, QoL, and safety from drug treatment. Table 3 provides an overview of the classes 
of evidence that may have been evaluated and reported by Australian, English, and 
French authorities to assess OS, QoL, and safety. 
 
Literature reviews represent a “systematic, explicit, comprehensive and reproducible method for identifying, 
evaluating, and interpreting the existing body of original work produced by researchers and scholars.”(357) Within 
this context, narrative synthesis exists as a flexible analytical tool that can be used to synthesize and extract meaning 
from quantitative and qualitative evidence, and to “[aggregate] information into a new and unified whole”.(358) There 
has traditionally been no ‘codified’ procedure for the narrative synthesis of qualitative evidence—there are a number 
of different approaches to narrative data synthesis.(359) Still, a general set of practices should be followed to ensure 
that the synthesis of data occurs through a rigorous and transparent manner. These general practices are reviewed 
here; further detail can be found elsewhere.(359) In addition, a brief methodological description is provided to explain 
the procedures that were used in this study to comply with these general practices. 
 
• Develop a theory of how the intervention works, why and for whom.(359) This study reviewed the clinical 
endpoints that may be used in oncology drug trials, and collected PICO parameters.  
• Conduct a preliminary synthesis of the studies that are included to inform the collection and synthesis of 
research findings.(359) Here, two researchers performed an initial review of technological appraisals to 
develop a coding system that could systematically and comprehensively synthesize HTA agency 
conclusions regarding drug-related effects on OS, QoL, and safety.  
• Narrative data analyses should subsequently explore relationships in the data to consider the impact from 
heterogeneity in the studies that are used.(359) This study evaluates relationships in the evidence that is 
disseminated by HTA agencies, and it considers the impact from defining features of the drug assessment 
process.  
• Finally, the research should assess the robustness of the synthesis, which is itself dependent on the amount 
and quality of the evidence and the methods used to synthesize the evidence.(359) This study pre-specified 
the process for reviewing evidence; it was carried out with a priori knowledge of the parameters that could 
be used by HTA agencies to evaluate OS, QoL, and safety benefits (Table 3); and internal validation was 
sought through a consensus-seeking procedure.  
Box 1. Overview of Review with Narrative Syntheses in Qualitative Research 
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Outcome Measure Evidence 
Overall Survival Median OS,1,2,3 mean OS, 1,3 survival probability (%),2,3 OS (mean/median, NOS),2,3 
expectations of impact on mortality (NOS)2  
Quality of Life Symptom improvement, 1,2 time to change (deterioration/improvement) in functioning or 
symptoms,1,2,3 QoL instruments,1,2,3,4 impact on utility,1 patient representative/clinical 
expert inputs,1,2,5 expectations of impact on QoL (NOS)1,2,3,6 
Safety Incidence of AEs,1,2,3,7 incidence of severe or serious AEs,1,2,3,8 time to first AE (≥ grade III),1 
treatment discontinuation or dose reduction,1,2,3 overall tolerance and safety profile 







4 For example, FACT-An questionnaire, time without symptoms and toxicity (TwiST) and quality-adjusted survival and 
toxicity (Q-TwiST); SF12 v2, EQ-5D, EQ-5D-VAS; FACT-G; BPI-SF; FACT-Lym; FKSI-DRS index; FKSI-15 Index; FACT-P; 
QLQ-C30; QLQ-MY20; CTSQ; EORTC-QLQ; Karnofsky performance status; ECOG performance status; LCSS 
5 May include inputs on preference for oral/IV administration, amount of time in hospital, number of hospitalizations, 
meaningfulness of improvements in symptoms (e.g. fatigue, pain), and ability to perform daily activities 
6 Internal HTA agency opinion or expectation regarding aspects of clinical impact, not directly informed by the 
available evidence.  
7 Described as AEs (NOS), TEAEs without specification of serious grade, grade I/II AEs, AEs of mild to moderate 
intensity  
8 Described as SAEs, grade III/IV AEs, treatment-related syndromes (e.g. systemic inflammatory response syndrome)  
9 For example, discussion of overall tolerance and safety profile without reporting of primary evidence in assessment. 
10 Including grade V AEs. 
11 Examples of inputs from patients, patient representatives, or clinical experts included comments on patient 




A rules-based process was undertaken to evaluate evidence reported by HTA agencies. 
For this, the following were considered from HTA agencies: overall judgements of the 
available evidence on OS, QoL, and safety from summary sections; acknowledgement of 
the significance of clinical trial results; or referral to prior evaluations of the primary 
evidence. If these were absent, or if an HTA agency concluded that clinical benefits could 
not be assessed, corresponding extraction parameters were marked as missing. 
Disagreement on how to interpret HTA agency summaries of the clinical impact from 
treatment were resolved through consensus. 
 
Defining features of each drug appraisal, including FDA approval date, first FDA-
approved indication, FDA Accelerated Approval status, HTA appraisal date, type of 
supporting evidence, comparison type, EU orphan status, biologic status, and 
comparator, were also recorded. A clinical expert also used FDA-approved primary 
indications to classify all new cancer medicines by their therapeutic target. Across the 
entire sample, medicines were classified as being indicated for malignant ascites, soft 
tissue sarcoma, thyroid cancers, GI cancers, lung cancers, hematological malignancies, 
prostate cancers, skin cancers, renal cancers, and breast cancers.  
 
The narrative synthesis approach was particularly useful for this study: though they may 
be consistently structured, appraisals are meant as critical evaluations by HTA agencies 
of the clinical and economic evidence. The evidence that is therefore discussed within 
appraisals can vary and may depend on what is submitted, the availability of quantitative 
or qualitative evidence, as well as its acceptability and pertinence to the review. This 
approach also captured key outcome measures that are regularly considered during 
formal drug reviews, and which are reflected in ASCO’s recently published conceptual 
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framework for measuring the value of cancer treatment options.(12) An overview of the 
regulatory evidence used in this analysis is provided in Appendix 2.1. 
 
Overall Survival  
Both reviewers independently identified and extracted OS estimates for the first 
approved indication of each newly licensed cancer drug. To do so, this study considered 
summary judgments of the available evidence on OS, acknowledgment of the 
significance of clinical trial results, or referral to prior evaluations of the supporting 
evidence. An overview of the OS evidence that was considered by each HTA agency is 
given in Table 3. The second, independent reviewer assisted with data collection. I 
conceived and designed studies, acquired, analyzed, and interpreted data, and drafted 
this chapter, as well as the associated publication. 
 
Quantitative measures of the drug-related impact on OS were also coded as a categorical 
variable. HTA documents, particularly those from NICE, take drug-related 
improvements in OS of greater than or less than 3 months over best alternative 
treatments (145) as an indicator of the likelihood of benefit. According to England’s HTA 
agency, OS benefits of at least three months provide “sufficient evidence to indicate that 
the treatment offers an extension to life.”(117) This approach also reflected the 
magnitude of OS benefits that are considered large enough by English authorities to 
justify additional expense in end-of-life care,(146) and used at times by Australian 
authorities to assess new health technologies.(147) In other instances, agencies may also 
conclude that drugs are associated with an unquantifiable increase, or no demonstrable 




On this basis, drugs were classified as having a known OS benefit of ≥3 months if HTA 
agencies concluded that the drug was associated with a OS gain of ≥3 months (discrete 
value), or if one-sided directional or range estimates fell within this space. Other 
possible categories of OS benefits included: certain or uncertain increases of <3 months; 
an increase in survival, but of unknown magnitude; and no demonstrated increase in OS. 
After independent analysis, both researchers compared results and sought consensus if 
there was any disagreement in the extracted parameters. Inputs from a third researcher 
were sought if consensus could not be reached (this did not become necessary).  
 
To conservatively measure the therapeutic potential of new treatments, a composite 
measure of drug-related OS benefits corresponding to the maximum possible OS benefit 
from treatment was developed by aggregating data from the HTA agency appraisals that 
were available for each medicine. To do this, a hierarchical process was followed: if only 
one HTA agency evaluated a given drug, its assessment of gains in OS was taken. If drug 
appraisals were available from multiple HTA agencies, the largest estimate of the drug-
related survival benefit was taken to measure the clinical benefits that may be possible 
from treatment. If no difference in OS could be established by any of the three agencies, 
then the drug was taken to produce no measurable change in OS. Summary assessments 
of the clinical risks and benefits associated with new cancer medicines did not vary to 
any great extent across the three HTA agencies considered in this analysis (Appendix 
2.1). This may in part reflect the finding that assessments were often based on the same 




Treatment standards can also change over time as new medicines enter the market. To 
calculate the total average increase in OS between 2003-2013, the following approach was 
taken: where cancer drugs were associated with a composite gain in OS that was given as 
a range—representing a range in the maximum OS benefit that was accepted by English, 
French, and Australian HTA agencies—the midpoint was taken. New cancer drugs were 
then mapped against the treatment comparators that they would replace, as identified 
by HTA assessments. For this, it was necessary for primary treatment indications to be 
consistent across the new intervention and the mapped comparator. Drug-specific gains 
in OS were then summed across the mapped comparators.  
 
The following are two examples of how this process was carried out: subsequent to its 
approval by the FDA in 2004 for the treatment of malignant pleural mesothelioma, 
pemetrexed was used by French and Australian HTA agencies to evaluate the clinical 
effectiveness of crizotinib (approved by the FDA in 2011 for locally advanced or 
metastatic non-small cell lung cancer). While these two drugs were compared against 
each other, the first FDA-approved indication for each of these medicines was not 
identical. The FDA eventually granted pemetrexed a licensing extension in 2006 so that 
it could be used for the same indication as crizotinib, but this analysis did not consider 
non-primary indications in this study. Since pemetrexed and crizotinib therefore did not 
have an equivalent primary indication for use, their OS benefits were considered 
independently. In contrast, erlotinib was approved by the FDA in 2004 for patients with 
locally advanced or metastatic non-small cell lung cancer and evaluated against placebo 
and BSC. Afatinib was approved by the FDA in 2013 for the same clinical indication, and 
its clinical efficacy was compared against that of erlotinib and gefitinib by HTA agencies. 
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Since both afatinib and erlotinib were indicated for the same purpose, this analysis 
directly compared the OS benefits associated with each medicine.  
 
This exercise allowed for the mapping of changing clinical standards as new drugs 
entered the market, and to therefore estimate the total gain OS between 2003-2013 
within and across treatment indications. If a drug was approved by the FDA for two 
primary indications (sunitinib), the OS benefits associated with each indication was 
considered separately, since each pertained to different patient populations. Finally, 
average gains in OS were calculated by therapeutic target indications (malignant ascites, 
bladder, soft tissue, hematologicals, lung, GI, renal, breast, prostate, thyroid, skin). 
 
Quality of Life 
HTA summary evaluations of drug-related changes in QoL and safety were, in general, 
qualitative. Preliminary analysis revealed that, where discussed, HTA agency conclusions 
regarding QoL could be classified into four categories: an overall improvement or 
reduction in QoL, mixed evidence, or no established difference relative to best 
alternative treatments. A detailed description of the QoL-related evidence that was 
generally considered by each HTA agency is given in Table 3. 
 
To classify the overall effect on QoL from each drug, two researchers independently 
highlighted and synthesized all text on drug-related effects on QoL that was published 
within appraisal summary sections. In the few instances where multiple primary 
indications were evaluated concomitantly by any one HTA agency (e.g. renal cell 
carcinoma and gastrointestinal stromal tumor), or if conclusions were based on multiple 
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comparators, both reviewers took the most positive estimate of drug-related changes in 
QoL. For example, if one evaluation found there to be an improvement in QoL, but a 
second found no change, both reviewers marked the drug as producing an improvement 
in patient QoL. If there were two opposing conclusions—e.g. if QoL improved for one 
primary indication, but worsened in another—then both reviewers marked the drug as 
producing mixed evidence. Given the potential implications for clinical practice, this 
approach was designed to capture the maximum clinical benefit to patients that may be 
possible from treatment with new cancer medicines. Both researchers then compared 
results and sought consensus where disagreement existed. Inputs from a third researcher 
were sought if consensus could not be reached.  
 
A rules-based process was used to synthesize all available HTA agency assessments and 
generate a composite, qualitative rating of the impact on QoL from treatment with each 
drug-indication. If summary assessments from one HTA agency described an overall 
improvement in QoL, while another found no change, the drug was classified as being 
associated with improvements in QoL. If opposing interpretations of the available 
evidence existed—e.g. if one agency found an overall improvement in QoL, while 
another concluded that the drug-indication worsened QoL—the drug-indication was 
classified as being associated with mixed evidence. If no difference in QoL was 
established by any of the three agencies due to a lack or insufficiency of evidence, then 
the drug-indication was classified as having no established impact on QoL. For more 
information on the parameters typically used by HTA agencies to assess QoL, please 





HTA agency summaries regarding the effect on safety from drug treatment were also 
extracted from appraisals and sythesized. Discussions of treatment effects on the 
incidence of individual types of adverse events were not considered, unless HTA 
agencies explicitly stated that these were of significant concern. Instead, HTA summary 
assessments of the overall impact on safety from drug treatment were typically based on 
a review of the following types of evidence: treatment effect on incidence of all AEs, 
incidence of serious AEs, adverse drug reactions, treatment-related AEs, treatment 
discontinuations or required dose reductions due to AEs (Table 3). While EMA EPARs or 
TGA assessments of safety could have also been used for this analysis, their 
interpretations of the data are less relevant for pricing and coverage decisions than HTA 
agency reviews. Both reviewers compared results after independent analysis and sought 
consensus if there was disagreement on how to interpret summary HTA agency 
evaluations of the impact from treatment on patient safety. Inputs from a third 
researcher were sought where consensus could not be reached.  
 
A rules-based process was used to generate a composite, qualitative rating of the 
expected impact on patient safety from treatment with each drug-indication. This 
process followed the one that was described above to assess drug-related effects on QoL. 
Specifically, if summary assessments from one HTA agency described an overall 
improvement in safety, while another found no change, the drug was classified as being 
associated with improvements in safety. If opposing interpretations of the available 
evidence existed—e.g. if one agency found an overall improvement in safety, while 
another concluded that the drug-indication worsened patient safety (i.e. an overall 
increase in toxicity)—the drug-indication was classified as being associated with mixed 
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evidence. If no difference in safety was established by any of the three agencies due to a 
lack or insufficiency of evidence, then the drug-indication was classified as having no 
established impact on safety. For more information on the parameters typically used by 
HTA agencies to assess safety, please refer to Table 3. 
 
Analysis 
Overall Survival, Quality of Life, and Safety 
Descriptive statistics were used to analyze the composite classifications of clinical 
benefits across the entire sample of recently approved cancer drugs. For more 
information on how composite classifications of clinical benefits were constructed, 
please refer to the previous section. Secondary analyses also examined the association 
between defining features of the supporting clinical trial evidence—as reported within 
HTA agency appraisals—and summary conclusions of drug-related clinical benefits. 
 
Krippendorff’s alpha coefficient (α) was used to assess interagency agreement of 
summary assessments of drug-related effects on OS, QoL and safety, and to inform the 
wider interpretation of results.(148) The α statistic was computed using the krippalpha 
package in Stata 13 (College Station, TX: StataCorp LP).(149) Composite measures of OS 
benefits were categorized as clinically significant gains of ≥3 months, marginal gains of 
<3 months, an increase in OS but of uncertain magnitude, and no increase. Composite 
measures of the impact on QoL and safety were also coded as improvement, mixed 
evidence, reduction, and no difference. Base case analyses calculated Krippendorff’s 
alpha coefficient with rank-ordered data. To nevertheless check for robustness, 
80 
 
sensitivity analyses also modeled clinical benefits as nominal variables. A brief overview 
of this statistic is provided in Box 2, along with a justification of its use in this study. 
 
Clinical Benefits from Treatment 
Finally, descriptive statistics were used to summarize composite measures of the impact 
on OS, QoL, and safety associated with all medicines that were considered in this 
analysis. Drugs were considered to be associated with at least some evidence of an 
improvement in OS if their composite classification of the impact on OS was: an increase 
of ≥3 months, <3 months, or an unquantifiable increase. Drugs were considered to be 
associated with at least some evidence of an improvement in QoL or safety if their 
composite classification of the impact on QoL or safety was: improvement in QoL or 









Surrogate measures of efficacy were not considered in this analysis. This approach was 
taken to reflect the fact that surrogate efficacy measures: are not consistently weighed 
during regulatory evaluations;(95) may be subject to assessment bias or variability from 
IRA is defined as “the extent to which different raters assign the same precise value for each item being rated.”(360) 
Several measures exist to measure IRA, including Cohen’s unweighted kappa, weighted kappa, Fleiss’ kappa, 
Krippendorff’s alpha, Kendall’s W, and intraclass correlation coefficients.(360) Which statistic is used to measure IRA 
should reflect the nature of the data that is being evaluated. Specifically, selection of an IRA measure should be based 
on the purpose of the analysis, the importance of the absolute value or trend in ratings, the type of variable that is 
being analyzed, and the number of raters involved.(360) Some may only be appropriate for use when there are 2 raters 
(k = 2; Cohen’s unweighted kappa, weighted kappa), while others can be used in analyses that include a larger number 
of raters (e.g. Fleiss’ kappa, Krippendorff’s alpha, Kendall’s W, intraclass correlation coefficients). Measurement scales 
should also factor into the selection of an IRA statistic: some indices—such as Cohen’s unweighted kappa, Fleiss’ 
kappa—should only be used when working with nominal, non-ordered data, while more flexible alternatives—
including the unweighted kappa and Krippendorff’s alpha—can also accommodate ordinal data. Kendall’s W can be 
used with ordinal data, while intraclass correlations can be used when observations exist on an interval/ratio scale.  
 
Krippendorff’s alpha has several features that make it particularly useful for this analysis. First, it is a generalization of 
several known reliability indices.(361) It can be applied to contexts that have any number of observers—useful here, as 
this analysis evaluates data from three HTA agencies—any number of categories or measures—each of the measures 
of clinical benefit includes four categories—any metric or level of measurement—including, nominal, ordinal, 
interval, ratio—settings that have incomplete or missing data—useful in this analysis since clinical effectiveness may 
not have been evaluated for each drug by all three HTA agencies—and for large and small samples. (361) 
Krippendorff’s alpha was therefore chosen to measure agreement between categorical measures of the overall survival, 
quality of life, and safety benefit assigned to each drug on the basis of English, French, and Australian HTA 
appraisals.(361)  
 
Krippendorff (2004) provides both an in-depth discussion on the logic behind Krippendorff’s alpha, as well as details 
on how to calculate the statistic—an  overview of this publication is provided below.(361) Briefly, Krippendorff’s alpha 
in general form is given as: 
 















𝑜𝑐𝑘 𝑚𝑒𝑡𝑟𝑖𝑐 represents the frequency of observed coincidences within units of analysis for values 𝑐 and 𝑘, as tabulated in 
reliability data matrices, and 𝛿𝑐𝑘
2  is a difference function (representing the squared difference between coinciding 
values) that serves to weight observed and expected coincidences and to therefore account for different metrics or 
levels of measurement.𝐷𝑒 represents the disagreement that would be expected when values are assigned to units by 










To interpret his coefficient, Krippendorff indicates that it is “customary to require α ≥ .800. Where tentative 
conclusions are still acceptable, α≥ .667 is the lowest conceivable limit”.(362) 
 
Box 2. Overview of Krippendorf's Alpha Coefficient to Measure Interrater Agreement 
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measurement of radiologic or clinical measures and assessment schedules;(96,97) should 
not be used to assess efficacy within value studies if OS is reported;(12) have been 
inconsistently associated with objective measures of clinical benefit in the literature, 
with reported associations between OS and PFS varying considerably by cancer type, and 
even within cancer types;(111) and since their predictive value in measuring clinical 
outcomes remains debated.(111) Indeed, Bognar and colleagues (2017) take this to argue 
that surrogates “imperfectly predict clinical benefits,” and therefore offer “weaker 
evidence of benefit than … ‘hard’ or final outcome evidence.”(102) Even if they did, 
surrogacy implies that these measures proxy for the efficacy measure that is considered 
in this analysis, OS. 
 
This approach was also designed to reflect guidance to healthcare professionals on the 
use of surrogate efficacy measures, ongoing clinical discussions related to their use, as 
well as guidance from ASCO on measuring the value of new cancer treatments. The FDA 
states that while surrogate markers of efficacy may be predictive of clinical benefits, they 
are “not themselves a measure of clinical benefit”.(108) For their part, Bognar and 
colleagues (2017) report growing discomfort among clinicians and payers over the impact 
from growing use of surrogate endpoints by regulators on the quality of evidence 
supporting the use of new medical technologies.(102) Moreover, ASCO’s recently 
published Value Framework for cancer treatment options recommends that efficacy 
benefits be measured through two surrogate efficacy endpoints—PFS and RRs—only if 
OS is not reported.(12) 
 
Within this backdrop, this analysis assessed clinical efficacy benefits by reviewing 
regulatory assessments of drug-related effects on OS, an unambiguous marker of clinical 
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efficacy in oncology drug trials.(64,93,94) If, however, surrogate markers of clinical 
efficacy do in fact represent unique dimensions to the clinical benefit from new 
treatments, then their absence would mean that this analysis is incomplete. Further 
studies may wish to extend this analysis to include surrogate efficacy markers, 
particularly as consensus is reached on how well they reflect objective clinical benefits to 
patients. 
 
The clinical impact of prescribed treatments may vary across cancer stages. This study 
reviewed HTA reports to assess the clinical risks and benefits from the use of new 
medicines that corresponded to the first approved indication, which often includes a 
recommended stage for use. The approved indication for new cancer medicines typically 
pertained to advanced or metastatic disease, with the exception of hematologicals 
(Appendix 2.1). Due to an insufficient sample, this study therefore did not assess whether 
there is an association between OS benefits and disease staging. Practically-speaking, 
real-world clinical practice may also employ new therapies outside of their 
recommended indication. In the absence of internationally comparable data on actual, 
patient-level drug consumption,(75) this study is unable to explore the impact from 
preferences and timing for treatment across cancer stages. Future studies should 
nevertheless leverage real-world data to evaluate whether and to what extent value 
assessments are affected by disease staging. 
 
This analysis examines the clinical risks and benefits associated with new cancer 
medicines by reviewing HTA agency appraisal summaries of the scientific evidence. To 
provide an estimate of the clinical impact that would be expected in practice, HTA 
agencies synthesize and evaluate the published and unpublished clinical trial evidence 
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and report their conclusions in appraisals. Still, trial-based summary assessments of 
clinical impact do not always translate to the real-world, and may not adequately reflect 
the clinical risks and benefits to individual patients. To more precisely measure the 
clinical risks and benefits from treatment, future studies should extend this analysis by 
also incorporating post-marketing studies,(150) or using observational data or pragmatic 
clinical trial evidence, as it becomes available. Future academic initiatives may be able to 
leverage data from the National Cancer Institute’s upcoming National Cancer Knowledge 
System—a component of the US Precision Medicine Initiative® that will integrate 
genomic information with clinical response data and outcomes information—to assess 
the real-world clinical impact from newly developed cancer drugs. Such analyses may 
help further inform value-based decision-making on cancer drug use, coverage, pricing, 
and reimbursement. 
 
On this point, there is no known large-scale, international, patient-level registry on 
cancer treatment and outcomes occurring prior to and following entry of new cancer 
medicines. In its absence, this study undertook a systematic process to review regulatory 
assessments and to examine the impact on therapy that would be expected from recent 
cancer drug innovations. Results from clinical trials may go unpublished, and primary 
clinical trial data is often not available for secondary analysis. HTA agencies, in contrast, 
may have the authority to require submission of all applicable clinical data, published 
and unpublished,(151) in theory minimizing the level of bias in their assessment. By 
drawing on these, and in the absence of observational data, this synthesis reflects the 





Finally, this study focused on the first FDA- or EMA-approved anticancer indication for 
NMEs. Following initial approval, medicines may receive licensing extensions for other 
indications. This thesis did not consider the survival benefits associated with secondary 
indications. This approach was consistent with the available literature: the benefits 
associated with these indications may be unknown to manufacturers at the time of 
market launch, and are therefore unknown to regulators and HTA authorities, making 
them difficult to incorporate into intial pricing decisions.(73) This however does not bias 
the analyses that are carried out in this thesis, since it focuses on drug-indications 
pertaining to initial approvals. Future studies should however incorporate clinical and 




A total of 62 new active molecules were approved by the FDA or EMA between 2003-2013 
with a primary anticancer indication. Molecule descriptors for each of these medicines—
including name of active ingredient, FDA/EMA licensure status, primary FDA or EMA 
indication, date of initial approval, ATC code, orphan status, and clinical target—are 
provided in Table 4.  
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Table 4. Sample of Cancer Medicines 
Active Ingredient Licensure FDA or EMA Primary Indication1 
Initial 
Approval2 
ATC Code Orphan Status Target Organ 
abiraterone acetate FDA / EMA 
A CYP17 inhibitor indicated for use in combination with prednisone for the 
treatment of patients with metastatic castration-resistant prostate cancer 
who have received prior chemotherapy containing docetaxel. 
Apr-11 L02BX03 - Prostate 
afatinib FDA / EMA 
A kinase inhibitor indicated for the first-line treatment of patients with 
metastatic non-small cell lung cancer (NSCLC) whose tumors have 
epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 
(L858R) substitution mutations as detected by an FDA-approved test. 




An asparagine specific enzyme indicated as a component of a multi-agent 
chemotherapeutic regimen for the treatment of patients with acute 
lymphoblastic leukemia (ALL) who have developed hypersensitivity to E. 
coli-derived asparaginase. 
Apr-11 L01XX02 EU Hemat. 
axitinib FDA / EMA 
A kinase inhibitor indicated for the treatment of advanced renal cell 
carcinoma after failure of one prior systemic therapy. 
Jan-12 L01XE17 EU (w) Renal 
azacitidine 
FDA / EMA 
 
Indicated for treatment of patients with the following myelodysplastic 
syndrome subtypes: refractory anemia or refractory anemia with ringed 
sideroblasts (if accompanied by neutropenia or thrombocytopenia or 
requiring transfusions), refractory anemia with excess blasts, refractory 
anemia with excess blasts in transformation, and chronic myelomonocytic 
leukemia. 
May-04 L01BC07 US / EU Hemat. 
bendamustine FDA / EMA 
An alkylating drug indicated for the treatment of patients with chronic 
lymphocytic leukemia (CLL). Efficacy relative to first line therapies other 
than chlorambucil has not been established. 
Oct-08 L01AA09 US Hemat. 
bevacizumab FDA / EMA 
In combination with intravenous 5-fluorouracil–based chemotherapy, 
indicated for first- line treatment of patients with metastatic carcinoma of 
the colon or rectum. 
Feb-04 L01XC07 - GI 
bortezomib FDA / EMA 
Indicated for the treatment of multiple myeloma patients who have 
received at least two prior therapies and have demonstrated disease 
progression on the last therapy. The effectiveness of VELCADE is based on 
response rates (see CLINICAL STUDIES section). There are no controlled 
trials demonstrating a clinical benefit, such as an improvement in survival. 
May-03 L01XX32 US Hemat. 
bosutinib FDA / EMA 
A kinase inhibitor indicated for the treatment of adult patients with 
chronic, accelerated, or blast phase Ph+ chronic myelogenous leukemia 
(CML) with resistance or intolerance to prior therapy. 
Sep-12 L01XE14 US / EU Hemat. 
brentuximab vedotin FDA / EMA 
A CD30-directed antibody-drug conjugate indicated for: a) The treatment of 
patients with Hodgkin lymphoma after failure of autologous stem cell 
transplant (ASCT) or after failure of at least two prior multi-agent 
chemotherapy regimens in patients who are not ASCT candidates. b) The 
Aug-11 L01XC12 US / EU Hemat. 
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treatment of patients with systemic anaplastic large cell lymphoma after 
failure of at least one prior multi-agent chemotherapy regimen. These 
indications are based on response rate.  
cabazitaxel FDA / EMA 
A microtubule inhibitor indicated in combination with prednisone for 
treatment of patients with hormone-refractory metastatic prostate cancer 
previously treated with a docetaxel-containing treatment regimen. 
Jun-10 L01CD04 - Prostate 
cabozantinib FDA / EMA 
A kinase inhibitor indicated for the treatment of patients with progressive, 
metastatic medullary thyroid cancer (MTC). 
Nov-12 L01XE26 US Thyroid 
carfilzomib FDA / EMA 
A proteasome inhibitor indicated for the treatment of patients with 
multiple myeloma who have received at least two prior therapies including 
bortezomib and an immunomodulatory agent and have demonstrated 
disease progression on or within 60 days of completion of the last therapy. 
Approval is based on response rate.  
Jul-12 L01XX45 US / EU Hemat. 
catumaxomab EMA 
Indicated for the intraperitoneal treatment of malignant ascites in adults 
with EpCAM-positive carcinomas where standard therapy is not available or 
no longer feasible. 
Apr-09 L01XC09 US / EU Ascites 
cetuximab FDA / EMA 
Used in combination with irinotecan for the treatment of EGFR-expressing, 
metastatic colorectal carcinoma in patients who are refractory to 
irinotecan-based chemotherapy. // cetuximab administered as a single 
agent is indicated for the treatment of EGFR-expressing, metastatic 
colorectal carcinoma in patients who are intolerant to irinotecan-based 
chemotherapy.  
Feb-04 L01XC06 - GI 
clofarabine FDA / EMA 
Treatment of pediatric patients 1 to 21 years old with relapsed or refractory 
acute lymphoblastic leukemia after at least two prior regimens. This use is 
based on the induction of complete responses. Randomized trials 
demonstrating increased survival or other clinical benefit have not been 
conducted. 
Dec-04 L01BB06 US / EU Hemat. 
crizotinib FDA / EMA 
A kinase inhibitor indicated for the treatment of patients with locally 
advanced or metastatic non-small cell lung cancer (NSCLC) that is 
anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-
approved test. This indication is based on response rate.  
Aug-11 L01XE16 - Lung 
dabrafenib FDA / EMA 
A kinase inhibitor indicated for the treatment of patients with unresectable 
or metastatic melanoma with BRAF V600E mutation as detected by an 
FDA-approved test. 
May-13 L01XE23 - Skin 
dasatinib FDA / EMA 
Indicated for the treatment of adults with chronic, accelerated, or myeloid 
or lymphoid blast phase chronic myeloid leukemia with resistance or 
intolerance to prior therapy including imatinib. // dasatinib is also 
indicated for the treatment of adults with Philadelphia chromosome-
positive acute lymphoblastic leukemia with resistance or intolerance to 
prior therapy. 
Jun-06 L01XE06 US / EU Hemat. 
decitabine FDA / EMA 
Indicated for treatment of patients with myelodysplastic syndromes (MDS) 
including previously treated and untreated, de novo and secondary MDS of 
May-06 L01BC08 US / EU Hemat. 
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all French-American-British subtypes (refractory anemia, refractory anemia 
with ringed sideroblasts, refractory anemia with excess blasts, refractory 
anemia with excess blasts in transformation, and chronic myelomonocytic 
leukemia) and intermediate-1, intermediate-2, and high-risk International 
Prognostic Scoring System groups. 
degarelix FDA / EMA 
A GnRH receptor antagonist indicated for treatment of patients with 
advanced prostate cancer. 
Dec-08 L02BX02 - Prostate 
enzalutamide FDA / EMA 
An androgen receptor inhibitor indicated for the treatment of patients with 
metastatic castration-resistant prostate cancer who have previously received 
docetaxel. 
Aug-12 L02BB04 - Prostate 
eribulin FDA / EMA 
A microtubule inhibitor indicated for the treatment of patients with 
metastatic breast cancer who have previously received at least two 
chemotherapeutic regimens for the treatment of metastatic disease. Prior 
therapy should have included an anthracycline and a taxane in either the 
adjuvant or metastatic setting. 
Nov-10 L01XX41 - Breast 
erlotinib FDA / EMA 
Indicated for the treatment of patients with locally advanced or metastatic 
non-small cell lung cancer after failure of at least one prior chemotherapy 
regimen. 
Nov-04 L01XE03 - Lung 
everolimus FDA / EMA 
A kinase inhibitor indicated for the treatment of patients with advanced 
renal cell carcinoma after failure of treatment with sunitinib or sorafenib. 
Mar-09 L01XE10 EU (w) Renal 
gefitinib FDA / EMA 
Indicated for the treatment of adult patients with locally advanced or 
metastatic non-small cell lung cancer (NSCLC) with activating mutation of 
EGFR-TK. 
May-03 L01XE02 - Lung 
ibrutinib FDA / EMA 
A kinase inhibitor indicated for the treatment of patients with mantle cell 
lymphoma (MCL) who have received at least one prior therapy. This 
indication is based on overall response rate.  
Nov-13 L01XE27 US / EU Hemat. 
ipilimumab FDA / EMA 
A human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody 
indicated for the treatment of unresectable or metastatic melanoma. 
Mar-11 L01XC11 - Skin 
ixabepilone FDA 
A microtubule inhibitor, in combination with capecitabine is indicated for 
the treatment of metastatic or locally advanced breast cancer in patients 
after failure of an anthracycline and a taxane. // ixabepilone as 
monotherapy is indicated for the treatment of metastatic or locally 
advanced breast cancer in patients after failure of an anthracycline, a 
taxane, and capecitabine. 
Oct-07 L01DC04 - Breast 
lapatinib FDA / EMA 
A kinase inhibitor, indicated in combination with capecitabine, for the 
treatment of patients with advanced or metastatic breast cancer whose 
tumors overexpress HER2 and who have received prior therapy including an 
anthracycline, a taxane, and trastuzumab. 
Mar-07 L01XE07 - Breast 
lenalidomide FDA / EMA 
Indicated for the treatment of patients with transfusion-dependent anemia 
due to Low- or Intermediate-1-risk myelodysplastic syndromes associated 
with a deletion 5q cytogenetic abnormality with or without additional 
cytogenetic abnormalities. 
Dec-05 L04AX04 US / EU Hemat. 
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nelarabine FDA / EMA 
Indicated for the treatment of patients with T-cell acute lymphoblastic 
leukemia and T-cell lymphoblastic lymphoma whose disease has not 
responded to or has relapsed following treatment with at least two 
chemotherapy regimens. This use is based on the induction of complete 
responses. Randomized trials demonstrating increased survival or other 
clinical benefit have not been conducted. 
Oct-05 L01BB07 US / EU Hemat. 
nilotinib FDA / EMA 
A kinase inhibitor indicated for the treatment of chronic phase and 
accelerated phase Philadelphia chromosome positive chronic myelogenous 
leukemia (CML) in adult patients resistant to or intolerant to prior therapy 
that included imatinib. 
Oct-07 L01XE08 US / EU Hemat. 
obinutuzumab FDA / EMA 
A CD20-directed cytolytic antibody and is indicated, in combination with 
chlorambucil, for the treatment of patients with previously untreated 
chronic lymphocytic leukemia. 
Nov-13 L01XC15 US / EU Hemat. 
ofatumumab FDA / EMA 
A CD20-directed cytolytic monoclonal antibody indicated for the treatment 
of patients with chronic lymphocytic leukemia (CLL) refractory to 
fludarabine and alemtuzumab. The effectiveness of ofatumumab is based on 
the demonstration of durable objective responses.  
Oct-09 L01XC10 US / EU Hemat. 
omacetaxine 
mepesuccinate 
FDA / EMA 
Indicated for the treatment of adult patients with chronic or accelerated 
phase chronic myeloid leukemia (CML) with resistance and/or intolerance 
to two or more tyrosine kinase inhibitors (TKI). This indication is based 
upon response rate.  
Oct-12 L01XX40 US Hemat. 
panitumumab FDA / EMA 
Indicated for the treatment of EGFR-expressing, metastatic colorectal 
carcinoma with disease progression on or following fluoropyrimidine-, 
oxaliplatin-, and irinotecan-containing chemotherapy regimens.  
Sep-06 L01XC08 - GI 
pazopanib FDA / EMA 
A kinase inhibitor indicated for the treatment of patients with advanced 
renal cell carcinoma. 
Oct-09 L01XE11 EU (w) Renal 
pemetrexed FDA / EMA 
In combination with cisplatin is indicated for the treatment of patients with 
malignant pleural mesothelioma whose disease is either unresectable or 
who are otherwise not candidates for curative surgery. 
Feb-04 L01BA04 US / EU (w) Lung 
pertuzumab FDA / EMA 
A HER2/neu receptor antagonist indicated in combination with 
trastuzumab and docetaxel for the treatment of patients with HER2-positive 
metastatic breast cancer who have not received prior anti-HER2 therapy or 
chemotherapy for metastatic disease. 
Jun-12 L01XC13 - Breast 
pomalidomide FDA / EMA 
A thalidomide analogue indicated for patients with multiple myeloma who 
have received at least two prior therapies including lenalidomide and 
bortezomib and have demonstrated disease progression on or within 60 
days of completion of the last therapy. Approval is based on response rate.  
Feb-13 L04AX06 US / EU Hemat. 
ponatinib FDA / EMA 
A kinase inhibitor indicated for the treatment of adult patients with chronic 
phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) 
that is resistant or intolerant to prior tyrosine kinase inhibitor therapy or 
Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) 
Dec-12 L01XE24 EU Hemat. 
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that is resistant or intolerant to prior tyrosine kinase inhibitor therapy. This 
indication is based upon response rate.  
pralatrexate FDA / EMA 
A folate analogue metabolic inhibitor indicated for the treatment of 
patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). 
This indication is based on overall response rate.  
Sep-09 L01BA05 EU Hemat. 
radium Ra 223 
dichloride 
FDA / EMA 
An alpha particle-emitting radioactive therapeutic agent indicated for the 
treatment of patients with castration-resistant prostate cancer, 
symptomatic bone metastases and no known visceral metastatic disease. 
May-13 V10XX03 - Prostate 
regorafenib FDA / EMA 
A kinase inhibitor indicated for the treatment of patients with metastatic 
colorectal cancer (CRC) who have been previously treated with 
fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-
VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy. 
Sep-12 L01XE21 - GI 
romidepsin FDA / EMA 
A histone deacetylase (HDAC) inhibitor indicated for: Treatment of 
cutaneous T-cell lymphoma (CTCL) in patients who have received at least 
one prior systemic therapy. 
Nov-09 L01XX39 US / EU Hemat. 
ruxolitinib FDA / EMA 
A kinase inhibitor indicated for treatment of patients with intermediate or 
high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia 
vera myelofibrosis and post-essential thrombocythemia myelofibrosis. 
Nov-11 L01XE18 US / EU (w) Hemat. 
sipuleucel-T FDA / EMA 
An autologous cellular immunotherapy indicated for the treatment of 
asymptomatic or minimally symptomatic metastatic castrate resistant 
(hormone refractory) prostate cancer. 
Apr-10 L03AX17 - Prostate 
sorafenib FDA / EMA Indicated for the treatment of patients with advanced renal cell carcinoma. Dec-05 L01XE05 US / EU Renal 
sunitinib FDA / EMA 
Indicated for the treatment of gastrointestinal stromal tumor after disease 
progression on or intolerance to imatinib mesylate. // sunitinib is indicated 
for the treatment of advanced renal cell carcinoma. Approval for advanced 
renal cell carcinoma is based on partial response rates and duration of 
responses. There are no randomized trials of sunitinib demonstrating 
clinical benefit such as increased survival or improvement in disease-related 
symptoms in renal cell carcinoma. 
Jan-06 L01XE04 EU Renal 
tegafur / gimeracil / 
oteracil 
EMA 
Indicated in adults for the treatment of advanced gastric cancer when given 
in combination with cisplatin. 
Mar-11 L01BC53 EU (w) GI 
temsirolimus FDA / EMA 
A kinase inhibitor indicated for the treatment of advanced renal cell 
carcinoma. 
May-07 L01XE09 US / EU Renal 
tositumomab FDA / EMA 
Indicated for the treatment of patients with CD20 positive, follicular, non-
Hodgkin's lymphoma, with and without transformation, whose disease is 
refractory to Rituximab and has relapsed following chemotherapy. 
Jun-03 V10XA53 US / EU (w) Hemat. 
trabectedin EMA 
Indicated for the treatment of adult patients with advanced soft tissue 
sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited 
to receive these agents. 
Sept-07 L01CX01 - Soft Tissue 
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trametinib FDA / EMA 
A kinase inhibitor indicated for the treatment of patients with unresectable 
or metastatic melanoma with BRAF V600E or V600K mutations as detected 
by an FDA-approved test. 
May-13 L01XE25 - Skin 
trastuzumab emtansine FDA / EMA 
HER2-targeted antibody and microtubule inhibitor conjugate indicated, as 
a single agent, for the treatment of patients with HER2-positive, metastatic 
breast cancer who previously received trastuzumab and a taxane, separately 
or in combination. Patients should have either: a) Received prior therapy 
for metastatic disease, or b) Developed disease recurrence during or within 
six months of completing adjuvant therapy. 
Feb-13 L01XC14 - Breast 
vandetanib FDA / EMA 
A kinase inhibitor indicated for the treatment of symptomatic or 
progressive medullary thyroid cancer in patients with unresectable locally 
advanced or metastatic disease. 
Apr-11 L01XE12 US / EU (w) Thyroid 
vemurafenib FDA / EMA 
A kinase inhibitor indicated for the treatment of patients with unresectable 
or metastatic melanoma with BRAFV600E mutation as detected by an FDA-
approved test. 
Aug-11 L01XE15 - Skin 
vinflunine EMA 
Indicated in monotherapy for the treatment of adult patients with advanced 
or metastatic transitional cell carcinoma of the urothelial tract after failure 
of a prior platinum-containing regimen. 
Sept-09 L01CA05 - Bladder 
vismodegib FDA / EMA 
A hedgehog pathway inhibitor indicated for the treatment of adults with 
metastatic basal cell carcinoma, or with locally advanced basal cell 
carcinoma that has recurred following surgery or who are not candidates for 
surgery, and who are not candidates for radiation. 
Jan-12 L01XX43 - Skin 
vorinostat FDA / EMA 
A histone deacetylase (HDAC) inhibitor indicated for: treatment of 
cutaneous manifestations in patients with cutaneous T- cell lymphoma 
(CTCL) who have progressive, persistent or recurrent disease on or 
following two systemic therapies. 
Oct-06 L01XX38 US Hemat. 
ziv-aflibercept FDA / EMA 
In combination with 5-fluorouracil, leucovorin, irinotecan- (FOLFIRI), 
indicated for patients with metastatic colorectal cancer (mCRC) that is 
resistant to or has progressed following an oxaliplatin-containing regimen. 
Aug-12 L01XX44 - GI 
 
Source:  
Authors’ analysis of data, as described in Methods section. 
Notes: 
 
1 EMA indication given if FDA had not issued marketing license through end of study period. 





The number of new cancer molecules receiving licensure per year in the US slowed 
between 2006-2009, but has more recently increased (Table 4). Of the 62 initial FDA or 
EMA approvals with a primary anticancer indication, the largest share (n = 24, 39%) were 
indicated for treatment of hematological malignancies. Representation across the 
remaining indications was fairly evenly distributed: 1 of the 62 new cancer molecules 
(2%) was indicated to treat malignant ascites; 1 (2%) was indicated to treat bladder 
cancer; 5 (8%) for breast cancer; 6 (10%) for gastrointestinal cancer; 1 (2%) for both 
gastro-intestinal and renal cancers (two primary anticancer indications); 5 (8%) for lung 
cancer; 6 (10%) for prostate cancer; 5 (8%) for renal cancer; 5 (8%) for skin cancer; 1 (2%) 
for soft tissue sarcomas; and 2 (3%) for thyroid cancer. There were no initial drug 
approvals for a variety of other cancer types, including cervical, bladder, and nervous 
system cancer.  
 
Of the 62 new active cancer medicines approved by the FDA or EMA between 2003-2013, 
35 (56%) have an active or withdrawn orphan designation. The proportion of newly 
licensed cancer medicines receiving orphan designation has remained fairly stable over 
time (Table 4). A majority of orphan medicines (24/35, or 69%) were indicated for 
hematological malignancies. A far smaller proportion were indicated for renal cancer 
(6/35, or 17%), thyroid cancer (2/35, or 6%), ascites (1/35, or 3%), GI cancer (1/35, or 3%), 
and lung cancer (1/35, or 3%). Of the 58 new active cancer molecules approved by the 
FDA between 2003-2013, 17 were approved under the Accelerated Approvals program. 
 
4 of the 62 molecules were approved by the EMA but not the FDA through May 2015. Of 
the 62 drugs, 52 (85%) were assessed for OS by at least 1 of the 3 HTA agencies that were 
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considered in this study, Australia’s PBAC, France’s HAS, or England’s NICE. The 
remaining 9 molecules may have had evaluations published after May 2015; may not have 
been reviewed by HTA agencies if considered low-priority therapies;(152) or may have 
been rejected by European (EMA) or national licensing authorities. Of the 53 drugs that 
were therefore included in this study, 35 were assessed by all 3 agencies, 7 were assessed 
by 2, and 11 were assessed by 1 HTA agency. In most cases HTA agency assessments were 
based on the same set of comparators (Appendix 2.1). 
 
Clinical Benefits 







Table 5. Therapeutic Profile of All Cancer Medicines Approved by the FDA or EMA between 2003-2013 for a Primary Anti-cancer Indication 
Active ingredient 







QoL effect Safety effect 
Ascites 
catumaxomab Ascites (EMA) Dec-09 paracentesis NE NE NE 
Bladder 
vinflunine 







trastuzumab emtansine Breast cancer Mar-14–Nov-14 lapatinib + capecitabine ≥ 3 (5.8) Improvement Mixed evidence 
eribulin Breast cancer Jul-11–Nov-13 TPC < 3 (2.5–2.7) NE Reduction 
ixabepilone Breast cancer n/a n/a n/a n/a n/a 
lapatinib Breast cancer Nov-07–May-10 capecitabine monotherapy < 3 (0.3–2.4) NE Reduction 
pertuzumab Breast cancer Jul-13–Mar-14 trastuzumab + docetaxel ≥ 3 (15.7) Improvement Reduction 
Gastro-intestinal 
bevacizumab Colorectal carcinoma Jun-05–Jul-08 IFL/5-FU/LV ≥ 3 (3.0–4.7) NE Reduction 




panitumumab Colorectal carcinoma Apr-08–Nov-13 BSC/cetuximab (safety) ≥ 3 (2.7–3.2) NE NE 
regorafenib Colorectal cancer May-14–Jul-14 placebo < 3 (1.4) NE Reduction 
tegafur/gimeracil/oteracil Gastric cancer (EMA) Oct-12–Mar-13 5-FU/cisplatin NE NE NE 
ziv-aflibercept Colorectal cancer Jul-13–Mar-14 placebo < 3 (1.4) Improvement Reduction 
Gastro-intestinal/Renal 
sunitinib 
Gastrointestinal stromal tumor / 










Acute lymphoblastic leukemia n/a n/a n/a n/a n/a 
azacitidine Myelodysplastic syndromes Jul-09–Mar-11 conventional care ≥ 3 (9.4–9.6) Improvement Reduction 
bendamustine Lymphocytic leukemia Oct-10–Feb-11 chlorambucil NE Reduction Reduction 
bortezomib Multiple myeloma Oct-04–Oct-07 high-dose dexamethasone ≥ 3 (6.1–11.5) Improvement Mixed evidence 
bosutinib Chronic myelogenous leukemia Nov-13–Feb-14 BSC 











NE Mixed evidence 
carfilzomib Multiple myeloma n/a n/a n/a n/a n/a 
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clofarabine Acute lymphoblastic leukemia Dec-06 non-comparative NE NE NE 
dasatinib 
Chronic myeloid leukemia // Acute 
lymphoblastic leukemia 
Mar-07–Jan-12 non-comparative NE NE Mixed evidence 
decitabine Myelodysplastic syndromes n/a n/a n/a n/a n/a 
ibrutinib Mantle cell lymphoma n/a n/a n/a n/a n/a 
lenalidomide 
Transfusion-dependent anemia due 






Acute lymphoblastic leukemia / 
Lymphoblastic lymphoma 
Dec-07 non-comparative NE NE NE 
nilotinib Chronic myelogenous leukemia Feb-08–Jan-12 non-comparative NE NE Improvement 
obinutuzumab Chronic lymphocytic leukemia Jul-14–Mar-15 chlorambucil 
Exact magnitude 
uncertain 
Mixed evidence Mixed evidence 
ofatumumab Chronic lymphocytic leukemia Oct-10–Nov-14 chlorambucil NE NE NE 
omacetaxine 
mepesuccinate 
Chronic myeloid leukemia n/a n/a n/a n/a n/a 
pomalidomide Multiple myeloma Jan-14–Mar-15 
standard care / high-dose 
dexamethasone (safety) 




Chronic myeloid leukemia / Acute 
lymphoblastic leukemia 
Nov-14–Jan-15 dasatinib/nilotinib NE NE Reduction 
pralatrexate Peripheral lymphoma n/a n/a n/a n/a n/a 
romidepsin Cutaneous lymphoma n/a n/a n/a n/a n/a 




tositumomab Non-Hodgkin’s lymphoma n/a n/a n/a n/a n/a 
vorinostat Cutaneous lymphoma Mar-11 BSC NE NE Mixed evidence 
Lung 
afatinib Non-small cell lung cancer Jul-13–Apr-14 erlotinib/gefitinib NE Improvement Reduction 
crizotinib Non-small cell lung cancer Sep-13–Nov-14 pemetrexed ≥ 3 (3.1–3.5) Improvement NE 
erlotinib Non-small cell lung cancer Mar-06–Nov-08 placebo/BSC < 3 (2.0) Improvement Mixed evidence 
gefitinib Non-small cell lung cancer Nov-09–Jul-13 paclitaxel + carboplatin NE Improvement Improvement 
pemetrexed Pleural mesothelioma Mar-05–Jan-08 cisplatin ≥ 3 (2.8–3.3) Improvement Reduction 
Prostate 
abiraterone acetate Prostate cancer Feb-12–Jul-12 BSC (prednisolone) ≥ 3 (3.9–4.6) Improvement Improvement 
cabazitaxel Prostate cancer Nov-11–Oct-12 mitoxantrone ≥ 3 (2.4–4.2) NE Reduction 
degarelix Prostate cancer Sep-09–Apr-14 
leuproprelin + LHRH 
agonists 
NE NE Reduction 
enzalutamide Prostate cancer Nov-13–Jul-14 placebo ≥ 3 (4.5–4.8) Improvement Mixed evidence 
radium-223 dichloride Prostate cancer Apr-14 placebo < 3 (2.8) NE NE 




axitinib Renal cell carcinoma Jan-13–Feb-15 BSC 
≥ 3 (exact gain 
uncertain) 
NE Mixed evidence 
everolimus Renal cell carcinoma Nov-09–Apr-11 BSC ≥ 3 (5.2) Improvement Reduction 
pazopanib Advanced renal cell carcinoma Feb-11–Jun-13 BSC/interferon-alfa 
≥ 3 (exact gain 
uncertain) 
NE Mixed evidence 
sorafenib Renal cell carcinoma Sep-06–Aug-09 BSC 
≥ 3 (exact gain 
uncertain) 
Improvement Reduction 
temsirolimus Renal cell carcinoma Feb-08–Aug-09 interferon-alfa ≥ 3 (3.6) Improvement Improvement 
Skin 






ipilimumab Melanoma Nov-12–Nov-14 dacarbazine ≥ 3 (5.7) NE Reduction 




vemurafenib Melanoma Oct-12–Mar-13 dacarbazine ≥ 3 (3.3–3.9) Improvement Reduction 
vismodegib Basal cell carcinoma Dec-13 non-comparative NE NE NE 
Soft tissue 
trabectedin Soft tissue sarcoma (EMA) Apr-08–Feb-10 BSC 




cabozantinib Medullary thyroid cancer Dec-14 placebo NE NE Reduction 
vandetanib Medullary thyroid cancer Jun-12 placebo NE NE NE 
 
Source:  
Authors’ analysis of data, as described in Methods section. 
Notes: 
 
1 Change in OS, QoL, and safety is given as a composite score of the therapeutic improvement from each new drug relative to therapeutic comparators. 
n/a = no appraisal available from Australian (PBAC), French (HAS), or English HTA agencies through May 2015. 
NE = none established 
2 EMA indication used in instances where FDA approval was not available. 
3 OS benefits are classified as a categorical variable. Where multiple evaluations were available across Australian (PBAC), French (HAS), and English (NICE) HTA agencies, a range (in parentheses) 




23 of the 53 drugs that were analyzed in this study (43%) were confirmed by at least one 
HTA agency to increase OS by at least three months. HTA agencies were however unable 
to quantify an exact magnitude of increase for 6 of these 23 medicines. 6 of the 53 drugs 
(11%) increased OS by less than 3 months, and 8 (15%) produced an increase in OS of 
unknown magnitude. The remaining 16 (30%) cancer medicines did not demonstrate an 
increase in OS over alternative treatments, either because no difference was found or 
because a determination was not or could not be made by HTA agencies on the basis of 
the available evidence (Table 5). There was no clear association between expected OS 
benefits from treatment and disease stage.  
 
Total increases in OS over the last decade were examined by mapping new interventions 
against the treatment comparators that would be replaced, as identified in HTA 
assessments (Figure 5). In all cases where comparative differences in OS could be 
quantified, the average OS benefit from all new cancer medicines was 3.43 ± 0.63 months 
(0.29 ± 0.05 years) relative to 2003 treatment standards.  
 
These benefits, however, varied significantly across and within treatment indications: 
drugs indicated for thyroid cancers produced an average (SEM) increment of 0 (0) 
months in OS; ascites, 0 (0) months; lung cancers, 2.09 (0.75) months; hematological 
cancers, 2.61 (1.69) months; gastrointestinal cancers, 2.90 (1.12) months; prostate cancers, 
3.17 (0.69) months; skin cancers, 4.65 (1.05) months; renal cancers, 6.27 (1.92) months; 








Authors’ analysis of data, as described in Methods section. 
Notes: 
1
 Pemetrexeda represents use for a nonprimary indication—it is therefore considered independently of the pemetrexed indication that is evaluated in this study.  
2
 Development of new cancer medicines (2003-2013), mapped according to therapeutic comparator used by health technology appraisal agencies in appraisal 
documents to assess therapeutic value. “First generation” drugs are the set of comparators not approved between 2003 and 2013, whereas “third generation” 
drugs are those that were evaluated against medications that were newly licensed in the study period (“second generation”).  
3
 Survival benefits associated with parallel treatment pathways (afatinib-erlotinib/gefitinib; ponatinib-nilotinib/dasatinib) are considered independently of each 
other, as are those associated with multiple primary indications (sunitinib). The gain in overall survival (OS) relative to initial standards of care, for all drugs 
where marginal increases in OS could be quantified, is provided with the use of bars that represent the number of months gained (rounded to nearest integer). 
If a range of values corresponding to OS benefits were available across health technology appraisal agencies, an average was taken. Uncertain increase in OS is 
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For the drugs that were evaluated by all three HTA agencies, England’s HTA agency was 
most likely to attribute significant OS improvements to new medicines (Figure 6). This 
contrasted with Australia’s HTA agency, which appeared to be more cautious in its 
acceptance of significant OS-related benefits (Figure 6). HTA agencies may rely on 
different sources of evidence, including RCTs, extension trials, RWE, and indirect 
comparisons, to assess the clinical impact from treatment. For a detailed description of 
the evidence used by HTA agencies to inform these assessments, please refer to 
Appendix 2.1. Future studies should thoroughly compare and contrast the evidence used 
by the three HTA agencies to inform clinical impact assessments, and how assessments 












































NICE HAS PBAC NICE HAS PBAC NICE HAS PBAC















Number of Jointly Evaluated Cancer Drugs Assigned Different Levels of Clinical 
Benefit, by HTA Agency
≥ 3 months < 3 months Increase, Mag Uncertain No Increase Improvement Mixed Evidence Reduction No Difference
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Across all available drug-specific assessments of OS, Krippendorff’s alpha (α) equaled 
0.38, suggesting a low- to moderate-level of agreement in assessments of OS benefits 
among all 3 HTA agencies (Table 6). Interagency agreement was however higher when 
English evaluations (α=0.62) and drugs that produced large improvement in OS (α=0.63) 
were excluded. This may suggest that regulators take different approaches to the 
evaluation of new cancer medicines, and that regulators become increasingly uncertain 




Table 6. Interagency Agreement – Krippendorff’s Alpha Coefficients 
Rater 
OS QoL Safety 
Entire 
Sample 














0.380235 0.632742 0.608365 0 0.230789 -0.143208 
NICE + 
HAS 
0.316244 0.525054 0.608365 0 0.592507 0.127778 
NICE + 
PBAC 
0.233290 0.775789 0.055263 - -0.033927 -0.439335 
HAS + 
PBAC 





0.354930 0.475309 0.535817 0 0.285894 0.126514 
NICE + 
HAS 
0.319274 0.412811 0.549839 0 0.508850 0.396648 
NICE + 
PBAC 
0.343593 0.618462 0.027027 - 0.205556 0.080808 
HAS + 
PBAC 
0.403390 0.354115 0.547619 1 0.174041 0.080808 
Units 186 117 186 117 186 147 
 
Source:  
Authors’ analysis of data, as described in Methods section. 
 Notes:  
1 Krippendorff’s alpha coefficients were used to measure interagency agreement on the level of clinical benefit assessed 
by each agency. Krippendorff’s alpha coefficients were measured for different agency pairings (left) and for either the 
entire sample (“Entire Sample”) or for drugs that were not associated with an increase in OS of greater than or equal to 
3 months (“!= ≥ 3 months”) or with an improvement in QoL or safety (“!= Improvement”). Given the inherent order in 
the clinical benefit classifications used (OS: ≥3 months, <3 months, increase but magnitude uncertain, no increase; 
QoL, safety: improvement, mixed evidence, reduction, no difference), base case Krippendorff's alpha coefficient were 
calculated by modeling clinical benefit data as an ordinal variable (top). To test for robustness, sensitivity analyses 
modelled the data as a nominal variable (bottom). 
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Indeed, this points to the question of whether trial-based HTA assessments may 
translate to real-world clinical practice. HTA agency conclusions for 10 of the 23 drugs 
that were deemed to increase OS by ≥3 months (axitinib, bosutinib, crizotinib, 
everolimus, panitumumab, pazopanib, pomalidomide, sorafenib, sunitinib and 
trabectedin) were based on modeled data, indirect comparisons, or agency opinions. 
Axitinib, for example, was classified as increasing OS by ≥3 months relative to BSC based 
on an evaluation from NICE, which concluded that a gain of >3 months was “likely”. The 
agency’s conclusion however was based on indirect and simulated treatment 
comparisons, and it did not provide an exact magnitude of increase.  
 
Furthermore, for 5 of the 23 drugs (axitinib, crizotinib, enzalutamide, panitumumab and 
pazopanib), significant OS benefits were found relative to one treatment comparator, 
but were not established in relation to other possible comparators. England’s NICE, for 
instance, determined that bevacizumab was associated with a 4.7-month increase in 
median OS compared to IFL (irinotecan, bolus 5-FU and leucovorin), but no significant 
difference in OS compared to 5-FU/LV. Elsewhere, 5 of the 53 drugs that were assessed 
for OS (clofarabine, dasatinib, nelarabine, nilotinib, vismodegib) were based exclusively 
on non-comparative trials that could not estimate gains in OS, making it difficult to 
quantify their impact on therapy.  
 
Quality of Life 
Of the 53 drugs that were evaluated by at least one HTA agency, 22 (42%) improved QoL, 
2 (4%) reduced QoL, 1 (2%) was associated with mixed evidence, and 28 (53%) did not 
demonstrate a difference in QoL relative to best alternative treatments (Table 5). For 
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more information on the quality of life parameters that were evaluated by HTA agencies 
to summarize the clinical impact from treatment, and which are therefore reflected in 
this chapter, please refer to Table 3. 
 
As for OS, England’s HTA agency was most likely to find an improvement in QoL from 
new cancer medicines. Across the entire sample, there was a moderate to high level of 
agreement among HTA agencies in the assessed level of QoL benefit from new cancer 
drugs (α=0.61)(Table 6). This suggests that HTA agencies tend to similarly interpret the 
QoL evidence—more so than that of OS—and may therefore lend confidence to the 
notion that new cancer drugs are providing QoL benefits to patients. 
 
Still, regulatory opinions of treatment-related effects on QoL were not always based on 
empirical data. Of the 22 drugs that were deemed to improve QoL, evaluations for 17 
were based on a review of empirical evidence, including data from validated QoL 
instruments. The QoL benefits associated with the remaining 5 drugs (pertuzumab, 
trametinib, ziv-aflibercept, sipuleucel-T, vemurafenib) were based exclusively on 
comments or testimony from patients and clinical experts. For example, HAS and PBAC 
both published evaluations of pertuzumab through May 2015. In their appraisals, based 
on evidence from the FACT-B questionnaire, HAS concluded that pertuzumab was not 
expected to have any impact on patients’ QoL. The PBAC, in contrast, noted strong 
support for pertuzumab from the consumer comments facility describing a range of 





Eight (15%) of the 53 drugs that were evaluated by HTA agencies were found to improve 
safety. A far larger share (24, or 45%), however, reduced patient safety. Ten (19%) were 
associated with mixed evidence and 9 (21%) failed to demonstrate any difference in 
safety compared to alternative treatments (Table 5). For more information on the safety 
parameters that were evaluated by HTA agencies to summarize the clinical impact from 
treatment, and which are therefore reflected in this chapter, please refer to Table 3.  
 
Mirroring earlier trends for OS, English and Australian authorities were least and most 
likely to determine that new cancer medicines reduced patient safety, respectively. 
Across the entire sample, there was low level of interagency agreement between all HTA 
agencies on the impact on safety from new cancer medicines (α=0.23)(Table 6). This was 
however driven by a lack of consensus with Australia’s HTA agency: interagency 
agreement was moderate to high when limited to English and French assessments 
(α=0.59).  
 
Joint Benefits from Treatment 
Of the 23 drugs that significantly increased OS by at least three months, 15 (65%) were 
also found to improve QoL, while the remaining 8 (35%) produced no measurable 
change. In contrast, of the 23 drugs that significantly extended OS, 5 (22%) improved 
safety, 11 (48%) reduced safety, 5 (22%) were associated with mixed evidence, and 2 (9%) 
produced no difference in safety relative to existing standards of care. Most new cancer 
medicines that significantly extend life therefore also improve QoL, but reduce patient 




There was a noticeably smaller improvement in QoL in the set of drugs that produced a 
marginal to no improvement in OS. Of the 30 evaluated drugs that did not increase OS 
by at least 3 months, 7 (23%) were found to improve QoL, 2 (7%) worsened QoL, 1 (3%) 
had a mixed effect, and 20 (67%) did not demonstrate any change in QoL. Safety 
nevertheless remained a concern. Of the 30 drugs that did not increase OS by at least 3 
months, 3 (10%) were classified as improving safety, 13 (43%) reduced patient safety, 5 
(17%) were associated with mixed evidence; the remaining 9 (30%) did not demonstrate 
any difference in safety over alternative treatments.  
 
Across the entire sample, 42 of the 53 new cancer drugs (79%) licensed in the US and the 
EU between 2003 and 2013, and evaluated by Australian, English, or French HTA 
agencies through May 2015, demonstrated at least some evidence of an OS, QoL, or 
safety benefit. These results were supported by the feedback that was received from 2 
anonymous medical experts from the FDA, both of whom generally agreed with the 
results that were obtained. One—an oncologist—stated that the results summarized in 
Table 5 were “in line with [his personal] perceptions” of the added clinical benefits of the 
new cancer medicines evaluated in this study. 
 
Discussion 
All new cancer medicines licensed between 2003-2013 by the FDA and EMA extended OS 
by an average (SEM) of 3.43 (0.63) months (0.29 [0.05] years) over 2003 treatment 
standards. This figure is based on regulatory assessments, and is consistent with two 




While perhaps modest, this improvement in OS represents an important step forward 
for patients and society, as even minor improvements in survival can have a large 
aggregate effect on mortality at the population-level.(154) It is therefore promising to 
find that a majority of newly approved cancer drugs were associated with some known 
(55%) or unknown (70%) benefit in OS, with the largest share (43%) extending life by ≥3 
months, an amount that English and Australian authorities consider to be clinically 
significant.(121,147) 
 
This analysis is the first to use a recently published conceptual framework on the value 
of new anticancer treatments (12) to characterize the OS, QoL, and safety benefits 
associated with new cancer medicines. It finds that most newly approved cancer 
medicines (79%) increased OS by some known or unknown magnitude, or demonstrated 
at least some evidence of improved QoL or safety over alternative treatments. Most new 
cancer medicines are therefore bringing at least some benefit to cancer patients.  
 
However, there was evidence to suggest that these benefits are concentrated within 
particular classes of therapeutics. Ten immunologic drugs were present in this sample, 
most of which function by antigenic targeting of cancer cells. Ipilimumab was the only 
drug of a novel class of immunomodulating agents, the immune checkpoint modulators. 
With the exception of bevacizumab—which elicits an antiangiogenic response—
immunologic drugs were, on average, better at extending OS compared to non-
immunologic drugs (5.02 vs 2.30 months). However, this was not true of all immunologic 
drugs—catumaxomab and ofatumumab, for instance, produced no discernible 
improvement in OS compared to paracentesis and chlorambucil, respectively, while 
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brentuximab and cetuximab were associated with an increase in OS, albeit one that was 
unquantifiable. Therefore, while cancer drug innovation is in general benefitting 
patients, the magnitude of those benefits appears to differ across medicines and 
therapeutic classes.  
 
Though perhaps promising, findings from this study should be interpreted with caution. 
To validly draw inference on the impact from new immunologic drugs and other cancer 
therapeutics, this analysis should be repeated as the number of available molecules 
grows. Across the entire sample, regulatory evidence is sometimes based on modeled 
data, non-validated inputs, or comparisons against non-targeted or older active 
treatments (e.g. BSC, chlorambucil), though these may reflect clinical best practices. 
Interagency agreement on drug-related OS benefits also decreases as the level of benefit 
increases, indicating that there may be greater uncertainty about the value from new 
cancer drugs that claim to bring the greatest health benefit. And, as shown with 
frequently contrasting English and Australian assessments, the regulatory milieu seems 
to shape the interpretation of clinical evidence supporting the use of new medicines. For 
example, while both English and Australian regulators accepted that sunitinib extended 
life by 7.8 months relative to BSC for gastrointestinal stromal tumors, Australia’s HTA 
agency expressed some unease with this claim, noting that this survival benefit “may be 
an overestimate” given limitations in the supporting evidence. 
 
These findings raise important questions about how clinical benefits are measured and 
used to inform evidence-based policy, and they give reason to adapt treatment 




Regulators often have the authority to require submission of all applicable clinical data 
that is “necessary to address the remit and scope of the technology appraisal.”(151) To 
estimate the clinical value of new medicines in the absence of real-world, observational 
data, the approach used in this study may therefore be preferable to secondary of the 
published scientific literature.  
 
Still, technological assessments may not always reflect the full extent of clinical risks and 
benefits that are observed in practice. For instance, as is the case for KRAS expression in 
colon cancer, particular genomic profiles are now known to predict OS benefits. In part 
for this reason, gene expression profiling is increasingly recommended as a tool to help 
guide chemotherapy decisions.(155,156) Since many new anticancer drugs target proteins 
that are downstream of genes with driver somatic mutations,(155) any misapprehension 
about the genetic mediators of disease may prevent regulators from fully appreciating 
their clinical value. Indeed, validated biomarkers often do not exist to guide the selection 
of patients in clinical trials who most likely benefit from treatment.(92) Clinical practice 
may instead incorporate new evidence on the genetic predictors of respons,e as and 
when it develops,(155) enabling personalized and cost-efficient care that optimizes 
patient outcomes. To better reveal the real-world benefits from new cancer medicines, 
future studies should therefore periodically repeat this analysis with post-
marketing,(150) observational or pragmatic clinical trial evidence. The National Cancer 
Institute’s upcoming National Cancer Knowledge System may provide crucial insights in 
this regard.  
 
As it stands, 1 in 3 (30%) of all newly approved cancer medicines were not associated 
with any OS benefit, while 1 in 5 (20%) neither extend life nor improve QoL or safety. 
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While perhaps reflective of non-active comparisons, the approval of new medicines for 
orphan indications with no alternative treatment, or the growing use of surrogate 
efficacy endpoints during regulatory evaluations,(64) these findings indicate that 
expenditures for up to 1 out of every 5 cancer drugs may be spent without any OS, QoL, 
or safety benefit to the patient.  
 
In the short term, these findings help to inform clinical decision-making by patients and 
clinicians who, in personalizing treatment, may have to consider the economic 
implications of drug prescriptions alongside individual preferences for treatment-related 
risks and benefits. This may be true for US cancer patients, who typically shoulder high 
amounts of cost-sharing, but also if public health systems (e.g. England’s NHS) do not 
publicly reimburse for new cancer medicines. Over the longer term, efforts should build 
on ASCO’s Value Framework for cancer treatment options by developing evidence on 
mechanisms to weight clinical outcome measures according to their value to patients, 
and aligning these developments with drug review processes.(157) Future studies may 
start on this endeavour by evaluating whether measures of the expected clinical impact 
from new cancer medicines are reflected in HTA agency listing recommendations.  
 
These findings raise a number of important questions about value-for-money in 
oncology. This analysis finds that there is in fact a wide distribution in the therapeutic 
benefits associated with recent cancer drug innovations, suggesting a similarly wide 
variation in the value that they bring to society. Some medications (e.g. pertuzumab) 
have significantly extended life, perhaps justifying large and growing expenditures. 
Others, however, appear to bring little to no tangible benefit to health, raising questions 
about the justification for additional expense over alternative treatments. Though 
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further research is needed, this analysis may indicate that spending on new cancer drugs 
is not always commensurate with their clinical benefits. This may give reason for 
patients and clinicians to take pause when considering new treatments, particularly if 
related expenditures are of concern.  
 
Therefore, cancer drug innovation over the past decade has brought notable 
improvements in OS and QoL. These gains however are unevenly distributed across 
newly licensed cancer medicines, they often come at the cost of safety, and there are 
reasons to believe they may not always translate to real-world clinical practice. As calls 
for value-based healthcare grow, this analysis raises questions about how clinical 
benefits are measured by regulators, and how regulatory evidence is used to inform 
clinical decision-making. It also casts doubt on the assumption that at a societal level the 
cost of a given cancer medicine is associated with its beneficial impact for patients. 
Subsequent chapters take different approaches to explore this issue. 
 
Key Learnings and Implications 
• All newly licensed cancer medicines have extended OS by an average (SEM) of 
3.43 (0.63 months) over 2003 treatment standards.  
• Most newly approved cancer drugs were associated with some known (55%) or 
unknown (70%) benefit in OS, with the largest share (43%) extending life by ≥3 
months. 
• English HTA agencies were most likely to determine that new cancer medicines 
improved overall survival, QoL, and reduced patient safety. 
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• 1 in 3 of all newly approved cancer medicines were not associated with any OS 




3  Generating Evidence on the Use 




Recent rates of growth in prescription drug prices and long-running increases in health 
needs have left health systems around the world grappling with rapidly growing 
expenditures. As policymakers attempt to control growing costs, while also protecting 
patient health, interest has grown in value-based healthcare models that couple 
expenditure with clinical outcomes.  
 
This is reflected in the literature. Within the field of cancer, for instance, several recent 
studies have sought to determine whether growing expenditures on cancer care are 
“worth it.” Comparing cancer survival differences to the relative costs from treatment in 
the US and European countries, Philipson and colleagues (2012) for instance find that 
high-cost US cancer care generated $598 billion of additional value to US patients who 
were diagnosed between 1983 and 1999.(8) Soneji and Yang make a similar claim,(9) but 
also find that net economic returns vary by cancer indication and is often less than that 
achieved in Western European countries. To date, however, the literature has for the 
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most part been unable to assess the value of different cancer tools and treatments, 
including medicines.(8)  
 
Several streams of evidence are needed to systematically do so. ASCO recently published 
Value Framework, for instance, identifies the clinical outcome parameters that can be 
used to measure the value of cancer therapeutics. Chapter 2 used it as a framework to 
systematically assess the clinical risks and benefits of new cancer medicines. However, 
how and to what extent these clinical risks and benefits are reflected in real-world 
clinical populations depends on their utilization by patients. Moreover, as ASCO points 
out, there is also the assumption that the “cost of a given intervention should bear a 
relationship to the beneficial impact” of cancer therapies. Therefore, in addition to 
evidence on their utilization, evidence on costs is also needed to assess the value 
associated with new cancer medicines.   
 
Yet, even as interest grows in value-based healthcare, there is a dearth of reliable, 
comparative evidence on cancer drug utilization (74,75, ) and costs (159) that would 
otherwise support international research into the value from cancer drug spending.  
 
Drug Utilization 
There is as of yet no single dataset that provides comparable evidence on the utilization 
of cancer medicines at a patient-level.(74,75, ) Several nation-wide initiatives have 
made progress towards this end, yet each also faces its own set of challenges. The UK, for 
instance, created the SACT dataset in 2014, a national mandatory system collecting 







providers.(160) SACT nevertheless continues to face questions regarding data quality, 
completeness, and access. The scope of SACT is also limited to cancer drug use in the 
UK, making it difficult to examine the value from cancer drug use and cost within a 
comparative framework.  
 
There are a similar set of challenges in the US. The SEER program of the US NCI 
provides information on cancer incidence and survival. The SEER-Medicare linked 
dataset links clinical, demographic, and cause of death data from SEER with claims data 
for Medicare beneficiaries, including Medicare reimbursements and physician-
administered drugs. The SEER-Medicare linked dataset nevertheless has limitations that 
are worth noting. The SEER registry covers only 28% of the US population,(161,162) and 
there are reasons to believe that the SEER-Medicare linked dataset captures an even 
smaller fraction of eligible cancer patients: Medicare data does not include claims for 
Health Management Organization enrollees; care provided in other settings, such as the 
Veterans Administration; care for patients where Medicare is the secondary payer; 
reimbursement for covered services not captured by Medicare data, such as out of 
pocket expenditures; or coverage provided by Medigap policies.(163) Sample bias in the 
SEER-Medicare linked dataset may therefore be of concern, raising questions about how 
well it reflects the use of cancer medicines throughout the US. Indeed, prior empirical 
studies have found that the SEER cancer program tends to underrepresent US cancer 
site-specific mortality rates of certain demographic groups, that underrepresentation is 
observed across most SEER registries, and that underrepresentation varies across US 
states.(164) The possibility of sample bias and non-representativeness complicates 
potential comparisons with data from other international settings, such as that of the 







Similarly, a number of factors may make it difficult to carry out systematic and large-
scale analyses of cancer drug costs using existing data sources.(165) As Onakpoya and 
colleagues (2015) highlight, treatment costs for orphan drugs—many of which are 
indicated for use in cancer (159,166)—may vary according to the “individual patients’ 
needs including body size, disease progression, or complications of disease.”(159) In the 
absence of publicly available, patient-level cancer drug registries that also provide real-
world information on how these dose-determining factors contribute to heterogeneity in 
per patient costs, studies have often relied on questionable methods and costing data. 
Evidence has all the while been sourced from different time periods or places,(159,166) 
potentially biasing cost comparisons within and between countries. The issues that arise 
In the US, the SEER program, and the SEER-Medicare Linked Database, collects and reports data on cancer incidence, 
prevalence, and survival, as well as treatment and costs. Private registries, including the NCDB, also exist, though they 
may not be designed for researchers to thoroughly evaluate patient-level cancer drug use and outcomes on a national 
scale. More information on the NCDB is provided below. The AHRQ sponsors the HCUP and its digital query system 
and portal (HCUPnet) to provide health statistics pertaining to inpatient admissions and emergency department 
utilization. This data source does not provide information on services or healthcare products prescribed or delivered 
within ambulatory care settings, or in-hospital or retail pharmacy settings, limiting its usefulness in this study.  
 
The NCDB is a nationwide oncology outcomes database capturing 70 percent of all newly diagnosed cases in the US, 
and is jointly administered by the CoC of the ACoS and the ACS.(363) The NDCB maintains a number of useful online 
data applications to “evaluate and compare the cancer care delivered to patients diagnosed and/or treated at their 
facility with that provided at the state, regional, and national levels.”(364) Key reporting applications include the: 
HCBR, NCDB Survival Reports (Survival), CP3R, RQRS, and the CQIP. These resources allow CoC-accredited cancer 
programs to evaluate and compare patient survival (Survival), facility level compliance (CP3R), short- and long-term 
quality and outcome data (CQIP), and perform real-time assessments of hospital-level adherence with NQF-endorsed 
quality of care measures for selected cancers (RQRS).(364) They do not however provide data on the patient-level 
drug care that is delivered to patients. By also focusing on the care that is prescribed or delivered within CoC-
accredited cancer programs, these resources are also unable to capture the filling of scripts that may occur outside of 
hospital settings, e.g. through retail pharmacies.  
 
In summary, even in the US, the resources that are available to collect evidence on cancer drug use and cost are, in 
many ways, limited. There and elsewhere, these gaps in evidence makes it difficult to reliably assess the value from 
cancer drug expenditures, and it therefore presents a challenge for value-based decision-making in healthcare. 
 
Box 3. Overview of Available Cancer Registries in the US 
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from a lack of evidence, and their implications for rigorous and transparent research, are 
discussed in more detail below. 
 
In the absence of a single, reliable data source for drug treatment costs in the UK, 
Onakpoya and colleagues (2015) performed a secondary search of the UK Medicines 
Information, the National Electronic Library for Medicines, North East Treatment 
Advisory Group, Scottish Medicines Consortium, and All Wales Medicines Strategy 
Group databases “for the most recent evidence.” Where these sources of information 
were deemed to be inadequate to compute annual drug costs, Onakpoya and colleagues 
(2015) also searched the websites of The Pharma Letter, PharmaTimes, and Google 
Scholar. A similar issue exists in the US, where cost inputs may have to be obtained from 
“administrative databases and the published literature.”(166) The expansiveness of these 
secondary searches reflect the lack of a single source of evidence on the cost of cancer 
medicines. It also raises questions on how reliably data from each of these sources can be 
compared and used in country-level studies. Indeed, Onakpoya and colleagues (2015) 
report finding “inconsistencies” in their estimates of drug costs and therefore call for a 
“more detailed and transparent analysis” of the costs of orphan medicines.  
 
These issues have been highlighted in the field of cancer. In their review of economic 
studies in colorectal cancer, Yabroff and colleagues (2013) report that there is (167): 
 
“significant heterogeneity across populations examined, healthcare delivery 
settings, methods for identifying incidence and prevalent patients, types of 




As a consequence, the authors argue that (167): 
 
“findings from studies with seemingly the same objective (e.g. [identifying] 
costs of chemotherapy in year following CRC diagnosis) are difficult to 
compare. Across countries, aggregate and patient-level estimates vary in so 
many respects that they are almost impossible to compare.” 
 
Moreover, as for utilization, there is often a significant amount of uncertainty in the total 
cost that will be incurred from treatment with cancer medicines. This owes in part to an 
unpredictable DoT, which is defined by patient progression-free survival, as well as 
incidence of unacceptable toxicities, and death.[e.g. (69–71)] Unlike in other disease 
areas, response to cancer treatment is often highly variable, and associated with a wide 
distribution in length of treatment. To bypass this issue, cancer drug costs may be 
annualized,(159) or evaluated as monthly DAC or the ETP,(12,73) both of which refer to 
the monthly cost for acquisition of cancer medicines based on list prices. However, 
besides being non-systematic, this approach does not adjust for potential differences in 
treatment duration across cancer medicines, and may therefore bias comparisons of drug 
costs. As a result, it may be difficult for researchers to test the hypothesis that drug 
clinical benefits are associated with their cost for treatment.  
 
These challenges have made it difficult to develop comparable costing data to examine 
the value associated from cancer drug spending in any one context. Even in the UK—
which provides universal healthcare coverage to all normal residents through the NHS 
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(168)—there is a lack of reliable, nationally-representative data on the cost of cancer 
care.(165) Hall and colleagues (2015) comment on this (169):  
 
“[In the UK,] detailed claims databases do not exist, either fail to capture local 
variation and full data granularity or require a heavy data collection burden; 
accurate and easily reproducible estimates of the true cost of care therefore 
remain elusive.” 
 
PLICS are being adopted to improve the accuracy and standardization of methods to 
calculate tariff-based payments for defined, hospital-based episodes of care.(170) Their 
adoption is however still underway, with only 64% of trusts indicating that their 
organizations were using PLICS as of 2013.(171) Trusts may also regard PLICS data as 
commercially sensitive and so may not share it, even with commissioners,(172) raising 
questions of bias if and when it is to be used in secondary research. And, even with 
workarounds,(173) PLICS only provide data on hospital-based care, and may therefore 
exclude the use of cancer medicines outside of this setting.  
 
Recent efforts have attempted to link patients in the NCDR with data on hospital activity 
and NHS costs (NSRC).(165,174) While this approach utilizes well-regarded data sources 
to evaluate cancer treatment costs, it does have several limitations that are worth 
considering: while the NSRC dataset is said to provide the “most detailed picture 
available on the cost of the health services delivered by NHS organisations”,(175) the 
NSRC is not designed to provide reference costs for treatment with individual medicines. 
At the same time, the NCDR only provides merged, patient-level data for 1990-2010,(176) 





Patient-level data linking drug exposure with costs and outcomes is rarely available for 
researchers to conduct independent clinical and economic evaluations.(177) This may 
owe in part to the organizational challenges that exist in systematically collecting this 
data. Anticancer medicines are generally prescribed within secondary care. Those 
medicines can however be dispensed from a number of settings, including hospital 
outpatient departments or retail pharmacies. To be representative, patient-level cancer 
drug registries must therefore be designed to collect data from various points of sale, and 
across multiple time periods. The creation of national registries on the use and cost of 
cancer therapeutics therefore demands scaled electronic data systems that collect 
information on drug prescriptions or dispensation. 
 
Alternatively, privately-held datasets, such as QuintilesIMS’s MIDAS, may collect 
representative data on cancer drug sales and pricing from a number of countries by 
combining data from local market audits. Previous studies have used cancer drug 
utilization through a volume proxy.(74,75) However, because cancer drug use is highly 
individualized and may occur over wide dosage ranges,(178) it may be difficult to 
compare drug utilization through volume measures. A similar argument applies to 
cancer drug pricing data, which requires some method of standardizing for the interval 
over which prices are incurred.(12,73,159) If and when PLICS data become available for 
secondary research in the UK, reference costs for expensive medicines may for example 
be calculated using the currency of patient months on treatment.(173) Without any 
information on treatment dosing and duration distributions for a population, it is 
difficult to evaluate and interpret volume-based utilization and drug pricing measures. 
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This evidence could be particularly useful for payers and policymakers, who may need to 
consider both the location and spread of costing distributions during value-based 
decision-making. 
 
These issues apply both to the US and to Europe. Past initiatives—including EURO-
MED-STAT (179) and the European Surveillance of Antimicrobial Consumption (ESAC-
Net) (180)—have attempted to gather data on drug pricing, expenditure, and utilization. 
However, these have failed to generate comparable or robust pharmaceutical pricing and 
use data from hospital or ambulatory care settings for a number of disease categories, 
including cancer, and for any length of time.(74)  
 
Context and Empirical Gaps 
In the absence of comparable, patient-level data, studies have attempted to measure 
international variations in cancer drug utilization by examining differences in drug sales 
volumes.(74,75) This has been described as the preferred approach in the field of 
cancer,(74) where there is as of yet no widely accepted method for standardizing the 
usage of treatments. Indeed, unlike for other disease areas, the WHO does not publish 
data on DDDs—an average measure of the maintenance dose associated with individual 
treatments—for cancer medicines due to their “highly individualized use and wide 
dosage ranges.”[e.g. (178)] However, because they may fail to account for drug dosage 
and treatment duration, it is difficult to rely on volume-based utilization measures in 




There is also a dearth of reliable costing data that can be used in comparative analyses of 
the value associated with cancer medicines.(165) This owes in part to a lack of publicly 
available, patient-level data on cancer drug utilization, and on the factors that influence 
total prescribable drug dosage, including anthropometrics and DoT. In its absence, 
relevant studies have used costing estimates that may not adequately reflect the full cost 
from treatment with cancer medicines, potentially biasing comparative analyses. Cheng 
and colleagues (2012) find an overall dearth of cost-effectiveness studies for orphan 
medicines, and in oncology as a whole, and argue that this may reflect “evidence 
limitations or publication bias.”(166) For orphan medicines, smaller patient populations 
may make it particularly costly and challenging to develop evidence.(166) Alternative 
approaches must be used to account for these issues.(78)  
  
From a methodological perspective, patient-level data linking drug exposure with costs 
and outcomes is rarely available for researchers to conduct independent clinical and 
economic evaluations.(177) Although the US FDA in 2013 discussed making de-identified 
and masked clinical trial data available,(181) there have been no further developments 
since. The EMA also announced that it would publish patient-level data from 2014 
onwards, but this has since been delayed.(181) Stand-alone clinical trial data is also often 











To conduct comparative analyses of the cost and clinical impact of new cancer 
medicines, these challenges must first be addressed. 
 
Summary of Research 
This chapter generates comparative evidence on the expected course, use, and costs from 
treatment with recently launched cancer medicines in Australia, France, the UK, and the 
US. For this, , using recent methodological 
advances (78,79)  is used to account for gaps 
in the existing data. The evidence that is generated is then used in subsequent chapters 




All medicines that were included in Chapter 2 were eligible for inclusion in this study. As 
in Chapter 2, the methods from Roberts and colleagues (125) were used to identify all 
initial cancer drug approvals by the US FDA and EU EMA occurring between 2003-2013. 
All NMEs approved by the FDA or EMA over this period with a primary indication for 
oncology were eligible for inclusion. Any molecule that did not receive licensure by 
either the FDA or EMA between 2003-2013, and which did not have an initial, primary 
anticancer indication was therefore excluded. Supplemental applications to the US FDA 
or EU EMA, new non-active treatments, licensing supplements, labeling revisions, and 






This chapter conducted two sequential stages of analysis to model the a) treatment 
dosing and duration, and b) treatment utilization and cost associated with each drug. It 
focused exclusively on anticancer medicines approved with single, primary indications. 
Medicines were excluded from the first and second stage of analysis if they had been 
approved with multiple primary FDA indications, for multiple disease conditions—as 
data from QuintilesIMS did not provide drug indication—or if the treatment duration or 
dosing schedule was not available from regulatory sources. Medicines were excluded 
from the second stage of analysis if price or volume data were not available from 


















• brentuximab vedotin 
• dasatinib  
• nilotinib 
• omacetaxine mepesuccinate 
• ponatinib  




#2: Initial treatment duration or dosing schedule 

















(n = 62 drugs; n = 63 drug-indications) 
Criteria: 
       Primary oncology; initial approval (NME); active anticancer treatment 
Sources: 
       1) Roberts et al. 2011 (drugs approved between 2003-2010)(n = 31) 
2) FDA Drugs@FDA database (drugs approved between 2011-2013)(n = 27) 
3) EMA EPAR database (drugs approved between 2011-2013)(n = 4) 
Included: Treatment use and cost 
(n = 43 drugs / drug-indications) 
 




• pomalidomide  









Included: Treatment dosing and duration 
(n = 47 drugs / drug-indications) 
Figure 7. Drug Sample Inclusion/Exclusion Criteria 
Source: 




Cancer drug pricing and volume data was obtained from QuintilesIMS MIDAS. The 
extract that was used in this analysis provided pricing and volume sales data captured at 
the point-of-sale for all cancer drug molecules marketed at any point between 2004 and 
2015 in Australia, France, the UK, and the US. The extract aggregated pricing and volume 
data across both hospital and retail pharmacy settings for each year in the study period. 
Unit-level data on drug sales volume was given both in terms of standard dose units (e.g. 
capsule, tablet) and kilograms. Anticancer medicines were defined by QuintilesIMS as 
any molecule with an L01 or L02 ATC classification. Adjunctive therapies and products 
with other ATC codes were excluded from this dataset. Due to licensing restrictions, this 
thesis does not publish any raw volume or pricing data from QuintilesIMS. 
 

























 This study focused exclusively on the clinical 
trials that were considered to be pivotal by the FDA, as these are designed to provide 




























This approach was designed to reflect regulatory recommendations on when 
to stop treatment: if end-of-therapy is based on symptom assessment rather than a pre-
defined treatment duration, the FDA for instance often explicitly recommends that 
treatment continue until clinical benefits cease, progressive disease occurs, or 
unacceptable toxicity develops.[e.g. (69–71)] Similar recommendations are made by 
other regulators: in its product labeling for cancer medicines, the EMA often 
recommends that treatment be continued until end-of-therapy, unacceptable toxicity, or 
“until progression of the underlying disease”.[e.g. (219)] As is evidenced by the phase III 
study for vinflunine (VFL 302),(220) clinical trials are themselves often designed for 
ethical reasons to discontinue treatment or allow for patient cross-over once symptoms 
deteriorate, toxicity develops, or progression occurs.(221,222) Oncologists may also re-
assess the use of treatments if disease progression occurs, functional status worsens, or 











Disease condition and rarity may impact the total use or price paid 
for cancer medicines.(50,227–229) US and EU orphan drug status and ATC classifications 
for FDA-approved indications were therefore obtained from orpha.net and the WHO’s 
ATC/DDD index,(230,231) while Australian orphan drug status was obtained from the 
TGA’s orphan drug registry.(232) Unlike recent studies,(78) latest available 
anthropometric reference data were obtained for the different countries in this analysis, 
and were also stratified by age and sex to account for age- (adult/pediatric) and sex-










 used to model expected treatment dosing and 






here builds on the available literature, as well as existing health economic modeling 
procedures.4 
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Treatment Cost and Utilization  
In the absence of any international registry capturing drug usage by patients, previous 
studies have recommended that volume be taken as a proxy measure of consumption, as 
sales data may be affected by exchange rate fluctuations and differing price levels.(74,75) 
To account for variations in drug potency, volume should be expressed in terms of 
DDDs—a measure of the average maintenance daily dose for the primary indication in 
adults—“wherever possible.”(74) In oncology, however, this approach is complicated by 
the fact that DDDs are not published for cancer drugs by the WHO due to their “highly 
individualized use and wide dosage ranges.”[e.g. (178)]. Without this standardized unit, 































First, England’s NICE may publish Costing Statements as part of its evaluation of new 
health technologies to provide guidance on their expected impact on resource use in the 
NHS.[e.g. (248)] Costing Statements typically provide forecasts of the total number of 
patients who would be expected to use or be eligible for treatment in the UK. However, 
Costing Statements are often not published by NICE for new technologies;[e.g. 
cabozantinib, carfilzomib (249,250)] even if they are, the methods underlying these 
forecasts often lack transparency; they do not always provide forecasts on the number of 
patients who will be treated with new medicines;[e.g. (251)] they do not provide 
comparable estimates on drug utilization and costs for countries outside of the UK; and 
they only provide forecasts, rather than real-world figures. While they therefore cannot 
be systematically used as a resource for evidence on the real-world use and cost of cancer 



































































Several points should however be considered: regulators use the single pivotal trials that 
typically follow feasibility stages as “primary clinical support” of marketing 
applications,  and health systems may refer to them to support decision-making on 
drug coverage, pricing, and reimbursement. Pivotal clinical trials may be expected to 
include medicines as they are likely to be used in the clinic,  
 This reflects their objective, which is to provide 










































With greater understanding of the biological mediators 
of clinical response, future studies may be able to use individual data, including genomic 















While this limitation is acknowledged, it is important to consider several points. First, 
the country, age (adult/pediatric), and sex (male/female) stratifications that are used in 
this study are already an advance over the recently published literature. In their 
comparative study of drug costs and benefits of medical treatments in  
 assume a standard weight  and BSA 
 for a hypothetical patient.(78) The study makes no attempt to adjust these 
figures by country or disease indication, suggesting that this approach may bias 
estimates of standard posology.  
  
 
Unfortunately, this approach may also be used by England’s own HTA agency, NICE, 
when assessing new health technologies. For example, in its TA 216 for 
bendamustine,(263) NICE takes the mean cost of bendamustine per person from the 
manufacturer’s submission (£4741.54). This figure, however, was estimated by assuming 
a fixed BSA (1.72 m2) and an average treatment course of 4.9 cycles. Notably, 
anthropometric assumptions may not be used consistently across all TAs: in TA135, for 
example, NICE provides an expected cost for treatment with pemetrexed by assuming 
five treatment cycles, and a BSA of 1.8 m2.(264) The basis for these figures is also often 
not given. These issues raise concerns over transparency and evidence-based decision-

























62 anticancer molecules were approved by the US (FDA) and EU (EMA) between 2003-
2013 with a primary indication for oncology, and were therefore eligible for inclusion. Of 
those, treatment duration and recommended dosing information was not available for 6 
medicines, while another 9 were approved for multiple primary indications or disease 
conditions, a level that could not be reconciled with the pricing and volume data that 
was available in this study. Treatment dosing and duration were therefore estimated for 
the remaining 47 medicines. Of these, volume and pricing data was not available from 
the QuintilesIMS pricing and volume data extract for 4 medicines, leaving 43 drugs that 





The drug sample was well-distributed in terms of the cancer indications that were 
represented (Table 8). One of the 47 drugs that were included in this analysis was 
indicated for malignant ascites, five for breast cancer, five for GI cancer, five for lung 
cancer, six for prostate cancer, five for renal cancer, three for skin cancer, and one for 
thyroid cancer; the remaining 16 were indicated as hematologicals. 24 medicines had an 
active or withdrawn orphan status in the US or EU. Of these, one was indicated for 
malignant ascites (catumaxomab), one for lung cancer (pemetrexed), and one for thyroid 
cancer (cabazantinib); all medicines that were approved for renal (n = 5) or 
hematological (n = 16) neoplasms were also associated with an orphan status. 
 
Chapter 2 describes the clinical benefits associated with each of the medicines that were 
included in this study, as well as the methods that were used to obtain this information. 
A brief overview is also provided here. There was a wide distribution in the OS benefits 
associated with each of the medicines included in this study (Table 8). Ranked by 
indication, all treatments that were newly licensed for breast cancer by the US FDA and 
EU EMA between 2003-2013 extended survival by the largest average amount between 
2003-2013 (8.48 months). This was followed by medicines that were indicated for renal 
cancer (6.27 months), skin cancers (4.65 months), prostate cancers (3.17 months), GI 
cancers (2.90 months), hematological cancers (2.61 months), lung cancers (2.09 months), 
malignant ascites (0 months), and thyroid cancers (0 months).   The largest share of 
these medicines improved (42%) QoL, but reduced (45%) patient safety. For more 
information on the clinical risks and benefits of new cancer medicines, including how 




Of the 47 drugs that were included in this study, 22 were associated with an explicit 
recommendation to treat patients until clinical benefits end, progressive disease occurs, 
or unacceptable toxicity develops. Although the FDA did not explicitly recommend that 
treatment stop at time of disease progression or upon the occurrence of unacceptable 
toxicity for 15 medicines, its medical reviews explicitly indicated that the pivotal clinical 
trials for most of these (n = 12) were designed to do so.  
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Table 8. Drug Sample Eligible for Study Inclusion, Therapeutic Characteristics, First FDA-Approved Change to Indicated Treatment, and Maximum OS Benefit Relative to Clinical 
Comparator, as Measured Across English, French, and Australian HTA Agencies 















Indicated for use in combination with prednisone 
for the treatment of patients with metastatic 
castration-resistant prostate cancer who have 
received prior chemotherapy containing docetaxel. 











First-line treatment of patients with metastatic non-
small cell lung cancer (NSCLC) whose tumors have 
epidermal growth factor receptor (EGFR) exon 19 
deletions or exon 21 (L858R) substitution mutations 
as detected by an FDA-approved test. 












An asparagine specific enzyme indicated as a 
component of a multi-agent chemotherapeutic 
regimen for the treatment of patients with acute 
lymphoblastic leukemia (ALL) who have developed 
hypersensitivity to E. coli-derived asparaginase. 









Treatment of advanced renal cell carcinoma after 
failure of one prior systemic therapy. 












Treatment of patients with the following 
myelodysplastic syndrome subtypes: refractory 
anemia or refractory anemia with ringed 
sideroblasts (if accompanied by neutropenia or 
thrombocytopenia or requiring transfusions), 
refractory anemia with excess blasts, refractory 
anemia with excess blasts in transformation, and 
chronic myelomonocytic leukemia. 











Treatment of patients with chronic lymphocytic 
leukemia (CLL). 









In combination with intravenous 5-fluorouracil–
based chemotherapy, indicated for first- line 
treatment of patients with metastatic carcinoma of 
the colon or rectum. 







3.0-4.7 IFL / 5-FU/LV 
bortezomib 
Treatment of multiple myeloma patients who have 
received at least two prior therapies and have 












demonstrated disease progression on the last 
therapy.  
cabazitaxel 
Indicated in combination with prednisone for 
treatment of patients with hormone-refractory 
metastatic prostate cancer previously treated with a 
docetaxel-containing treatment regimen. 









A kinase inhibitor indicated for the treatment of 
patients with progressive, metastatic medullary 
thyroid cancer (MTC). 









Treatment of patients with multiple myeloma who 
have received at least two prior therapies including 
bortezomib and an immunomodulatory agent and 
have demonstrated disease progression on or within 
60 days of completion of the last therapy. 









(EMA) Indicated for the intraperitoneal treatment 
of malignant ascites in adults with EpCAM-positive 
carcinomas where standard therapy is not available 
or no longer feasible. 









Used in combination with irinotecan, indicated for 
the treatment of EGFR-expressing, metastatic 
colorectal carcinoma in patients who are refractory 
to irinotecan-based chemotherapy. 












Treatment of pediatric patients 1 to 21 years old with 
relapsed or refractory acute lymphoblastic leukemia 
after at least two prior regimens. 











Treatment of patients with locally advanced or 
metastatic non-small cell lung cancer (NSCLC) that 
is anaplastic lymphoma kinase (ALK)-positive as 
detected by an FDA-approved test.  









Treatment of patients with unresectable or 
metastatic melanoma with BRAF V600E mutation as 
detected by an FDA-approved test. 














Treatment of patients with myelodysplastic 
syndromes (MDS) including previously treated and 
untreated, de novo and secondary MDS of all 
French-American-British subtypes (refractory 
anemia, refractory anemia with ringed sideroblasts, 
refractory anemia with excess blasts, refractory 
anemia with excess blasts in transformation, and 
chronic myelomonocytic leukemia) and 










intermediate-1, intermediate-2, and high-risk 
International Prognostic Scoring System groups. 
degarelix 
Treatment of patients with advanced prostate 
cancer. 











Treatment of patients with metastatic castration-
resistant prostate cancer who have previously 
received docetaxel. 









Treatment of patients with metastatic breast cancer 
who have previously received at least two 
chemotherapeutic regimens for the treatment of 
metastatic disease. Prior therapy should have 
included an anthracycline and a taxane in either the 
adjuvant or metastatic setting. 









Treatment of patients with locally advanced or 
metastatic non-small cell lung cancer after failure of 
at least one prior chemotherapy regimen. 







2 placebo / BSC 
everolimus 
Treatment of patients with advanced renal cell 
carcinoma after failure of treatment with sunitinib 
or sorafenib. 









Indicated for the treatment of adult patients with 
locally advanced or metastatic non-small cell lung 
cancer (NSCLC) with activating mutation of EGFR-
TK. 











Treatment of patients with mantle cell lymphoma 
(MCL) who have received at least one prior therapy. 









A human cytotoxic T-lymphocyte antigen 4 (CTLA-
4)-blocking antibody indicated for the treatment of 
unresectable or metastatic melanoma. 









In combination with capecitabine, indicated for the 
treatment of metastatic or locally advanced breast 
cancer in patients after failure of an anthracycline 
and a taxane. // Ixabepilone as monotherapy is 
indicated for the treatment of metastatic or locally 
advanced breast cancer in patients after failure of an 
anthracycline, a taxane, and capecitabine. 









In combination with capecitabine, indicated for the 
treatment of patients with advanced or metastatic 
breast cancer whose tumors overexpress HER2 and 
who have received prior therapy including an 
anthracycline, a taxane, and trastuzumab. 













Treatment of patients with T-cell acute 
lymphoblastic leukemia and T-cell lymphoblastic 
lymphoma whose disease has not responded to or 
has relapsed following treatment with at least two 
chemotherapy regimens. 











Indicated in combination with chlorambucil for the 
treatment of patients with previously untreated 
chronic lymphocytic leukemia. 












Treatment of patients with chronic lymphocytic 
leukemia (CLL) refractory to fludarabine and 
alemtuzumab.  









Treatment of EGFR-expressing, metastatic 
colorectal carcinoma with disease progression on or 
following fluoropyrimidine-, oxaliplatin-, and 
irinotecan-containing chemotherapy regimens.  












Treatment of patients with advanced renal cell 
carcinoma. 













In combination with cisplatin, indicated for the 
treatment of patients with malignant pleural 
mesothelioma whose disease is either unresectable 
or who are otherwise not candidates for curative 
surgery. 









Indicated in combination with trastuzumab and 
docetaxel for the treatment of patients with HER2-
positive metastatic breast cancer who have not 
received prior anti-HER2 therapy or chemotherapy 
for metastatic disease. 











A thalidomide analogue indicated for patients with 
multiple myeloma who have received at least two 
prior therapies including lenalidomide and 
bortezomib and have demonstrated disease 
progression on or within 60 days of completion of 
the last therapy. Approval is based on response rate. 







≥ 3 months 
(Magnitude 
uncertain) 




radium Ra 223 
dichloride 
An alpha particle-emitting radioactive therapeutic 
agent indicated for the treatment of patients with 
castration-resistant prostate cancer, symptomatic 
bone metastases and no known visceral metastatic 
disease. 









Treatment of patients with metastatic colorectal 
cancer (CRC) who have been previously treated with 
fluoropyrimidine-, oxaliplatin- and irinotecan-based 










chemotherapy, an anti-VEGF therapy, and, if KRAS 
wild type, an anti-EGFR therapy. 
romidepsin 
Treatment of cutaneous T-cell lymphoma (CTCL) in 
patients who have received at least one prior 
systemic therapy. 









Treatment of patients with intermediate or high-
risk myelofibrosis, including primary myelofibrosis, 
post-polycythemia vera myelofibrosis and post-
essential thrombocythemia myelofibrosis. 
L01XE18 Hematological 













An autologous cellular immunotherapy indicated 
for the treatment of asymptomatic or minimally 
symptomatic metastatic castrate resistant (hormone 
refractory) prostate cancer. 









Treatment of patients with advanced renal cell 
carcinoma. 












A kinase inhibitor indicated for the treatment of 
advanced renal cell carcinoma. 









Treatment of patients with CD20 positive, follicular, 
non-Hodgkin's lymphoma, with and without 
transformation, whose disease is refractory to 
Rituximab and has relapsed following 
chemotherapy. 









Treatment of patients with unresectable or 
metastatic melanoma with BRAF V600E or V600K 
mutations as detected by an FDA-approved test. 













Indicated as a single agent for the treatment of 
patients with HER2-positive, metastatic breast 
cancer who previously received trastuzumab and a 
taxane, separately or in combination. Patients 
should have either: a) Received prior therapy for 
metastatic disease, or b) Developed disease 
recurrence during or within six months of 
completing adjuvant therapy. 











Treatment of cutaneous manifestations in patients 
with cutaneous T- cell lymphoma (CTCL) who have 
progressive, persistent or recurrent disease on or 
following two systemic therapies. 









Indicated in combination with 5-fluorouracil, 
leucovorin, irinotecan- (FOLFIRI) for patients with 
metastatic colorectal cancer (mCRC) that is 


















1 Orphan status obtained from orpha.net for the US and EU, and from the TGA’s Orphan Drug registry for Australia. 
2 Initial approval for 1o FDA indication. 
3 New/Modified Indication (target), New Dosage Regimen, or Alteration to Patient Population by the FDA, or EMA, occurring within three years of initial approval (Y + 2), through 1 Jan 2016. For 
Australia, a search of ARTG registrations, AusPARs, Orphan Drugs, PBS, PI sheets from the TGA, and the TGA website was conducted. Adis Insight drug profiles were also searched if these data 





Dosing and Treatment Duration 





































































































































































































































































































Several streams of evidence are needed to assess the value of cancer tools and 
treatments. As ASCO’s recently published Value Framework highlights, a systematic 
approach is needed to assess the clinical risks and benefits of new cancer medicines. 
Chapter 2 of this thesis adapted ASCO’s Value Framework to gather this evidence for all 
new anti-cancer medicines that were approved by the US FDA or EU EMA between 2003 
and 2013. However, the extent to which drug-related clinical risks and benefits manifest 
in real-world settings depends on the use of new drugs by patients. ASCO’s Value 
Framework also assumes that rigorous costing data would be available to determine 
whether drug health benefits are commensurate with their cost.   
 
There is nevertheless a dearth of reliable, comparative evidence on cancer drug 
utilization (74,75, ) and costs (159) that would otherwise support international 


















   
 
Dosing and Treatment Duration 
There is a wide variation in the total dose that would be expected from a full course of 



































These findings are consistent with the notion in the health economics literature that 
payers may pay premium prices for drugs that treat rare diseases,(227) as well as a body 
of empirical evidence.(166) Yet, it also appears to contradict Onakpoya and colleagues 
(2015),(159) who find no significant relationship in scatterplots of disease prevalence 
against annual cancer drug costs. This apparent contradiction may however be explained 
by methodological differences in the costing of cancer medicines: unlike Onakpoya and 
colleagues (2015), who evaluate annualized drug costs, this analysis uses  




















Values for the expected total cost per patient per  treatment typically, but 
not always, increased after initial market entry. These results corresponded with a 
compound annual growth rate of +10.7% in the total average cost per patient per  
treatment in France between the first and third year of marketing. 
The US and the UK experienced a similar, albeit moderated, increase in the compounded 
annual growth rate in this parameter (+5.3%, +1.7%, respectively). On a volume-weighted 
basis, where total expected drug costs were weighted by their expected utilization, the 
compound annual growth rate in the average per patient cost of treatment with new 
cancer medicines was highest in the US (+33%), followed by Australia (+24.3%), France 
(+23.7%), and the UK (-12.7%), over the first three years of marketing. Chapter 5 









in subsequent years, are associated with the added clinical benefits of new cancer 
medicines, as is assumed by ASCO’s Value Framework.  
 











Cancer drug utilization varied across treatment indications. Lung cancer medicines were 
associated with the largest average number of expected patients  
 In contrast, hematological 
medicines were associated with the least number of patients  
 These findings are consistent with cancer incidence in the US, where 
it was highest in 2000, 2005, 2010, and 2015, for skin, prostate, breast, tracheal, bronchus, 
and lung cancers.(266) These results were also consistent with orphan designations: 
most of the medicines (85%) with orphan status designations in the US were indicated 
for either hematological or renal cancers. Both indications were, on average, also 




























Additional studies are needed to examine the implications for value-based spending. 
Although initial uptake of new medicines is faster in the US and France than in Australia 
or the UK, this gap diminishes in subsequent years. Delayed uptake of new medicines 




to signal the value to patients and payers from new medicines. If this is the case, and if 
domestic policies and processes are successful in signaling value, one would expect there 
to be a closer relationship between cancer drug utilization and the scale of their clinical 
benefits. As for cost, this issue is examined in Chapter 5.  
 
Key Learnings and Implications 
• There is a wide variation in the total dose and total duration of treatment that 
would be expected   
• Mean estimates of the total expected cost from treatment varied widely across all 
newly licensed cancer drugs, were highest for hematologicals, increased over 
time, and varied across countries, with mean total drug costs consistently highest 
in the US.  
• Cancer drug utilization also varied over time and across medicines, and were 










With annualized cancer drug costs now often exceeding US$100,000,(44) US 
policymakers and academics have increasingly raised questions over the justification for 
high drug prices.(32,269) Building off the notion that “price must reflect worth,”(32) 
Kantarjian and colleagues (2013) argue that newer drugs should only be endorsed when 
“clinical benefits truly reflect incremental value worth the differential price.”(32) Despite 
growing calls for value-based healthcare, there is relatively little empirical evidence 
comparing spending on cancer medicines against measures of their clinical 
impact.(22,32–35)  
 
To date, the literature has focused on value from the perspective of cancer care, 
aggregating medical treatment with drug therapeutics. Using conventional approaches 
to valuing statistical lives, studies have reported that high-cost cancer care in the US 
provides net positive value to society, and that higher spending correlates with gains in 
life expectancy.(8) Others have added nuance, finding that US cancer care provides net 
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positive value for most cancer indications, though at considerably lower return than in 
Western Europe.(9)  
 
Context and Empirical Gaps 
These studies nevertheless have several limitations that are worth considering. First, 
international differences in clinical standards, resources, and practices make it difficult 
to reliably compare value obtained from medical care. This is arguably less of a concern 
for drug therapeutics, which can be licensed for use in a number of countries. By 
focusing on total cancer care, the literature is also unable to disentangle the value from 
different tools and treatments,(8) such as cancer medicines. Prescription drugs are a 
mainstay in cancer care: they are instrumental in preventing metastases, slowing disease 
progression, curing cancer, and prolonging survival. A different approach to measuring 
value in oncology is therefore needed, particularly as drug innovations in therapeutic 
targeting, multi-agent therapy, and cancer immunotherapy transform patient care. 
 
Considered alongside notable price increases,(44) it remains unclear how much value 
growing cancer drug expenditures bring to society. This owes in part to a dearth of 
reliable comparative data on cancer drug development, utilization, and expenditure, 
three key factors in the extraction of benefit from care.(270) Some have suggested, for 
instance, that the certainty of positive returns on investment incentivizes drug 
innovation in the US,(271) in turn expanding choice and value to the patient. Dedicated 
funding programs—such as England’s CDF—may have helped in this regard by 
promoting access to the newest, but least cost-efficient, cancer medicines, though these 
today face funding shortfalls, cutbacks, and questions regarding value.(89,272) 
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Expenditures on cheaper, older generics could instead expand access to life-saving 
treatment and minimize the social burden from disease, particularly if cost-associated 
noncompliance is of concern (273) or if new medicines provide marginal survival 
benefits. 
 
Summary of Research  
The literature has generally adopted two approaches to determine whether spending on 
new tools or treatments provide value-for-money. The first approach assesses whether 
spending on new treatments results in net positive economic returns to patients and 
society.(22,33,35,80–82) This chapter adopts a cost-benefit approach to analyze whether 
the monetized value of survival gains attributable to cancer drug innovation, and based 
on patients’ willingness to pay for a diminished risk of mortality, exceeds growth in drug 
spending, both at a societal- and drug-level. Chapter 5 adopts the second approach and 
assesses whether and to what extent spending on treatments is associated with measures 
of their clinical benefit.(73,85,274–277) 
 
This chapter uses a proprietary dataset from QuintilesIMS to first describe real-world 
cancer drug development, utilization, and expenditure observed in Australia, France, the 
UK, and the US between 2004 and 2014. It then takes two different approaches to 
examine the net long-term value generated from spending on cancer medicines. First, 
using country-level, longitudinal data on neoplasm-related YPLLs, as well as aggregate 
spending data from QuintilesIMS, this chapter adapts the methods used by Eggleston 
and colleagues (2009)(82) to quantify the net long-term value generated at both a 
neoplasm- and country-level from cancer drug spending in Australia, France, the UK, 
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and the US. This assessment is based on patients’ willingness to pay for a diminished risk 
of mortality owing to cancer drug treatment. Second, the methods by Eggleston and 
colleagues (2009)(82) are adapted into a simulation-based analysis that incorporates 
data from previous chapters—including evidence on expected drug use, cost and survival 
benefits—to calculate plausible estimates of the net value to patients and society from 
spending on each new cancer medicine.   
  
Methods 
Sample Selection  
Since they build on prior chapters, country-level analyses were limited to Australia, 
France, the UK, and the US. To assess the clinical impact from all new cancer medicines 
approved in the US or EU between 2003-2013, Chapter 2 took a systematic approach to 
evaluate HTA appraisals from English (NICE), French (HAS), and Australian (PBAC) 
HTA agencies published through May 2015. As was described there, these organizations 
are required to evaluate the clinical risks and benefits of new medicines in relation to 
existing clinical standards that are used for the same indication,(121–123) and their 
assessments are often used in value-based decision-making on issues including coverage, 




All medicines that were included in Chapters 2 and 3 were eligible for inclusion in drug-




the methods from Roberts and colleagues (33) were used to identify all initial cancer 
drug approvals by the US FDA and EU EMA occurring between 2003-2013. All NMEs 
approved by the FDA or EMA over this period with a primary indication for oncology 
were eligible for inclusion. Any molecule that did not receive licensure by either the FDA 
or EMA between 2003-2013, and which did not have an initial, primary anticancer 
indication was therefore excluded. Supplemental applications to the US FDA or EU EMA, 
new non-active treatments, licensing supplements, labeling revisions, and new or 
modified indications were not considered. Medicines were excluded from drug-level 
analyses if Chapter 2 was unable to quantify the OS benefits of new cancer medicines, 
either because HTA appraisals were not available from English, French, or Australian 
HTA agencies through May 2015, or because HTA agencies were not able to quantify OS 
benefits. For more information, please refer to Chapter 2. The drug selection process is 






















Included: Value generated from treatment 
(n = 29 drugs / drug-indications) 
abiraterone, afatinib, azacitidine, bendamustine, bevacizumab, bortezomib, cabazitaxel, cabozantinib, 
catumaxomab, clofarabine, crizotinib, degarelix, enzalutamide, eribulin, erlotinib, everolimus, gefitinib, 
ipilimumab, lapatinib, nelarabine, ofatumumab, panitumumab, pemetrexed, pertuzumab, regorafenib, 
temsirolimus, trastuzumab emtansine, vorinostat, ziv-aflibercept 




• brentuximab vedotin 
• dasatinib  
• nilotinib 
• omacetaxine mepesuccinate 
• ponatinib  




#2: Initial treatment duration or dosing schedule 

















(n = 62 drugs; n = 63 drug-indications) 
Criteria: 
       Primary oncology; initial approval (NME); active anticancer treatment 
Sources: 
       1) Roberts et al. 2011 (drugs approved between 2003-2010)(n = 31) 
2) FDA Drugs@FDA database (drugs approved between 2011-2013)(n = 27) 
3) EMA EPAR database (drugs approved between 2011-2013)(n = 4) 
#4: Health technology appraisal not available or 
unquantifiable OS benefit 
 
• axitinib 
• carfilzomib  
• cetuximab 
• dabrafenib 
• decitabine  
• ibrutinib  
• ixabepilone  
• obinutuzumab 
• pazopanib 
• romidepsin (NA) 
• ruxolitinib 









Included: Treatment use and cost 
(n = 43 drugs / drug-indications) 
 




• pomalidomide  









Included: Treatment dosing and duration 
(n = 47 drugs / drug-indications) 
 
Figure 8. Drug Sample Inclusion/Exclusion Criteria 
Source: 




Unit-level pricing and volume data was obtained from QuintilesIMS’s proprietary 
MIDAS database. This data package provided yearly cross-sectional public pricing, sales 
volume, and molecule descriptors—manufacturer, product name, international product 
name, molecule, ATC code, and patent status—for all new and existing cancer medicines 
marketed between 2004-2014 across retail and hospital settings in Australia, France, the 
UK, and the US. Public price data in euros was captured at the point of sale to 
consumers, while sales volume was given both in terms of single standard dose units 
irrespective of presentation (e.g. capsule, tablet, ampoule) and kilograms. As in previous 
studies,(74,75) sales volume was used as a proxy measure of utilization. Cancer drugs 
were defined by QuintilesIMS as all molecules with an L1 or L2 ATC classification. 
Adjuvant therapies were excluded from this dataset.  
 
Yearly incidence of malignant neoplasms was obtained from the OECD’s OECD.stat 
registry (278) and the US CDC’s USCS registry,(279) while one- and five-year average 
cancer prevalence data was obtained from the WHO’s GLOBOCAN registry (280) for 
2012, the only year for which data was available. YPLLs from all neoplasms were used as a 
population-based mortality indicator. This metric has previously been used in length-of-
life applications to measure cancer burden on society,(281–284) impact of treatment 
exposure on survival,(285–287) and to compare health burdens across disease areas, 
years, and countries.(284,288) Unlike other related metrics of health burden, such as 
DALYs and YLDs, YPLLs do not subjectively value the state of health. Rather, they 
measure health burdens as the number of additional years that the patient could have 
potentially lived in the absence of disease. This metric is also used by health regulators 
and policy stakeholders—including, England’s NICE and the HSCIC—to measure the 
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impact from efforts to avert premature death from causes that are considered to be 
amenable to healthcare, including neoplasms.(286,287)  
 
Total neoplasm-related years of potential life lost (YPLL) per 100,000 population (age-
standardized, both sexes) were obtained from the IHME GBD 2013 registry, which 
provides rigorous and comparable measures of epidemiological levels and trends 
worldwide.(289,290) For reference, these YPLL data were not adjusted for cancer 
incidence, but for total population. An overview to the IHME’s methods for calculating 
comparative and cause-specific YPLLs is provided in Appendix 4.1. 
 
To account for time discontinuities in these two data sources, a simple linear regression 
was used to extrapolate neoplasm-related YPLLs per 100,000 population and total yearly 
neoplasm incidence for each country in this analysis.  
 
To do so, the following model was used over the entire panel for which YPLL data was 












The dependent variable in Eq. ( 6 ) reflects the neoplasm-related YPLLs per 100,000 




Table 11. Simple Regression with Panel Data, Neoplasm-Related YPLL / 100,000 Population (IHME) 
 Model Summary Parameter Estimates 
 R2 F df1 df2 Sig. Constant Year 
Australia 0.8451 10.91 1 2 0.0807 57760.310 -27.364280 
France 0.9908 215.89 1 2 0.0046 84516.246 -40.359178 
UK 0.9701 64.88 1 2 0.0151 91142.443 -43.788774 
US 0.9754 79.26 1 2 0.0124 62509.710 -29.616311 
 
Source: 





A simple linear regression was also used to account for time discontinuities in the total 
neoplasm incidence data that was available. This analysis first obtained total yearly 
number of new cases of malignant neoplasms for Australia, France, the UK and the US 
from the OECD’s OECD.stat registry for the entire panel of available years between 2000 
and 2012 (latest available year).(278) For most countries in this sample, the OECD 
provided data for four years within this period, 2000, 2002, 2008 and 2012. For Australia, 
yearly neoplasm incidence data was only available for 2002, 2008 and 2012. Incidence was 
available from the OECD for the US. However, while the simple linear model shown 
above closely fit the data for most countries—R2 values for country-level regressions 
ranging between 0.95 and 0.99—its fit with US data was unusually poor (R2 = 0.67), 
perhaps pointing to reliability issues in the US data that is published by the OECD for 
this parameter. To correct for this, US OECD total malignant neoplasm incidence data 
was replaced by total malignant neoplasm incidence data from the US CDC USCS 
registry for 2000, 2002, 2008 and 2012.(279) This parameter was then used as the 
dependent variable in the following model to examine the relationship between total 
malignant neoplasm incidence and year:  
 
 𝑁𝑒𝑜𝐼𝑛𝑐𝑐𝑡 = 𝑐𝑜𝑛𝑠 + 𝑌𝑒𝑎𝑟𝑐𝑡 + 𝑐𝑡 ( 7 ) 
 
The dependent variable in Eq. ( 7 ) reflects total neoplasm incidence in country 𝑐 and 
year 𝑡. The model incorporating OECD data for Australia, France, the UK, as well as US 
CDC data for the US, performed well, resulting in an R2 value of between 0.95 and 0.99 
for Australia, France, and the UK, and now resulting in an acceptable R2 value of 0.88 for 
the US. The results from this regression are provided in Table 12. 
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Table 12. Simple Regression with Panel Data, Total Neoplasm Incidence (OECD, US CDC) 
 Model Summary Parameter Estimates 
 R2 F df1 df2 Sig. Constant Year 
Australia 0.9991 1143.67 1 1 0.0188 -7013069.60 3546.092100 
France 0.9747 77.2 1 2 0.0127 -16186658.00 8221.719800 
UK 0.9563 43.73 1 2 0.0221 -12444331.00 6350.076900 
US 0.8821 14.97 1 2 0.0608 -47024263.00 24154.247000 
 
Source: 





Neoplasm-related YPLL data was incidence-adjusted to account for international 
differences in risk of illness and need for treatment.(291) Finally, annual population size 
estimates were obtained from the World Bank,(292) as were consumer price inflation 





To shed light on drug development as a marker for patient choice, four parameters were 
calculated within each country-year cross-section: total unique cancer drug molecules 
available; percent of total US cancer molecules available; manufacturers per available 
cancer molecule; and percent of total unique molecules available exclusively in branded 
form. Drug availability was calculated in terms of unique molecules marketed in each 
country, and was defined by yearly sales volume ≥1 standard unit. 
 
Utilization and Expenditure 
Cancer drug utilization is difficult to compare internationally. In part because drug 
dosages can vary, previous studies have recommended that volume be used to compare 
utilization across settings, and that volume be expressed in terms of DDDs “wherever 
possible.”(74) Cancer drugs, however, are unique in that they are not typically assigned 
DDDs by the WHO due to their “highly individualized use and wide dosage ranges.”[e.g. 
(178)] In the absence of other utilization measures—including number of patients 
treated with individual medicines—previous studies have suggested that comparative 
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analyses of cancer drug utilization use grams of active molecule as a standard measuring 
unit.(74,75) This is echoed by the WHO, which also recommends that the utilization of 
antineoplastic agents be measured in grams, given the lack of other publicly-available 
volume measures.[e.g. (178)] In line with published studies,(74,75) country-level analyses 
of cancer drug utilization in this chapter were based on gram units.  
 
Total drug spending was derived through the following process: nominal euro public 
pricing per standard unit was first converted to constant 2014 terms by using consumer 
price inflation indices from the World Bank. Euro pricing was converted to US dollar 
equivalents using period average euro-USD exchange rates for Q4 2014, the delivery 
quarter of the QuintilesIMS dataset. Unit-level public drug prices were then multiplied 
by standard unit sales for each marketed molecule to derive annual unit-level 
expenditures. Finally, annual unit-level expenditures and utilization volumes were 
summed by drug patent status, ATC group, and country.  
 
Crude comparisons of cancer drug use and spending may be misleading if associated 
populations are of unequal size or have unequal epidemiological risks of disease.(291) 
Spending on anticancer medicines is not meant to prevent disease, but to actively 
mitigate its impact on health once disease has occurred. From the perspective of this 
study, countries with an unusually high number of incident cancer cases could therefore 
be expected to have higher rates of cancer drug use, expenditure, and YPLLs, ceteris 
paribus, while the opposite claim could also apply for countries with an unusually low 
incidence of cancer. Different epidemiological risks of disease may reflect prevention-
related factors (e.g. environmental risks) that are not the focus of this study. While 
prevention is certainly an important dimension to drug spending, and is therefore 
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deserving of attention, this study instead focused on the remedial value of spending on 
active treatment once disease has occurred. To therefore adjust for potential differences 
in the total population across countries, and in relative risks associated with developing 
cancer, this study adjusts country-level drug sales volume, expenditure, and YPLLs per 
100,000 population by yearly incidence of malignant neoplasms. This methodology has 
been advocated in the literature as a means of reliably comparing cancer drug utilization 
across country settings.(74,75) 
 
In line with established methods,(74,75) base-case analyses therefore adjusted drug 
utilization and expenditure by the total annual incidence of malignant neoplasms 
between 2004-2014. Total annual incidence of malignant neoplasms was derived for each 
country through a simple linear regression using country-level panel data from the 
OECD and US CDC, as described above. Incidence-adjusted cancer drug spending and 
utilization was then calculated by dividing country-level spending and utilization figures 
by yearly estimates of total new cases of malignant neoplasm. To test for robustness, 
sensitivity analyses also adjusted cancer drug utilization and expenditure by the total 
population in each country-year, and the one- and five-year cancer prevalence in each 
country for 2012 (data only available for one year). For reference, one-year cancer 
prevalence figures correspond to the initial stage treatment, while five-year cancer 
prevalence figures instead typically correspond to the cured stage.(295) These methods 
are adapted from previous studies comparing international prescription drug 
usage.(74,75) The reasons for preferring this approach are also described below.   
 
First, in line with previous reports,(74,75) base case analyses adjusted total yearly cancer 
drug utilization and expenditure by total cancer incidence observed in each country-year 
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between 2004-2014. Sensitivity analyses also adjusted cancer drug utilization and 
expenditure by one- and five-year cancer prevalence, which was only available from the 
WHO GLOBOCAN registry for 2012. As is discussed later in this chapter, the overall 
trends from this analysis were consistent with incidence-adjusted results. Besides 
providing a measure of validation for base-case analyses, this finding also suggests that 
cancer incidence is similarly proportional to cancer prevalence across the sample of 
countries that are included in this study. A similar outcome was observed when analyses 
were adjusted by total population in each country-year.  
 
Second, as there is no comparable, patient-level registry on actual cancer drug use,(75) 
this approach was used to adjust for the number of patients expected to be on active 
anticancer treatment. As it applies to cancer, prevalence can be defined as the number of 
living patients who have ever been diagnosed with cancer, including those who were 
treated for cancer in the past and who may be receiving adjuvant therapy. One-year 
cancer prevalence is in fact defined by the GLOBOCAN registry as the number of cancer 
patients still alive one year after diagnosis; a similar definition exists for five-year cancer 
prevalence.(295) Since antineoplastic agents are only indicated for use in patients with 
active malignancies, it would be inappropriate to adjust current utilization of, and 
expenditure on, active chemotherapeutic agents by prevalence figures that include 
patients with non-active disease. Furthermore, the methods used in Chapter 3 could in 
theory be used to adjust for the total number of patients on active, anticancer therapy in 
each country-year. Country-level analyses in this study however evaluated aggregate 
sales volumes, and therefore were not adjusted using estimates of the number of patients 




Third, adjusting cancer drug utilization and expenditure by incidence rather than 
prevalence arguably provides a more accurate estimate of the total value obtained from 
expenditure on cancer drugs. Yearly cancer incidence captures all new cancer cases 
occurring within that year, while cancer prevalence is defined as the total number of 
patients who are still alive within some period after diagnosis.(295) Total yearly 
incidence can therefore be thought of as an upper limit to the one-year prevalence of 
cancer, and both parameters would, in theory, equal one another were no deaths to 
occur. Given the often-lethal nature of cancer, however, estimates of total yearly cancer 
incidence are expected to be higher than one-year cancer prevalence in most settings. 
Country-level estimates of yearly cancer incidence from the GLOBOCAN registry are in 
fact often greater than those observed for one-year cancer prevalence. A similar 
argument applies to total incidence of malignant neoplasms over a five-year period, and 
the corresponding five-year prevalence value.  
 
As with incidence, adjusting for cancer prevalence helps to overcome potential biases 
from international differences in the risk of illness onset, and therefore helps to compare 
drug usage internationally.(74,75) However, adjusting for prevalence—as defined by 
GLOBOCAN—fails to account for patients who die within one year of diagnosis but who 
nevertheless would be expected to receive at least some treatment for active 
malignancies. In the absence of observational data that is internationally 
comparable,(75) total incidence of malignant neoplasms is therefore taken as the most 
representative estimate of the number of patients with active malignancies who would 
be expected to receive treatment. It is therefore used to adjust country-level estimates of 





On an aggregate level, cancer drug spending is generally meant to prolong life once 
disease has occurred. YPLLs due to all neoplasms is therefore taken over time as a 
country-level indicator of the impact on health from cancer drug spending. The 
incremental change in total, incidence-adjusted drug expenditures and neoplasm-related 
YPLLs were calculated for each country-year in this analysis relative to their base values 
in 2004. Both parameters were then used to derive incremental cost-effectiveness ratios 
corresponding to the incremental change in expense and the incremental change in 
health between 2004 and year 𝑡. Long-term estimates of net value were calculated by 
subtracting incidence-adjusted excess treatment costs (∆𝐶) from the monetized value of 
survival gains (∆𝑉) observed in each country 𝑐 between 2004 and year 𝑡 (Eq. ( 8 )), based 
on patients’ willingness to pay for a diminished risk of death from drug treatment.(82) 
This approach was adapted from Eggleston and colleagues (2009),(82) who used it to 
estimate the net value of health care for patients with type 2 diabetes. The recent 
literature has also adopted this approach to examine the value from long-term changes 
in healthcare spending and cancer survival in cancer populations.(22,33,35,80) For 
reasons explained in Chapter 3, its use of US SEER data nevertheless makes it difficult to 
conduct this analysis across country settings. 
 





Country-level analyses used US$100,000 to conservatively value a statistical life year in 
the absence of disease (𝑉𝑆𝐿𝑌). Given its centrality to this study, a brief overview to the 




To then estimate the long-term net value generated by each country from cancer drug 
spending, yearly, incidence-adjusted estimates of the net value generated from survival 
gains were multiplied by country-level estimates of the total yearly number of incident 
cases of neoplasm.  
 
To examine the net value from spending on cancer medicines, in particular, it was 
necessary to assume that some percentage of survival improvements were attributable to 
pharmaceutical innovation (𝑎). Eq.( 8 ) was modified to account for this:  
The concept of the  𝑉𝑆𝐿 and 𝑉𝑆𝐿𝑌 is explained in detail elsewhere.(365) An overview to this concept is nevertheless 
provided here. The 𝑉𝑆𝐿  is a monetary figure representing the amount of wealth (𝑊) that an individual would be 
willing to forgo in return for a reduction in the probability of death (𝑃). The 𝑉𝑆𝐿𝑌 specifically relates to the monetary 
sum that an individual would be willing to forgo in return for some probabilistic increase in extending life by one 







1 − (1 + 𝑟)−𝐿
 
 
Where 𝐿 is defined as life expectancy, and 𝑟 is the discount rate, which is assumed to be 3%.(299) 
 
The value that is assigned to life does not need to be constant, and can vary across individuals due to a number of 
different factors, including personal wealth and preferences, and is frequently calculated through stated 
preferences.(365) Disease type and severity can also impact the value that is assigned to life, with the literature 
suggesting that a premium applies to cancer. Nevertheless, since modern health systems generally involve a tradeoff 
between health and wealth, the concepts of 𝑉𝑆𝐿 and 𝑉𝑆𝐿𝑌 can be used to represent the transactions that are incurred 
by payers in return for treatment that is believed to be associated with some probabilistic extension to life. The 
literature has provided many estimates for the 𝑉𝑆𝐿𝑌, though most generally range between $100,000–
$300,000.(33,80,297–300,366–371) New treatments for use in cancer at the end of life may be valued at the higher end 
of this range, or ~$300,000 per life year.(304) Alternative methods for measuring patients’ willingness to pay for 
improve survival may try to calculate a patient’s WTP for longevity gains using lifetime income data, while accounting 
for discrete increases in survival probabilities.(303) Studies that have adopted this approach in cancer estimate that 
the annual value placed on CML treatment, based on the average lifetime income of patients, is ~$110,000 per life year 
gained.(35) Within this backdrop, this chapter takes $100,000 per life year gained from treatment as a conservative 
VSLY estimate. 




 𝑁𝑉𝑐𝑡 = [(𝑎𝑐𝑡 ∗ |∆𝑌𝑃𝐿𝐿𝑐𝑡|) ∗ 𝑉𝑆𝐿𝑌] −  Δ𝐶𝑐𝑡 ( 9 ) 
 
 
Base-case levels of attribution were calculated for each country as the percentage 
between country-specific improvements in neoplasm-related YPLLs and the average, 
total improvement in OS of 3.43 (SEM, 0.63) months between 2003-2013 from all new 
anticancer medicines approved by the US FDA or EU EMA over this period, a finding 
from Chapter 2 of this thesis. This figure represented 19%, 14%, 17%, and 26% of the total 
improvement in neoplasm-related YPLLs observed in Australia, France, the UK, and the 
US, respectively, between 2004-2014 (Table 13). These values were consistent with a 
recent study reporting that all 58 cancer drugs newly marketed over the 18-year period 
1995-2013 increased cancer life expectancy by an average of 0.46 years in the US.(73) 
They are however somewhat more conservative than those reported by Jönsson & 
Wilking (2007), in which 44% of the increase in the cancer survival rate observed in the 




Table 13. Attribution of Long-Term Improvement in Cancer Patient Survival to Cancer Drug Innovation 
Country 
ΔOSdrugs, 03-13 (years)1 ΔYPLLcountry, 04-14 
(years)2 
Attribution (%)3 
Mean -SEM +SEM aMean a-SEM a+SEM 
Australia 0.29 0.23 0.34 1.472 19% 16% 23% 
France 0.29 0.23 0.34 2.053 14% 11% 16% 
UK 0.29 0.23 0.34 1.641 17% 14% 21% 
US 0.29 0.23 0.34 1.109 26% 21% 31% 
 
Source: 
Authors’ analysis of data, as described in Methods section. 
 Notes: 
1 From chapter 2, average (SEM) OS benefits between 2003-2013 associated with all anticancer medicines newly licensed 
by the US FDA and EU EMA over this period.  
2 Total, country-level, incidence-adjusted, neoplasm-related YPLLs. For convenience, values for the change in YPLL 
between 2004-2014 are multiplied by -1. 
3 Percentage of the improvement in total, country-level, incidence-adjusted, neoplasm-related years of potential that 




A multivariate linear regression was used to examine the country-level determinants of 
value from cancer drug spending. In particular, previous studies have explored the 
relationship between country-level expenditures on total cancer care and cancer 
outcomes,(8) but have not accounted for patterns of cancer drug utilization. To begin to 
explore the relationship between country-level patterns of cancer drug use and patient 
outcomes, this study examined the association between incidence-adjusted, country-





The methods outlined by Eggleston and colleagues (2009) were also used within a 
simulation-based analysis to estimate the long-term net value from spending on new 
anticancer medicines. This approach was designed to help account for parameter 
uncertainty, and to estimate the range of plausible outcomes pertaining to the net 
economic value from drug-related extensions to life.  
 
In this section, health gains were defined in terms of the expected OS benefit to patients 
from treatment with new medicines (𝑂𝑆𝑖). Estimates of the total OS benefit from new 
cancer drugs over best alternative therapies were extracted from Australian, English, and 
French health technology appraisals, as explained in Chapter 2. A triangular distribution 
was used to model any variability in the magnitude of drug-specific OS benefits accepted 
by English, French, and Australian HTA agencies. Survival benefits were monetized 
using a triangular distribution of published estimates for values of a statistical life year 
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(𝑉𝑆𝐿𝑌), which typically range between US$100,000-US$300,000 per life year.(80,297–
300) A peak probabilistic weight was assigned to the midpoint of any range in these 
measures. This approach builds on the methods used elsewhere: Lakdawalla and 
colleagues (2009, 2015) take a fixed estimate of $200,000 to assign monetary value to 
gains in life-years, while assessing the impact from uncertainty in this parameter with 
the use of sensitivity analyses.(80,301) 
 
In the absence of patient-level registries to describe the total cost of treatment associated 
with comparator therapies, excess treatment costs per patient 𝑖 in each country 𝑐 and 
year 𝑡 following market entry (𝑒𝑇𝐶𝑖𝑐𝑡) were estimated by assuming that they equaled 
10%, 50%, or 90% of the full, expected cost for treatment with the new intervention. Data 
on the expected drug costs for treatment with new cancer medicines was obtained from 
Chapter 3. Base-case analyses considered a conservative excess treatment cost estimate 
equal to 10% of total cost per treatment with each new medicine, and 
assumed that treatment duration  For more information 
on how these estimates were derived, please refer to Chapter 3. 
 
This approach is consistent with recent articles describing growth in cancer drug pricing. 
Kantarjian and colleagues (2013) suggest that cancer drug pricing is often not based on 
evidence, but rather set to reflect what the market can bear, arguing (32): 
 
“pharmaceutical companies seem to analyse the market response to the most 






Rockoff (2015) similarly describes an “arcane” drug pricing process for Pfizer’s Ibrance 
that considered two benchmarks, Herceptin—a widely used medicine for breast cancer 
that looked “about as good” as Ibrance, according to clinical experts—and Afinitor—
Ibrance’s most direct and recently developed competitor. On a monthly basis, Herceptin 
was priced ~50% ($4,775 in late 2013) below the agreed-upon price for Ibrance ($9,850). 
Meanwhile, the monthly price for Afintor was initially “slightly [below]” that of Ibrance.  
 
The deterministic model of the net value generated per patient 𝑖 from treatment with 
each new medicine in each country 𝑐 and year 𝑡 following market entry (𝑁𝑉𝑖𝑐𝑡) is 




The total, expected net economic value generated at a societal level from extensions to 
life from individual cancer medicines was then estimated. For this, per patient estimates 
of net value generated from drug spending in each country-year (𝑁𝑉𝑖𝑐𝑡) were multiplied 
by the total expected number of patients receiving treatment in each year following 
market entry (𝑇𝑃𝑐𝑡), with the latter variable populated using data from Chapter 3. For 
more information on the methods used to estimate 𝑇𝑃𝑐𝑡, please refer to Chapter 3. 
 
 𝑁𝑉𝑐𝑡 = 𝑁𝑉𝑖𝑐𝑡 ∗ 𝑇𝑃𝑐𝑡 ( 11 ) 
 




A series of 2,000 Monte Carlo simulations were used to generate a range of plausible 
estimates of the net economic value per patient and to society from spending on 
individual cancer medicines. Since new or modified indications can be approved over the 
active life cycle of new medicines, this analysis was limited to the first three years of 
marketing after initial licensing (Y0, Y1, and Y2). Yearly observations were also censored 
once new or modified indications (target conditions), dosing regimens, or modifications 
to the approved patient population were approved for new medicines. For more 




Failure to adjust for population and epidemiological factors can confound country-level 
comparisons of cancer drug utilization and expenditure.(74,75) In the absence of 
international registries providing long-term data on patient care and outcomes,(75) this 
study adjusted country-level analyses of cancer drug utilization and expenditure by total 
yearly incidence of neoplasms, drawing on data that was available over the entire 2004-
2014 period. Yearly cancer incidence captures all new cancer cases occurring within that 
year. In contrast, one- and five-year cancer prevalence is defined by the GLOBOCAN 
registry as the number of cancer patients still alive one- or five-years after first receiving 
their diagnosis.(295) This approach is preferred as antineoplastic agents are, by 
definition, typically given to patients with active malignancies. Adjusting for 
prevalence—as it is defined by GLOBOCAN—fails to capture the full population of 
patients who die within one year of diagnosis but who nevertheless may be expected to 




test for robustness, sensitivity analyses adjusted country-level estimates of cancer drug 
utilization and expenditure by total population and cancer prevalence.  
 
Base case values of the percentage of long-term survival gains that could be attributed to 
pharmaceutical innovation were calculated on the basis of findings from Chapter 2. 
Chapter 2 found that all anticancer medicines newly licensed by the US FDA and EU 
EMA extended OS by a total average of 3.43 (SEM, 0.63) months between 2003-2013, 
which represented 19%, 14%, 17%, and 26% of the total improvement in neoplasm-related 
YPLLs observed in Australia, France, the UK, and the US, respectively, between 2004-
2014 (Table 13). Under the assumption that new medicines were integrated into 
Australian, French, UK, and US markets after receiving licensure by regulatory 
authorities, these figures were taken as base case estimates of the percentage of long-
term, country-specific survival gains that could be attributed to drug development. To 
account for uncertainty in these parameters, two sensitivity analyses were performed. 
The first re-calculated attributable health gains using ± 1 SE (0.63 months) of the mean, 
total long-term OS benefit (3.43 months). The second assumed that 10%, 25%, 50%, 75%, 
or 90% of the survival gains that were observed in this study owed to the development of 
new medicines.  
 
Country-level analyses assumes that the total yearly incident population represents the 
total number of cancer patients receiving cancer drug treatment. Given that patients 
may survive from earlier periods and require systemic, anticancer treatments over a 
multi-year period, the actual patient population in any year may be larger than the total 
number of new cancer cases. If the treatment population is indeed larger than the 
population with incident disease, this approach would likely overestimate per-patient 
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costs and utilization of treatment. There are several reasons to nevertheless believe that 
this is not a major concern in this study: even if one were to assume that some number 
of actively treated patients (𝑥) carry-over from the previous year (𝑦 − 1), a similar 
number of patients (~𝑥) are also likely to carry over to the following year (𝑦 + 1). In the 
absence of an international registry providing comparable data on cancer drug use, this 
chapter also conducted a sensitivity analysis to model the potential impact from such a 
scenario by assuming that the total population receiving treatment was 50% larger than 
the total number of incident cancer cases.  
 
Moreover, differences in value obtained from spending on cancer medicines are likely to 
partially reflect differences in the mode and intensity of treatment. To shed light on how 
these factors could account for differences in the value obtained from the cancer drug 
expenditures that were observed in this study, main analyses were stratified by dosage 
form (oral, injectable) and years since market launch (0-5 years, 6-10 years, >10 years).  
 
Limitations 
QuintilesIMS drug pricing data reflects the list price rather than transaction price; 
discounts and rebates are not built in. Given the potentially guarded nature of drug 
procurement, it is impossible for this study to systematically adjust for pricing discounts. 
Regardless, any level of discount would mean that this analysis overestimates drug 
expenditures and underestimates value. It is however unclear whether this limitation has 
any practical impact on this study: this issue applies to costing estimates for all drugs 
and all four countries, and medicines in the same therapeutic category often receive 
comparable levels of discount.(302) The interpretation of this analysis nevertheless 
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remains valid with respect to costs that are based on list prices. Future studies should 
however explore this issue. 
 
Yet, QuintilesIMS data also does not incorporate costs associated with drug dispensing, 
administration, or supportive care, suggesting that this analysis underestimates the 
social cost associated with cancer treatment. This issue may be particularly important in 
oncology, where drug treatments are often dispensed in dissolvable preparations for 
intravenous, intramuscular, or subcutaneous administration in inpatient or outpatient 
settings.  
 
This chapter conducts a cost-benefit analysis, and uses the VSLY to monetize life years 
gained. This approach is adopted from previous studies examining the value of new 
healthcare interventions,(82) including for cancer.(22,35,80) Alternative methods for 
health economic evaluation exist, including cost-effectiveness and cost-utility analyses. 
Cost-utility analyses, for instance, can adjust clinical outcomes by measures of quality of 
life, but require that quality weights be derived through standardized procedures. Cost-
benefit analysis is designed to address the question of whether the benefits of an 
intervention exceed its costs, and is therefore used in this chapter. This approach was 
also adopted to assess all new cancer drug treatments, rather than focus on specific 
agents.(22)  
 
One challenge to c0st-benefit analysis is in the assignment of monetary values to health 
benefits. This study was designed to assess the value generated from drug-related 
survival benefits based on the VSLY, which measures patients’ willingness to pay for 
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improved survival. Alternative approaches include using classic WTP thresholds, or 
calculating a patient’s WTP for longevity gains using lifetime income data, while 
accounting for discrete increases in survival probabilities.(303) Yin and colleagues 
describe the use of this approach in CML (35): 
 
“the annual value of TKI-related survival gains is equivalent to the increase in 
annual income necessary to make a CML patient indifferent to the pre- and 
post-treatment survival curves, which is also equivalent to the patient’s 
willingness to pay for treatment.” 
 
Using this approach, Yin and colleagues (2012) estimate that the annual value placed on 
treatment with first-line imatinib, based on the average lifetime income of patients, is 
~$110,000 per life year gained.(35) This value is similar to, yet still higher, than the VSLY 
used in this chapter. It is also unclear whether patients may in fact be willing to “pay 
nearly their entire end-of-life wealth for as little as a few extra weeks of life.”(33)  
 
Unlike other approaches, the VSLY elicits stated preferences, and may therefore provides 
a more objective measure of the value from probabilistic extensions to life. This may be 
particularly important in cancer, where premiums may apply to end-of-life 
valuations.(304) Even where alternative approaches have been used to monetize life 
gains, the VSLY-based approach is accepted as a viable “method for estimating the value 
of cancer survival improvements.”(33) The more recent literature has also relied on this 
approach.(22,80) It is nevertheless important to interpret results with caution: while this 
chapter adopts established methods, and uses a conservative VSLY estimate, 
standardized VSLY estimates may not apply consistently to all patients and contexts. 
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Future studies may build on this analysis by deriving VSLY estimates that are specific to 
drug-indication settings. 
 
In the absence of RWD on the clinical impact from entry and uptake of new cancer 
medicines, base-case calculations of net value attributed 19%, 14%, 17%, and 26% of the 
total, long-term improvement in neoplasm-related YPLLs in Australia, France, the UK, 
and the US, respectively, to cancer drug innovation. This approach was based on the 
finding from Chapter 2 that all anticancer medicines newly licensed by the US FDA and 
EU EMA between 2003-2013 increased OS by 3.43 (SEM, 0.63) months. The US figure was 
also consistent with those reported in US-based studies.(73,296) To nevertheless 
examine the impact from any uncertainty in attributing health gains to the development 
of new cancer medicines, a sensitivity analysis was performed by assuming that 
anywhere between 10% and 90% of long-term health gains could be attributed to 
pharmaceutical innovation. Since recent pharmacological breakthroughs exist alongside 
innovations in medical care,(305) and evolving public health systems, it is unreasonable 
to presume that drug development accounts for none (0%) or all (100%) of the long-term 
improvement in cancer survival observed in any country. 
 
Since internationally comparable data on actual drug use is not yet available for all 
marketed cancer medicines,(75) country-level analyses used sales volume as a 
proxy.(74,75) In theory, there may be some disparity between sales volume and drug 
utilization. This however is unlikely to be a major concern in cancer, where drug 
adherence is likely to be high: cancer treatment is often dispensed at time of prescription 
or in professional healthcare settings, and even if it is not, cancer patients would be 




Cancer drugs were excluded from drug-level analyses if HTA agencies were unable to 
quantify their impact on OS, as this evidence is necessary to monetize drug-related gains 
in life-years. While there is no reason to believe that this restriction introduces bias, 
future studies should attempt to validate this approach by incorporating more recent 
and definitive evidence of the impact on survival from new cancer medicines.  
 
The MIDAS extract from QuintilesIMS only included pricing and volume data for cancer 
medicines that were licensed between 2003-2013. Without the means for estimating the 
costs for all therapeutic comparators, uncertainty in excess treatment costs was 
addressed through sensitivity analysis: this parameter was set to equal 10%, 50%, and 
90% of the total cost  of treatment with each new medicine 
(Chapter 3), with base-case analyses based on the first, and most conservative, scenario. 
There is a dearth of systematic, publicly available evidence describing how treatment 
costs evolve over time. The approach used here was nevertheless consistent with a recent 
article describing the “arcane” drug pricing process for Pfizer’s Ibrance (306): around the 
time of market entry, the monthly price of a widely-used breast cancer medicine that 
clinical experts suggested was clinically comparable was ~50% less than that of Ibrance. 
Ibrance’s price was, at the same time, “slightly above” that of its most direct and recently 
developed comparator, Novartis AG’s Afinitor. To nevertheless reduce the uncertainty in 
excess treatment cost estimates, future studies should extend this analysis by licensing 
an unrestricted pricing and volume dataset and by using RWD, as it becomes available.  
 
In line with previous studies,(82) this analysis monetizes survival exclusively, and does 




while the largest share of new cancer medicines is associated with QoL benefits, a 
similarly large share reduces patient safety. Improvements in QoL would be expected to 
increase the value that patients give to health, which would likely skew the monetized 
value of survival gains upward; reductions in safety would do the opposite. That cancer 
patients may exhibit negative time discounting (307)—perhaps explaining “cancer 
premiums” that apply to VSLYs (298)—could suggest that temporary reductions in safety 
have a relatively low impact on the net value derived from treatment if it means longer 
overall life. This is in fact reflected in ASCO’s Value Framework for cancer treatment 
options, where survival benefits are given the most weight when estimating NHB scores 
for new medicines.(12) The degree to which this is true may however vary by cancer 
staging, severity, and personal preferences.  
 
In the absence of patient-level data to monetize changing health states across all new 
cancer medicines, this chapter does not attempt to model the economic value from 
drug-related changes in QoL and safety. To address this gap, future studies could 
attempt to bridge the methodology used here with the valuing health literature, as well 
as recent empirical advances quantifying the willingness-to-pay for QoL benefits.(308) 
 
Finally, the lack of a comparable, international cancer drug registry also prevents this 
study from exploring how personal and demographic factors, as well as local preferences 
for treatment across cancer stages, that may impact the association between spending 
and clinical outcomes. Although these analyses would help inform the interpretation of 
results, their absence does not bias this study. Future investigations may nevertheless 








All countries witnessed an increase in the total number of available cancer drug 
molecules between 2004-2014, though rates of entry vary (Table 14). Availability of 
cancer drug molecules today is highest in the US, with the UK and France close behind. 
With the exception of Australia, global cancer drug availability has moved towards parity 
with the US (Table 14), suggesting comparable levels of value to patients from drug 
development.  
 
There has been a decline in the branded drug share of oncology drug markets, with 
countervailing growth in the number of generic medicines. A majority of cancer 
molecules nevertheless remain available exclusively in branded form (Table 14). Among 
the four countries, France has led the decline in branded market share, though the 
country continues to have the highest proportion of cancer drugs available exclusively in 
branded form. Unlike other countries included in this analysis, Australia witnessed a 
modest increase in branded market share between 2004-2014 (Table 14), perhaps owing 
to delays in drug entry.(309) 
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Table 14. Description of Cancer Drug Markets, Sales Volume, and Expenditures, 2004-2014 
 Australia France UK US 
 2004 2014 2004 2014 2004 2014 2004 2014 
Market         
Total molecules available 75 97 87 126 81 127 86 131 
Percent of US molecules 87% 74% 101% 96% 94% 97% 100% 100% 
Manufacturers / drug  1.8 2.8 1.6 2.8 2.2 2.6 2.3 2.7 
Percent total molecules, branded1 48% 54% 79% 71% 63% 63% 66% 65% 
Sales Volume         
Total2 4039 6897 17567 25131 13552 23103 69527 87786 
Incidence-adjusted3 43291 53565 60645 67577 48189 67019 50351 54109 
Incidence-adjusted, branded3 35542 44346 49508 52478 36587 21307 17953 15597 
Incidence-adjusted, generic3 7749 9219 11137 15099 11603 45712 32397 38512 
Expenditures     
Total4 $1.6 $3.4 $7.4 $13.7 $4.3 $11.2 $53.3 $119.9 
Incidence-adjusted5 $17,515 $26,498 $25,601 $36,830 $15,461 $32,615 $38,571 $73,920 
Incidence-adjusted, branded5 $15,121 $23,919 $24,091 $32,304 $13,600 $25,826 $35,701 $66,088 
Incidence-adjusted, generic5 $2,393 $2,579 $1,511 $4,527 $1,861 $6,789 $2,870 $7,831 
 
Source: 
Authors’ analysis of data, as described Methods section. 
 Notes: 
1 Percentage of total available molecules sold exclusively in branded form. 
2 Volume sales given in terms of kilograms (million milligrams). 
3 Volume sales given in terms of incidence-adjusted milligrams. 
4 Expenditures given in terms of billion constant 2014 US dollars. 





There were wide variations in incidence-adjusted cancer drug use across the four 
countries. Relative to other countries, Australia consistently used a low volume, while 
France used a high volume, of cancer medicines. Total, incidence-adjusted volumes of 
utilization are now significantly greater than the global average in France and the UK, 
and significantly less than the global average in Australia and the US (Figure 9).  
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Patterns of drug utilization however varied by patent status, over time (Figure 9), and 
across cancer drug classes (Figure 10). The US, for instance, was associated with a 
consistently high volume of use of generics, but a low volume of use of branded 
medicines, relative to the other countries in this analysis. In 2014, the US fell above the 
95% confidence interval for the global average sales volume of antimetabolites (L1B) 
proportional to country-specific, incidence-adjusted sales volumes of all cancer 
medicines. The same was also true for all other antineoplastics (L1X), and cytostatic 
hormone antagonists (L2B), suggesting comparatively high levels of utilization of these 
molecules. The US however fell below the global 95% confidence interval for sales 
volume of platinum antineoplastics (L1F), monoclonal antibody antineoplastics (L1G), 
and cytostatic hormones (L2A)(Figure 10).   
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Total Cancer Drug Sales Volume(mg), Incidence-Adjusted, by Country and ATC, 
2004-2014




Global expenditures on cancer drugs have risen sharply between 2004-2014, in total and 
across both branded and generic drug markets. Compound annual growth rates in total, 
incidence-adjusted cancer drug expenditures varied widely, averaging 4% in France, 4% 
in Australia, 7% in the US, and 8% in the UK (Table 14). 
 
Total expenditures on branded medicines accounted for a sizeable portion of the overall 
increase in expenditure on cancer drugs, with incidence-adjusted compound annual 
growth rates in expenditure on all branded drugs of 3% in France, 5% in Australia, 6% in 
the US, and 7% in the UK. Expenditures on branded medicines increased even as their 
market share declined, reflecting branded drug prices that rose at a compounded annual 
rate of 1% in France, 4% in the UK, 8% in the US, and 9% in Australia.  
 
Incidence-adjusted expenditure on generic medicines nevertheless rose at a faster rate in 
most countries, rising at a compounded rate of 1% in Australia, 11% in the US, 12% in 
France, and 14% in the UK per annum (Table 14). Increases in generic drug expenditure 
reflected increased generic drug use, but also increases in generic drug price. At a 
country-level, these rose at a compounded rate of 0.3% in Australia, 4% in the US, 5% in 
the UK, and 9% in France. 
 
Total expenditures on cancer medicines also varied widely, even after standardizing for 
cancer epidemiology (Figure 11). On an incidence-adjusted basis, the US has consistently 
outspent other countries across all classes of cancer therapeutics, as well as both 
branded and generic drug markets.  
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Growth in total US drug spending appears to be associated with increased spending on 
monoclonal antibody antineoplastics (L1G) and protein kinase inhibitor antineoplastics 
(L1H)(Figure 12). The UK has risen from fourth to third in total, incidence-adjusted 
expenditures on cancer medicines relative to the other countries in this analysis, and, 
except for the US, it now outspends all other countries on generic medicines. Australia, 
in contrast, has consistently controlled its expenditures on cancer medicines, and now 
spends less than all other countries in this analysis on both branded and generic 
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Total Cancer Drug Expenditures, Incidence-Adjusted, by Country and ATC, 2004-
2014




All countries witnessed an increase in incidence-adjusted total expenditure on cancer 
drugs between 2004-2014, as well as a decline in YPLLs from all neoplasms (Table 15).  
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t = 2004 t = 2014 Δ t t = 2004 t = 2014 Δ t4 
France $25,601.27 $36,830.44 $11,229.17 7.835 5.781 2.053 $5,468.52 
Australia $17,514.54 $26,498.12 $8,983.58 6.304 4.832 1.472 $6,102.50 
UK $15,460.92 $32,614.71 $17,153.79 7.193 5.553 1.641 $10,456.35 
US $38,571.21 $73,919.51 $35,348.30 6.720 5.610 1.109 $31,861.53 
 
Source: 
Authors’ analysis of data, as described in Methods section. 
Notes: 
1 Adjusted to reflect incidence-adjusted expenditure (cost, C) or YPLLs (effect, E). 
2 Figures given in terms of constant 2014 US dollars. 
3 Effect is given in terms of YPLL. 
4 For convenience, values for the change in YPLL between 2004-2014 are multiplied by -1. 




For all countries in this analysis, the incremental cost-effectiveness ratio corresponding 
to the long-term change in cost per year of potential life lost averted between 2004 and 
2014 fell within the north-east quadrant of the cost-effectiveness plane (Table 15), as have 
those for intervening years (Figure 13). These findings suggest that while cancer drugs 
have grown more expensive since 2004, they have also become more effective. 
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However, there is significant heterogeneity in this measure of health economic value 
over time and across countries. ICERs have generally improved over the last decade for 
most countries in this analysis. The UK however is a major outlier in this measure: 
relative to 2004, it spent $8,678.01 more per year of potential life lost averted in 2014 than 
it did in 2005. This is indicative of increases in expenditure on cancer treatments that are 
proportionally larger than improvements in health outcomes, and may reflect 
governmental policies to modernize research and services, e.g. as stipulated in the 1999 
White Paper Saving Lives: Our healthier nation and the 2000 NHS Cancer Plan.(310) 
 
In general, although the past decade has witnessed an improvement in the incremental 
cost effectiveness ratio associated with cancer drug treatment—which reached their 
nadir in or around 2006—for most countries (particularly the US) there has been a 
recent reduction between 2013-2014 in the value obtained from long-term increases in 
cancer drug spending. The US is also consistently associated with the lowest 
improvements in health from cancer drug spending, spending more than three times as 
much as the next country (UK) per year of potential life lost averted in 2014 (Figure 13). 
At the extremes, France obtained close to six times as much return in health gains per 
dollar spent on cancer drugs as the US in 2014. 
 
Estimates of net value were calculated by assuming that 19%, 14%, 17%, and 26% of the 
long-term improvement in YPLLs in Australia, France, the UK, and the US, respectively 
(𝑎𝑀𝑒𝑎𝑛) owe to innovations in cancer medicines (Table 16). For all countries except the 
US, cancer drug care produced net positive value under all scenarios (Table 16). 
Although the US did not obtain net positive economic returns from long-term increases 
in cancer drug spending under base case assumptions, this analysis indicates that 
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positive returns from spending on cancer medicines would have been generated in 2014 
if ≥32% of the long-term improvement in YPLLs had been attributable to drug 
development (Table 16). 
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Table 16. Net Value from Cancer Drug Spending, per Neoplasm and to Society, Country Mean ± Standard 
Error Level of Attribution (a), 2004-2014 
Country 
Net Value per Neoplasm3,4 Net Value to Society5 
a-SEM aMean a+SEM a-SEM aMean a+SEM 
Australia $14,351.57 $19,601.97 $24,852.38 $1.85 $2.52 $3.20 
France $12,108.95 $17,360.03 $22,611.11 $4.50 $6.46 $8.41 
UK $6,172.63 $11,421.08 $16,669.52 $2.13 $3.94 $5.75 
US -$12,005.81 -$6,753.75 -$1,501.69 -$19.48 -$10.96 -$2.44 
 
Source: 
Authors’ analysis of data, as described in Methods section. 
Notes: 
1 Country records sorted by estimates of the net value generated per neoplasm when the percentage of long-term 
survival gains attributed to cancer drug innovation equals aMean. See 
ERGEFORMAT Table 13 for the values of attribution a that are used in this analysis 
(mean, SEM). 
2 Values may not sum due to rounding errors. 
3 Adjusted to reflect incidence-adjusted expenditure (cost, C) or YPLLs (effect, E). 
4 Figures given in terms of constant 2014 US dollars. 
5 Figures given in terms of billion, constant 2014 US dollars.  
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Across the four countries, total net positive economic returns from oncology drug care 
amounted to US$1.96 billion in 2014 under the base case assumption that cancer 
medicines contributed to 19%, 14%, 17%, and 26% of the long-term improvement in 
YPLLs in Australia, France, the UK, and the US, respectively (𝑎𝑀𝑒𝑎𝑛) (Table 16). From the 
perspective of value, the US accounted for 80.9% of total expenditures on cancer drugs 
across the four countries evaluated in this study, yet it was the only country to obtain 
negative net economic returns (-$10.96 billion) in 2014 from oncology drug spending 
under base case assumptions (Figure 14). 
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Figure 14. Country-Level Expenditure and Net Positive Returns Generated from Cancer Drugs as a Share of 
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Base-case, country-level analyses indicate that long-term increases in total US 
expenditures on cancer medicines resulted in a net negative return of -$10.96 billion in 
2014 (Figure 15). A notable uptick in the net value derived from cancer drug spending 
was observed between 2007-2013, perhaps reflecting therapeutic developments. 
However, long-term estimates of the net value derived from cancer drug spending has 
more recently begun to trend downwards (Figure 15). The US lags behind Australia 
(Appendix 4.2), France (Appendix 4.3), and the UK (Appendix 4.4) in total net economic 
returns generated in 2014 from cancer drug spending.  
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Net Value Generated from Oncology Drug Care by Level of Attribution to Health 
Gains, United States, 2004-2014
US (10%) US (-SE: 21%) US (25%) US (Mean: 26%) US (+SE: 31%) US (50%) US (75%) US (90%) 
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Multivariate linear regressions with longitudinal data were used to explore the 
association between country-level drug development, patterns of utilization, and 
improvements in cancer outcomes (Table 17). The analysis suggests that generic drug use 
may be weakly associated with reductions in neoplasm-related YPLLs. While the 
complexity of country-level associations requires that these results be interpreted with 
caution, results from this analysis suggest that it may be possible to optimize patient 




Table 17. Country-Level Multivariate Linear Regression Analysis with Panel Data, Cancer Drug Use and 
Health Outcomes for Australia, France, the UK, and the US 
Variable Model1 
 (A) (B) (C) (D) (E) (F) (G) (H) 
Dep. Var. YPLLi YPLLi YPLLi YPLLi YPLLi YPLLi YPLLi YPLLi 
Ind. Var2 1 1, 2 1, 3 1, 2, 3 1, 4 1, 2, 4 1, 2, 4, 5 
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Country FE Yes Yes Yes Yes Yes Yes Yes Yes 
Observations 44 44 44 44 40 40 40 40 
R2 0.465 0.801 0.953 0.959 0.470 0.775 0.829 0.965 
Adj R2 0.452 0.791 0.937 0.943 0.442 0.756 0.810 0.947 
 
Source: 
Authors’ analysis of data, as described in Methods section. 
Notes: 
1 Table provides estimated coefficients (SEM) of country-level associations between total cancer drug sales volume (kg) 
per incident neoplasm, percentage of total cancer drugs sales volume (kg) associated with generics, year dummies, and 
1-year lags on the mean number of neoplasm-related YPLLs per incident neoplasm (YPLLi) for Australia, France, the 
UK, and the US between 2004-2014. 
2 1: kg_inc; 2: % kg generic; 3: year dummies; 4: 1 lag, kg_inc; 5: 1 lag, % kg generic. 
2 Reference categories: Year = 2004. 






The net value generated per patient from spending on the 43 new cancer medicines that 
were included in this analysis varied widely (Appendix 4.5), with base-case estimates for 
the US ranging between -$17,243.59 for clofarabine (SD: $8,613.28; p25: -$22,812.32; p50: -
$15,358.18; p75: -$8,096.32) to $248,579.01 for pertuzumab (SD: $54,323.34; p25: 
$209,067.44; p50: $249,569.02; p75: $286,987.97) in the first year of marketing, Y0. On 
average, breast cancer medicines generated the greatest net value per patient in Y0 in the 
US (mean: $97,902.34; SD: $103,844.52; p25: $29,754.25; p50: $61,003.71; p75: $166,050.42). 
This was followed by medicines that were indicated for renal cancer (mean: $85,131.96), 
skin cancer (mean: $81,378.06), prostate cancer (mean: $44,982.75; SD: $31,990.41; p25: 
$22,421.62; p50: $55,565.09; p75: $67,543.87), hematological malignancies (mean: 
$35,779.39; SD: $76,495.91; p25: -$11,465.04; p50: -$5,696.81; p75: $143,898.71), GI cancer 
(mean: $34,507.83; SD: $19,877.37; p25: $18,074.36; p50: $31,444.72; p75: $50,941.30), and 
lung cancer (mean: $16,817.91; SD: $26,606.78; p25: -$5,421.28; p50: $15,782.75; p75: 
$39,057.10).  
 
On average, orphan medicines were associated with larger estimates of net value per 
patient (in Y0, US, mean: $56,575.10; SD: $82,528.27; p25: -$6,239.54; p50: $32,081.61; p75: 
$85,131.96) than non-orphan medicines (in Y0, US, mean: $38,194.40; SD: $27,223.74; p25: 
$18,074.36; p50: $41,126.96; p75: $62,067.36).   
 
For the medicines with data from all four countries, estimates of the net value generated 
from treatment were, on average, lowest in the US, where the mean value in Y0 equaled 
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$63,466.25 (SD: $73,565.29; p25: $19,121.10; p50: $44,900.46; p75: $83,521.84). It was 
followed by the UK (mean: $64,328.22; SD: $72,738.03; p25: $20,402.78; p50: $46,952.83; 
p75: $84,905.70), Australia (mean: $66,010.31; SD: $74,734.34; p25: $7,986.16; p50: 
$48,730.35; p75: $90,800.33), and France (mean: $66,370.62; SD: $73,322.31; p25: $21,119.12; 
p50: $48,107.37; p75: $89,577.93).  
 
Average estimates of net value generated from treatment with new cancer medicines 
generally remained stable over time. In the US, the average net value generated from 
treatment across all available medicines equaled $47,752.36 in Y0 (SD: $61,911.10; p25: -
$516.12; p50: $38,485.59; p75: $69,067.28), $49,632.04 in Y1 (SD: $64,183.89; p25: -$541.42; 
p50: $41,160.46; p75: $69,581.06), and $48,934.91 in Y2 (SD: $65,816.26; p25: -$569.36; p50: 
$38,381.60; p75: $68,466.99). Similar trends were observed in Australia, France, and the 
UK.  
 
Estimates of the total, net value generated in each country-year from spending on new 
cancer medicines were obtained by incorporating evidence on the total, expected 
number of patients completing  therapy (Chapter 3). As for per-
patient estimates, these varied across the medicines that were included in this analysis 
(Appendix 4.6). In the US, for instance, they ranged between -$29,418,407.46 for gefitinib 
to $1,347,571,272.95 for bevacizumab (SD: $10,646,925,469.84; p25: $234,944,619.8; p50: 
$485,167,041.94; p75: $1,084,290,490.7) in the first year of marketing. Skin cancer 
medicines were associated with the largest, mean estimate of the total net value to 
society (in Y0, US, mean: $430,737,678.65). This was followed by medicines that were 
indicated for GI cancer (mean: $369,118,531.96; SD: $652,690,640.30; p25: $28,306,866.88; 




cancer (mean: $259,771,283.99; SD: $204,679,388.61; p25: $124,710,255.54; p50: 
$265,614,620.88; p75: $394,832,312.44), prostate cancer (mean: $205,688,538.29; SD: 
$311,439,301.31; p25: $15,800,134.13; p50: $78,690,304.54; p75: $395,576,942.45), 
hematological malignancies (mean: $171,086,530.49; SD: $349,949,920.85; p25: 
$585,458.55; p50: -$281,151.49; p75: $280,327,191.87), and lung cancer (mean: $10,355,135.93; 
SD: $37,171,965.43; p25: -$15,059,216.68; p50: $5,548,619.32; p75: $35,769,488.54).  
 
On average, orphan medicines generated less net economic value to society (in Y0, US, 
mean: $178,051,798.02; SD: $278,908,048.57; p25: -$301,814.16; p50: $11,797,264.53; p75: 
$280,327,191.87) than non-orphan medicines (in Y0, US, mean: $249,232,516.85; SD: 
$405,199,198.15; p25: $10,870,158.03; p50: $55,689,749.24; p75: $358,381,684.49).   
 
For the medicines where data was available for all four countries, net economic returns 
to society from treatment were, on average, highest in the US, equaling $833,662,703.21 
in the first full-year of marketing, Y1 (SD: $1,323,311,438.70; p25: $76,277,447.07; p50: 
$351,281,540.48; p75: $972,972,604.57). It was followed by France (mean: $145,663,116.87; 
SD: $160,736,281.77; p25: $19,921,205.64; p50: $113,410,323.10; p75: $175,896,680.35), the UK 
(mean: $31,894,554.48; SD: $42,745,035.32; p25: $1,496,828.38; p50: $16,551,287.97; p75: 
$31,742,701.25), and Australia (mean: $15,365,191.83; SD: $32,935,125.41; p25: $656,894.02; 
p50: $6,488,406.44; p75: $11,812,920.16).  
 
Net value to society from treatment with new cancer medicines increased over time, and 
at a rate that exceeded that of the net value generated per patient, likely reflecting drug 
uptake. In the US, for instance, the average net economic return to society from 
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treatment with all new cancer medicines equaled $212,218,543.06 in Y0 (SD: 
$339,800,361.84; p25: -$281,151.49; p50: $39,090,377.37; p75: $286,025,690.33), 
$636,228,222.82 in Y1 (SD: $1,078,218,732.48; p25: -$770,489.23; p50: $222,401,594.82; p75: 
$796,987,759.35), and $598,576,135.72 in Y2 (SD: $865,388,893.90; p25: -$888,589.92; p50: 
$249,123,692.86; p75: $684,800,599.36). Estimates of the total net value to society from 
cancer drug spending also increased over time in France, the UK, and Australia. 
 
Sensitivity Analysis 
To examine the impact from uncertainty in the actual treatment population size on 
country-level analyses, a sensitivity analysis was performed using a modeled total patient 
population size that equaled 1.5x the total number of incident cases of neoplasm that 
were calculated for each year-country. This adjustment had a negligible impact on long-
term ICERs (Appendix 4.7), and though it scaled down estimates of the net economic 
return from cancer drug expenditures, they remained positive under most circumstances 
(Appendix 4.8).  
 
Sensitivity analyses were also conducted by assuming that between 10%-90% of the long-
term, country-level improvements in survival could be attributed to cancer drug 
development (Appendix 4.9). This finding suggests that the US requires proportionally 
larger survival benefits from new cancer medicines for current levels of spending to 
provide net economic returns that mirror what is achieved elsewhere. 
 
Adjusting cancer drug usage and expenditure by total population and cancer prevalence 
did not significantly alter the findings from country-level analyses. Cancer drug 
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utilization and expenditure trends were also largely consistent across oral and injectable 
cancer drug dosage forms, as well as cancer drug age groups. One exception to this was 
the group of drugs that were first marketed 6-10 years ago: countries tended to limit 
utilization of these medicines, instead making use of newer (0-5 years) or older (>10 
years) alternatives.  
 
Discussion 
Global expenditures on cancer drug care rose between 2004-2014, but so too has cancer 
drug development contributed to improvements in patient survival. Internationally, 
however, there appears to be a significant amount of heterogeneity in the value obtained 
from expenditures on cancer medicines. At a country-level, France achieved close to six 
times as much return in total gains in neoplasm-related survival per dollar spent on 
cancer drugs as the US. This disparity is not only driven by economics: while the US 
consistently outspent other countries on cancer medicines between 2004-2014, it also 
witnessed one of the smallest improvements in cancer-related YPLLs.  
 
Nevertheless, expenditures on cancer medicines appear to provide most countries with 
positive economic value. Using data from Chapter 2, base-case, country-level analyses 
suggest that Australia, France, and the UK obtained net positive returns of $2.52, $6.46, 
and $3.94 billion in 2014, respectively, from expenditures on cancer medicines. There has 
been a gradual increase in the value obtained over time, and sensitivity analyses also 




The US however can do better. At a country-level, the US outspends all other countries 
on cancer medicines, despite having the highest level of generic penetration and 
comparable levels of cancer drug utilization. This finding persists even after adjusting for 
population and cancer epidemiology,(74,75) and is consistent across branded and 
generic markets, cancer drug classes, and over time. Country-level analyses suggest that 
growth in US cancer drug expenditures is not primarily driven by utilization—arguably 
key to improving patient outcomes (270)—but rather by high drug prices. From the 
perspective of value, the US was the only country of the four analyzed in this study to be 
associated with net negative economic returns from total, long-term increases in 
aggregate cancer drug spending—at a country-level, the monetized value of long-term 
improvements in cancer survival owing to new medicines, based on patients’ willingness 
to pay for a diminished risk of death from drug treatment, was less than the long-term 
increase in cancer drug spending. The US accounted for 80.9% of total cancer drug 
expenditures in 2014 across the four countries evaluated in this study, yet it received 0% 
of the global total net positive economic returns generated that year from spending on 
cancer medicines (Figure 14). 
 
These findings were consistent with drug-level analyses. Estimates of the net economic 
value generated from the use of new cancer medicines were highest in France, followed 
by Australia and the UK. They were however consistently greater than those observed in 
the US. Under the assumption that the monetized value of survival gains is consistent 
across the four countries, this analysis suggests that lower economic returns from cancer 




Even though aggregate cancer drug expenditures continue to result in net positive value 
in most places, there are reasons to take caution. Globally, while aggregate expenditures 
on branded cancer medicines have risen to new highs, even as volumes have fallen, 
expenditures on generic cancer drugs have often risen at a faster pace and are not fully 
accounted for by increases in utilization. On an incidence-adjusted basis, the UK now 
spends nearly as much as the US on generic cancer drugs, and France and the UK are 
today spending about as much as the US did ten years ago for all cancer medicines. At 
the same time, most of the countries evaluated in this chapter have witnessed a 
compound annual growth rate in total cancer drug expenditures that exceeds historical 
rates of general and medical inflation, and which are comparable to, if not greater than, 
cancer drug expenditure growth in the US. The UK has in fact witnessed the fastest rate 
of compounded growth per annum in cancer drug expenditures (8%), closely followed by 
the US (7%). While these findings suggest that these expenditures continue to provide 
net positive value in Australia, France, and the UK, it is unclear whether this is 
sustainable over the long-term.  
 
Moreover, new cancer medicines have not necessarily resulted in net positive value. Over 
the past ten years, the monetized value of drug-related survival gains has greatly 
exceeded increases in cost for some indications, but not for others, represented at the 
extremes by breast and lung cancers. The unevenness in the magnitude of net economic 
returns is even more pronounced at a drug-level. Pharmaceutical innovations have, in 
some instances, brought large, positive economic returns from their impact on survival 
(e.g. pertuzumab). In other cases, the use of some new medicines is expected to have 
generated little, or indeed negative, net value. This appears to validate reporting from 
Bach & Pearson (2015), who state that currently “some drug prices do not seem to be 
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consistent with the drug’s benefits, while some other prices do.”(311) From this 
perspective, health systems should not necessarily regard growing cancer drug costs as 
an issue. Of greater importance is the development and preferential use of cancer 
medicines that provide the greatest therapeutic good to patients. 
 
To conclude, country- and drug-level analyses both suggest that greater value will not be 
obtained by simply cutting expenditures on cancer medicines. Australia, for instance, 
witnessed the smallest rate of growth in cancer drug expenditures between 2004-2014. 
Yet, it also experienced one of the smallest, country-level improvements in patient 
survival. France, on the other hand, controlled overall growth in total cancer drug 
expenditures—and those for branded drugs in particular—while also achieving greater 
improvements in health outcomes. Net economic returns from use of new cancer 
medicines were higher in France than in the UK in the first full-year of drug marketing. 
This was despite the UK and France having comparable population sizes, and incidence-
adjusted total drug expenditures were higher in France than in the UK throughout the 
entire period of analysis. Since net value also varies across new cancer medicines, 
indiscriminate cuts to drug expenditures are unlikely to be value-optimizing if they do 
not consider the clinical impact from treatment. Greater value therefore may not 
necessarily result from cost containment, but appears to more closely be associated with 
greater access to clinically meaningful medicines. Given an appropriate policy and 
clinical context, it seems possible to meet growing health needs while managing 
increases in cost. Instead of focusing exclusively on expenditure, a more constructive 
approach may be to coordinate across siloed objectives in policy and health with the aim 




Key Learnings and Implications 
• Base-case, country-level analyses found that Australia, France, and the UK 
obtained net positive economic returns of $2.52, $6.46, and $3.94 billion in 2014, 
respectively, from long-term increases in spending on cancer medicines.  
• The US outspends other countries on cancer medicines, even after adjusting for 
population and cancer epidemiology, and was the only country of the four to be 
associated with a net negative economic return from total, long-term increases in 
aggregate cancer drug spending.  
• At a drug level, the monetized value of drug-related survival gains has exceeded 










Cancer medicines have driven new brand spending over recent years, with spending in 
oncology rising from $0.5bn in 2009 in the US to $2.1bn in 2013.(23) Spending has in fact 
risen faster for cancer medicines than for many other diseases, in part because of rapidly 
growing drug prices, as well as increased rates of use.(312) 
 
Faced with rapidly growing drug costs, ASCO recently developed its Value Framework to 
compare the relative clinical benefits, toxicity, and costs from cancer treatments, 
providing physicians and patients with a standardized approach to assess the value of 
new medicines.(12) Their efforts are based on the assumption that, at a societal level (12):  
 
“the cost of a given intervention … bears a relationship to the beneficial 




This assumption underpins other value-based healthcare initiatives: in the US, for 
instance, the Institute for Clinical and Economic Review and the DrugAbacus both work 
on determining prices for medicines that are commensurate with their impact on 
health.(59) From this perspective, value-based spending on cancer medicines—a product 
of drug costs and utilization—should be associated with their therapeutic benefits to 
patients. 
 
This position is increasingly adopted in the literature. Despite concerns over affordability 
and clinical adherence,(44,90) some have argued that high costs may be warranted if 
new cancer treatments also bring significant benefits to patients.(44,46) Fojo and 
colleagues (2014) argue that pharmaceutical companies in fact deserve to charge 
premium prices for therapies offering premium benefits, but that marginal benefits 
should not be rewarded.(313) This position may in part be justified if value-based drug 
spending incentivizes the development of medicines that offer meaningful therapeutic 
improvements to patients.(313)  
 
As financial pressures mount, countries have taken different approaches to ensure value-
for-money in drug spending. Direct or indirect mechanisms of regulating price and 
pharmaceutical access exist, and may be informed by assessments of the clinical risks 
and benefits of new medicines. On the supply side, countries may also allow for free 
pricing of medicines, with no policies or regulations to ensure that pharmaceutical 
expenditures are commensurate with value to patients and society. An overview of 
policies to ensure value-for-money in pharmaceutical spending in Australia, France, the 
UK, and the US is provided in Box 5. 
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Countries may negotiate drug pricing directly with manufacturers on the basis of the comparative clinical 
effectiveness of new medicines. France, for instance, assesses the ATV of newly licensed medicines against existing 
comparators on a five-point Likert scale (ASMR), which ranges between major improvement (I) and no improvement 
(V). Along with other factors that include sales forecasts and size of the target population,(50) ATV is then used to 
inform price negotiations with manufacturers.(329) Medicines that provide no added clinical benefit to patients can 
only be listed if they cost less than their competitors.(372) In contrast, medicines that are rated with an ATV of I-IV 
have the possibility of higher pricing relative to competitors.(372) Those that are highly rated (ATV I-III) may not 
require price negotiations, a policy that may also expedite access to the most clinically meaningful medicines.(372) 
ATV is then re-assessed every five years, or sooner if independent scientific commissions believe it appropriate.(329)  
 
At a high-level, Australia uses a similar system to control drug spending. Once medicines have been licensed for use 
by the national TGA, manufacturers must file an application with the PBAC to receive reimbursement through the 
country’s PBS. The PBAC assesses the comparative clinical- and cost-effectiveness of new medicines to determine 
whether to recommend their listing on the PBS, along with other criteria that include budget impact, severity of the 
treatment condition, and availability of alternative therapies.(327) Most prescription drugs are however included on 
the PBS,(373) providing patients with subsidized access to medicines. Following a positive PBAC recommendation, 
the PBS’s Pricing Section undertakes pharmaceutical price negotiations that may be based on prescription volumes, 
economies of scale, and various pricing methods, including the cost-plus method and reference pricing. To 
recommend pharmaceutical pricing to the minister, the Pricing Section may also consider PBAC advice on clinical 
and cost-effectiveness.(49) Unlike France, however, Australia does not provide a clear framework describing the 
process that is used to link drug prices to their clinical benefits. Once listed on the PBS, medicines may be sold at the 
price that is set by the PBS, and at a fixed copayment.(374) 
 
Indirect methods of price regulation also exist. In the UK, pricing of all licensed, branded drugs is not directly 
regulated, but is often managed through the voluntary PPRS, which institutes mechanisms for price cuts, as well as 
profit controls that weigh price and volume. Reserve statutory powers to control pharmaceutical prices also exist for 
medicines that are not regulated through the PPRS.(56) While the latest version of the PPRS failed to incorporate VBP 
mechanisms linking national health technology assessments to price setting due to “technical problems and 
uncertainty,”(57) it may offer a platform to directly negotiate VBP of medicines in the future. In response to prior calls 
for value-based pricing, PPRS 2009 nevertheless implemented a flexible pricing arrangement that, among other 
stipulations, allowed companies to increase or decrease their original list price once by up to 30% in light of new 
evidence.(56) The UK’s use of cost-effectiveness as a key criterion in decision-making on reimbursement can however 
indirectly pressure manufacturers to lower drug prices when cost-effectiveness is not realized.(375)  Indeed, as of 2016, 
all new anti-cancer medicines are referred to NICE for evaluation, which issues recommendations on whether they 
should be made available for routine commissioning throughout the NHS.(43) This reflects the agency’s core mission, 
which is to “assess and signal value on behalf of the entire NHS.”(376) The UK may nevertheless use financially- or 
output-based patient access schemes that allow early access to medicines, and help manufacturers improve their 
clinical- or cost-effectiveness.(56) To allay concerns regarding accessibility, the UK utilizes a dedicated funding 
scheme for cancer medicines—the CDF—that provides access to medicines that are not routinely available through 
the NHS. The CDF was initially established in 2011 as a three-year stopgap measure to ensure access to cancer 
medicines while also acting as a bridge to a new system of VBP.(43) To ensure that spending on the CDF provides 
value-for-money, the UK recently reformed the program by: capping the program’s yearly budget to £340m; re-
designing the program as a Managed Access Scheme; where optimized draft recommendations exist, only providing 
interim funding  to subgroups within the optimized recommendation; only providing interim funding from the NHS 
to manufacturers if they sign onto a non-negotiable funding contract that subjects them to, as required, expenditure 
control mechanisms; only providing access through the program to medicines that NICE considers to demonstrate a 
“plausible potential for [satisfying] the criteria for routine commissioning, but [which are associated with] significant 
remaining clinical uncertainty”; and only providing 2-year interim funding for medicines that sign onto a Managed 
Access Agreement, which stipulates the requirements for continued data collection and the level of reimbursement 
that brings plausible cost-effectiveness estimates to below acceptable thresholds.(43) The option for individual 
funding requests from public payers exists to fund treatment with non-recommended medicines, however it only 
applies to “clinically exceptional” cases.(43) 
 
High-level policies or regulations to control pharmaceutical spending are not used in the US. By law, the social 
insurance programs Medicare and Medicaid are not allowed to directly negotiate pharmaceutical pricing,(59) may not 
consider costs within the drug reimbursement decision-making process, and yet may be required to cover new 
medicines.(60) Indeed, the MMA of 2003 issued guidance through contract provisions to Medicare PDPs to cover “all 
or substantially all” medications within six protected classes of medicines, including antineoplastics and 
immunosuppressants. The MIPPA of 2008 codified CMS guidance and established the Six Protected Classes of drugs 
under Medicare Part B, with the PPACA of 2010 providing additional protection.(61) CMS proposed limiting the 
protected drug classes to exclude antidepressants and immunosuppressants in 2015; this measure was not adopted 
due to opposition from patients, providers, and advocates.(61) Bach and Pearson (2015) argue that Medicare’s ability 
to apply a VBP system is hindered by policies that require Part D private drug plans to cover all drugs of certain 
protected classes, while a flat co-insurance rate without an upper limit has put highly effective but expensive 
medicines out of reach for Medicare beneficiaries without supplemental health insurance.(59) Private insurers are 
required to provide coverage for most new medicines, and may be unable to obtain significant price concessions from 
manufacturers, especially for drugs offering clinical advantages or using novel mechanisms of action.(59) While 
insurers may negotiate lower prices for drugs that have therapeutic substitutes or questionable benefits by excluding 
them from formularies,(62) the extent to which this occurs in the US remains unclear.  
Box 5. Overview of Approaches to Ensure Value-for-Money in Drug Spending  
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Context and Empirical Gaps 
To date, it remains unclear whether spending on new interventions is associated with 
measures of their beneficial impact to patients, and how that association may vary across 
health systems.  
 
In the US, a key recent study reports a positive correlation between the ETP of new 
medicines—each drug’s monthly cost to the Medicare program—and incremental 
survival benefits, finding that US prices for anticancer medicines increase by 120 percent 
for each additional life-year gained.(73) Several limitations however should be 
considered. First, the lack of an international comparison prevents researchers from 
judging the strength of any country correlation between drug spending and their clinical 
benefits.(314) Second, monthly ETPs, or similar concepts,(159) may not adequately reflect 
actual treatment costs, and may therefore bias drug cost comparisons. Howard and 
colleagues (2015) in fact admit that a “drug’s treatment episode price is not a 
comprehensive measure of the impact of that drug on health care costs.”(73) Third, 
survival is generally taken as the gold standard among oncology efficacy 
endpoints.(64,93,94) Focusing on survival exclusively however is inconsistent with 
ASCO’s Value Framework, which argues that patients may also consider other clinical 
outcomes, including QoL and safety.(12) By not accounting for other potential clinical 
benefits, regression-based studies examining the relationship between drug costs and 
their clinical impact are likely to suffer from misspecification bias.  
 
These limitations reflect the dearth of publicly-available evidence. As was explained in 
Chapter 3, there is as of yet no international dataset that provides reliable and 
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comparable evidence on the use or cost of cancer medicines. Its absence makes it 
difficult for researchers to examine whether spending on new cancer medicines is indeed 
related to their clinical impact, and to determine how and to what extent this 
relationship varies across country settings. 
 
Summary of Research 
The literature has generally adopted two methodological approaches to determine 
whether spending on new tools or treatments provide value-for-money. Chapter 4 made 
use of the first by adopting a cost-benefit approach to analyze whether the monetized 
value of survival gains attributable to cancer drug innovation, and based on patients’ 
willingness to pay for a diminished risk of mortality, exceeds growth in drug spending, 
both at a societal- and drug-level. 
 
The second approach assesses whether and to what extent spending on treatments is 
associated with measures of their clinical benefit.(73,85,274–277) Extending this 
approach, this chapter uses regression analysis to test the value-based hypothesis that 
spending on new cancer medicines is associated with their beneficial impact to patients, 
measured through drug-related effects on overall survival, quality of life, and safety. To 
do so, it incorporates data on the clinical risks and benefits associated with new cancer 
medicines from Chapter 2, as well as  evidence on the use and cost of new 
cancer medicines from Chapter 3. To provide comparative insights on the extent to 
which this occurs, this analysis is carried out using data from Australia, France, the UK, 
and the US. This chapter finds that spending on new cancer medicines may only weakly 




however varies across countries, and is most prominent in the UK, suggesting that it may 





All medicines that were included in Chapters 2, 3, and 4 were eligible for inclusion in this 
study. As in Chapters 2 and 3, the methods from Roberts and colleagues (2011) were used 
to identify all initial cancer drug approvals by the US FDA and EU EMA occurring 
between 2003-2013.(125) All NMEs approved by the FDA or EMA over this period with a 
primary indication for oncology were eligible for inclusion. Any molecule that did not 
receive licensure by either the FDA or EMA between 2003-2013, and which did not have 
an initial, primary anticancer indication was therefore excluded. Supplemental 
applications to the US FDA or EU EMA, new non-active treatments, licensing 
supplements, labeling revisions, and new or modified indications were not considered.  
 
In this study, medicines were excluded if Chapter 3 had been unable to generate 
estimates on the total cost or use associated with each treatment. For more information, 












Included: Treatment use and cost, value from treatment 
(n = 43 drugs / drug-indications) 
abiraterone, afatinib, axitinib, azacitidine, bendamustine, bevacizumab, bortezomib, cabazitaxel, 
cabozantinib, carfilzomib, catumaxomab, cetuximab, clofarabine, crizotinib, dabrafenib, decitabine, 
degarelix, enzalutamide, eribulin, erlotinib, everolimus, gefitinib, ibrutinib, ipilimumab, ixabepilone, 
lapatinib, nelarabine, obinutuzumab, ofatumumab, panitumumab, pazopanib, pemetrexed, pertuzumab, 
regorafenib, romidepsin, ruxolitinib, sorafenib, temsirolimus, tositumomab, trametinib, trastuzumab 
emtansine, vorinostat, ziv-aflibercept 




• brentuximab vedotin 
• dasatinib  
• nilotinib 
• omacetaxine mepesuccinate 
• ponatinib  




#2: Initial treatment duration or dosing schedule 

















(n = 62 drugs; n = 63 drug-indications) 
Criteria: 
       Primary oncology; initial approval (NME); active anticancer treatment 
Sources: 
       1) Roberts et al. 2011 (drugs approved between 2003-2010)(n = 31) 
2) FDA Drugs@FDA database (drugs approved between 2011-2013)(n = 27) 
3) EMA EPAR database (drugs approved between 2011-2013)(n = 4) 




• pomalidomide  









Treatment dosing and duration 
(n = 47 drugs / drug-indications) 
 
Figure 16. Drug Sample Inclusion/Exclusion Criteria 
Source: 




Summary measures of the effect on OS, QoL, and safety from treatment with each new 
cancer medicine were obtained from Chapter 2. As was previously explained, 
information on recommended patient populations (treatment indications, usage 
restrictions), novel interventions [ATC code, therapeutic target], and therapeutic 
comparators were extracted from English, French, and Australian appraisals for each 
eligible drug-indication.  
 
As was explained in Chapter 2, a narrative synthesis approach was used to classify 
summary HTA agency assessments of the drug-related impact on OS, QoL, and safety. 
These assessments are based on a comparison against main therapeutic comparators—
defined as the therapy that would most likely be replaced by the new intervention (121–
123)—which do not often differ across appraisals.(315) Where available, quantitative 
estimates of the impact on OS for the first approved indication of each newly licensed 
cancer medicine were extracted. In some instances, HTA agencies may have concluded 
that new medicines are associated with an unquantifiable increase in OS. OS was 
therefore also coded as a categorical variable: drugs could be associated with a known or 
unknown OS benefit of ≥3 months; <3 months; an increase in survival, but of unknown 
magnitude; and no demonstrated increase in OS. HTA agency summary assessments of 
the overall effect on QoL and safety were classified into four categories: an overall 
improvement or reduction in QoL or safety, mixed evidence, or no established difference 
relative to best alternative treatments. For more information on the methods used to 




For each country, mean and median estimates of the total cost  
of treatment, and expected number of patients completing  
therapy, with each new medicine in the first (Y0), second (Y1), and third (Y2) year of 




For all drugs that met inclusion criteria, the FDA’s Drugs@FDA database was used to 
obtain FDA prescription drug labels, as well as medical and statistical reviews, 
corresponding to the year initial licensure was received. Prescription drug labels were 
used to extract FDA approved primary indications, FDA approval type (biologic licensing 
application, new drug application), date of initial FDA approval, date of first FDA-
approved new or modified indication (target), new dosing regimen, or modified patient 
population through 1 Jan 2016, recommended dose and treatment duration, if available, 







Value-based policies that are meant to rationalize pharmaceutical spending may 
consider condition and its rarity.(50,227–229,322,323) US and EU orphan drug status and 
ATC classifications for FDA-approved indications were therefore obtained from 







obtained from the TGA’s orphan drug registry.(232) A clinical expert also used FDA-
approved primary indications to classify all new cancer medicines by their therapeutic 
target. Across the entire eligible sample, medicines were classified as being indicated for 
malignant ascites, thyroid cancers, GI cancers, lung cancers, hematological malignancies, 
prostate cancers, skin cancers, renal cancers, and breast cancers.  
 
Annual population size estimates were obtained from the World Bank,(292) as were 
consumer price inflation indices.(293) Nominal pricing data was converted to constant 
2015 terms by using consumer price inflation indices from the World Bank, as described 
in Chapter 2. Yearly incidence of malignant neoplasms was derived for Australia, France, 
the UK, and the US using data from the OECD’s OECD.stat registry (278) and the US 
CDC’s USCS registry.(279) For this, simple linear regressions were used to account for 
time discontinuities. For more information on these data sources or methods, please 
refer to Chapter 4. 
 
Analysis 
In line with Howard and colleagues (2015),(73) this analysis focused exclusively on initial 
FDA- or EMA-approved anticancer indications. New or modified indications can be 
approved over the active life cycle of new medicines. In the absence of data on indication 
for use from QuintilesIMS, analyses were limited to the first three years of marketing 
after initial licensing. Yearly observations were also censored once new or modified 
indications, dosing regimens, or modifications in approved patient populations were 




As is explained in previous chapters, crude comparisons of cancer drug use may be 
misleading if associated populations are of unequal size or have unequal epidemiological 
risks of disease.(291) Countries with an unusually high number of incident cancer cases 
would be expected to have higher rates of cancer drug use and expenditure, ceteris 
paribus. To therefore adjust for potential differences in the total population size across 
countries, and in the relative risks associated with developing cancer, base-case analyses 
adjust drug utilization measures—number of patients completing  
therapy in each country-year—using data from Chapter 4 on the total yearly incidence 
of malignant neoplasms. This methodology has previously been advocated as a means of 
comparing cancer drug utilization across different settings.(74,75) 
 
 If cancer drug spending provides patients and society with value-for-money, then 
measures of their beneficial impact to patients should in theory be positively associated 
with spending on those new treatments.(12) This hypothesis extends from the notion 
that clinical decision-making is likely to consider drug-related effects on efficacy, as well 
as QoL and safety.(12) 
 
The extent to which this hypothesis holds true may vary across countries, depending on 
the effectiveness of local policies that are meant to ensure value-for-money in drug 
spending. At the same time, payers may be willing to accept a higher maximum cost per 
unit of outcome obtained from the use of new medicines if they are given a high social 
value.(228) Social valuations of new health technologies may be associated with lifetime 
health prospects and dependencies,(325) treatment intent,(322,326) unmet health needs, 
availability of alternative treatments, and rarity of the treated 




evidence on the association between cost-sharing features of prescription drug benefits 
and prescription drug use, and find that consumer sensitivity to cost sharing depends on 
a drug’s therapeutic class and importance.(328) 
 
The following linear model was therefore used to examine whether the beneficial impact 
associated with new cancer medicines bears positively on spending, and whether the 
relationship is mediated by country setting: 
 
 𝑌𝑖𝑐 = 𝛽0 + 𝑖. 𝑖𝑛𝑑𝑖𝑐𝑎𝑡𝑖𝑜𝑛𝑖 + 𝑜𝑟𝑝ℎ𝑎𝑛𝑖𝑐 + 𝑐𝑜𝑢𝑛𝑡𝑟𝑦𝑐 + 𝑂𝑆𝑖
+ ෍(𝑂𝑆𝑖 ∗ 𝑐𝑜𝑢𝑛𝑡𝑟𝑦𝑐)
4
𝑐=1
+ 𝑄𝑜𝐿𝑖 + ෍(𝑄𝑜𝐿𝑖 ∗ 𝑐𝑜𝑢𝑛𝑡𝑟𝑦𝑐)
4
𝑐=1




( 12 ) 
 
 
On the left-hand side of this model, 𝑌𝑖𝑐 is used to represent the two dependent variables 
of interest that are constituent to drug spending: total cost per patient per  
 treatment and number of patients completing  therapy 
with each new medicine 𝑖 in country 𝑐. Data are also considered by year  (𝑡 = 0, 1, 2). On 
the right-hand side of this model, 𝑖. 𝑖𝑛𝑑𝑖𝑐𝑎𝑡𝑖𝑜𝑛𝑖 accounted for the target condition of 
each new medicine 𝑖 included in this chapter—ascites, breast, GI, haematological, lung, 
prostate, renal, skin, and thyroid malignancies—while binary variable 𝑜𝑟𝑝ℎ𝑎𝑛𝑖 
represented the orphan status of each medicine 𝑖 in country 𝑐. To examine the 





cancer medicines, main effects from OS (𝑂𝑆𝑖), QoL (𝑄𝑜𝐿𝑖), and safety (𝑠𝑎𝑓𝑒𝑡𝑦𝑖) were 
included. The unit of observation is therefore cost and utilization measures (𝑌𝑖𝑐) for each 
drug-indication, country, and year considered. 
 
Any country-level difference in value-based policy may mean that the association 
between measures of clinical benefit and spending on new cancer medicines depends on 
setting. To test the hypothesis that the relationship between the focal independent 
variables measuring clinical benefits and cancer drug spending varies by setting, 
interaction effects with country as the mediator variable were also considered. 
 
Multiple linear regression was used to test the value-based proposition that spending on 
new cancer medicines is associated with their beneficial impact to patients. Drug-related 
effects on OS, QoL, and safety were assumed to be time-invariant in relation to 
comparator treatments. This approach was consistent with regulatory mechanisms that 
may re-assess the added therapeutic value of new medicines every five years after initial 
licensure.(329) An annual cross-sectional study design with robust standard errors was 
therefore used to model the association between drug clinical benefits and spending, 
with data from the first year of marketing (Y0) used in base-case analyses.  This approach 
is consistent with that used by Howard and colleagues (2015).(73)  
 
To help ensure that the normality assumption was met, the Shapiro-Wilk test was used 
to determine whether to use a square root, log, or inverse transformation on the 
dependent variables of interest. Base-case analyses modelled OS as a continuous 
variable, used mean estimates of the total cost per patient per  (b) (4)
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treatment, and number of patients completing  therapy, with 
each new cancer medicine,  
 
 
 For primary analyses, a p value of less 
than 0.05 was needed to reach statistical significance. t tests were used to test the null 
hypothesis that coefficients were equal to zero. All analyses were performed in Stata 14 
(College Station, TX: StataCorp LP), and hypothesis testing was 2-sided. 
 
Sensitivity Analysis 
As explained in Chapter 2, HTA agencies may give quantitative or qualitative 
assessments of the impact on OS from treatment with new medicines. They may, for 
instance, accept a measurable improvement in OS relative to best alternative treatments, 
or conclude that a new medicine is associated with an unquantifiable increase in OS, 
with the latter likely suggesting less certainty about drug-related clinical benefits. Base-
case analyses were therefore limited to the set of medicines with quantifiable changes in 
OS. To nevertheless gauge the impact from this approach, sensitivity analysis was used 
by coding drug-related effects on OS as a categorical variable. 
 
An annual cross-sectional study design was used to reflect the time-invariance that was 
assumed for drug-related effects on OS, QoL, and safety, with base-case analyses using 
data from the first year of drug marketing (Y0). To examine whether results persisted 







Failure to adjust for population and disease epidemiology can confound international 
comparisons of cancer drug utilization.(74,75) In the absence of international registries 
providing long-term data on patient care and outcomes,(75) this study adjusted 
measures of cancer drug utilization by total yearly neoplasm incidence. To test for 
robustness, and to also examine whether rates of cancer incidence are comparable 
throughout populations in Australia, France, the UK, and the US, sensitivity analyses 
adjusted measures of cancer drug utilization by the total population in the country-year 
that corresponded with drug sales. 
 
Base-case analyses were based on mean rather than median estimates of the dependent 
variables of interest.  
 
 From a societal perspective, decision-making that 
tries to efficiently allocate scarce resources must consider the cost and outcomes 
associated with treatment of all eligible patients. To nevertheless examine the impact on 
this study from this approach, sensitivity analyses used median estimates for the 
dependent variables of interest. 
 
Without publicly-accessible, and internationally comparable, long-term data on patient 

















drug pricing data reflects the list price rather than the transaction price; confidential 
discounts and rebates are not built in.(330) Price discounts may be increasingly common 
in high-income country community settings,(331) but information on how they are 
applied to patented pharmaceuticals remains scarce. Given the potentially guarded 
nature of drug procurement, it is impossible to systematically adjust for pricing 
discounts. Any discount would mean that this analysis is based on overestimates of drug 
costs, and any such measurement error in the dependent variable may bias cross-country 
comparisons. It is however unclear whether this limitation has any practical impact on 
this study: first, this issue applies to costing estimates for all drugs and all four countries. 
Second, medicines in the same therapeutic category often receive comparable levels of 
discount.(302) Based on the disclosed rebate offers by CMS, international studies may in 
fact assume a constant 23% price reduction for purchasers of specialty medicines, except 
in Brazil, India, Egypt, and Mongolia, where special pricing arrangements or generic 
licensing agreements apply.  Moreover, the average value of confidential discounts as 
a share of the official list price for specialty medicines also clusters around 10-30% for 







remains valid with respect to costs that are based on list prices. Future studies should 
however explore this issue. 
 
Moreover, 43 medicines were eligible for inclusion in this study, with additional subsets 
of data available by country, year,  and mean/median statistics. 
Although this sample encompasses all medicines that had been approved by either the 
FDA or EMA with a single, primary anti-cancer indication over the 10-year period 2003-
2013, and which could be reconciled with the longest longitudinal dataset that is 
available from QuintilesIMS, this remains a relatively small sample. Future studies 
should build on this analysis by extending it to other countries, or by re-running it as 
additional anti-cancer medicines are approved. 
 
This study focuses on drug-related effects on OS, QoL, and safety. This approach is 
designed to reflect ASCO’s Value Framework, which argues that decision-making over 
treatment options considers drug-related effects on efficacy, QoL, safety, and cost. In 
contrast to previous studies that have focused exclusively on the correlation between 
drug pricing and efficacy,(73) this study therefore accounts for any concomitant impact 
from treatment on QoL and safety that may be value-optimizing. 
 
However, this study did not consider surrogate measures of efficacy, including 
progression-free survival and response rates. If it is accepted that surrogate efficacy 
markers represent unique dimensions to the clinical benefits from treatment, then their 
absence would mean that regression analyses in this chapter may be prone to 




value to patient health is at least in part captured by the three clinical outcome measures 
that are considered in this analysis—OS, QoL, and safety. This study was also designed 
to reflect ASCO’s Value Framework, which argues that efficacy should be measured using 
surrogate markers if data on OS is not available. For its part, the FDA states that while 
surrogate markers of efficacy may be predictive of clinical benefits, they are “not 
themselves a measure of clinical benefit”.(108) And, there is evidence to suggest that any 
difference between OS and PFS is often negligible: in their sample of 20 drugs, Howard 
and colleagues (2015) found that the absolute difference between these two measures 
was less than one month for five drugs, and less than two months for 13 drugs.(73) 
Similarly, in the instances where OS data may not be available, DrugAbacus considers 
the margin of gain in PFS to be equivalent to the gain in OS. 
 
Results 
62 anticancer molecules were approved by the US (FDA) and EU (EMA) between 2003-
2013 with a primary indication for oncology, and were therefore eligible for inclusion. Of 
those, treatment duration and recommended dosing information was not available for 6 
medicines, while another 9 were approved for multiple primary indications or disease 
conditions, information that could not be reconciled with the level of specificity in the 
pricing and volume data that had been licensed for use in this study. Of those that 
remained, volume and pricing data was not available from the QuintilesIMS data extract 
for 4 medicines. Chapter 3 was therefore able to generate  for the 
total cost per patient per  treatment, and number of patients 
completing  therapy, in each country-year for 43 new anticancer 































There was a positive correlation between OS and the total expected cost per patient per 
 treatment in each of the countries examined in this analysis 
(Figure 17). The strength of correlation however varied across the countries that were 
considered, with a simple linear regression indicating that gains in OS predicted square 
root transformed total drug costs per patient per  treatment in the 
UK (b = 9.57, t(25) = 2.37, p = 0.026) and France (b = 7.00, t(20) = 2.28, p = 0.034). While 
still positive, regression coefficients did not reach either the 0.05 or 0.10 significance 
level in either the US (b = 6.02, t(23) = 1.46, p = 0.156) or Australia (b = 1.67, t(14) = 0.35, p 
= 0.734). Drug costs tended to rise with improvements in QoL in France and the UK 











Multivariate linear regression analysis was used to determine whether clinical benefits 
from new medicines predicted the dependent variable of interest, the total cost per 
patient per  treatment with new medicines (Table 18). In line with 
results from the Shapiro-Wilk test, a square root transformation was used in base-case 
analysis to correct for nonlinearity.  
 
Models (H) and (E) resulted in the best goodness-of-fit. Compared with model (E), 
including QoL terms increased the amount of variance in total drug costs that could be 
explained [model (H)], suggesting that drug-related effects on QoL can help explain drug 
costs more than OS alone. However, in relation to base model (A), a majority of the 
model’s explanatory power came from accounting for drug-related effects on OS [model 
(E)]. In contrast, including drug-related effects on safety—model (F)—decreased model 
explanatory power.   
 
Accounting for treatment descriptors, OS, and QoL, cancer drug costs per patient per 
treatment were highest in the US under model (H), followed by 
the UK. Orphan status was found to have a significant effect on cancer drug treatment 
costs. Cancer drug costs were significantly higher for breast, GI, hematological, skin, and 
thyroid indications than for malignant ascites. There was also a positive, albeit 
insignificant, main effect from gains in OS. Although the coefficients for the interactions 
between country and OS on cancer drug costs were not significant, they were 
consistently positive and their magnitude varied widely between countries, led by the 
UK. Interaction terms between there being no drug-related effect on QoL and both the 
UK and France were significant and negative, pointing to country-moderated effects on 





Table 18. Multivariate Linear Regression Analysis, Total Cost per Patient per  
Treatment with New Medicines and their Beneficial Impact to Health in the First Year of Drug Marketing in 
Australia, France, the UK, and the US 
Variable Model1 






















Ind. Var2 1 2 3 4 1, 2 1, 3 1, 4 1, 2, 3 1, 2, 4 
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131 90 119 119 90 119 119 90 90 90 
R2 0.161 0.174 0.147 0.188 0.388 0.308 0.306 0.452 0.482 0.54 
Adj R2 0.099 0.104 0.041 0.07 0.254 0.149 0.129 0.26 0.245 0.242 
 
Source: 
Authors’ analysis of data, as described Methods section. 
Notes: 
 
1 Base-case analysis with a sqrt transformation of the dependent variable, total cost per patient per  
 treatment (TCp) in the first year of marketing (mean estimate  from Chapter 3), assuming 
treatment duration   
2 1: Treatment descriptors (treated condition, rarity); 2: OS; 3: QoL; 4: safety. 
3 Reference categories: ascites; AU; QoL: improve; safety: improve. 






























There was a positive correlation between OS and the total, incidence-adjusted number of 
patients completing  treatment with new cancer medicines 
across each of the countries examined in this analysis (Figure 18). However, the strength 





OS was a significant predictor of the natural log-transformed number of patients 
completing therapy in Y0 in the UK (b = 0.215, t(25) = 3.17, p = 
0.004). It was followed by the US (b = 0.144, t(23) = 1.22, p = 0.233), Australia (b = 0.112, 
t(17) = 1.13, p = 0.275) and France (b = 0.062, t(23) = 0.33, p = 0.743). In all four countries, 











Multivariate linear regression analysis was used to examine the relationship between the 
dependent variable of interest, the total number of patients completing  
 treatment per 100,000 cases of incident neoplasm with each new medicine, and 
drug clinical benefits. In line with results from the Shapiro-Wilk test, a natural log 
transformation was used in base-case analyses to correct for nonlinearity.  
 
Compared with model (E), inclusion of both QoL [model (F)] and safety [model (G)] 
terms improved adjusted R2 estimates (Table 19), suggesting that drug-related effects on 
both QoL and safety can help better explain variance in rates of incidence-adjusted 
cancer drug use than OS alone. Compared to base model (A), drug-related effects on 
QoL [model (G)] accounted for the most variance in cancer drug use. This was followed 
by drug-related effects on safety [model (G)] and OS [model (E)]. Full model (J) was 
associated with the highest adjusted R2 value.  
 
Controlling for treatment descriptors, OS, QoL, and safety, cancer drug utilization per 
100,000 cases of incident neoplasm was significantly higher in the US than in Australia 
under Model (J). Although there was no main effect from the UK on incidence-adjusted 
cancer drug use, it was the only country in which there was a trend towards significance 
in the interaction between country identifier and drug-related OS benefits (p = 0.123). 
Clinical decision-makers in the UK therefore appear to be most likely to adopt new 
treatments when they provide the greatest survival benefit to patients. Interaction terms 
between there being a drug-related reduction in QoL and France, as well as no effect on 
safety and the US, were significant and negative. These results point to country-





Table 19. Multivariate Linear Regression Analysis, Total Number of Patients Completing  
Therapy with New Medicines per 100,000 Incident Cases of Neoplasm and their Beneficial Impact 
to Health in the First Year of Drug Marketing in Australia, France, the UK, and the US 
Variable Model1 






















Ind. Var2 1 2 3 4 1, 2 1, 3 1, 4 1, 2, 3 1, 2, 4 

























































































































































































































4.349*   
[2.053] 
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137 96 125 125 96 125 125 96 96 96 
R2 0.101 0.25 0.33 0.325 0.311 0.418 0.409 0.443 0.531 0.633 
Adj R2 0.037 0.19 0.251 0.232 0.172 0.292 0.268 0.265 0.335 0.419 
 
Source: 
Authors’ analysis of data, as described in Methods section. 
Notes: 
 
1 Base-case analysis with a natural log transformation of the dependent variable, total number of patients completing  
 therapy in the first year of marketing per 100,000 incident cases of neoplasm (TPi)(mean 
estimate  from Chapter 3), assuming treatment duration    
2 1: Treatment descriptors (treated condition, rarity); 2: OS; 3: QoL; 4: safety. 
3 Reference categories: ascites; AU; QoL: improve; safety: improve. 














Sensitivity analyses were used to examine the impact from: re-coding OS benefits as a 
categorical variable (Appendix 5.5; Appendix 5.6), using data from the second and third 
year of drug marketing (Appendix 5.7; Appendix 5.8; Appendix 5.9; Appendix 5.10), using 
population-adjusted cancer drug utilization measures (Appendix 5.11), using median 
rather than mean estimates from generated distributions of the dependent variables of 
interest (Appendix 5.12; Appendix 5.13),  
 
. Results were often consistent with main analyses, 
particularly in the direction of significant regression coefficients. 
 
Sensitivity analysis re-coded the drug-related impact on OS as a categorical variable. 
Model (E) explained the highest proportion of variance in cancer drug costs (Appendix 
5.5), while Model (J) continued to explained the largest amount of variance in incidence-
adjusted use (Appendix 5.6). Although the direction of parameter estimates was largely 
stable, this approach often reduced their significance. 
 
To examine whether results were consistent over time, regression equations were run 
using data from the second and third year of marketing. Compared to main analyses, 
there was little change in the amount of variance in drug costs per patient per  
 treatment that was accounted for by models in either the second 
(Appendix 5.7) or third (Appendix 5.9) year of drug marketing. As in base-case analyses, 
model (J) accounted for the most variance in incidence-adjusted cancer drug use in the 






considered characteristics of disease and the drug-related impact on safety, provided the 
best fit of cancer drug use data in the second year of drug marketing (Appendix 5.8).    
 
Adjusting the total number of expected patients completing  
therapy by country-year population size rather than by neoplasm incidence produced 
highly similar results to base-case analyses (Appendix 5.11). This finding suggests that 
rates of incidence of neoplasm are comparable throughout populations in Australia, 
France, the UK, and the US.  
 
Using median rather than mean estimates for total drug costs per patient per  
 treatment (Appendix 5.12) resulted in model (I) explaining the most 
variance in the dependent variable, followed by model (J). There was however little 
difference in the parameter estimates that resulted. Using median rather than mean 
estimates did not change which model best explained variance in number of patients 




 resulted in model (E) best able to account for variance in total drug 
costs per patient per  treatment. Parameter estimates were 
however largely consistent, irrespective of  that was assumed for 
treatment duration. Assuming that DoT  











most variance in number of patients completing treatment, and 
had little impact on the parameter estimates that resulted. 
 
Discussion 
Against the backdrop of growing cancer drug expenditures, ASCO recently published its 
Value Framework to compare the relative clinical impact and cost associated with new 
cancer treatments. The framework gives clinical decision-makers a means of 
systematically assessing the value of new cancer therapies to patients and society. 
ASCO’s efforts are based on the assumption that, at a societal level (12):  
 
“the cost of a given intervention … bears a relationship to the beneficial 
impact it has for patients who receive that treatment.”  
 
This study used evidence from earlier chapters to test the proposition that spending on 
new cancer medicines—defined by both their cost and use—is predicted by their 
beneficial impact to patients. 
 
Within the sample of new and eligible anticancer medicines that were licensed between 
2003-2013, this chapter finds that drug-related improvements in OS, QoL, or safety may 





This study finds that per patient cancer drug costs are generally highest in the US and 
the UK, followed by France and Australia. Incidence-adjusted cancer drug use is also 
highest in the US, followed by France, the UK, and Australia. These findings are broadly 
consistent with the existing literature: In their sample of 31 cancer medicines, Vogler and 
colleagues (2015) find that cancer drug list prices are on average highest in France, 
followed by the UK and Australia.(77) Their findings are consistent with Goldstein and 
colleagues (2016), who also report that median monthly prices for cancer medicines are 
far higher in the US than in the UK and Australia.(265) On a per capita basis, Richards 
(2010) and O’Neill & Sussex (2013) report that cancer drug use is generally highest in 
France and the US, and lowest in the UK and Australia.(74,75) 
 
This study finds that cancer drug costs and utilization may be positively correlated with 
their impact on OS (Figure 17), QoL (Appendix 5.1), and safety (Appendix 5.2) in 
Australia, France, the UK, and the US. At least with respect to drug-related effects on OS, 
these findings are also consistent with Howard and colleagues (2015) who—despite 
methodological limitations6—report a positive correlation between treatment episode 
prices and incremental survival benefits in the US.(73)  
 
However, that is not to say that cancer drug spending is necessarily worth the cost to 
patients or health systems. This chapter finds positive interactions between drug-related 
                                                     
6 These have previously been described. Briefly, however, they include: the lack of an international 
comparison to provide a benchmark for evaluation of US figures; potentially biased monthly pricing 
estimates that may not adequately reflect the full expected cost from treatment with each new medicine; the 
failure to account for disease-specific factors that may impact on pricing, as well as other clinical outcome 
measures, such as quality of life and toxicity. This reflects an inconsistency with ASCO’s Value Framework 
over how to measure clinical impact from new medicines, and may therefore indicate the use of mis-
specified models.  
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improvements in OS and cancer drug costs, particularly in the UK and France. 
Interaction terms between there being no drug-related effect on QoL and cancer drug 
costs in both the UK and France were also significant and negative. A positive, albeit 
non-significant, interaction between drug-related improvements in OS and incidence-
adjusted utilization of new anticancer medicines was also found in the UK and the US, 
with parameter estimates for the former nearing significance at the 0.10 level. Interaction 
terms between there being a drug-related reduction in QoL and France, as well as no 
effect on safety and the US, were also significant and negative. These findings suggest 
that countries are, to some degree, able to mediate the relationship between spending 
and measures of clinical benefit from new cancer medicines. The extent to which they 
do, however, differs.  
 
To conclude, ASCO’s proposition that “the cost of a given intervention [in oncology] … 
bears a relationship to the beneficial impact it has for patients who receive that 
treatment” does not necessarily play out in the real-world. While there often appears to 
be a positive association between spending on new cancer medicines and measures of 
their clinical benefit to patients, the strength of this association varies widely across 
countries, and is not significantly different from zero in some settings. The UK and 
France, for instance, appear to be particularly successful in ensuring that the costs for 
new cancer medicines reflect their clinical benefits to patients. The association between 
the use of new cancer medicines and their clinical benefits is also strongest in the UK 
and US. However, even in settings where there is evidence to suggest a positive 
association between cancer drug spending and drug clinical benefits, that association 
may only be weak. Countries therefore differ in how successfully they mediate the 
relationship between cancer drug spending and clinical benefits to patients from 
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treatment, yet all can do more to improve value-for-money in cancer drug spending. In 
summary, there may be an opportunity to improve the degree to which spending on 
cancer medicines is value-based.  
 
Key Learnings and Implications 
• Per patient drug utilization and costs are generally higher in the US than in 
Australia, France, and the UK.  
• Cancer drug costs and utilization may be weakly correlated with their impact on 
OS, QoL, and safety in Australia, France, the UK, and the US.  
• There may be a positive interaction between drug-related improvements in OS 
and costs, though the strength of this association varies across countries, and is 
highest in the UK and France. Interaction terms between there being no drug-
related effect on QoL and cancer drug costs in both the UK and France were also 
significant and negative.  
• A positive, albeit non-significant, interaction between drug-related 
improvements in OS and incidence-adjusted utilization of new anticancer 
medicines was found, though the strength of this association was highest in the 
US and, particularly, the UK. Interaction terms between there being a drug-
related reduction in QoL and France, as well as no effect on safety and the US, 




6  Synthesis and Conclusion 
 
 
Drug spending has grown significantly over recent years, with global pharmaceutical 
expenditures rising from approximately $750 billion to $1.1 trillion between 2007 and 
2015.(24) New anticancer medicines, in particular, have driven recent increases in 
spending,(23) and projections estimate that they will contribute the most to global 
pharmaceutical spending growth through 2021, particularly in developed countries.(24)  
 
As fiscal budgets have tightened, rapid increases in pharmaceutical spending have not 
gone unnoticed.(3) Over recent years, US policymakers have, for instance, launched 
investigations into drug pricing and price competition,(3) while UK policymakers have 
sought to reform the CDF to provide patients and the UK health system with greater 
value-for-money.(88,89) For their part, clinicians have criticized the growth in cancer 
drug prices as excessive and unsustainable,(44) and have argued that growing cancer 
drug costs may undermine patient access and clinical compliance.(44,90) 
 
Contributing to this debate is the argument that increases in spending on medicines 
should nevertheless be considered alongside their clinical benefits. Recent publications 
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have argued that while cancer drug pricing may be excessive,(44) high costs may be 
justified if new cancer treatments bring equally large benefits to patients.(22,44,46) Fojo 
and colleagues (2014) take this one step further by arguing that pharmaceutical 
companies deserve to charge premium prices for therapies offering premium benefits, 
while marginal benefits should not be rewarded.(313) There is the notion that a value-
based approach to drug spending—where payments are linked to drug clinical benefits—
would incentivize the development of medicines that bring greater meaningful 
improvements to therapy.(313) 
 
Yet, relatively little empirical evidence exists to examine whether spending on cancer 
medicines is worth it to patients and society.(22,32–35) This likely owes in part to two 
factors. First, the historical lack of a framework on how to measure value within the field 
of cancer therapeutics has made it difficult to reach consensus on the clinical objectives 
of cancer drug spending. The dearth of comparative evidence on the use or cost of cancer 
medicines has also made it difficult to assess whether and to what extent expenditures 
are value-based. 
 
This thesis was designed to address these challenges, and to provide insights on the 
question of whether spending on new cancer medicines is providing value-for-money to 
patients and society. Briefly, Chapter 2 was the first to build on ASCO’s recently 
published Value Framework to shed light on the clinical risks and benefits associated 
with all newly licensed cancer medicines. Chapter 3  
 to generate comparative evidence on their expected use and cost in Australia, 
France, the UK, and the US. Incorporating data from these chapters, Chapters 4 and 5 




these countries. In particular, Chapter 4 adapted the methods used by Eggleston and 
colleagues (2009)(82) to analyze whether growing cancer drug expenditures generate net 
positive value, both at a societal- and drug-level. Chapter 5 then used regression analysis 
to test the value-based hypothesis that spending on new cancer medicines is associated 
with their beneficial impact to patients. 
 
The following pages synthesize findings from this thesis, discuss their implications, and 
provide a conclusion on the issue of value-for-money from cancer drug spending. 
 
Synthesis 
Clinical Risks and Benefits from New Cancer Medicines 
Chapter 2 of this thesis first adopted ASCO’s recently published Value Framework for 
cancer therapeutics, and performed a systematic review with narrative synthesis of 
corresponding appraisals from Australian, English, and French HTA authorities, to assess 
their clinical risks and benefits.  
 
62 new medicines with a primary anti-cancer indication were licensed by the US FDA or 
EU EMA between 2003-2013. Measures of clinical impact varied widely across the 53 
cancer medicines that were eligible for inclusion, as well as across treatment indications. 
Throughout the entire eligible sample, 32% of new anti-cancer medicines increased 
overall survival by three months or more; 11% by an unknown magnitude of greater than 
three months; 11% by less than three months; and 15% by some unknown amount. A 
further 30% did not improve overall survival relative to alternative treatments. Just 
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under half of new cancer drugs increased cancer patients’ quality of life, and the largest 
share (45%) reduced patient safety.  
 
Taken together, this chapter found that approximately one in three newly approved 
cancer medicines are not associated with any overall survival benefit, while one in five 
neither extend life nor improve quality of life or safety.  
 
Licensure however does not necessarily mean that new medicines are used by patients, 
or generously rewarded by payers. Subsequent chapters incorporate other streams of 
evidence to compare drug clinical benefits and levels of spending. Findings from this 
chapter nevertheless have several implications for health policy, clinical practice, and 
research.  
 
Most immediately, they raise questions over whether there is any value from even 
minimal additional expense on a subset of new cancer medicines. Findings from Chapter 
2 are however based on a review of expert, regulatory evaluations of explanatory clinical 
trial evidence. To better reveal the real-world clinical risks and benefits from new cancer 
medicines, future studies should periodically repeat this analysis using post-
marketing,(150) observational or pragmatic clinical trial evidence. The National Cancer 
Institute’s upcoming National Cancer Knowledge System may provide crucial insights in 
this regard.  
 
From a policy perspective, limits to health resources would mean that spending on 
certain medicines may not benefit patients, and could instead come with significant 
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opportunity costs to society. As cancer drug spending grows, how should health systems 
therefore respond to these findings?  
 
To address this question, it may be useful to first consider several points.  
 
First, Chapter 2 focused on the overall survival, quality of life, and safety benefits of new 
cancer medicines. Briefly, ASCO’s Value Framework is based on the notion that value-
based clinical decision-making should consider cancer drug costs alongside their impact 
on efficacy, toxicity, and quality of life. With respect to efficacy, overall survival is 
generally taken as the gold standard among oncology efficacy endpoints,(64,93,94) and 
the FDA takes overall survival as the only “universally accepted direct measure of 
benefit” in oncology drug trials.(95) Whereas surrogate clinical endpoints such as PFS 
may be subject to assessment bias or variability in the measurement of radiologic or 
clinical measures and assessment schedules,(96,97) the interpretation of overall survival 
is objective and not prone to investigator bias.(98) Dodd and colleagues (2008) in fact 
claim overall survival to be the “most objective end point to measure patient 
benefit,”(99) and the FDA itself describes overall survival as the “most reliable cancer 
endpoint.”(95) Perhaps as a result, surrogate efficacy measures are not regularly 
considered during regulatory evaluations,(95) and their predictive value in measuring 
clinical outcomes remains debated.(111) ASCO’s Value Framework encapsulates this line 
of thinking by arguing that overall survival should be used, where it is reported, to assess 
the clinical efficacy benefit of treatments for advanced disease. Surrogate measures of 
efficacy were therefore not considered in this analysis. However, if surrogate efficacy 
markers do in fact represent unique clinical benefits, then their absence from Chapter 2 
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would mean that the findings described above represent an upper limit in the percentage 
of new cancer medicines that provide therapeutic advantages.  
 
Second, cancer medicines can have a variable impact on real-world clinical populations. 
Biological response to new anticancer medicines may vary, and may partly depend on 
unknown factors.(332) Scientific advances on the mechanisms of disease, however, 
continue to emerge.(332) As they do, it may become increasingly possible to stratify 
patient subgroups and personalize clinical decision-making to improve the therapeutic 
effects from cancer drug use.(332) Trastuzumab has, for instance, achieved blockbuster 
status, yet is only efficacious in patients with breast cancer that is HER2/neu-
positive.(332) 
 
Variability in clinical response may in part reflect uncertainty over the mechanisms of 
disease, as 28% of Phase II/III trials still have unidentified targets.(333) This may make it 
difficult to measure the benefit from new treatments in any clinically relevant way within 
the limited timeframes of trial studies.(334) From a regulatory perspective, any 
misapprehension over the biological mediators of disease may therefore mean that 
regulators are unable to fully appreciate their value to patients.  
 
The implications of there being any uncertainty in decision-making that can affect drug 
access are morally fraught in cancer, where medicines are often used to treat life-
threatening diseases. Within this context, granting conditional marketing authorization 
may be in the interest of public health if the benefit of immediate availability outweighs 
the risk of incomplete data.(334) Even if early market authorization provides clinical 
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benefits to patients, it may also limit data availability for value-based pricing and 
reimbursement decisions,(334) and lead to hard increases in the cost of care for patients. 
Complementary efforts to resolve clinical uncertainty, which include phase IV post-
marketing surveillance trials, may therefore ensure clinical benefits to patients and 
value-based spending. Coverage with evidence development and managed access 
schemes, including England’s CDF,(43) are two policy tools that balance access to new 
treatments with evidence development. If the objective is to optimize the value obtained 
from spending on new and existing cancer medicines, policymakers should prioritize 
basic research into the mechanisms of disease. Moreover, drug access and evidence 
development are both needed to optimize patient well-being. Resources are therefore 
needed to assess the value from existing clinical and economic information, and to 
develop tools that can provide value insights using existing data. 
 
Indeed, this thesis found evidence to indicate that clinical uncertainty can directly 
impact drug evaluations. Agreement between HTA agencies on the accepted overall 
survival benefit from new medicines, for instance, was found to decrease as the 
magnitude of the purported benefit increased, suggesting that the regulatory milieu may 
shape the interpretation of clinical evidence. For example, while both English and 
Australian regulators accepted that sunitinib extended life by 7.8 months relative to BSC 
for gastrointestinal stromal tumors, Australia’s HTA agency expressed some unease with 
this claim, noting that this survival benefit “may be an overestimate” given limitations in 
the supporting evidence. Additional research is needed to help explain the causes of 




How should health systems respond to the findings described above? New medicines 
with an uncertain impact on health may benefit certain patients. Yet, and if only to 
incentivize clinically meaningful drug innovation,(313) health systems may still be 
expected to link expenditure with therapeutic impact. They must therefore optimize use 
of limited resources and reward meaningful innovation, while also facilitating access to 
treatments and acting in the face of uncertainty.  
 
Mechanisms for tiered drug use may provide health systems with an opportunity to 
balance these concerns. The UK provides a case study on how to design and implement 
such a system. In the UK, most care is funded by the public sector, which accounts for 
83.3% of total healthcare expenditures in 2013.(335) As of 2016, England’s NICE has been 
tasked with evaluating the clinical- and cost-effectiveness of all new anti-cancer 
medicines under an accelerated appraisal timetable, and issuing recommendations on 
whether they should be made available for routine commissioning throughout the 
country’s publicly-funded healthcare system, the NHS.(43) NHS England and Wales is 
then legally obliged to fund new medicines that are recommended by NICE,(54) 
prioritizing the uptake of medicines that bring the greatest health benefit to society. To 
nevertheless alleviate concerns over accessibility, the agency can recommend that new 
medicines be made available through the CDF if it believes that they may satisfy the 
criteria for routine commissioning, but significant clinical uncertainty remains. As a 
managed access fund, the CDF is designed to provide access to cancer medicines that are 
not routinely available through the NHS, while also aiming to reduce clinical 
uncertainty.(43) Its annual budget is however capped at £340m: the CDF is not intended 
to substitute for NICE-recommended treatments, but to help promote drug access and 
evidence development of new medicines and, as is demonstrated by recent reforms to 
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the program,(43) drive stronger value-for-money in drug spending. Health systems can 
therefore prioritize the use of cost-efficient care that provides the greatest good to 
society, while at the same time providing access to treatments with unclear health 
benefits and incentivizing the development of clinically meaningful therapeutics.   
 
Spending on New Cancer Medicines 
Chapter 3  
 
to generate comparative evidence on the use and cost of individual cancer 
medicines. Building on recent publications,(78,159) these methods offer a transparent 
and evidence-based approach to examine both elements to drug spending,  
 
 
The chapter finds that per patient drug costs vary widely across all newly licensed 
medicines, but also between countries. Per patient drug costs are consistently higher in 
the US compared with Australia, France, and the UK. This is true even when the drug 
sample is limited to those medicines that are marketed across all four countries. Holding 
all else equal, these findings suggest that the US regularly pays a premium for the same 
cancer medicines.  
 
This finding may reflect national policies on pharmaceutical spending. To lower drug 
prices, the US Department of Commerce in 2004 characterized the American strategy as 
one that relies on added competitive pressures from a strong generic pharmaceutical 





than competition.”(336) In Australia, France, and the UK, this was represented by price-
volume agreements for new medicines, price and profit controls, encouragement of use 
of generics and patient co-payments, publication of “negative lists” and “selected lists,” 
and campaigns to encourage doctors to control drug expenditures.(336) Thesis findings 
have several implications for policy and research that extend from this characterization 
of national strategies for pharmaceutical spending. 
 
First, findings from this thesis suggest that US payers and patients are willing to accept 
higher drug costs, without any clear difference in the pharmaceutical goods that are 
provided. Arguing that manufacturers may delay drug launches in certain countries due 
to potential ‘spill-over’ effects on drug pricing, Danzon and colleagues (2007) find that 
countries with lower expected drug prices or a smaller expected market size have fewer 
launches or longer launch delays.(337) Higher drug pricing in the US after initial entry, 
but before subsequent launch in other countries, may therefore represent an “innovation 
premium” for faster access to new cancer medicines. This thesis in fact shows that most 
new anti-cancer medicines are initially launched in the US, though the delay to 
subsequent licensure in Australia, France, and the UK is often less than one year. From 
the perspective of value, additional research should nevertheless build on these findings 
to examine whether and to what extent faster access to new treatments provides real-
world health benefits to patients.      
 
However, this thesis also finds that higher US drug costs persist over time, and most US 
patients are treated with new medicines in the years after market entry. It is therefore 
unclear whether consistently higher US drug costs provide any additional benefit to 
most US cancer patients, as equivalent medicines may be available at lower cost outside 
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of the US in the years after market entry. Kantarjian and colleagues (2013) have 
questioned whether this is fair to US patients, as they pay “two to four times the price 
paid by patients in other countries for the same drug.”(32) 
 
The US accounts for 5% of the world’s population, but 30% of its drug revenue, leading 
some to argue that US patients and payers are “being asked to essentially fund [the 
world’s] drug development.”(338) The US does indeed often pay more for medicines than 
other countries, and higher US drug costs persist over time, suggesting that they may 
contribute proportionally more to pharmaceutical R&D. Recent studies have 
nevertheless found that the premiums pharmaceutical companies earn from charging 
higher drug prices in the US compared with other countries are considerably greater 
than how much they spend on global R&D, pointing to the notion that higher US drug 
prices are not necessary for its funding.(339) If new medicines are associated with 
objectively greater clinical benefits over existing treatments, then faster access to new 
medicines at higher cost may be to the benefit of US patients. The degree to which this 
may be true, however, diminishes once equivalent treatments are made available 
elsewhere at lower cost. In this sense, any additional expense borne by most US cancer 
patients may also represent a subsidy to those who are treated with new medicines 
immediately after their launch. Regardless, if higher US drug costs are justified by their 
impact on R&D, research is needed to evaluate whether US cancer drug price premiums 
incentivize clinically meaningful innovation.  
 
As these questions are investigated, US policymakers could make drug price premiums 
fairer for US patients by making it easier for international patients to access new 
treatments in the US. Depending on its implementation, such a system could help 
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reduce drug spending by US patients proportional to those from abroad, while still 
promoting early access to new treatments. Over the longer-term, the US will have to 
decide if US cancer drug price premiums represent a net benefit to the US health system 
and US patients. What is clear is that other countries—in this thesis, Australia, France, 
and the UK—have taken different approaches to regulate cancer drug spending. Were 
foreign price controls to be eliminated, some have suggested that global pharmaceutical 
revenues and R&D spending would increase.(336) Assuming that it is unrealistic for this 
to occur, however, price regulation in the US may be an alternative approach to making 
cancer drug prices fairer for US patients.  
 
Value-Based Spending on New Cancer Medicines 
However, to justify additional governmental fiat in US cancer drug expenditures, 
evidence is first needed to determine whether current levels of spending are rational and 
worth the cost to patients and society. Building on evidence from prior chapters, 
Chapters 4 and 5 take two different approaches to evaluate whether cancer drug 
expenditures are value-based.  
 
Chapter 4 extends the methods used by Eggleston and colleagues (2009) to determine 
whether the monetized value of health gains net of marginal increases in cancer drug 
spending result in positive value to US patients and society.(82) For this, evidence on the 
overall survival benefits associated with all new anti-cancer medicines was taken from 




The US promotes the generic pharmaceutical industry as a means of creating “added 
competitive pressure to lower drug prices,”(336) and therefore help moderate drug 
spending. Chapter 4 finds evidence to suggest that there is indeed a strong generic 
pharmaceutical industry in the US. However, the degree to which it has effectively 
helped lower drug prices and drug spending, in particular, is unclear. Between 2004-
2014, the US consistently utilized higher volumes of generic cancer medicines than 
Australia, France, and the UK. The US also experienced a lower compounded annual rate 
of growth in spending on generic drugs than the latter two countries.  
 
Yet, the US continued to outspend other countries across both generic and branded 
cancer drug markets. This finding was in spite it having the highest level of generic drug 
use and comparable levels of overall cancer drug utilization. It also persists after 
adjusting for population and cancer epidemiology,(74,75) and is consistent across cancer 
drug classes, many individual new medicines, and over time. These findings suggest that 
growth in US cancer drug expenditures is not primarily driven by utilization—arguably 
key to improving patient outcomes—but rather by high drug prices, particularly of 
branded medicines.  
 
There is therefore some evidence to suggest that a strong generic pharmaceutical 
industry may help lower growth in total cancer drug spending. However, if comparative 
rates of price growth offer any guide, this may be driven primarily through competition 
among generic medicines, rather than between new and older treatments for the same 
indication. Competition with branded medicines may help lower growth in total cancer 
drug expenditures, while also incentivizing the development of clinically meaningful 
medicines. For this to occur, however, economic theory suggests that reliable 
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information is needed on the comparative clinical risks and benefits between new and 
older medicines. Unfortunately, this may not always exist: accelerated approval 
procedures, for instance, may not always provide conclusive information on drug 
efficacy, and may therefore require phase IV confirmatory studies.(101)  
 
To moderate growth in total drug spending through competition among alternative 
treatments, policymakers may wish to consider providing additional support to the 
development of comparative clinical evidence, and re-doubling efforts on comparative 
efficacy research. In the US, this objective may be met by supporting the Patient-
Centered Outcomes Research Institute. 
 
With respect to the clinical impact from cancer drug spending, there was consistent 
evidence to suggest that the US can do more to improve value-for-money. Adapting the 
methods used by Eggleston and colleagues (2009),(82) this thesis found that country-
level, neoplasm-related, drug-attributable survival gains between 2004-2014 were among 
the lowest in the US,  in spite the country having the highest level of incidence-adjusted 
spending on cancer medicines. Unlike in Australia, France, and the UK, base-case, 
country-level analyses suggested that the monetized value of US survival gains that could 
be attributable to new medicines over this period were less than long-term increases in 
cancer drug costs. These findings suggest that US cancer drug costs are high compared 
to what is observed in Australia, France, and the UK, and that, at an aggregate level, the 





These findings were consistent with those from drug-level analyses. Again building on 
established methods,(82) and utilizing results from earlier chapters, Chapter 4 found 
that the net value from spending on individual cancer medicines was often lower in the 
US than in Australia, France, and the UK, due to generally higher cancer drug costs. 
However, this analysis also revealed that there is wide heterogeneity in the net economic 
value generated from spending on individual cancer medicines. Pharmaceutical 
innovations have, in some instances, brought large, positive economic returns from their 
impact on survival (e.g. pertuzumab). In other cases, the use of some new medicines has 
generated little, or indeed negative, net value. Even in the US, therefore, growth in 
cancer drug spending may, in some instances, provide net economic benefits to society. 
Rather than focus exclusively on growing cancer drug prices, policymakers may instead 
consider them alongside drug-related clinical benefits, and work to prioritize the 
development and use of cancer medicines that provide the greatest therapeutic good to 
patients. 
 
Chapter 5 goes on to show that, when deciding among alternative treatments, clinical 
decision-making is inconsistently associated with drug-related clinical benefits. The UK 
showed the strongest, albeit still non-significant, positive association between survival 
benefits and adoption of new cancer medicines; reductions in quality of life were most 
likely to reduce incidence-adjusted cancer drug utilization in France; and reductions in, 
or no established effect on, safety were most likely to reduce cancer drug utilization in 
the US. Additional research is needed to determine whether these findings reflect 




Moreover, little evidence was found to suggest that cancer-drug pricing is value-based, 
particularly in the US. Compared with France and the UK, the US was less likely to 
demonstrate evidence of an association between measures of clinical benefit and per 
patient drug costs. If we accept that the US relies more on market-based systems to 
moderate drug spending than other OECD countries,(336) these findings suggest that 
governmental fiat may, if properly designed, play an appropriate economic role in the 
VBP of cancer medicines.  
 
To conclude, growing expenditures on cancer medicines have not always been met with 
meaningful gains in value to patients and health systems. The magnitude of clinical 
benefits associated with all newly licensed cancer medicines varies widely: some new 
medicines have brought patients notable improvements in therapy, while others have 
not, raising questions of the value from additional expense. The monetized value of 
survival gains, net of changes in drug spending, varies by medicine and country, with the 
US notably lagging Australia, France, and the UK due in part to higher drug costs. There 
is some evidence to suggest that cancer drug use and cost may only weakly be value-
based, and the extent to which this is true also differs across country settings. Taken 
together, these findings raise several important questions about value-for-money in 
oncology, and they highlight the important role that health policy can have in value-base 
cancer drug spending.   
 
Conclusion 
Theory, Empirical Gaps, and Thesis Outline 
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This thesis collected data on the clinical impact, use, and cost associated with new 
cancer medicines, before then examining whether cancer drug spending provides 
patients and society with value-for-money. As is shown in Figure 3, these efforts were 
framed around ASCO’s Value Framework, and were designed to reflect its approach for 
assessing the value of new cancer treatments.  
 
Chapter 2 of this thesis used ASCO’s recently published Value Framework within the 
context of a systematic review with narrative synthesis to assess the clinical impact from 
new cancer medicines, while Chapter 3  to generate 
comparative evidence on their expected use and cost in Australia, France, the UK and 
the US. These data were then used in subsequent chapters to compare the costs and 
clinical impact from new medicines, and assess their value to patients and society. 
 
In particular, Chapters 4 and 5 incorporated evidence on the clinical impact from new 
cancer medicines (Chapter 2), and their use and cost (Chapter 3), to examine whether 
cancer drug spending is providing patients and society with value-for-money. Chapter 4 
adapted methods from previous studies to analyze whether the monetized value of 
survival gains attributable to cancer drug innovation exceeds growth in drug spending, 
both at a societal- and drug-level. Chapter 5 then incorporated evidence from prior 
chapters within a regression-based framework to test the value-based hypothesis that 
spending on new cancer medicines is associated with their beneficial impact to patients. 
The conceptual framework and empirical gaps underlying these efforts, as well as thesis 





Figure 19. Overview of Conceptual Framework, Empirical Gaps, Research Questions, Thesis Outline, and Key 
Research Findings 
Chapter 3: 
Empirical Gap: There is a dearth of publicly available and comparable 
evidence on the use and cost associated with new cancer medicines. 
 
Research Question: What is the utilization and cost (spending) associated 
with new cancer medicines? 
 
Key Research Findings:  
• There is a wide variation in the total dose and total duration of 
treatment that would be expected from  treatment with 
new cancer medicines.  
• Mean estimates of the total expected cost from treatment varied 
widely across all newly licensed cancer drugs, were highest for 
hematologicals, increased over time, and varied across countries, with 
mean total drug costs consistently highest in the US.  
• Cancer drug utilization also varied over time and across medicines, 
and were highest for lung cancer indications and non-orphan 
medicines. 
Chapter 2:  
Empirical Gap: Without a conceptual framework in place, it is difficult to 
systematically assess the clinical impact to cancer patients from new 
medicines. 
 
Research Question: What are the relative clinical risks and benefits 
(clinical impact) associated with new cancer medicines?  
 
Key Research Findings:  
• All newly licensed cancer medicines have extended OS by an average 
(SEM) of 3.43 (0.63 months) over 2003 treatment standards.  
• Most newly approved cancer drugs were associated with some known 
(55%) or unknown (70%) benefit in OS, with the largest share (43%) 
extending life by ≥3 months.  
• English HTA agencies were most likely to determine that new cancer 
medicines improved overall survival, QoL, and reduced patient safety.  
• 1 in 3 of all newly approved cancer medicines were not associated with 
any OS benefit, while 1 in 5 neither extend life nor improve QoL or 
safety. 
 
Overarching Research Question: Is cancer drug spending providing patients 
and society with value-for-money? 
Chapters 4 & 5: 
Empirical Gap: In the absence of information on the clinical impact (Ch 2), utilization or cost (Ch 3), associated with new cancer medicines, it is difficult to 
assess whether cancer drug spending provides patients and society with value-for-money. 
 
Research Question (Ch 4): Building on data collected from earlier chapters, is the net monetized value of survival gains that can be attributed to cancer 
drug innovation positive, both at a societal- and drug-level? 
Research Question (Ch 5): Building on data collected from earlier chapters, is spending on new cancer medicines associated with measures of their 
beneficial clinical impact to patients? 
 
 
Key Research Findings (Ch 4):  
• Base-case, country-level analyses found that Australia, France, and the UK obtained net positive economic returns of $2.52, $6.46, and $3.94 billion in 
2014, respectively, from long-term increases in spending on cancer medicines.  
• The US outspends other countries on cancer medicines, even after adjusting for population and cancer epidemiology, and was the only country of the 
four to be associated with a net negative economic return from total, long-term increases in aggregate cancer drug spending. 
• At a drug level, the monetized value of drug-related survival gains has exceeded increases in cost for some new cancer medicines, but not for all.  
 
Key Research Findings (Ch 5):  
• Per patient drug utilization and costs are generally higher in the US than in Australia, France, and the UK.  
• Cancer drug costs and utilization may be weakly correlated with their impact on OS, QoL, and safety in Australia, France, the UK, and the US.  
• There may be a positive interaction between drug-related improvements in OS and costs, though the strength of this association varies across countries, 
and is highest in the UK and France. Interaction terms between there being no drug-related effect on QoL and cancer drug costs in both the UK and 
France were also significant and negative.  
• A positive, albeit non-significant, interaction between drug-related improvements in OS and incidence-adjusted utilization of new anticancer medicines 
was found, though the strength of this association was highest in the US and, particularly, the UK. Interaction terms between there being a drug-related 
reduction in QoL and France, as well as no effect on safety and the US, were also significant and negative. 






Quality of Life 
Conceptual Framework (12): 
Overarching Conclusion: Generally-speaking, cancer drug spending may be providing 
patients and society with value-for-money, but the degree to which this is true varies by 





Contributions to Policy, Clinical Practice, and Research  
To the extent that it examined whether cancer drug spending is providing value-for-
money, this thesis may offer several insights to policymakers. There is often uncertainty 
over the clinical impact from new cancer medicines, pointing to the need for continued 
investments in basic biomedical and comparative effectiveness research. Such efforts 
may not only help improve patient care, but also better inform regulatory evaluations 
and optimize the value that is obtained from spending on new and existing cancer 
medicines. Over the shorter term, if the objective is to make efficient use of limited 
resources, while also rewarding meaningful innovation and facilitating access to 
treatments, policymakers may consider mechanisms for managed entry of new cancer 
medicines that promote evidence development. 
 
This thesis also finds that the magnitude of clinical benefits varies widely across newly 
licensed cancer medicines, clinical benefits often come at the cost of safety, and there 
may be reasons to doubt whether clinical efficacy has been matched by effectiveness in 
real-world clinical settings. By providing additional clarity on the potential risks and 
benefits of new cancer medicines, findings from this thesis provide an additional 
resource for clinical decision-making by patients and physicians. 
 
More so than to policy or clinical practice, the primary contributions from this thesis are 
methodological and empirical (Figure 19). This thesis makes five major contributions to 
the literature on value-based spending on cancer medicines. First, adopting the recently 
published ASCO Value Framework, this thesis finds that approximately one in three 
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newly licensed cancer medicines provide no known overall survival benefit, while one in 
five provide no known overall survival, quality of life, or safety benefit. Second, making 
novel use of methodologies to model treatment course and duration, this thesis finds 
that cancer drug costs and utilization vary greatly between individual medicines, and 
across Australia, France, the UK, and the US. Third, it also finds that the monetized 
value of survival gains attributable to development of new cancer medicines, net of 
growth in cancer drug spending, varies across individual medicines, and, at a country-
level, remains unambiguously positive in Australia, France, and the UK, but negative in 
the US. Fourth, spending on new cancer medicines is often only weakly associated with 
their clinical benefits. Fifth, the strength of this association nevertheless varies across 
countries, with the UK demonstrating the strongest evidence of value-based spending on 
new cancer medicines.  
 
Pharmaceutical innovations have occasionally brought meaningful clinical benefits to 
patients. From the perspective of value, growth in cancer drug spending may sometimes, 
but not always, be justified. Similar arguments have been made elsewhere.(8,9) At a 
country-level, the strength of association between cancer drug spending and drug 
clinical benefits varies, yet the evidence suggests that all countries can do more to 
improve value-for-money.  
 
Future Research Directions 
The work that is presented in this thesis outlines several areas for additional research. 
First, in the absence of real-world data, this thesis was based on pivotal clinical trial 
evidence. Future studies should extend this analysis by examining post-marketing, 
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observational or pragmatic clinical trial data, as it becomes available, and comparing 
against explanatory clinical trial results. Moreover, regulatory assessments of the clinical 
impact from new cancer medicines may differ, raising questions over whether they 
consistently reflect the value that patients ascribe to clinical outcome measures. Future 
studies should therefore examine how evidence on the clinical impact from new 
treatments is measured, weighted, and rewarded in decision-making by regulators and 
payers. Finally, the magnitude of association between cancer drug spending and drug 
clinical benefits varies across countries. Future studies should therefore examine the 
effectiveness of individual policies and regulations in linking evidence on the clinical 
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eTable 1. Healthcare-Related Bills Introduced during the 114th US Congress  
Legislation Congress 





















Part D Price 
Determination 



















Part C VBID 
Methodology 
Pharmaceutical Supply and Value Enhancement Act (S.3455) 114th    X             
Value-Based Insurance Design Seniors Copayment Reduction Act 
(S.1396) 
114th                X 
Fair Accountability and Innovative Research Drug Pricing Act 
(S.3335) 
114th          X       
Fair Accountability and Innovative Research Drug Pricing Act 
(H.R.6043) 
114th          X       
Medicare Prescription Drug Savings and Choice Act (H.R.3261) 114th        X         
Medicare Prescription Drug Savings and Choice Act (S.1884) 114th        X         
Prescription Drug Affordability Act (H.R.3513) 114th   X X X   X   X X  X   
Prescription Drug Affordability Act (S.2023) 114th   X X X   X   X X  X   
Closing Loopholes for Orphan Drugs Act (H.R.6174) 114th         X        
Prescription Drug Monitoring Act (S.3209) 114th               X  
Prescription Drug and Health Improvement Act (S.2858) 114th        X         
Lower Drug Costs through Competition Act (H.R.4784) 114th X X               
Medicare Fair Drug Pricing Act (H.R.4207) 114th       X          
Medicare Prescription Drug Price Negotiation Act (H.R.3061) 114th        X         
Safe and Affordable Prescription Drugs Act (S.1790) 114th    X             
Cancer Drug Coverage Parity Act (H.R.2739) 114th             X    
Cancer Drug Coverage Parity Act (S.1566) 114th             X    
Medicaid Generic Drug Price Fairness Act (H.R.2391) 114th            X     
Medicaid Generic Drug Price Fairness Act (S.1364) 114th            X     
Medicare Drug Savings Act (H.R.2005) 114th           X      
Prescription Drug Accountability Act (H.R.2046) 114th               X  
Safe and Affordable Drugs from Canada Act (H.R.2228) 114th    X             
FEHBP Prescription Drug Oversight and Cost Savings Act 
(H.R.2175) 
114th      X           
Medicare Drug Savings Act (S.1083) 114th           X      
Generic Complex Drugs Safety and Effectiveness for Patients Act 
(H.R.1576) 
114th                 
Safe and Affordable Drugs from Canada Act (S.122) 114th    X             
Medicare Prescription Drug Price Negotiation Act (S.31) 114th        X         
Source:  
Author’s coding of bills from congress.gov. 
Notes:  
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eTable 2. Regulatory Evidence in Support of Classification of Drug Clinical Benefits 
abiraterone acetate FDA primary indication 
ATC code: L02BX03 
A CYP17 inhibitor indicated for use in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer who 
have received prior chemotherapy containing docetaxel. 
 
Orphan Status: – 
Licensure: FDA/EMA 
Target: Prostate 
Agency  NICE HAS PBAC 
Appraisal date Jun-12 Feb-12 Jul-12 
Comparator BSC (prednisolone) BSC (prednisolone) BSC (prednisolone) 
Modelled/indirect comparison No No No 
Basis for classification OS: 4.6-month increase in median OS compared 
to prednisolone; estimated mean overall survival 
gain was greater than 3 months, though exact 
value was "commercial in confidence" 
 
QoL: Committee concluded that abiraterone 
offers a step change in treatment because it is an 
oral drug taken by patients at home, and is 
associated with few adverse reactions. The 
benefit related to being an oral drug was not 
captured in the analysis because the model 
applied the same utility benefit to abiraterone as 
to mitoxantrone. Committee therefore 
acknowledged that abiraterone provides HRQoL 
benefits other than those captured in the QALY 
calculation for patients currently receiving 
mitoxantrone 
OS: 3.9-month increase in median OS 
compared to placebo (prednisone or 
prednisolone) 
 
QoL: The patients’ quality of life deteriorates 
less under treatment than with placebo 
 
Safety: No judgment given on comparative 
differences in safety 
OS: 3.9-month increase in median OS compared to 
BSC (prednisone/ prednisolone plus other care); 
OS increase compared to mitoxantrone (based on 
indirect comparison), though magnitude of 
increase not given; no significant increase 
compared to cabazitaxel (based on indirect 
comparison) 
 
QoL: Statistically significant differences in 
functional assessment of cancer therapy – prostate 
(FACT-P) scores between the abiraterone and 
placebo arms of Trial 301 were demonstrated. 
However, the magnitude of changes in FACT-P 
Total Scores between trial arms were small and 





Safety: The Committee also noted that 
abiraterone is not associated with the more 
severe adverse reactions that can occur with 
cytotoxic drugs such as mitoxantrone. The 
Committee heard from the clinical specialists 
that abiraterone is a well-tolerated oral 
medication 
Safety: Whilst PBAC considered there were 
uncertainties inherent from indirect comparisons, 
it accepted the submission’s clinical claims:  
(1) abiraterone + prednisone/ prednisolone is 
equivalent in terms of comparative safety over BSC 
(prednisone/prednisolone alone);  
(2) abiraterone + prednisone/ prednisolone is 
superior in terms of comparative safety over 
mitozantrone plus prednisone/prednisolone alone;  
(3) abiraterone + prednisone/ prednisolone is 
superior in terms of comparative safety over 
cabazitaxel plus prednisone/prednisolone alone 
Effects Merged data    
OS increase 3.9–4.6 months ≥ 3 months ≥ 3 months ≥ 3 months 
QoL change + + + + 
Safety change + + NA 
No difference (BSC); + (mitoxantrone);  
+ (cabazitaxel) = + 
ado-trastuzumab 
emtansine 
FDA primary indication 
ATC code: L01XC14 
HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic 
breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: 
(a) Received prior therapy for metastatic disease, or 
(b) Developed disease recurrence during or within six months of completing adjuvant therapy. 
Orphan Status: – 
Licensure: FDA/EMA 
Target: Breast 
Agency  NICE HAS PBAC 
Appraisal date Aug-14 Mar-14 Nov-14 
Comparator lapatinib + capecitabine lapatinib + capecitabine lapatinib + capecitabine 
Modelled/indirect comparison No No No 
Basis for classification OS: 5.8-month increase in median OS compared 
to lapatinib + capecitabine 
QoL: The Committee was aware that EMILIA 
was an open- label trial, which may have 
OS: 5.8-month increase in median OS 
compared to lapatinib + capecitabine 
QoL: In view of the available results from 
clinical trials, especially the EMILIA study, ado-
OS: 5.8-month increase in median OS compared to 
lapatinib + capecitabine 
QoL: The PBAC noted strong support for the 
listing of T-DM1 received through the consumer 
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introduced bias in the outcomes reported by 
patients, but concluded that a marginally higher 
utility value for trastuzumab emtansine in the 
progression-free state could be accepted in this 
appraisal 
 
Safety: The Committee understood that fewer 
patients stopped treatment because of an 
adverse event in the trastuzumab emtansine 
group than in the lapatinib + capecitabine group 
trastuzumab is expected to have a moderate 
impact in terms of morbidity, mortality and 
QoL 
 
Safety: A smaller proportion of AEs of grade 3 
or worse and serious AEs (SAE) of grade 3 or 
worse was reported in the trastuzumab 
emtansine group compared to the control group 
comments facility expressing a range of benefits 
from treatment including improved QoL  
 
Safety: T-DM1 second-line: the previous 
resubmission described T-DM1 as superior in terms 
of comparative safety over lapatinib plus 
capecitabine. In March 2014, the PBAC accepted 
this clinical claim, although noted that some of the 
toxicity profile of T-DM1 was less favourable than 
that of its comparator 
Effects Merged data    
OS increase 5.8 months ≥ 3 months ≥ 3 months ≥ 3 months 
QoL change + + + + 
Safety change +/- + + +/- 
afatinib FDA primary indication 
ATC code: L01XE13 
A kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal 
growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test. 
  
Orphan Status: – 
Licensure: FDA/EMA 
Target: Lung 
Agency  NICE HAS PBAC 
Appraisal date Apr-14 Feb-14 Jul-13 
Comparator erlotinib, gefitinib cisplatin-based chemotherapy erlotinib, gefitinib 
Modelled/indirect comparison No No No 
Basis for classification OS: Committee concluded that on balance 
afatinib is likely to have similar clinical efficacy 
to erlotinib and gefitinib. Because of the 
immaturity of the OS data available, there was 
uncertainty about whether treatment with 
afatinib resulted in OS benefit compared with 
OS: In view of the available clinical data and in 
comparison with cisplatin-based chemotherapy, 
it should be noted that there is no improvement 
in terms of OS 
QoL: In view of the available clinical data and 
in comparison with cisplatin-based 
chemotherapy, a moderate additional impact 
OS: PBAC noted that there was no significant 
survival advantage reported for afatinib or the 
other two TKIs in trials considered. Comparing 
afatinib with chemotherapy, there was no observed 




chemotherapy, therefore no increase was 
established 
 
QoL: The Committee did not draw any specific 
conclusions about the HRQoL benefits and 
utility values 
 
Safety: The Committee concluded that 
although afatinib has a different adverse 
reaction profile from erlotinib and gefitinib, 
overall the toxicity of the tyrosine kinase 
inhibitors was similar 
QoL is expected in patients treated with first-
line afatinib. In the absence of any clinical data 
comparing afatinib with other tyrosine kinase 
inhibitors, the medicinal product afatinib is not 
expected to have any additional impact on QoL 
in the current treatment strategy for these 
patients 
 
Safety: While HAS makes a few claims on AE 
rates, the agency gives no assessment of 
comparative differences in safety 
QoL: PBAC considered that the benefit of afatinib 
was due only to a prolongation of PFS which is 
associated with some improvement in QoL 
 
Safety: PBAC considered that many serious adverse 
events including grade 3 or higher appeared more 
often in the afatinib arm compared to the 
cisplatin/pemetrexed arm. They noted that there 
were relatively high rates of adverse events (AEs) 
associated with afatinib relative to doublet 
platinum chemotherapy, including more Grade 3 or 
higher AEs, in the LUX Lung 3 trial. There was a 
higher proportion of dose reductions during 
treatment with afatinib compared to treatment 
with either gefitinib or erlotinib, although there 
were limitations for those indirect comparison 




None established None established None established 
QoL change + NA + + 
Safety change - No difference NA - 
asparaginase E. 
chrysanthemi 
FDA primary indication 
ATC code: L01XX02 
An asparagine specific enzyme indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute 
lymphoblastic leukemia (ALL) who have developed hypersensitivity to E. coli-derived asparaginase. 
 
  
Orphan Status: EU 
Licensure: FDA 
Target: Hematological 
Agency  NICE HAS PBAC 
Appraisal date NA NA NA 
Comparator NA NA NA 
Modelled/indirect comparison NA NA NA 
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Basis for classification NA NA NA 
Effects Merged data    
OS increase  NA NA NA 
QoL change  NA NA NA 
Safety change  NA NA NA 
axitinib FDA primary indication 
ATC code: L01XE17 
A kinase inhibitor indicated for the treatment of advanced renal cell carcinoma after failure of one prior systemic therapy.  
 
Orphan Status: EU (w) 
Licensure: FDA/EMA 
Target: Renal 
Agency  NICE HAS PBAC 
Appraisal date Feb-15 Jan-13 Nov-14 
Comparator BSC sorafenib everolimus 
Modelled/indirect comparison Yes No Yes 
Basis for classification OS: More than 3-month increase compared to 
BSC was "likely" (based on indirect and 
simulated treatment comparisons), though 
exact magnitude of increase was uncertain as 
the comparison results were "improbable"; 
Committee concluded that axitinib "was likely 
to have clinical effectiveness comparable to 
pazopanib and sunitinib" 
 
QoL: NICE was satisfied with the HRQoL data 
collected and found no significant difference 
versus sorafenib in FKSI-15. QoL was maintined 
while patients remained in both treatment 
groups. For EQ-5D, the overall between-
treatment comparison for axitinib compared 
with sorafenib was not statistically significant 
OS: An increase compared to sorafenib was not 
established in the overall population or patient 
subgroups as no statistically significant 
difference was observed; Committee considered 
that the indirect comparison to everolius was 
"exploratory in nature from [which] no 
conclusions can be drawn with a sufficient level 
of evidence" 
 
QoL: In view of the clinical study results 
showing no gain in terms of overall survival or 
quality of life, the expected impact of axitinib in 
terms of morbidity, mortality and quality of life 
can only be small 
OS: An increase compared to everolimus was not 
established given "the limitations of the 
comparative evidence and the methodological 
limitations of the simulated treatment comparison 
and matching-adjusted indirect comparison", 





Safety: PBAC accepted the clinical claim that 
axitinib is non-inferior to everolimus in terms of 
comparative effectiveness and safety 
319 
 
(no p value given); however, QoL was 
maintained while patients remained on 
treatment and declined when patients stopped 
trial medication 
 
Safety: The Committee noted that diarrhoea 
occurred with similar frequency in the axitinib 
and sorafenib groups. It was aware that 
hypertension, dysphonia, nausea and 
hypothyroidism occurred more frequently in the 
axitinib group, although hand–foot syndrome, 
rash and alopecia occurred more frequently in 
the sorafenib group. The Committee concluded 
that axitinib has a manageable adverse event 
profile compared with other treatments 
Safety: The frequency of serious adverse events 
was of the same order between axitinib and 
sorafenib 
Effects Merged data    
OS increase 
≥ 3 months 
(exact gain 
uncertain) 
≥ 3 months 
(exact gain uncertain) 




No difference No difference NA 
Safety change +/- +/- No difference No difference 
azacitidine FDA primary indication 
ATC code: VL01BC07 
Indicated for treatment of patients with the following myelodysplastic syndrome subtypes: refractory anemia or refractory anemia with ringed sideroblasts 
(if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts, refractory anemia with excess blasts 
in transformation, and chronic myelomonocytic leukemia.  
Orphan Status: US/EU 
Licensure: FDA/EMA 
Target: Hematological 
Agency  NICE HAS PBAC 
Appraisal date Mar-11 Apr-09 Jul-09 
Comparator conventional care conventional care conventional care 
Modelled/indirect comparison No No No 
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Basis for classification OS: 9.6-month increase in median OS 
compared to conventional care regimens (i.e. 
BSC, low-dose chemotherapy, and standard-
dose chemotherapy); OS increase significant 
compared to BSC and low-dose chemotherapy, 
but not significant compared to standard-dose 
chemotherapy though the Committee "was 
aware that the small patient numbers limited 
the precision and certainty of the outcome 
estimates in these groups" 
 
QoL: Committee heard from the patient experts 
that compared with other treatment options, 
azacitidine was associated with relief from 
fatigue, fewer infection-related hospitalisations, 
a decreased need for blood and platelet 
transfusion, and increased ability to perform 
day-to-day activities. No QoL data were 
collected in AZA-001, although EORTC data 
collected in CALGB 9221 suggested 
improvements in overall health with azacitidine.  
 
Safety: No comparative assessment made on 
AEs and safety 
OS: 9.4-month increase in median OS 
compared to conventional care regimens (i.e. no 
active treatment, low-dose cytarabine, and 
standard chemotherapy) 
 
QoL: In view of the available clinical data and 
current therapeutic strategies, azacitidine is 
expected to have a significant impact on 
morbidity, mortality and QoL 
 
Safety: No explicit judgment provided 
discussing the comparative evidence on drug-
related changes in AEs and safety 
OS: 9.4-month increase in median OS compared to 
conventional care regimens (i.e. BSC, low-dose 
cytarabine, and standard-dose chemotherapy) in 
patients with high risk MDS 
 
QoL: No explicit discussion on HRQoL data, 
though there is a brief discussion of the "paucity of 
available utility data" and the "uncertainty" in the 
values used in submitted health economic 
evaluations 
 
Safety: PBAC agreed that BSC (which included low 
dose cytarabine and standard chemotherapy) was 
the appropriate comparator and that the clinical 
trial data supported the claim that azacitidine was 
significantly more effective than conventional care 
but was associated with more toxicity when used 
for the treatment of INT-2/high risk MDS patients 
Effects Merged data    
OS increase 9.4–9.6 months ≥ 3 months ≥ 3 months ≥ 3 months 
QoL change + + + NA 
Safety change - NA NA - 
bendamustine FDA primary indication 
ATC code: L01AA09 
An alkylating drug indicated for the treatment of patients with chronic lymphocytic leukemia. Efficacy relative to first line therapies other than 
chlorambucil has not been established. 
 
  





Agency  NICE HAS PBAC 
Appraisal date Feb-11 Oct-10 NA 
Comparator chlorambucil chlorambucil NA 
Modelled/indirect comparison No No NA 
emBasis for classification OS: No statistically significant difference in 
median OS between bendamustine and 
chlorambucil 
 
QoL: During the treatment period, patients' 
QoL was assessed using the EORTC 
questionnaires. Patients' overall QoL was 
modestly improved in both groups during 
treatment, with no significant differences 
between the groups. The manufacturer 
explained in its submission that the QOL data 
collected during the trial showed that patients 
receiving the more effective therapy 
(bendamustine) experienced a greater number 
of adverse events during the treatment period, 
leading to a QoL detriment in some health 
dimensions 
 
Safety: The only available treatment for these 
patients is chlorambucil. The Committee heard 
that although bendamustine is slightly more 
toxic and is associated with more AEs, the 
clinical specialists considered bendamustine to 
be the more effective treatment. The Committee 
also noted the views of the patient groups in 
their submissions to NICE that because of its 
improved efficacy compared with chlorambucil, 
people with the condition would be willing to 
accept the side effects 
OS: Insignificant difference in terms of median 
OS compared to the benchmark (65.4 months 
in the chlorambucil group and not achieved in 
the bendamustine group) 
 
QoL: There is a lack of HRQoL data 
 
Safety: HAS noted that grade 3–4 adverse 
events were more common in the 
bendamustine group than in the chlorambucil 
group, especially haematological adverse events 
and infections 
NA 




None established None established NA 
QoL change - - NA NA 
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Safety change - - - NA 
bevacizumab FDA primary indication 
ATC code: L01XC07 
In combination with intravenous 5-fluorouracil–based chemotherapy is indicated for first- line treatment of patients with metastatic carcinoma of the 
colon or rectum. 
 
  
Orphan Status: – 
Licensure: FDA/EMA 
Target: GI 
Agency  NICE HAS PBAC 
Appraisal date Jan-07 Jun-05 Jul-08 
Comparator IFL IFL IFL or 5-FU/LV 
Modelled/indirect comparison No No No 
Basis for classification OS: 4.7-month increase in median OS compared 
to IFL (irinotecan, bolus 5-FU and leucovorin); 
no significant difference compared to 5-FU/LV 
(two studies); Committee noted that the 
comparators "cannot be considered current 
standard practice in NHS," though was 
"persuaded that the results seen in the studies 
could be considered generalizable to NHS 
practice"  
 
QoL: Committee recommends studies to 
investigate the impact of bevacizumab and 
cetuximab treatment on HRQoL 
 
Safety: In all the studies there was a higher 
incidence of grade 3 and 4 adverse events in the 
groups receiving bevacizumab compared with 
the control groups 
OS: 4.7-month increase in median OS 
compared to IFL (first-line); no significant 
difference in median OS was observed 
compared to FUFOL (5-FU plus folinic acid) 
 
QoL: Time to deterioration in QoL were similar 
in both groups  
 
Safety: In the pivotal study, grade 3-4 toxicity 
was higher in the IFL + Avastin group than in 
the IFL alone group 
OS: 3- to 4-month increase in OS compared to 
first-line chemotherapy (i.e. IFL or 5-FU/LV), 
although the differences were not statistically 
significant in two of the three trials; Committee 
also noted that IFL was "no longer accepted as best 
practice in Australia or the USA" 
 
QoL: No HRQoL data presented 
 
Safety: Overall, the risk of several AEs, particularly 
hypertension, proteinuria and arterial 
thromboembolic events, was found to be elevated 
following the addition of bevacizumab to 
chemotherapy 
Effects Merged data    




NA No Difference NA 
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Safety change - - - - 
bortezomib FDA primary indication 
ATC code: L01XX32 
bortezomib for injection is indicated for the treatment of multiple myeloma patients who have received at least two prior therapies and have 
demonstrated disease progression on the last therapy. The effectiveness of VELCADE is based on response rates (see CLINICAL STUDIES section). There 
are no controlled trials demonstrating a clinical benefit, such as an improvement in survival. 
  
Orphan Status: US 
Licensure: FDA/EMA 
Target: Hematological 
Agency  NICE HAS PBAC 
Appraisal date Oct-07 Oct-04 Mar-06 
Comparator high-dose dexamethasone Not given high-dose dexamethasone 
Modelled/indirect comparison No Yes No 
Basis for classification OS: 6.1-month increase in median OS compared 
to high-dose dexamethasone 
 
QoL: No HRQoL information provided. Further 
research into the effectiveness of bortezomib for 
the treatment of relapsed multiple myeloma is 
needed. Such studies should include: 
measurement of quality of life in patients with 
relapsed multiple myeloma, including the effect 
of treatment and adverse events 
 
Safety: Committee understood from the clinical 
specialists that there was a greater frequency of 
peripheral neuropathy and gastrointestinal 
adverse effects in the bortezomib arm, but that 
bortezomib was associated with less bone 
destruction and fewer infections than HDD 
OS: 8.5- to 11.5-month improvement in median 
survival based on comparison of OS data from 
single-arm bortezomib study and OS data from 
literature for similar patient population 
 
QoL: Regarding QoL treatment, improved 
items including the overall score of QoL, the 
physical score and social score were observed in 
2 of the three scales used (QLQ-C30 scale 
EORTC-QLQ Module MY24). Variation of the 
scores of the FACIT-Fatigue scale score was not 
statistically significant 
 
Safety: No comparative data 
OS: Committee "acknowledged that bortezomib 
has significant advantages in the short term over 
the comparator HDD in terms of…increasing the 
proportion of individuals alive at one year" but 
noted that "a number of uncertainties arose over 
the interpretation of the...trial results," including 
wide 95% confidence intervals, significant patient 
crossover, and "doubts about the acceptability of 





Safety: Overall incidence of AEs were similar in 
both groups, with 100% of bortezomib patients and 
98% of HDD patients experiencing one AE. Overall 
pattern of AE differed. Incidence of Grade 3 and 
those leading to discontinuation was higher in the 
bortezomib group 
Effects Merged data    
OS increase 6.1–11.5 months ≥ 3 months ≥ 3 months Uncertain 
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QoL change + NA + NA 
Safety change +/- +/- NA - 
bosutinib FDA primary indication 
ATC code: L01XE14 
A kinase inhibitor indicated for the treatment of adult patients with chronic, accelerated, or blast phase Ph+ chronic myelogenous leukemia (CML) with 
resistance or intolerance to prior therapy.  
Orphan Status: US/EU 
Licensure: FDA/EMA 
Target: Hematological 
Agency  NICE HAS PBAC 
Appraisal date Nov-13 Feb-14 NA 
Comparator BSC NA NA 
Modelled/indirect comparison Yes No NA 
Basis for classification OS: At least 3-month extension  compared to 
BSC, though exact magnitude of increase 




Safety: The Committee heard from a patient 
expert that, in their own experience, previous 
tyrosine kinase inhibitors had resulted in them 
being unable to work and needing cardiac and 
surgical interventions. However, bosutinib had 
been tolerated 
OS: An increase was not established given the 
lack of comparative data presented to the 
Committee 
 
QoL: The proprietary medicinal product 
bosutinib is not expected to have any impact on 
morbidity, mortality or QoL in comparison with 
cited treatments 
 
Safety: No comparative data available 
NA 
Effects Merged data    
OS increase 
≥ 3 months 
(exact gain 
uncertain) 
≥ 3 months 
(exact gain uncertain) 




NA No difference NA 
Safety change + + NA NA 
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brentuximab vedotin FDA primary indication 
ATC code: L01XC12 
A CD30-directed antibody-drug conjugate indicated for: (a) Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT) or after failure of at 
least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates; and (b) Systemic anaplastic large cell lymphoma after failure 
of at least one prior multi-agent chemotherapy regimen. These indications are based on response rate.  
Orphan Status: US/EU 
Licensure: FDA/EMA 
Target: Hematological 
Agency  NICE HAS PBAC 




non-comparative multi-agent salvage chemotherapy 
Modelled/indirect comparison NA No No 
Basis for classification NA OS: Median OS was not achieved during the 
primary analysis and does not enable 
conclusions to be drawn regarding this 
endpoint; available data are not sufficient 
(absence of comparative data in particular) to 
enable an evaluation of the expected impact of 
brentuximab vedotin on the morbidity, 




Safety: No comparative data available 
OS: The PBAC accepted the claim that BV is 
associated with significant additional OS and 
patient relevant efficacy in the first line salvage 
setting for patients that have had no prior SCT 
 
QoL: NA 
Safety: PBAC considered that the submission’s 
claim of less toxicity relative to multi-agent salvage 
chemotherapy was reasonable with respect to most 
acute toxicity, but that severe peripheral 
neuropathy was an important toxicity more likely 
in BV treated patients 









NA NA NA 
Safety change +/- NA NA +/- 
cabazitaxel FDA primary indication 
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ATC code: L01CD04 
A microtubule inhibitor indicated in combination with prednisone for treatment of patients with hormone-refractory metastatic prostate cancer 
previously treated with a docetaxel-containing treatment regimen. 
 
  
Orphan Status: – 
Licensure: FDA/EMA 
Target: Prostate 
Agency  NICE HAS PBAC 
Appraisal date May-12 Oct-12 Nov-11 
Comparator mitoxantrone mitoxantrone mitoxantrone 
Modelled/indirect comparison Yes No No 
Basis for classification OS: More than 3-month increase compared to 
mitoxantrone (4.2 months based on modeled 
mean OS gain); 2.4-month increase in median 
OS was observed in the trial 
 
QoL: No statistically significant difference in 
pain response between the treatment arms. No 
significant difference in time to pain 
progression between the treatment arms 
 
Safety: The Committee was initially concerned 
that in TROPIC more participants in the 
cabazitaxel arm died from cardiac and renal 
complications than in the mitoxantrone arm. 
The Committee concluded that there is no 
evidence of additional risk other than that 
included in the SPC and that the health 
economic model adequately reflected the 
disutility associated with adverse reactions. The 
Committee further heard that patient experts 
are aware that cabazitaxel is associated with 
serious ARs and that it would not be suitable for 
some patients who are not fit for chemotherapy 
OS: 4.1-month increase in median OS compared 
to mitoxantrone in subgroup of patients who 
had stopped treatment due to disease 
progression and had a histologically poorly 
differentiated tumor; 2.4-month increase in 
median OS compared to mitoxantrone in the 
whole trial population 
 
QoL: In the absence of data, the impact on the 
QoL of treated patients is not quantifiable. 
Nevertheless, a negative impact (safety issues) 
on QoL cannot be ruled out 
 
Safety: Safety was not as good in the 
cabazitaxel group as in the mitoxantrone group 
OS: 2.4-month increase in median OS compared to 
mitoxantrone; Committee stated that the modeled 
mean OS gain of 4.26 months appeared to be an 
overestimate and was uncertain 
 
QoL: A regulatory judgment of the submitted 
HRQoL (Q-TWIST) evidence is not given 
Safety: The PBAC agreed that the clinical claim 
that cabazitaxel is superior in terms of comparative 
effectiveness and inferior in terms of comparative 
safety over mitozantrone is reasonable 
Effects Merged data    






No difference NA NA 
Safety change - - - - 
cabozantinib FDA primary indication 
ATC code: L01XE26 




Orphan Status: US 
Licensure: FDA/EMA 
Target: Thyroid 
Agency  NICE HAS PBAC 
Appraisal date NA Dec-14 NA 
Comparator NA placebo NA 
Modelled/indirect comparison NA No NA 
Basis for classification NA OS: The available data showed no benefit, and 
given current therapeutic strategies, low impact 
in terms of morbidity and mortality is expected  
 
QoL: The available clinical data (including a 
Phase III placebo-controlled trial) showed a 
gain of 7 months progression-free survival with 
better response rates, but no benefit on overall 
survival or profit (or worsening) of QoL 
 
Safety: Treatment discontinuations due to 
adverse events were higher for patients in the 
cabozantinib group versus placebo patients 
NA 








NA No difference NA 
Safety change - NA - NA 
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carfilzomib FDA primary indication 
ATC code: L01XX45 
A proteasome inhibitor indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies including 
bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy. Approval 
is based on response rate. 
  
Orphan Status: US/EU 
Licensure: FDA/EMA 
Target: Hematological 
Agency  NICE HAS PBAC 
Appraisal date NA NA NA 
Comparator NA NA NA 
Modelled/indirect comparison NA NA NA 
Basis for classification NA NA NA 
Effects Merged data    
OS increase  NA NA NA 
QoL change  NA NA NA 
Safety change  NA NA NA 
catumaxomab FDA primary indication 
ATC code: L01XC09 




Orphan Status: US/EU 
Licensure: EMA 
Target: Ascites 
Agency  NICE HAS PBAC 
Appraisal date NA Dec-09 NA 
Comparator NA paracentesis NA 
Modelled/indirect comparison NA No NA 
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Basis for classification NA OS: Median OS did not differ between the two 
groups: 72 days in the REMOVAB group 
compared with 68 days in the control group 
 
QoL: In view of the methodology of the study 
(open-label), QoL data are difficult to interpret. 
The need for 11 days of hospitalisation for the 
treatment while no evidence is available of an 
improvement in QoL 
 
Safety: No comparative evidence presented 
NA 












NA NA NA 
cetuximab FDA primary indication 
ATC code: V L01XC06 
Used in combination with irinotecan for the treatment of EGFR-expressing, metastatic colorectal carcinoma in patients who are refractory to irinotecan-
based chemotherapy. cetuximab administered as a single agent is indicated for the treatment of EGFR-expressing, metastatic colorectal carcinoma in 
patients who are intolerant to irinotecan-based chemotherapy. 
  
Orphan Status: – 
Licensure: FDA/EMA 
Target: GI 
Agency  NICE HAS PBAC 
Appraisal date Jan-07 Mar-05 Mar-09 
Comparator cetuximab monotherapy cetuximab monotherapy BSC 
Modelled/indirect comparison No No Yes 
Basis for classification OS: No statistically significant difference in 
median OS between cetuximab-irinotecan 
combination therapy and cetuximab 
monotherapy. Relative effectiveness against 
OS: No gain in OS has been demonstrated 
between cetuximab-irinotecan and cetuximab 
monotherapy 
 
OS: PBAC noted 3.6-month survival gain over BSC 
arm in modeled data. However, submission 
estimate likely overestimated the OS. PBAC 
considered that the extent of OS benefit over BSC 
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current standard care remains uncertain 
 
QoL: The Committee recommends studies to 
investigate the impact of bevacizumab and 
cetuximab treatment on health-related quality 
of life 
 
Safety: In the RCT the incidence of some AEs 
was higher in patients receiving cetuximab plus 
irinotecan compared with those receiving 
cetuximab alone: grade 3 and 4 adverse events; 
diarrhoea; neutropenia; grade 3 or 4 acne-like 
rash. 
QoL: Available data do not allow to quantify 
the contribution of cetuximab in terms of 
quality of life vis-à-vis existing therapies 
 
Safety: 71% of patients in the combination 
group experienced at least one Grade 3–4 events 
against 53% monotherapy group 
in the KRAS subgroup remained uncertain 
 
QoL: For key results, see Nov 2008 PSD. No 
information indicating drug-induced change 
 
Safety: For key results, see Nov 2008 PSD. 
Cetuximab in combination with irinotecan tended 
to have more serious AEs and Grade 3/4 AEs 
compared to cetuximab monotherapy. These AEs 
were expected to be less in the BSC group. 
Cetuximab monotherapy had a greater incidence of 
any adverse event of grade 3 or higher compared to 
the BSC group (p<0.001). Patients in the cetuximab 
monotherapy group had a higher incidence of rash, 
infection without neutropenia, confusion and other 
pain as well as hypomagnesemia and infusion 
reactions 









NA NA NA 
Safety change - - NA - 
clofarabine FDA primary indication 
ATC code: L01BB06 
Treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens. This use is 
based on the induction of complete responses. Randomized trials demonstrating increased survival or other clinical benefit have not been conducted. 
  
Orphan Status: US/EU 
Licensure: FDA/EMA 
Target: Hematological 
Agency  NICE HAS PBAC 
Appraisal date NA Dec-06 NA 
Comparator NA non-comparative NA 
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Modelled/indirect comparison NA Yes NA 
Basis for classification NA OS: Expected to have an impact in terms of 
morbi-mortality by facilitating access to an 
allograft. However, in the absence of a 
formalized comparison with historic data, the 
impact can only be small. Moreover, because of 
the uncertainty about drug tolerance, 
extrapolation of the test results to real life is 
itself uncertain. 
 
QoL: No comparative data presented to 
evaluate HRQoL 
 
Safety: Tolerance data are limited at present. 
No comparative evaluation of drug-related 
safety as comparator arm unavailable. 
Additional absence of "formalized comparisons 
with historical data on relapsed or refractory 
patients having had at least two previous 
treatments" 
NA 












NA NA NA 
crizotinib FDA primary indication 
ATC code: L01XE16 
A kinase inhibitor indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic 
lymphoma kinase (ALK)-positive as detected by an FDA-approved test. This indication is based on response rate. 
  
Orphan Status: - 
Licensure: FDA/EMA 
Target: Lung 
Agency  NICE HAS PBAC 
332 
 
Appraisal date Sep-13 Apr-13 Nov-14 
Comparator docetaxel pemetrexed or docetaxel pemetrexed 
Modelled/indirect comparison Yes No Yes 
Basis for classification OS: Committee "accepted that treatment would 
result in  gain compared with docetaxel but the 
exact magnitude was uncertain; Committee 
"considered that the IPTCW2 method, which 
resulted in an OS benefit of 7.1 months, may be 
a reasonable assumption given the lack of 
robust data" but that "an exact value could not 
be reliably established" 
QoL: Committee heard from the clinical 
specialists that patients with progressed disease 
continued to experience some additional health-
related QoL benefit for some time after 
treatment was withdrawn compared with those 
on chemotherapy, but that this would 
deteriorate over time. It accepted that some 
utility benefit might be expected from crizotinib 
discontinued at disease progression, though 
there are no data to suggest how great a benefit 
this might be or for how long it would persist. 
The Committee was also aware that there might 
be a benefit to utility of continuing crizotinib, 
but there were no data to show whether such 
continued treatment benefits patients or for 
how long 
 
Safety: The Committee concluded that 
crizotinib is associated with some ADRs but 
these would be tolerable for most patients and 
generally easily managed. 
OS: An increase compared to chemotherapy 
(i.e. docetaxel or pemetrexed) not established as 
no statistically significant difference was 
observed 
 
QoL: In view of the available clinical data, 
crizotinib showed a significant improvement in 
QoL versus docetaxel or pemetrexed 
Safety: No judgment given on comparative 
differences in drug-related safety profile 
OS: Committee considered the "likely incremental 
gain "is between 3.1 to 3.5 months compared to 
pemetrexed (based on modeled data); Committee 
concluded that "given both the limitations of the 
randomized trial (small sample size, immature 
follow-up and post-progression cross-over to 
crizotinib in the pemetrexed arm) and also the 
usual concerns with attempting comparative 
treatment effect inferences by comparing across 
results for different groups of patients, no 
completely compelling conclusions could be drawn 
about the extent of incremental overall survival 
gain for crizotinib over pemetrexed" 
 
QoL: Consumer comments described a range of 
benefits, including the ability to return to work 
 
Safety: The PBAC accepted the claims for 
crizotinib having superior effectiveness and non-
inferior safety compared to pemetrexed 
Effects Merged data    
OS increase 3.1–3.5 months Uncertain None established ≥ 3 months 




NA NA No difference 
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dabrafenib FDA primary indication 
ATC code: L01XE23 




Orphan Status: – 
Licensure: FDA/EMA 
Target: Skin 
Agency  NICE HAS PBAC 
Appraisal date Oct-14 May-14 Mar-13 
Comparator dacarbazine dacarbazine DTIC 
Modelled/indirect comparison No No No 
Basis for classification OS: The Committee concluded that compared 
with dacarbazine, dabrafenib probably 
improved OS, but it was unable to draw firm 
conclusions about the magnitude of the benefit 
 
QoL: The mean change in EQ-5D utility index 
score from baseline to week 15 was lower in the 
dabrafenib group than in the dacarbazine group 
 
Safety: The Committee concluded that the 
current evidence suggests that ADRs from 
dabrafenib treatment were not a major concern 
when compared with those from alternative 
treatments 
OS: In view of the available data, which shows 
no increase, the impact of dabrafenib on 
morbidity and mortality is considered low. On 
this date, there was no difference between the 
two therapeutic groups, dabrafenib vs 
dacarbazine (at six months) 
 
QoL: evaluatation using EORTC QLQ-C30 and 
EuroQoL EQ-5D questionnaires did not show 
any difference between the two treatment 
groups 
 
Safety: Treatment discontinuations due to 
adverse events were similar in both groups 
OS: Dabrafenib, unlike vemurafenib, has not 
demonstrated an unequivocal advantage over 
DTIC. There was no statistically significant 
difference both treatment groups. However, OS 
data at time of cut-off was not mature, therefore no 




Safety: Dabrafenib and DTIC have different 
toxicity profiles, with dabrafenib being associated 
with manageable toxicity versus DTIC. PBAC noted 
that dabrafenib has a preferable toxicity profile vs 
vemurafenib as evidenced by fewer and less 
extensive dose intensity reductions and by 
favourable differences in rates for AEs such as 
photosensitivity, cutaneous squamous cell 
carcinoma – but not pyrexia 





Uncertain None established None established 
QoL change - - No difference NA 
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Safety change + No difference No difference 
NA (dacarbazine); + (vemurafenib) =  
+ 
dasatinib FDA primary indication 
ATC code: L01XE06 
Indicated for the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia with resistance or 
intolerance to prior therapy including imatinib. 
Also indicated for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior 
therapy.  
Orphan Status: US/EU 
Licensure: FDA/EMA 
Target: Hematological 
Agency  NICE HAS PBAC 
Appraisal date Jun-12 Mar-07 Jul-07 
Comparator non-comparative non-comparative non-comparative 
Modelled/indirect comparison Yes Yes Yes 
Basis for classification OS: Clinical trials were non-comparative, of 
short duration and had used surrogate 
outcomes to predict OS. The Committee noted 
the poor quality of the evidence base 
 
QoL: No regulatory judgment made on 
comparative differences in HRQoL 
 
Safety: Committee concluded that dasatinib 
and nilotinib are better tolerated than imatinib, 
and that older treatments, particularly 
interferon alfa, can be poorly tolerated 
OS: Available clinical studies do not evaluate 
OS benefits directly 
 
QoL: No comparative data presented  
with which to evaluate comparative differences 
in HRQoL 
 
Safety: While safety of dasatinib evaluated, no 
comparison against other treatments is made 
OS: Clinical benefits as determined by number of 
patients achieving complete cytogenic response. 
Outstanding areas of concern for the Committee 
were whether cytogenetic response outcomes later 
in the course of the chronic phase of CML result in 





Safety: Evaluation indicated that dasatinib has 
significant advantages in effectiveness over 
imatinib but has more toxicity 








NA NA NA 
Safety change +/- + NA - 
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decitabine FDA primary indication 
ATC code: L01BC08 
Indicated for treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all 
French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia 
with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic 
Scoring System groups.  
Orphan Status: US/EU 
Licensure: FDA/EMA 
Target: Hematological 
Agency  NICE HAS PBAC 
Appraisal date NA NA NA 
Comparator NA NA NA 
Modelled/indirect comparison NA NA NA 
Basis for classification NA NA NA 
Effects Merged data    
OS increase NA NA NA NA 
QoL change NA NA NA NA 
Safety change NA NA NA NA 
degarelix FDA primary indication 
ATC code: L02BX02 




Orphan Status: – 
Licensure: FDA/EMA 
Target: Prostate 
Agency  NICE HAS PBAC 
Appraisal date Apr-14 Sep-09 Jul-10 
Comparator LHRH agonists leuproprelin leuproprelin 
Modelled/indirect comparison No No No 
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Basis for classification OS: Committee noted that duration of trials was 
short and were not sufficiently powered to 
detect differences between treatment groups. 
Mixed treatment comparison also did not show 
statistically significant differences. Lack of 
evidence to support OS benefit compared with 
LHRH agonists 
 
QoL: Patient experts noted that subcutaneous 
injections of degarelix are administered monthly 
and this dosing schedule may be inconvenient 
for some patients compared with subcutaneous 
administration of the LHRH agonists every 3 
months. The manufacturer presented data for 
HRQoL, which was assessed using different 
measures and questionnaires. All the SF12 v2 
scores were comparable across treatment groups 
and study days. 
 
Safety: The Committee heard from the patient 
experts that the safety profile is comparable to 
that of the LHRH agonists and the potential 
benefits of outweigh the adverse effects 
associated with it 
OS: Not expected to have impact on morbidity 
and mortality. No clinical data demonstrating 
the benefits of this product in the treatment of 
prostate cancer 
QoL: Degarelix has not been shown to provide 
any improvement in treated patients 
 
Safety: The safety profiles of the two treatments 
were similar, apart from the emergence of anti- 
degarelix antibodies. There was no observed 
correlation between emergence of these 
antibodies and the efficacy and safety of 
degarelix after one year of treatment 
OS: Submission provided no evidence to 
demonstrate whether outcomes observed in the 
first month of possible long-term treatment with 
degarelix would have significant effects on overall 




Safety: The PBAC noted that there are more 
injection site reactions compared with leuprorelin 
and therefore degarelix may not be non-inferior 
with regards to safety. The majority of treatment-
emergent ADRs were general disorders and 
administration site conditions including injection-
site reactions which occurred in 73 patients in the 
degarelix 240/80 mg group compared with 1 patient 
in the leuprorelin arm 








No difference No difference NA 
Safety change - No difference No difference - 
enzalutamide FDA primary indication 
ATC code: L02BB04 









Agency  NICE HAS PBAC 
Appraisal date Jul-14 Nov-13 Jul-14 
Comparator placebo placebo abiraterone 
Modelled/indirect comparison No No Yes 
Basis for classification OS: 4.5-month increase in median OS compared 
to placebo; no statistically significant difference 
compared to abiraterone (based on indirect 
comparison) 
 
QoL: There was a statistically significant 
difference in QoL for patients receiving 
enzalutamide compared with placebo, as 
measured using Functional Assessment of 
Cancer Therapy-Prostate (FACT-P) 
 
Safety: NICE noted that ADRs were generally 
manageable and reversible. However, the 
Committee was aware of the increased risk of 
seizures with enzalutamide treatment, and 
noted that the summary of product 
characteristics advises caution when treating 
people with a history of seizures or other 
predisposing factors for seizures 
OS: 4.8-month increase in median OS 
compared to placebo; Committee noted that 
there was no comparison to active comparators 
 
QoL: The fragmented QoL data cannot quantify 
the impact of enzalutamide on the QoL of the 
patients treated 
 
Safety: Although the Committee refers to 
differences in the safety profile of enzalutamide 
versus placebo, the Committee judges neither 
the strength nor direction of difference 
OS: An increase compared to abiraterone was not 
established given limitations associated with the 
indirect comparison, though Committee accepted 
claim of non-inferiority 
 
QoL: The comments describe a range of benefits 
from treatment with enzalutamide, including 
improvement in survival and QoL 
 
Safety: PBAC considered that the claim of non-
inferior comparative safety was reasonable 
Effects Merged data    
OS increase 4.5-4.8 months ≥ 3 months ≥ 3 months None established 
QoL change + + NA + 
Safety change +/- +/- NA No difference 
eribulin FDA primary indication 
ATC code: L01XX41 A microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic 
regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic 
setting. 
  





Agency  NICE HAS PBAC 
Appraisal date Nov-13 Jul-11 Nov-13 
Comparator TPC TPC TPC 
Modelled/indirect comparison No No No 
Basis for classification OS: 2.7-month increase in median OS compared 
with TPC in the overall ITT population. The 
Committee considered that it had not seen 
sufficient evidence to indicate that eribulin 
offers an extension to life of at least 3 months 
 
QoL: The Committee noted that no HRQoL 
data were collected during the EMBRACE trial 
and that data were presented from two phase II 
trials in which there was no comparator arm 
 
Safety: It was also aware of the importance of 
the side effects of hair loss, grade 3 and 4 
peripheral neuropathy and febrile neutropenia, 
all of which occurred more frequently with 
eribulin than with TPC. The Committee 
concluded that eribulin was associated with a 
greater overall survival benefit compared with 
TPC but with a less favourable toxicity profile 
OS: 2.5-month increase in median OS (primary 
endpoint) in the eribulin mesylate group versus 
TPC group 
 
QoL: The impact of the treatment on the QoL is 
not documented; no QoL data available 
 
Safety: The incidence of grade 3-4 adverse 
events was higher in the eribulin mesylate 
group than those treated with TPC 
OS: 2.5-month increase in median OS (primary 
endpoint) in the eribulin mesylate group versus 
TPC group 
 
QoL: The impact of the treatment on the QoL is 
not documented; no QoL data available 
 
Safety: The incidence of grade 3-4 adverse events 
was higher in the eribulin mesylate group than 
those treated with TPC 
Effects Merged data    




NA NA NA 
Safety change - - - - 
erlotinib FDA primary indication 
ATC code: L01XE03 Indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy 
regimen. 
 Orphan Status: – 
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Licensure: FDA/EMA   
Target: Lung 
Agency  NICE HAS PBAC 
Appraisal date Nov-08 Mar-06 Nov-07 
Comparator No treatment placebo BSC 
Modelled/indirect comparison No No No 
Basis for classification OS: 2.0-month increase in median OS compared 
to no treatment. Difference in benefit with 
docetaxel is uncertain in the absence of direct 
comparisons 
 
QoL: Committee noted that patients may prefer 
erlotinib treatment to docetaxel because it is 
orally administered and they would therefore 
need to spend less time in hospital receiving 
treatment 
 
Safety: Clinical specialists and patient experts 
emphasised erlotinib’s favourable toxicity 
profile, with fewer serious AEs reported during 
treatment with erlotinib than with docetaxel 
OS: 2.0-month increase in median OS (primary 
endpoint) compared to placebo. No survival 
benefit in patients treated whose tumor EGFR 
expression was negative 
 
QoL: Time to deterioration of the three 
symptoms (cough, dyspnoea and pain) was 
significantly increased in patients treated with 
erlotinib: cough 2.9 months, dyspnoea 2 months 
and pain approximately 1 month 
 
Safety: The most commonly reported 
undesirable effects in the comparative study 
were diarrhoea and a skin rash. The dose was 
reduced because of undesirable effects in 19% of 
patients in the erlotinib group compared with 
2% in the placebo group. Treatment was 
withdrawn from 5% of patients in the erlotinib 
group. Although AE rates and incidence is 
given, overall assessment of drug-related 
change in safety is not given by HAS 
OS: Statistically significant differences versus BSC 
regarding all event rates, including overall survival. 
Statistically significant differences versus BSC 
regarding all event rates, including overall survival. 
Although exact gain in OS is not given, the label 
refers to various, placebo-controlled trials in the 
NEJM (referred to as BSC in a PBAC label published 
in 2006) which indicate that gain in OS associated 




Safety: Study BR.21 showed that erlotinib was 
associated with significantly more rash and 
diarrhoea compared to placebo, although they were 
mild to moderate intensity. There was no relevant 
haematological toxicity reported. For PBAC’s 
comments on these results, see Recommendation 
and Reasons 
Effects Merged data    
OS increase 2.0 months < 3 months < 3 months < 3 months 
QoL change + + + NA 
Safety change +/- + NA - 
everolimus FDA primary indication 
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ATC code: L01XE10 
A kinase inhibitor indicated for the treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib. 
 
  
Orphan Status: EU (w) 
Licensure: FDA/EMA 
Target: Renal 
Agency  NICE HAS PBAC 
Appraisal date Apr-11 Jan-10 Nov-09 
Comparator BSC placebo BSC 
Modelled/indirect comparison Yes No No 
Basis for classification OS: More than 3-month increase compared to 
BSC (exact magnitude of was uncertain given 
that it was "based on modelled data as opposed 
to data directly observed in the trial"); 
Committee considered a modelled 5.2-month 
increase compared to BSC "more plausible" than 
the 8.2-month increase derived by the 
manufacturer 
 
QoL: Time to deterioration in 
functioning/symptoms was delayed with 
everolimus + BSC by 3.5 months compared with 
placebo + BSC. The median time to 
deterioration according to FKSI–DRS score was 
7.4 months for everolimus + BSC and 3.9 
months for placebo + BSC. Difference was 
statistically significant 
 
Safety: The Committee noted the increased 
frequency of AEs (including serious) associated 
with everolimus treatment. There was a greater 
incidence of AEs (including serious) reported in 
the everolimus + BSC arm (40.1%) than the 
placebo + BSC arm (22.6%) 
OS: An increase compared to placebo (optimum 
symptomatic treatments) not established as no 
improvement was observed; Committee 
acknowledged that an assessment was difficult 
"given the premature termination of the pivotal 
study and the fact that patients whose disease 
had demonstrably progressed were allowed to 
transfer" 
 
QoL: No improvement was demonstrated in the 
pivotal study (QLQ-C30) 
 
Safety: More patients in the everolimus group 
stopped treatment as a result of adverse effects 
than in the placebo group 
OS: No statistically significant difference was 
observed compared to BSC 
 
QoL: PBAC considered that the results for 
Karnofsky performance status, physical function, 
and QoL scores showed no statistically significant 
differences and performance status between 
everolimus and placebo treated patients. However, 
these results are difficult to interpret because of the 
substantial crossover of placebo patients to 
everolimus treatment 
 
Safety: Everolimus has significant on-treatment 
toxicity compared to placebo, including increased 
risk of serious infection, non-infectious 
pneumonitis, dyspnea, stomatitis, hyperglycaemia, 
anaemia, lymphopenia as well as neurotoxicity 
Effects Merged data    
OS increase 5.2 months ≥ 3 months None established None established 
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QoL change + + No difference No difference 
Safety change - - - - 
gefitinib FDA primary indication 
ATC code: L01XE02 
EMA Primary Indication 




Orphan Status: – 
Licensure: FDA/EMA 
Target: Lung 
Agency  NICE HAS PBAC 
Appraisal date Jul-2010 Nov-2009 Jul-2013 
Comparator paclitaxel + carboplatin paclitaxel + carboplatin paclitaxel + carboplatin 
Modelled/indirect comparison No No No 
Basis for classification OS: Committee was aware that the analysis of 
OS was an interim analysis of immature data. 
The Committee noted that a longer progression-
free survival may correlate with improved 
overall survival in NSCLC, but there was 
uncertainty around this 
 
QoL: Committee agreed that treatment … offers 
an advantage because it can be taken at home. 
Committee accepted the ERG's view that EGFR-
TK mutation-positive patients who were 
randomised to receive gefitinib had a clinically 
relevant improvement in health-related quality 
of life and disease symptoms compared with 
patients randomised to receive paclitaxel and 
carboplatin 
 
Safety: The Committee concluded that gefitinib 
was associated with an improved adverse effects 
profile compared with platinum-based 
chemotherapy. Clinical specialists confirms that 
OS: Median overall survival did not differ 
between the two groups (18.6 months in the 
IRESSA group and 17.3 months in the 
comparator group). The overall survival results 
are not mature (number of events not reached) 
 
QoL: quality of life analysis results showed an 
improvement in the IRESSA group in two of the 
three scales used (FACT-L and TOI) 
 
Safety: No comparative data presented 
OS: The data were updated for trials NEJ002 and 
WJTOG3405, but were still immature for the 
WJTOG3405 trial. As seen in the IPASS (paclitaxel 
+ carboplatin) and First-SIGNAL (cisplatin + 
gemcitabine) trials, there was no significant 
difference between the two treatment arms in 
terms of OS (NEJ002 HR=0.89; 95% CI: 0.63, 1.24; 
WJTOG3405: HR=1.19; 95% CI: 0.77, 1.83) 
 
QoL: The PBAC accepted that the clinical benefit 
of listing gefitinib in patients with EGFR M+ 
NSCLC as first-line treatment in addition to the 
current listing for second-line treatment is an 
improvement in quality of life 
 
Safety: Overall, safety profiles varied across the 
treatment arms, but gefitinib appeared to have less 
serious toxicity than platinum-based therapy … the 
PBAC accepted that gefitinib appears to have less 




gefitinib had been shown to be well tolerated in 
clinical practice 




None established None established None established 
QoL change + + + + 
Safety change + + NA + 
ibrutinib FDA primary indication 
ATC code: L01XE27 
A kinase inhibitor indicated for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. This indication 
is based on overall response rate. 
 
  
Orphan Status: US/EU 
Licensure: FDA/EMA 
Target: Hematological 
Agency  NICE HAS PBAC 
Appraisal date NA NA NA 
Comparator NA NA NA 
Modelled/indirect comparison NA NA NA 
Basis for classification NA NA NA 
Effects Merged data    
OS increase  NA NA NA 
QoL change  NA NA NA 
Safety change  NA NA NA 
ipilimumab FDA primary indication 
ATC code: L01XC11 A human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for the treatment of unresectable or metastatic melanoma. 
  





Agency  NICE HAS PBAC 
Appraisal date Jul-14 Nov-14 Nov-12 
Comparator dacarbazine dacarbazine / temozolomide / vemurafenib Dacarbazine 
Modelled/indirect comparison No Yes Yes 
Basis for classification OS: 5.7-month increase in mean OS compared 
to dacarbazine when given as first-line (2.1-
month increase in median OS); mean OS was 
available because of the long duration of the 
trial and lack of crossover 
 
QoL: First- and second-line, no HRQoL data 
reported 
 
Safety: Severe, serious, drug-related and AEs 
leading to discontinuation were all more 
frequent in the ipilimumab 10 mg/kg + 
dacarbazine group than in dacarbazine alone 
group. In second-line treatment, the Committee 
concluded that the ADRs and mortality 
associated with ipilimumab seen in the 
MDX010-20 trial were considerable 
OS: Committee noted that the results of an 
indirect comparison with several comparators 
(dacarbazine, temozolomide, and vemurafenib) 
suggested that OS improved with ipilimumab, 
but did not allow for a formal conclusion 
QoL: A negative impact on quality of life cannot 
be ruled out mainly because of significant side 
effects experienced. No explicit judgment on 
comparative differences in HRQoL given  
 
Safety: The safety data provided in this new 
indication are comparable to the safety profile 
seen to date for this specialty 
OS: Committee considered that the "magnitude of 
the incremental benefit of ipilimumab remained 
uncertain" compared to dacarbazine as the 
submission was "reliant on extrapolation of trial 




Safety: Ipilimumab has a different safety profile 
than BSC (DTIC/fotemustine), with irAEs 
(immune-related adverse events) which are 
manageable and controllable. Even though the 
PBAC considers this claim reasonable, it does not 
indicate whether it believes differences to be 
clinically meaningful and does not give a value 
judgment 
Effects Merged data    




NA NA NA 
Safety change - - No difference NA 
ixabepilone FDA primary indication 
ATC code: L01DC04 A microtubule inhibitor, in combination with capecitabine is indicated for treatment of metastatic or locally advanced breast cancer in patients after 
failure of an anthracycline and a taxane.  
Orphan Status: – 
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Licensure: FDA Also indicated as monotherapy for treatment of metastatic or locally advanced breast cancer in patients after failure of an anthracycline, a taxane, and 
capecitabine. 
Target: Breast 
Agency  NICE HAS PBAC 
Appraisal date NA NA NA 
Comparator NA NA NA 
Modelled/indirect comparison NA NA NA 
Basis for classification NA NA NA 
Effects Merged data    
OS increase NA NA NA NA 
QoL change NA NA NA NA 
Safety change NA NA NA NA 
lapatinib FDA primary indication 
ATC code: L01XE07 
A kinase inhibitor, indicated in combination with capecitabine, for the treatment of patients with advanced or metastatic breast cancer whose tumors 
overexpress HER2 and who have received prior therapy including an anthracycline, a taxane, and trastuzumab. 
  
Orphan Status: – 
Licensure: FDA/EMA 
Target: Breast 
Agency  NICE HAS PBAC 
Appraisal date May-10 Jul-08 Nov-07 
Comparator capecitabine monotherapy capecitabine monotherapy capecitabine monotherapy 
Modelled/indirect comparison No No No 
Basis for classification OS: 2.4-month increase in overall median 
survival; certainly not enough evidence that the 
extension of life provided was 3 months or 
greater 
 
OS: At the cut-off point for the first interim 
analysis, no difference was observed between 
the two treatment arms. In view of the 
premature termination of the study, the benefit 
of lapatinib + capecitabine compared with 
OS: 1.1-week increase in median overall survival. 
However, study was terminated early by 
independent monitoring board, and patient 
crossover. Early termination reduces the likelihood 
of detecting a significant difference in overall 
survival. There is some evidence improves survival 
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QoL: No HRQoL information presented in 
report 
 
Safety: The lapatinib + capecitabine group had 
a marginally higher incidence of diarrhoea and 
palmar-plantar erythrodysaesthesia than the 
capecitabine monotherapy group 
capecitabine alone in terms of overall survival 
cannot be evaluated 
 
QoL: The available data are insufficient to 
estimate the impact of lapatinib + capecitabine 
in reducing the morbidity and mortality 
associated with metastatic breast cancer and in 
improving QoL, compared with the current 
form of management 
 
Safety: Main AEs were often raised in the 
lapatinib + capecitabine arm compared with the 
capecitabine arm, including for: diarrhoea, 
palmar-plantar erythrodysaesthesia, nausea, 
rash, and vomiting. However, the HAS does not 
make a judgment as to the statistical or clinical 
significance of these findings 
compared to capecitabine alone, but full extent of 
survival benefit is not known and is not statistically 




Safety: The overall safety profile of lapatinib + 
capecitabine, in terms of the incidence, types and 
intensities of adverse events, appears similar to 
that reported in the published studies for different 
trastuzumab-containing chemotherapies for 
patients with metastatic breast cancer 
Effects Merged data    




NA NA NA 
Safety change - - NA No difference 
lenalidomide FDA primary indication 
ATC code: L04AX04 
Indicated for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate-1-risk myelodysplastic syndromes associated with 
a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. 
 
 
Orphan Status: US/EU 
Licensure: FDA/EMA 
Target: Hematological 
Agency  NICE HAS PBAC 
Appraisal date Sep-14 Nov-14 Mar-13 
Comparator placebo placebo placebo (BSC) 
Modelled/indirect comparison No No No 
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Basis for classification OS: No statistically significant difference. 
Placebo arm could cross over to lenalidomide 
treatment, therefore benefit of lenalidomide 
may be underestimated. Lenalidomide could 
indirectly improve OS by improving transfusion 
independence, but this was uncertain 
 
QoL: Committee considered the results of the 
MDS-004 study: the rates of transfusion 
independence (at 26 weeks, lenalidomide 10 mg: 
56.1%, placebo: 5.9%) and improvements in the 
FACT-An questionnaire (mean change, 
lenalidomide 10 mg: 5.8, placebo: -2.5) were 
significantly better in people treated with 
lenalidomide compared with placebo 
 
Safety: Committee was aware that lenalidomide 
may be associated with higher rates of venous 
thrombo-embolism than placebo. A higher 
proportion of people in the lenalidomide 10 mg 
(95.7%) and 5 mg groups (98.6%) had at least 1 
drug-related AE compared with the placebo 
group (49.3%). However, it heard from the 
clinical specialist and patient experts that AEs 
associated with lenalidomide treatment are 
managed with dose interruptions and are 
generally well tolerated. The Committee 
concluded that, although lenalidomide is 
associated with some AEs, these can be 
managed by dose interruptions 
OS: Available clinical data shows better 
cytogenic response but without benefit in OS 
 
QoL: Given current therapeutic strategies, the 
available clinical data indicates a moderate 
impact in terms of morbidity and mortality and 
quality of life should be expected from 
lenalidomide. The "transferability of test results 
to the practice can be regarded as assured" 
 
Safety: The safety profile observed in the 
lenalidomide MDS patients of low risk 
associated with a deletion 5q was comparable to 
that already experienced in patients with 
myeloma. Regarding the first 16 weeks of the 
double-blind phase, at least one adverse event 
was observed in all patients of lenalidomide 
group (69 patients in the 5 mg group and 69 
patients in the 10 mg group) and in 96% of 67 
patients in the placebo group 
OS: While results did not show statistically 
significant change in OS, possibly owing to patient 
cross-over, the PBAC considered that there was a 
trend favoring lenalidomide 
 
QoL: For key results, see Mar 2011 PSD. PBAC 
noted clinical meaningful change in patients 
HRQoL after 24 weeks of treatment with 
lenalidomide and a worsening in placebo patients. 
However, the results were confounded due to loss 
to follow up 
 
Safety: PBAC considered that treatment with 
lenalidomide was associated with more toxicity 
than best supportive care and that dose reduction 
would be required to manage side effects in a 
number of patients 





Uncertain None established Uncertain 
QoL change + + + NA 
Safety change - - No difference - 
nelarabine FDA primary indication 
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ATC code: L01BB07 
Indicated for the treatment of patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma whose disease has not responded to 
or has relapsed following treatment with at least two chemotherapy regimens. This use is based on the induction of complete responses. Randomized trials 
demonstrating increased survival or other clinical benefit have not been conducted.  
Orphan Status: US?EU 
Licensure: FDA/EMA 
Target: Hematological 
Agency  NICE HAS PBAC 
Appraisal date NA Dec-07 NA 
Comparator NA non-comparative NA 
Modelled/indirect comparison NA Yes NA 
Basis for classification NA OS: Facilitates the use of allografts, therefore 
expected to have an impact on morbidity and 
mortality, which can only be low. Because of the 
uncertainty about the tolerability of this drug, 




Safety: There are "currently few safety data". 
Safety-related data drawn from non-
comparative adult and child studies 
NA 












NA NA NA 
nilotinib FDA primary indication 
ATC code: L01XE08 
A kinase inhibitor indicated for the treatment of chronic phase and accelerated phase Philadelphia chromosome positive chronic myelogenous leukemia 
(CML) in adult patients resistant to or intolerant to prior therapy that included imatinib. 
  





Agency  NICE HAS PBAC 
Appraisal date Jan-12 Feb-08 Mar-08 
Comparator non-comparative non-comparative non-comparative 
Modelled/indirect comparison Yes No Yes 
Basis for classification OS: Clinical trials were non-comparative, of 
short duration and had used surrogate 
outcomes to predict OS. The Committee noted 
the poor quality of the evidence base  
 
QoL: No regulatory judgment made on 
comparative differences in HRQoL 
 
Safety: Committee concluded that dasatinib 
and nilotinib are better tolerated than imatinib, 
and that older treatments, particularly 
interferon alfa, can be poorly tolerated 
OS: No comparative evaluation of OS relative to 
available treatments 
 
QoL: No comparative data presented 
Safety: There are currently few safety data. No 
comparative data presented 
OS: Committee does not present any conclusion 
regarding OS benefits. Evidence for nilotinib after 
imatinib and dasatinib treatment is from single 





Safety: PBAC noted that whilst nilotinib has a 
different safety profile to both high dose imatinib 
and dasatinib, there is considerable uncertainty 
around the claims that nilotinib has significant 
activity after failure of both imatinib and dasatinib 
and that nilotinib has a superior safety profile to 
dasatinib 








NA NA NA 
Safety change + + NA NA 
obinutuzumab FDA primary indication 
ATC code: L01XC15 









Agency  NICE HAS PBAC 
Appraisal date Mar-15 Feb-15 Jul-14 
Comparator chlorambucil rituximab / chlorambucil chlorambucil 
Modelled/indirect comparison No No No 
Basis for classification OS: Obinutuzumab + chlorambucil was 
associated with statistically significantly greater 
OS compared with chlorambucil monotherapy. 
However, the Committee acknowledged that 
the OS data were immature 
 
QoL: The clinical expert and patient expert 
acknowledged that some people may prefer oral 
treatment with chlorambucil instead of having 
to attend a day unit for intravenous treatment 
with obinutuzumab or bendamustine 
 
Safety: Some people may prefer to have 
obinutuzumab instead of bendamustine, 
because obinutuzumab is associated with fewer 
AEs. The Committee took into consideration the 
summary of product characteristics and 
concluded that obinutuzumab had an 
acceptable adverse event profile 
OS: Impact compared to the comparator (R-
Clb) is not quantifiable 
 
QoL: The impact compared to the comparator 
(R-Clb) is not quantifiable 
 
Safety: Compared to rituximab, the incidence 
of AEs ≥ grade 3 was higher in the G-Clb group 
than in the R-Clb group 
OS: PBAC accepted the claim that obinutuzumab + 
chlorambucil is superior in terms of comparative 
effectiveness and inferior in terms of comparative 
safety over chlorambucil alone. While hazard ratio 
for OS was not statistically significant, the trend 
was in favor of obinutuzumab + chlorambucil and 
the more recent data is approaching statistical 
significance 
 
QoL: Consumer comments captured the notion 
that obinutuzumab provides a treatment option for 
older, less fit patients with CLL and prolongs 
remission during which time patients can live a 
"normal life" 
 
Safety: PBAC accepted the submission’s claim that 
obinutuzumab + chlorambucil is inferior in terms 
of comparative safety over chlorambucil alone 





Uncertain None established Uncertain 
QoL change +/− - NA + 
Safety change +/− + - - 
ofatumumab FDA primary indication 
ATC code: L01XC10 A CD20-directed cytolytic monoclonal antibody indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) refractory to fludarabine 
and alemtuzumab. The effectiveness of ofatumumab is based on the demonstration of durable objective responses. 





Agency  NICE HAS PBAC 
Appraisal date Oct-10 Oct-10 Nov-14 
Comparator non-comparative non-comparative chlorambucil 
Modelled/indirect comparison Yes Yes No 
Basis for classification OS: No data on median OS available for patients 
responding to treatment because data were 
immature. Although it was likely that 
ofatumumab is effective based on the observed 
ORRs, and partly based on manufacturer's 
model regarding extensions to life (">5 months 
relative to BSC"), it was not possible to estimate 
the size of the effect with certainty because of 
the absence of robust and comparative evidence 
and the immaturity of the data 
 
QoL: No HRQoL information presented in 
report. HRQoL had not been collected in the 
pivotal study 
 
Safety: The Committee concluded that 
ofatumumab may be associated with AEs, but 
the extent and impact of these was uncertain 
owing to a lack of robust evidence and the lack 
of a group of patients who did not receive 
ofatumumab in the trial 
OS: The quality of the data available is not 
sufficient to allow an evaluation of the impact 
in terms of mortality of the medicinal product. 
Comparison of ofatumumab with historical data 
does not allows unbiased evaluation to be made 
of the size of effect, therefore it is not 




Safety: The efficacy and tolerance data are 
limited, as they are drawn from a non-
comparative phase II study 
OS: No difference was observed in direct 
comparison with chlorambucil, which may be due 
to the limited follow-up of the trial for patients 
with indolent CLL. Overall, incomplete and less 
than rigorous comparison of ofatumumab with 
rituximab (modelled evaluation) 
QoL: NA 
 
Safety: PBAC noted no important overall 
differences in adverse events 

















FDA primary indication 
ATC code: L01XX40 
Adult patients (injection) with chronic or accelerated phase chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine 
kinase inhibitors (TKI). This indication is based upon response rate. 
 
 
Orphan Status: US 
Licensure: FDA/EMA 
Target: Hematological 
Agency  NICE HAS PBAC 
Appraisal date NA NA NA 
Comparator NA NA NA 
Modelled/indirect comparison NA NA NA 
Basis for classification NA NA NA 
Effects Merged data    
OS increase  NA NA NA 
QoL change  NA NA NA 
Safety change  NA NA NA 
panitumumab FDA primary indication 
ATC code: L01XC08 
Indicated for the treatment of EGFR-expressing, metastatic colorectal carcinoma with disease progression on or following fluoropyrimidine-, oxaliplatin-, 
and irinotecan-containing chemotherapy regimens. 
 
  
Orphan Status: - 
Licensure: FDA/EMA 
Target: GI 
Agency  NICE HAS PBAC 
Appraisal date Jan-12 Apr-08 Nov-13 
Comparator BSC palliative care cetuximab 
Modelled/indirect comparison Yes No No 
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Basis for classification OS: Approximately 3-month extension to life 
compared to BSC (mean life extension 
estimated to be 2.7 to 3.2 months after adjusting 
for patient crossover in the trial); no statistically 
significant difference in overall survival was 
observed in the trial 
 
QoL: No HRQoL data presented in report 
 
Safety: Committee did not discuss specific 
issues around the AEs to the technologies 
appraised but it was aware of the special 
warnings and precautions for use outlined in the 
SPCs 
OS: An increase compared palliative care not 
established as no statistically significant 
difference was observed  
 
QoL: In light of the available data (just one post 
hoc analysis on subgroups of the pivotal study), 
the impact of panitumumab on morbidity, 
mortality and quality of life cannot be 
quantified 
 
Safety: Safety data are currently limited. There 
is no judgment of comparative differences in 
toxicity 
OS: No statistically significant difference was 




Safety: The PBAC considered the claim that 
panitumumab is non-inferior in terms of safety to 
cetuximab to be reasonable in the third-line setting 
where both drugs were used as monotherapy 
Effects Merged data    








NA NA No difference 
pazopanib FDA primary indication 
ATC code: L01XE11 




Orphan Status:  EU (w) 
Licensure: FDA/EMA 
Target:  Renal 
Agency  NICE HAS PBAC 
Appraisal date Feb-11 Jun-13 Mar-12 
Comparator BSC/interferon-alfa placebo/sunitinib BSC/sunitinib 
Modelled/indirect comparison Yes No Yes 
Basis for classification OS: More than 3-month increase compared to 
BSC (based on RPSFT model) and interferon-
OS: An increase compared to sunitinib not 
established (first-line) as no statistically 
OS: No statistically significant difference was 
observed compared to BSC (even after adjusting for 
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alfa (based on indirect comparison), though 
exact magnitude of increase uncertain; no 
significant difference compared to sunitinib 
based on results from head-to-head trial the 
Committee noted would be available in 2012 
 
QoL: For the VEG105192 trial, there were no 
statistically significant differences between 
pazopanib and placebo for any of the 
instruments used (European Organisation for 
Research and Treatment of Cancer [EORTC] 
QoL questionnaire – Core 30, EQ-5D, EQ-5D-
VAS) 
Safety: Committee heard from the clinical 
specialists that the evidence presented by the 
manufacturer suggested that pazopanib has a 
more favourable toxicity profile than sunitinib, 
especially in relation to hand-foot syndrome. 
The clinical specialists and patient experts were 
of the opinion that pazopanib is a useful option 
because it has a more favourable toxicity profile 
than sunitinib 
significant difference was observed; Committee 
noted that non-inferiority compared to 
sunitinib was "the subject of serious doubt"; 
increase compared to placebo not established as 
no statistically significant difference was 
observed 
 
QoL: No reliable conclusions could be drawn 
from evaluation scores as to any difference 
between the two treatments. In fact, results 
varied depending on the scale used: there was 
no difference on one scale (FACIT-F), although 
there were differences on the FKSI-19 and CTSQ 
scales but with values below the threshold for 
clinical relevance 
 
Safety: For 1st RCC, the safety profile differed 
between the two groups, with notably a higher 
incidence of abnormal liver function tests in the 
pazopanib group and a higher incidence of 
hand-foot syndrome in the sunitinib group. For 
2nd RCC, treatment discontinuation due to AEs 
was twice as common in the pazopanib group as 
in the placebo group 
patient crossover with IPCW and RPSFT models); 
no statistically significant difference was observed 





Safety: PBAC concluded that pazopanib has a 
different side-effect profile to sunitinib. Patients 
taking sunitinib tend to experience events such as 
diarrhoea, fatigue, hypertension, mucositis, hand- 
foot syndrome, and myelosuppression; patients 
taking pazopanib tend to experience diarrhoea, 
hypertension and liver dysfunction. These 
differences are insufficient to change an overall 
conclusion that pazopanib is non-inferior to 
sunitinib in terms of safety. 
Effects Merged data    
OS increase 
Exact gain over 
3 months 
uncertain 
≥ 3 months 
(Exact gain over 3 months uncertain) 




No difference No difference NA 
Safety change +/− + +/− (1st RCC); − (2nd RCC) = +/− No difference 
pemetrexed FDA primary indication 
ATC code: L01BA04 In combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are 
otherwise not candidates for curative surgery.  
 
 




Target: Lung  
Agency  NICE HAS PBAC 
Appraisal date Jan-08 Mar-05 Nov-07 
Comparator cisplatin cisplatin cisplatin 
Modelled/indirect comparison No No No 
Basis for classification OS: 2.8-month increase in median OS compared 
to cisplatin 
 
QoL: Committee noted that there was some 
evidence showing that pemetrexed plus 
cisplatin was associated with significant 
symptomatic improvements compared with 
cisplatin alone. Committee agreed that the 
economic analyses may have underestimated 
the overall quality of life benefits of pemetrexed 
in people with MPM. Combination treatment 
appears to demonstrate advantages in QoL 
 
Safety: Severe to life-threatening or disabling 
adverse events were statistically significantly 
more frequent in patients receiving pemetrexed 
plus cisplatin than in those receiving cisplatin 
alone 
OS: 3.3-month increase in median OS compared 
to cisplatin in subgroup of patients fully 
supplemented with vitamins; 2.8-month 
increase in median OS compared to cisplatin in 
the intention-to-treat population 
 
QoL: It was also observed a reduction of certain 
clinical symptoms (dyspnea, pain) related to the 
disease and improving lung function 
 
Safety: No comparative data presented 
OS: 2.8-month increase in median OS  
 
QoL: data from the pivotal trial using the Patient 
Lung Cancer Symptom Scale (LCSS) were 
presented. There were significant improvements in 
fatigue, dyspnea, pain, symptom distress, activity 
level, and overall LCSS, except for hemoptysis, in 
the pemetrexed+ cisplatin treatment arm. 
Although the global QoL scale did not show 
significant changes, the total LCSS as an average of 
all nine items reached a statistically significant 
difference in favor of pemetrexed 
 
Safety: Serious AEs occurred more frequently in 
the PMT+cisplatin arm than the cisplatin alone 
arm. Overall, frequency of Grade 3/4 laboratory 
toxicity was higher in the PMT+cisplatin arm than 
in the cisplatin alone arm. Severe toxicity was 
uncommon in the cisplatin arm, compared to the 
PMT+cisplatin arm where Grade 3⁄4 neutropenia 
were the most common haematologic toxicities 
Effects Merged data    
OS increase 2.8–3.3 months < 3 months ≥ 3 months < 3 months 
QoL change + + + + 
Safety change - - NA - 
pertuzumab FDA primary indication 
ATC code: L01XC13 
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Orphan Status: – A HER2/neu receptor antagonist indicated in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic 
breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. 
  Licensure: FDA/EMA 
Target: Breast 
Agency  NICE HAS PBAC 
Appraisal date NA Jul-13 Mar-14 
Comparator NA trastuzumab + docetaxel trastuzumab + docetaxel 
Modelled/indirect comparison NA No No 
Basis for classification NA OS: An increase compared to trastuzumab + 
docetaxel was observed (by a second interim 
analysis not scheduled in the protocol), but the 
size of the increase was uncertain given that 
median OS had not yet been achieved 
 
QoL: The treatment is not expected to have any 
impact on patients’ quality of life evaluated 
using the FACT-B questionnaire specific to the 
disease 
 
Safety: In addition to similar drop-out rates 
from AEs, no difference was seen between the 
two groups (pertuzumab vs placebo) as regards 
the incidence of grade 3-4 events 
OS: 15.7-month increase in median OS compared 
to trastuzumab + docetaxel 
 
QoL: PBAC noted strong support for  
pertuzumab received through the consumer 
comments facility expressing a range of benefits 
from treatment including improving QoL 
 
Safety: PBAC considered the claim that 
pertuzumab, when used in combination with 
trastuzumab + docetaxel, to be "slightly worse" in 
terms of comparative safety. PBAC considered the 
trial results indicated that adding pertuzumab to 
trastuzumab + docetaxel results in statistically 
significant increased toxicity in trastuzumab naïve 
(sensitive) compared to trastuzumab + docetaxel 
Effects Merged data    
OS increase 15.7 months NA Uncertain ≥ 3 months 
QoL change + NA No difference + 
Safety change - NA No difference - 
pomalidomide FDA primary indication 
ATC code: L04AX06 A thalidomide analogue indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and 
bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy. Approval is based on response rate. 





Agency  NICE HAS PBAC 
Appraisal date Mar-15 Jan-14 Jul-14 
Comparator standard care high-dose dexamethasone high-dose dexamethasone 
Modelled/indirect comparison Yes No No 
Basis for classification OS: At least 3-month extension compared to 
standard NHS care (e.g. bendamustine) (based 
on modeled data); Committee was "not able to 
judge with any confidence how much more 
effective pomalidomide was compared with the 
current treatment options based on the 
available evidence"; nevertheless, the 
Committee was "persuaded that pomalidomide 
extends life for at least 3 months on average 
when compared with standard NHS care" based 
on data modeled data that was "not considered 
robust" 
 
QoL: HRQoL was measured using the EORTC 
questionnaire for patients with cancer (QLQ-
C30), the EORTC multiple myeloma module 
(QLQ-MY20) and the EuroQol-5 dimensions 
survey (EQ-5D). Most results presented by the 
company suggest favourable trends with 
pomalidomide compared with dexamethasone 
 
Safety: The Committee noted that the 
proportion of patients with adverse reactions 
were similar between those taking 
pomalidomide and high-dose dexamethasone 
OS: An increase compared palliative care not 
established; median OS was not reached in 
pomalidomide treatment arm; Committee 
noted that 29% of patients in the high-dose 
dexamethasone group had received 
pomalidomide because of disease progression 
 
QoL: In light of the available clinical trial data, 
no impact in terms of morbidity and mortality 
and QoL is expected for the proprietary 
medicinal product pomalidomide in 
combination with dexamethasone 
 
Safety: The most commonly observed serious 
AEs had a comparable incidence in the two 
groups, in particular pneumonia and 
deterioration in general health 
OS: Committee considered that OS increased 
compared to high-dose dexamethasone, but the 
magnitude of the increase was redacted 
 
QoL: The PBAC also noted that the EQ- 
5D showed a trend towards improved QoL with 
pomalidomide + LDD compared with HDD, noting 
however that the differences in the EQ-5D utility 
index score between treatment arms were generally 
not statistically significant 
 
Safety: The PBAC considered that pomalidomide 
has inferior, but manageable, safety compared with 
HDD 
Effects Merged data    
OS increase 
≥ 3 months 
(exact gain 
uncertain) 
≥ 3 months 
(exact gain uncertain) 
None established Uncertain 
QoL change + + No difference + 
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Safety change - No difference - - 
ponatinib FDA primary indication 
ATC code: L01XE24 
A kinase inhibitor indicated for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) that 
is resistant or intolerant to prior tyrosine kinase inhibitor therapy or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) that is 
resistant or intolerant to prior tyrosine kinase inhibitor therapy. This indication is based upon response rate.  
Orphan Status: EU 
Licensure: FDA/EMA 
Target: Hematological 
Agency  NICE HAS PBAC 
Appraisal date NA Jan-15 Nov-14 
Comparator NA non-comparative dasatinib / nilotinib 
Modelled/indirect comparison NA Yes Yes 
Basis for classification NA OS: No expected impact in terms of morbidity 
and mortality compared with current 
therapeutic management 
 
QoL: There is no expected impact in terms of 
morbidity and mortality and QoL for the 
specialty ponatinib compared with current 
management 
 
Safety: No comparative data available 
OS: There is no direct evidence available for the 
comparative efficacy of ponatinib vs dasatinib or 
nilotinib. Based on single-arm comparative 
evidence, it is not clear whether ponatinib is better 
or worse than dasatinib or nilotinib in the 




Safety: The PBAC considered that ponatinib had 
an inferior toxicity profile to imatinib, dasatinib, 
and nilotinib, especially with regard to serious 
vascular occlusive event 








NA No difference NA 
Safety change - NA NA - 
pralatrexate FDA primary indication 
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ATC code: L01BA05 
A folate analogue metabolic inhibitor indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This 
indication is based on overall response rate. 
 
  
Orphan Status: EU 
Licensure: FDA/EMU 
Target: Hematological 
Agency  NICE HAS PBAC 
Appraisal date NA NA NA 
Comparator NA NA NA 
Modelled/indirect comparison NA NA NA 
Basis for classification NA NA NA 
Effects Merged data    
OS increase NA NA NA NA 
QoL change NA NA NA NA 
Safety change NA NA NA NA 
radium Ra 223 dichloride FDA primary indication 
ATC code: V10XX03 
An alpha particle-emitting radioactive therapeutic agent indicated for the treatment of patients with castration-resistant prostate cancer, symptomatic 
bone metastases and no known visceral metastatic disease. 
 
  
Orphan Status: – 
Licensure: FDA/EMA 
Target: Prostate 
Agency  NICE HAS PBAC 
Appraisal date NA Apr-14 NA 
Comparator NA Placebo NA 
Modelled/indirect comparison NA No NA 
Basis for classification NA OS: 2.8-month increase vs placebo 





QoL: The expected impact on preserving QoL 
remains difficult to assess, improved time 
observed to degradation of FACT-P score and 
the EQ-5D utility score are not considered 
clinically relevant and the absence of pain 
assessment. In the absence of comparative data 
versus currently used treatments, the expected 
impact of radium-223 dichloride in terms of 
improving QoL compared to those treatments 
currently used cannot be quantified 
 
Safety: Although HAS discusses several adverse 
events that were observed more frequently in 
the radium-223 dichloride group than in the 
placebo group, the agency does not provide an 
overall assessment of drug-related changes in 
safety 
Effects Merged data    








NA NA NA 
regorafenib FDA primary indication 
ATC code: L01XE21 
A kinase inhibitor indicated for the treatment of metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- 
and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy. 
  
Orphan Status: - 
Licensure: FDA/EMA 
Target: GI 
Agency  NICE HAS PBAC 
Appraisal date NA May-14 Jul-14 
Comparator NA placebo placebo 
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Modelled/indirect comparison NA No No 
Basis for classification NA OS: 1.4-month increase in median OS in 
regorafenib group relative to placebo (primary 
analysis) 
 
QoL: It is not expected that this and a 
proprietary medicinal product will provide any 
additional impact in terms of morbidity and 
mortality or quality of life 
 
Safety: The overall incidence of serious adverse 
events considered as being treatment-related 
was higher in the regorafenib group 
OS: 1.4-month increase in median OS. PBAC 
considered that clinical evidence from the 
CORRECT clinical trial was mature, there was not 
cross-over and subsequent therapy was relatively 
balanced between treatment groups. CORRECT 
unlikely to have underestimated the effectiveness 
of regorafenib compared to BSC. However OS 
benefit not considered to be clinically significant 
 
QoL: PBAC noted that no patients in the trial had a 
complete response and that EQ-5D data showed no 
improvement compared to BSC 
 
Safety: PBAC agreed that regorafenib was inferior 
in comparative safety to BSC and noted severe AEs 
associated with the drug, particularly 
hepatotoxicity and hand-foot skin reactions 
Effects Merged data    




NA No difference No difference 
Safety change - NA - - 
romidepsin FDA primary indication 
ATC code: L01XX39 




Orphan Status: US/EU 
Licensure: EMA 
Target: Hematological 
Agency  NICE HAS PBAC 
Appraisal date NA NA NA 
Comparator NA NA NA 
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Modelled/indirect comparison NA NA NA 
Basis for classification NA NA NA 
Effects Merged data    
OS increase  NA NA NA 
QoL change  NA NA NA 
Safety change  NA NA NA 
ruxolitinib FDA primary indication 
ATC code: L01XE18 
A kinase inhibitor indicated for treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia 
vera myelofibrosis and post-essential thrombocythemia myelofibrosis. 
 
 
Orphan Status: US / EU (w) 
Licensure: FDA/EMA 
Target: Hematological 
Agency  NICE HAS PBAC 
Appraisal date Jun-13 Jan-13 Jul-13 
Comparator BSC placebo BSC (hydroxyurea and placebo) 
Modelled/indirect comparison Yes No Yes 
Basis for classification OS: The Committee concluded that it was 
plausible that ruxolitinib could offer a survival 
benefit. However, the reason for this benefit 
remained unclear 
 
QoL: The Committee noted that in COMFORT-
I significantly more patients treated had a 50% 
or more reduction in total symptom score than 
those on placebo, and that there was a 
significantly greater reduction in mean change 
from baseline total symptom score with 
ruxolitinib than placebo. 
 
OS: The impact of the treatment on OS and 
leukaemic transformation cannot be evaluated 
at present because of the small number of 
events reported 
 
QoL: Ruxolitinib is expected to have a low 
impact on the morbidity of patients treated. 
However, the impact of treatment on quality of 
life is difficult to evaluate (several reasons 
given) 
 
Safety: The overall incidence of serious adverse 
effects was similar in the treatment groups in 
the two pivotal studies at around 30%. 
OS: PBAC accepted the clinical claim of superior 
efficacy likely in OS, although the magnitude of the 
survival benefit is uncertain due to high number of 
cross-over and confounding factors 
 
QoL: PBAC accepted the claim of superior efficacy 
demonstrated in spleen response and QoL 
measures 
 
Safety: PBAC did not accept the claim for 
equivalence in comparative safety. Patients 
experienced significantly more drug-related AEs 
than patients treated with either BAT (in 
COMFORT-II) or placebo (in COMFORT-I). There 
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Safety: The Committee concluded that 
ruxolitinib did have a negative impact on 
haematological outcomes in the short term, but 
agreed that these were manageable 
were also significantly more cases of 
thrombocytopenia and anaemia in ruxolitinib 
treated patients compared to BAT treated patients 
in COMFORT-II 





Uncertain  None established Uncertain 
QoL change + + NA No difference 
Safety change - - + - 
sipuleucel-T FDA primary indication 
ATC code: L03AX17 
An autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone 
refractory) prostate cancer. 
  
Orphan Status: – 
Licensure: FDA/EMA 
Target: Prostate 
Agency  NICE HAS PBAC 
Appraisal date Feb-15 NA NA 
Comparator BSC NA NA 
Modelled/indirect comparison No NA NA 
Basis for classification OS: 4.0-month median extension compared to 
BSC (based on meta-analysis of three trials) in 
subgroup of patients who had not previously 
received chemotherapy; two of the showed that 
sipuleucel-T extended life, including the pivotal 
trial with a 4.1-month increase in median OS; 
Committee concluded that "it would be 
reasonable to assume that sipuleucel-T and 
abiraterone had similar effectiveness in 





QoL: Patient organisations expected sipuleucel-
T to reduce pain, improve mental and physical 
health, and offer an additional treatment option 
at an early stage of disease. The Committee 
concluded that patients would like to have the 
option of having treatment with sipuleucel-T 
within the NHS. 
 
Safety: The Committee noted that the European 
public assessment report stated that sipuleucel-
T is considered less toxic than other therapies 
(such as abiraterone, enzalutamide, docetaxel 
and cabazitaxel) that are currently used for 
treating metastatic hormone-resistant prostate 
cancer 
Effects Merged data    
OS increase 4.0 months ≥ 3 months + + 
QoL change + NA NA NA 
Safety change + NA NA NA 
sorafenib FDA primary indication 
ATC code: L01XE05 




Orphan Status: US/EU 
Licensure: FDA/EMU 
Target: Renal 
Agency  NICE HAS PBAC 
Appraisal date Aug-09 Sep-06 Mar-08 
Comparator BSC placebo BSC 
Modelled/indirect comparison Yes No No 
Basis for classification OS: More than 3-month increase compared to 
BSC was "likely" for people in whom 
OS: An increase compared to placebo not 
established (second-line); median OS was not 
OS: No statistically significant difference was 
observed compared to BSC, though Committee 
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immunotherapy has failed (second-line), though 
exact magnitude was uncertain; trial was 
"terminated early, on ethical grounds, after an 
independent review decided that sorafenib 
should be offered to participants who were 
receiving placebo" 
 
QoL: No HRQoL difference between placebo 
and sorafenib groups in mean FACT-G physical 
well-being score, nor any significant difference 
in mean FKSI−10 total score over the first 32 
weeks of treatment. However, median time to 
health status deterioration, as defined by a four-
point or more drop in FKSI-10 total score, was 
significantly greater than placebo. Those who 
had received sorafenib scored significantly 
better on the following items of the FKSI-15 
index: coughing; fever; worry about their 
disease; ability to enjoy life.  
 
Safety: associated with more AEs than BSC, 
particularly hand–foot skin reactions and 
hypertension. A significantly greater number of 
people reported ‘bothersome side effects of 
treatment’ than those receiving placebo. Skin 
rashes, hypertension, diarrhoea and hand–foot 
syndrome were more common in the sorafenib 
arm. 
reached in the sorafenib group before patients 
receiving placebo were allowed to switch to 
sorafenib on the basis of "encouraging" 
progression-free survival results 
 
QoL: After 24 weeks of treatment, an 
improvement was observed: in the FKSI-10 score 
(44% in sorafenib versus 22% in placebo); in the 
FACT-G score (47% in sorafenib versus 21% in 
placebo). According to the results of clinical 
trials sorafenib is expected, in theory, to have a 
moderate effect on morbidity, mortality and 
quality of life. 
 
Safety: No Committee evaluation provided to 
describe comparative differences in safety 
noted the influence that patient crossover had on 
the ability of the submission to demonstrate 
efficacy in terms of OS; Committee agreed that 
trial data suggested increase in progression-free 
survival as second-line treatment but "considered 
that the clinical importance of this gain had not 
been demonstrated…as a surrogate to predict 




Safety: PBAC noted that sorafenib is associated 
with a variety of AEs including dermatologic and 
gastrointestinal events, hypertension, sensory 
neuropathy, and neutropenia. Additionally, a six-
fold increase in cardiac ischaemia/infarction was 
found in Trial 11213 for sorafenib treated patients 
compared to placebo. Diarrhoea, rash, fatigue, 
hand-foot syndrome, alopecia and nausea were 
reported in >20% patients 
Effects Merged data    
OS increase 
≥ 3 months 
(exact gain 
uncertain) 
≥ 3 months 
(exact gain uncertain) 
None established None established 
QoL change + + + NA 
Safety change - - NA - 
sunitinib FDA primary indication 
ATC code: L01XE04 
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Orphan Status: EU Indicated for the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate. Aso indicated for the 
treatment of advanced renal cell carcinoma. Approval for advanced renal cell carcinoma is based on partial response rates and duration of responses. 
There are no randomized trials of sunitinib demonstrating clinical benefit such as increased survival or improvement in disease-related symptoms in 
renal cell carcinoma.  
Licensure: FDA/EMA 
Target: Renal 
Agency  NICE HAS PBAC 
Appraisal date 
Sept-09 (GIST)  
Mar-09 (RCC) 





BSC (GIST) / 
interferon-alfa (RCC) 
BSC (GIST) / 
interferon-alfa (RCC) 
BSC 
Modelled/indirect comparison Yes No Yes 
Basis for classification OS: More than 3-month increase compared to 
BSC as GIST treatment (7.8 months based on 
RPSFT model); more than 3-month increase 
compared to interferon-alfa as first-line RCC 
treatment (10 months according to model based 
on "Committee's preferred assumptions") 
 
QoL: More than 75% of people completed the 
EQ-5D questionnaire at each time point and 
there were no statistically significant differences 
reported. For RCC, overall results for HRQoL 
(total score and all subscales) were significantly 
better in the sunitinib arm compared with the 
IFN-α arm. 
 
Safety: For GIST, treatment-related AEs and 
serious AEs were more common in the sunitinib 
arm (83%) than in the placebo arm (59%). For 
RCC, the frequency of adverse events associated 
with sunitinib is comparable to that associated 
with IFN-α monotherapy. A total of 8% of 
participants receiving sunitinib discontinued 
treatment because of adverse events compared 
with 13% in the IFN-α arm. 
OS: An increase compared to placebo not 
established in GIST treatment given that 
median OS was not reached in both treatment 
arms; increase not established compared to 
interferon-alfa in first-line RCC treatment as 
median OS was not reached in either treatment 
arm before patients receiving interferon-alfa 
were allowed to cross over to sunitinib based on 
progression-free survival results 
 
QoL: For GIST, NA. For RCC, a moderate 
theoretical impact may be expected of sunitinib 
in terms of reducing morbidity and improving 
quality of life in comparison to interferon alpha, 
as a first-line treatment. Statistically and 
clinically significant improvement in QoL, 
analysed through 3 FACT-G, FKSI and EQ-5D 
questionnaires, was observed in the sunitinib 
group compared to the interferon alpha group 
Safety: For GIST, no regulatory judgment is 
given on the comparative differences in safety 
across groups. For RCC, Grade III AEs were 
more frequent in the sunitinib group compared 
to IFN-α arm 
OS: Committee considered that the magnitude of 
increase compared to BSC for treatment of GIST 
was "uncertain", noting that the 7.8-month 
survival benefit estimated by the RPSFT model 
"may be an overestimate"; no statistically 
significant difference was observed compared to 
interferon-alfa for treatment of RCC was 
observed, though Committee "acknowledged that 
because patients that progressed were allowed to 
cross-over this would bias later overall survival 
analyses towards the null, thereby 
underestimating the likely true difference 




Safety: For GIST, sunitinib is described as inferior 
in terms of comparative safety over placebo. For 
RCC, the PBAC noted the increase in AEs with 
sunitinib over BSC/placebo. Of particular concern 
to the PBAC was more recent evidence of cardiac 
side effects of ischemia and heart failure 









QoL change + No Difference (GIST); + (RCC) = + NA (GIST); + (RCC) = + NA (GIST); NA (RCC) = NA 
Safety change - − (GIST); No Difference (RCC) = − NA (GIST); − (RCC) = − − (GIST); − (RCC) = − 
tegafur/gimeracil/oteracil FDA primary indication 
ATC code: L01BC53 




Orphan Status:  EU (w) 
Licensure: EMA 
Target: GI 
Agency  NICE HAS PBAC 
Appraisal date NA Oct-12 NA 
Comparator NA fluorouracil (5-FU) / cisplatin NA 
Modelled/indirect comparison NA No NA 
Basis for classification NA OS: There was very little difference in median 
OS (primary endpoint) between the two groups: 
8.6 months in the TEYSUNO group vs 7.9 
months in the 5-FU group (HR = 0.92, 95% CI: 
[0.80; 1.05]). The median overall survival 
(primary endpoint) was similar across the two 
groups. As this was a superiority study, the 
primary objective was not achieved 
 
QoL: the overall FACT-Ga score, which 
evaluates quality of life, was also similar 
between the two groups. Available data do not 
show ... the improvement in quality of life 
 
Safety: Similar overall incidence of AEs of any 
grade across both groups. Treatment stopped 
due to AE in 10.7% of treated patients vs 14.4% 
of comparator patients. Incidence profile for 




treatment producing greater number of AEs in 
some cases, and comparator producing greater 
number of AEs in other cases. However, the 
primary superiority objective was not achieved 
(OS) … the results for the secondary endpoints, 
including safety, were of an exploratory nature 
and did not allow any conclusions to be drawn” 












NA No difference NA 
temsirolimus FDA primary indication 
ATC code: L01XE09 




Orphan Status: US/EU 
Licensure: FDA/EMA 
Target: Renal 
Agency  NICE HAS PBAC 
Appraisal date Aug-09 Feb-08 Jul-08 
Comparator interferon-alfa interferon-alfa BSC 
Modelled/indirect comparison No No Yes 
Basis for classification OS: 3.6-month increase in median OS  
 
QoL: Participants receiving temsirolimus had a 
significantly longer time in both TWiST and Q-
TWiST health states compared with participants 
receiving IFN-α alone 
 
OS: 3.6-month increase in median OS  
 
QoL: The available data are too limited for an 
evaluation of the product’s impact on quality of 
life 
 
Safety: Grades 3–4 adverse effects were more 
common in the interferon alpha arm 
OS: Committee considered "there was 
uncertainty about the magnitude of the treatment 
effect of temsirolimus compared with BSC" (based 
on indirect comparison); Committee was aware of 
the 3.6-month increase in median OS compared 





Safety: The frequency of treatment-related toxic 
events associated with bevacizumab plus IFN-α, 
sunitinib and temsirolimus appears to be 
comparable or slightly better than IFN-α, based 
on the data reported in these trials 
QoL: PBAC considered that there was uncertainty 
regarding the effect of temsirolimus on QoL, as 
the two trials in the submission used different 
QoL instruments 
 
Safety: PBAC noted that AEs occurred at a 
significantly greater frequency in temsirolimus-
treated patients compared to IFN-α patients and 
concluded that the profile of side effects for was 
different to I IFN-α, rather than that temsirolimus 
was better tolerated than IFN-α. However, PBAC 
considered that the submission did not consider 
the relative harms in comparison with BSC, 
including their impact on incremental QALYs and 
cost-effectiveness 
Effects Merged data    
OS increase 3.6 months ≥ 3 months ≥ 3 months Uncertain 
QoL change + + NA NA 
Safety change + + + NA 
tositumomab  FDA primary indication 
ATC code: V V10XA53 
Tositumomab and Iodine-131. Tositumomab is indicated for the treatment of patients with CD20 positive, follicular, non-Hodgkin's lymphoma, with and 
without transformation, whose disease is refractory to Rituximab and has relapsed following chemotherapy. 
 
  
Orphan Status: US/EU (w) 
Licensure: FDA/EMA 
Target: Hematological 
Agency  NICE HAS PBAC 
Appraisal date NA NA NA 
Comparator NA NA NA 
Modelled/indirect comparison NA NA NA 
Basis for classification NA NA NA 
Effects Merged data    
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OS increase NA NA NA NA 
QoL change NA NA NA NA 
Safety change NA NA NA NA 
trabectedin EMA primary indication 
ATC code: L01CX01 
Indicated for the treatment of adult patients with advanced soft tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to 
receive these agents. 
 
  
Orphan Status: – 
Licensure: EMA 
Target: Soft Tissue 
Agency  NICE HAS PBAC 
Appraisal date Feb-2010 Apr-2008  
Comparator BSC non-comparative NA 
Modelled/indirect comparison Yes No NA 
Basis for classification OS: Median OS was 13.9 months (95% CI 12.5 to 
18.6). The Committee concluded that the use of 
historical controls (BSC) was appropriate. The 
manufacturer reported increased median OS 
over historical control patients treated with 
ifosfamide 6.6 months (95% CI 5.0 to 9.0), 
dacarbazine 6.6 months (95% CI 4.3 to 8.4) and 
etoposide 6.3 months (95% CI 4.4 to 8.9). 
Although the Committee “considered the 
clinical effectiveness data presented by the 
manufacturer, and noted the median OS for 
patients randomised to the licensed dosage of 
trabectedin exceeded that for patients receiving 
BSC”, it does not indicate specify the exact gain 
in OS 
 
QoL: No comparative HRQoL data presented 
 
Safety: The Committee heard from the clinical 
specialist and patient experts that there were 
OS: There was no difference between the two 
groups with regard to median overall survival 
time: 13.9 months in the group receiving 
treatment once every three weeks versus 10.8 
months in the group receiving treatment every 
week 
 
QoL: No comparative evidence provided 
 




fewer, less severe and less frequent AEs than 
with the other agents. It understood that the 
AEs associated with trabectedin were 
manageable, but nevertheless important, as with 
other chemotherapy agents used to treat soft 
tissue sarcoma. 
Effects Merged data    
OS increase 
≥ 3 months 
(exact gain 
uncertain) 
≥ 3 months 
(exact gain over uncertain) 
None established NA 
QoL change No difference No difference NA NA 
Safety change + + NA NA 
trametinib FDA primary indication 
ATC code: L01XE25 
A kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected 
by an FDA-approved test. 
 
  
Orphan Status: – 
Licensure: FDA/EMA 
Target: Skin 
Agency  NICE HAS PBAC 
Appraisal date NA NA Nov-14 
Comparator NA NA dabrafenib 
Modelled/indirect comparison NA NA No 
Basis for classification NA NA OS: PBAC was satisfied that trametinib + 
dabrafenib, is more effective than dabrafenib 
alone, however the size of the incremental 
treatment effect is still uncertain, particularly for 
OS 
 
QoL: Report recalls consumer comments 
remarking on some benefits, including ability to 




Safety: PBAC considered that the  
revised claim of different, but no worse 
comparative safety of trametinib + dabrafenib to 
dabrafenib monotherapy was reasonable, noting a 
decrease in rate of cutaneous hyperproliferative 
events and photosensitivity, but increase in rate 
of pyrexia and ejection fraction decrease 





NA NA Uncertain 




NA NA No difference 
vandetanib FDA primary indication 
ATC code: L01XE12 




Orphan Status: US / EU (w) 
Licensure: FDA / EMA 
Target: Thyroid 
Agency  NICE HAS PBAC 
Appraisal date NA Jun-12 NA 
Comparator NA Placebo NA 
Modelled/indirect comparison NA No NA 
Basis for classification NA OS: Did not differ between the two groups 
during the analysis of the progression-free 
survival 
 
QoL: Impact is not measurable 
 
Safety: The Committee indicated that during 




was stopped due to adverse events for 12% of 
patients in the vandetanib arm and 3% of 
patients in the placebo arm. Grades ≥ 3 events 
involved 55% of patients in the vandetanib 
group and 24% of patients in the placebo group. 
However, the Committee did not provide an 
overall assessment of comparative changes in 
drug-related safety 












NA NA NA 
vemurafenib FDA primary indication 
ATC code: L01XE15 




Orphan Status: – 
Licensure: FDA/EMA 
Target: Skin 
Agency  NICE HAS PBAC 
Appraisal date Dec-12 Oct-12 Mar-13 
Comparator dacarbazine dacarbazine dacarbazine 
Modelled/indirect comparison No No No 
Basis for classification OS: 3.3-month increase in median OS; 
Committee "agreed it that it was appropriate to 
adjust the OS results…to control for switching 
using statistical modelling or other techniques" 
but "agreed that any estimate obtained using 
these techniques would be subject to 
uncertainty" 
OS: 3.6-month increase in median OS 
compared to dacarbazine (based on follow-up 
OS analysis not scheduled in protocol); 1.5-
month increase in median OS compared to 
dacarbazine (based on OS analysis scheduled in 
protocol) 
 
OS: 3.3-month increase in median OS compared 
to dacarbazine (without censoring at crossover); 
3.9-month increase in median OS compared to 
dacarbazine (with censoring at crossover); 
Committee considered “the true estimate" of OS 





QoL: The Committee agreed with the 
manufacturer's assumption of a higher utility 
value for progression-free survival, given its 
improved clinical profile, including oral 
administration compared with intravenous 
administration for dacarbazine 
 
Safety: Treatment-related AEs were recorded 
for more people who received vemurafenib, may 
be explained by the fact that they stayed on 
treatment longer than those on dacarbazine 
QoL: Although HAS indicates that a negative 
impact on quality of life cannot be ruled out, 
particularly in view of the safety problems 
encountered, there is no indication that it 
believes that worsened QoL is most likely 
outcome. The statement that worsened QoL can 
occur does not provide definitive proof one way 
or the other 
 
Safety: Safety data is limited due to the short 
follow-up period, especially in the pivotal study 
QoL: NA 
 
Safety: The PBAC concluded that vemurafenib 
and DTIC have different toxicity profiles, with 
vemurafenib being associated with manageable 
toxicity. PBAC also noted that dabrafenib has a 
preferable toxicity profile as evidenced by fewer 
and less extensive dose intensity reductions and 
by favourable differences in rates for AEs such as 
photosensitivity, cutaneous squamous cell 
carcinoma – but not pyrex 
Effects Merged data    
OS increase 3.3–3.9 months ≥ 3 months ≥ 3 months ≥ 3 months 
QoL change + + NA NA 
Safety change - - NA NA (dacarbazine); − (dabrafenib) = − 
vinflunine EMA primary indication 
ATC code: L01CA05 
Indicated in monotherapy for the treatment of adult patients with advanced or metastatic transitional cell carcinoma of the urothelial tract after failure 
of a prior platinum-containing regimen. 
  
Orphan Status:  – 
Licensure: EMA 
Target:  Bladder 
Agency  NICE HAS PBAC 
Appraisal date Jan-2013 Dec-2009 Nov-2011 
Comparator BSC BSC BSC 
Modelled/indirect comparison No No No 
Basis for classification OS: The Committee noted that the difference 
between the study arms was not statistically 
significant for the ITT population, but was 
significant for the eligible ITT population ... It 
considered that the results from the ITT 
OS: The study objective was not reached in the 
ITT population: median overall survival was 6.9 
months (95% CI [5.7 – 8.0 months]) in the 
JAVLOR arm versus 4.6 months (95% CI [4.1 – 
7.0 months]) in the comparator arm (RR= 0.88; 
OS: The PBAC noted that the increment is 
uncertain and, at best, is between 2.3 (ITT) and 
2.6 months (eligible ITT) … the selection of the 
eligible ITT population was considered highly 
uncertain … The PBAC agreed that the ITT 
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population were the most appropriate basis for 
its deliberations because randomisation had not 
been broken. It concluded that the extent of 
clinical effectiveness of vinflunine compared 
with BSC had not been conclusively 
demonstrated because of the uncertainty of the 
overall survival results 
 
QoL: There were no statistically significant 
differences in overall EORTC QLQ-C30 global 
health status score between the two arms 
(p=0.658). [The Committee] noted that there 
were no significant differences in HRQoL 
between patients receiving vinflunine and those 
receiving BSC alone 
Safety: Grade 3 or 4 toxicities relating to 
neutropenia, anaemia and constipation 
occurred in 50%, 19% and 16% respectively of 
patients in the vinflunine arm of study 302, 
compared with 1%, 8% and 1% of patients 
respectively in the best supportive care arm. 
Febrile neutropenia occurred in 6% of patients 
receiving vinflunine (none in the best 
supportive care arm). The Committee 
concluded that there were concerns about the 
tolerability of vinflunine 
95% CI [0.69 – 1.12], NS). Two other types of 
analyses (multivariate, eligible ITT) discussed, 
but focus given on describing results for ITT 
population 
 
QoL: There was no difference in the quality of 
life assessment and clinical benefit between the 
two [study] arms. 
 
Safety: Treatment discontinuations more likely 
in the vinflunine arm compared with BSC alone 
arm. Grade 3-4 neutropenia and anaemia was 
higher in treatment arm. Higher incidence of 
non-haematological AEs reported in treatment 
arm. 
population should be used in considering the 
effectiveness of vinflunine. The PBAC accepted 
that vinflunine may be superior in terms of 
comparative efficacy over BSC although the 
magnitude of the overall survival gain is uncertain 
(less than 3 months) 
 
QoL: No comparative data presented 
 
Safety: AEs significantly more frequent in 
treatment arm included abdominal pain, 
constipation, diarrhea, nausea, stomatitis, 
vomiting, among others. Grade III/IV AEs 
experienced more frequently included abdominal 
pain, constipation, nausea, vomiting, fatigue, 
among others. One death directly related to 
vinflunine, though 6% in vinflunine and 1% in 
BSC died within 30 days of final dose. PBAC noted 
that rates of AEs were higher in the treatment 
arm than in the BSC alone arm, and that the 
pattern of AE and serious AEs suggested very high 
levels of toxicity. 









No difference No difference NA 
Safety change - - - - 
vismodegib FDA primary indication 
ATC code: L01XX43 A hedgehog pathway inhibitor indicated for the treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma 
that has recurred following surgery or who are not candidates for surgery, and who are not candidates for radiation. 





Agency  NICE HAS PBAC 
Appraisal date NA Dec-13 NA 
Comparator NA non-comparative NA 
Modelled/indirect comparison NA No NA 
Basis for classification NA OS: In light of the available clinical trial data in 
a non-comparative phase II study, an impact in 
terms of morbidity is not expected. In the 
efficacy trial (ERIVANCE), median OS was 
deemed not evaluable in the mBCC or laBCC 
cohorts 
 
QoL: In light of the available clinical trial data, 
an impact in terms of morbidity or QoL is not 
expected 
 
Safety: No comparative data presented 
NA 












NA NA NA 
vorinostat FDA primary indication 
ATC code: L01XX38 
A histone deacetylase (HDAC) inhibitor indicated for: treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who 
have progressive, persistent or recurrent disease on or following two systemic therapies. 
 
 





Agency  NICE HAS PBAC 
Appraisal date NA NA Mar-11 
Comparator NA NA BSC 
Modelled/indirect comparison NA NA No 
Basis for classification NA NA OS: No survival data are available from study 
P001 or from the non-comparative chemotherapy 
studies. Quality of data is extremely limited. 
Vorinostat has superior efficacy to palliative care, 
however, no conclusion can be reach with respect 




Safety: The PBAC agreed that vorinostat has 
significant toxicities, and is inferior in safety to 
palliative care. However, expert testimony 
suggests it is less toxic than cytotoxic 
chemotherapies 








NA NA NA 
Safety change +/- NA NA − (placebo); + (chemotherapy) = +/− 
ziv-aflibercept FDA primary indication 
ATC code: L01XX44 
In combination with 5-fluorouracil, leucovorin, irinotecan- (FOLFIRI) indicated for metastatic colorectal cancer (mCRC) that is resistant to or has 
progressed following an oxaliplatin-containing regimen. 
 
  
Orphan Status: – 
Licensure: FDA/EMA 
Target: GI 
Agency  NICE HAS PBAC 
Appraisal date Mar-14 Jul-13 Jul-13 
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Comparator placebo placebo placebo 
Modelled/indirect comparison Yes No No 
Basis for classification OS: 1.4-month increase in median OS. The 
Committee was not satisfied that estimates 
produced by the model were sufficiently robust 
to accept that the 3-month life extension 
criterion is fulfilled 
 
QoL: Although the Committee, echoing 
comments from a patient expert, would have 
liked the manufacturer to have collected trial 
data on HRQoL, the Committee noted that 
patients consider therapies such as ziv-
aflibercept to improve QoL compared with 
chemotherapy 
 
Safety: The Committee concluded that 
treatment with aflibercept + ziv-aflibercept was 
associated with a considerable burden of AEs, 
but that, being a new treatment, less is known 
about its AE profile than for other available 
treatments. 
OS: 1.4-month increase in median OS 
 
QoL: The expected additional impact of this 
medicinal product in terms of morbidity and 
mortality and QoL can only be very small 
 
Safety: Comparing ziv-aflibercept arm to 
placebo arm, frequency of treatment 
discontinuations due to AEs was greater 
OS: 1.4-month increase in median OS compared 
to placebo for the K-RAS mutant patient 
population. The PBAC considered this survival 
gain to be modest and the clinical relevance and 




Safety: PBAC considered the claim that ziv-
aflibercept is non-inferior in terms of comparative 
safety over cetuximab to not be a reasonable 
assumption, considering treatment to be 
potentially worse in comparative harms 
Effects Merged data    
OS increase 1.4 months < 3 months < 3 months < 3 months 
QoL change + + No difference - 
Safety change - - - - 
 
Source: 
Authors’ analysis of data, as described in Methods section. 
Notes: 



























































































Overview of IHME methods to calculate global YPLLs 
 
A thorough explanation of IHME methods for calculating country- and cause-specific 
YPLLs are provided elsewhere.(281,282) A brief overview of methods that are key to this 
study is nevertheless provided for reference. The IHME GBD study computes YPLLs by 
multiplying deaths from each cause in each age group by the reference standard life 
expectancy for that age group. One standard reference life table is used for both sexes 
across all countries,(353) and was developed by the IHME using the lowest observed 
death rate in each age group across countries with a population greater than 5 million. 
These methods reflect the IHME’s assumption that, in the absence of any influence from 
outside factors, everyone should be expected to live equally long life in health.(354) By 
applying a normative standard life expectancy, IHME methods enable the use of GBD 
YPLL data as a neoplasm-related mortality indicator that is globally comparable and 
which tracks over time. Age-standardized YPLLs are also computed using an update to 
the world population age standard issues by the WHO in 2001.(282) Mathematically, 
YPLLs are calculated using the following equation: 
 
 ෍ 𝑑𝑥(𝐿 − 𝑥)
𝐿
𝑥=0










Authors’ analysis of data, as described in Methods section. 
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Net Value Generated from Oncology Drug Care by Level of Attribution to Health 
Gains, Australia, 2004-2014










Authors’ analysis of data, as described in Methods section. 
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Net Value Generated from Oncology Drug Care by Level of Attribution to Health 
Gains, France, 2004-2014










Authors’ analysis of data, as described in Methods section. 
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Net Value Generated from Oncology Drug Care by Level of Attribution to Health 
Gains, United Kingdom, 2004-2014




eTable 9. Net Long-Term Value per Patient, First Year of Marketing, Assuming Treatment Duration  (2015 USD) 
Drug Measure 
AU FR UK US 
10% 50% 90% 10% 50% 90% 10% 50% 90% 10% 50% 90% 
abiraterone 
mean $68,764.33 $60,822.31 $52,253.17 . . . $66,250.83 $48,320.98 $28,850.73 $66,020.46 $47,175.25 $26,705.91 
p5 $43,945.59 $34,059.92 $21,375.08 . . . $41,109.22 $14,843.53 $-21,235.40 $40,769.96 $12,919.01 $-25,188.06 
p25 $57,781.34 $49,541.64 $39,624.13 . . . $55,288.42 $34,754.47 $10,413.56 $55,099.92 $33,402.92 $7,434.56 
p50 $68,402.60 $61,066.07 $52,781.71 . . . $66,023.59 $49,466.36 $31,708.36 $65,727.58 $48,478.26 $29,601.81 
p75 $79,239.15 $71,917.46 $64,922.63 . . . $76,681.61 $62,324.69 $49,241.87 $76,527.63 $61,578.22 $47,894.68 
p95 $94,118.60 $87,066.20 $82,665.17 . . . $92,038.08 $80,068.19 $73,550.10 $91,846.01 $79,475.79 $72,486.66 
afatinib 
mean $-3,811.55 $-19,138.03 $-34,458.33 $-3,996.96 $-20,069.00 $-36,134.57 $-5,917.69 $-29,713.10 $-53,498.91 $-10,326.44 $-51,849.71 $-93,356.24 
p5 $5,938.13 $29,491.07 $53,173.74 $-6,227.00 $-30,925.66 $-55,760.39 $-9,219.36 $-45,786.89 $-82,555.86 $-16,087.89 $-79,898.67 $-144,060.95 
p25 $4,710.59 $23,503.03 $42,574.92 $-4,939.73 $-24,646.34 $-44,645.98 $-7,313.51 $-36,490.06 $-66,100.47 $-12,762.16 $-63,675.59 $-115,346.10 
p50 $3,737.53 $19,261.51 $34,311.43 $-3,919.34 $-20,198.49 $-35,980.52 $-5,802.77 $-29,904.80 $-53,270.84 $-10,125.91 $-52,184.24 $-92,958.25 
p75 $2,894.22 $14,620.78 $26,452.14 $-3,035.01 $-15,332.01 $-27,738.91 $-4,493.47 $-22,699.76 $-41,068.75 $-7,841.16 $-39,611.35 $-71,665.46 
p95 $1,691.62 $8,582.85 $16,122.78 $-1,773.91 $-9,000.36 $-16,907.08 $-2,626.35 $-13,325.46 $-25,031.72 $-4,583.02 $-23,253.08 $-43,680.64 
azacitidine 
mean $156,009.48 $145,320.82 $133,127.38 $151,542.78 $123,674.25 $95,281.25 $146,039.09 $95,716.56 $41,978.93 $151,156.37 $121,388.26 $88,911.16 
p5 $100,394.74 $87,216.87 $63,640.18 $95,858.56 $32,451.02 $-54,797.67 $88,990.85 $-46,424.91 $-205,006.62 $95,772.65 $30,687.18 $-62,637.77 
p25 $132,878.30 $121,094.03 $107,726.24 $128,166.69 $96,604.38 $63,736.94 $121,974.26 $66,505.16 $-8,192.07 $127,610.54 $94,906.74 $55,507.40 
p50 $156,048.27 $146,740.64 $135,858.12 $152,338.58 $129,648.67 $110,248.63 $147,240.96 $110,287.68 $77,323.42 $151,870.83 $127,185.41 $105,961.92 
p75 $179,141.67 $169,573.74 $161,535.62 $175,030.42 $158,806.96 $146,480.75 $170,110.55 $143,449.03 $126,140.45 $174,437.42 $154,434.53 $141,433.06 
p95 $209,692.86 $201,199.76 $195,218.95 $206,090.33 $194,476.83 $184,306.49 $201,345.49 $183,165.98 $169,299.44 $205,280.04 $191,568.66 $180,495.70 
bendamustine 
mean . . . $-825.71 $-4,122.79 $-7,412.56 $-1,454.13 $-7,274.94 $-12,853.25 $-6,239.54 $-31,392.10 $-55,395.91 
p5 . . . $-1,751.40 $-8,484.46 $-15,798.91 $-2,518.74 $-12,744.88 $-22,118.69 $-10,780.61 $-54,674.32 $-96,356.51 
p25 . . . $-1,096.67 $-5,508.35 $-9,826.17 $-1,883.10 $-9,302.00 $-16,384.34 $-7,990.21 $-40,141.07 $-70,075.12 
p50 . . . $-743.77 $-3,728.64 $-6,753.04 $-1,365.61 $-6,942.99 $-12,075.84 $-5,948.88 $-30,108.63 $-52,846.18 
p75 . . . $-458.67 $-2,346.07 $-4,229.78 $-966.38 $-4,869.44 $-8,689.84 $-4,165.03 $-21,187.77 $-37,650.89 
p95 . . . $-189.41 $-941.72 $-1,712.53 $-601.59 $-3,007.08 $-5,357.77 $-2,515.75 $-12,581.66 $-23,001.18 
bevacizumab 
mean $51,316.39 $-2,981.53 $-54,199.29 $61,210.19 $49,883.94 $39,455.89 $60,222.92 $44,424.84 $29,495.29 $58,114.26 $33,799.74 $9,254.44 
p5 $21,298.82 $123,078.11 $259,858.90 $37,403.41 $18,193.24 $-5,751.04 $36,165.57 $5,139.94 $-30,744.22 $33,496.07 $-19,337.16 $-96,867.34 
p25 $39,174.06 $30,150.70 $101,500.62 $51,060.75 $37,924.92 $26,235.36 $49,756.03 $31,757.22 $13,325.11 $47,592.13 $18,754.29 $-13,037.26 
p50 $51,888.81 $12,882.73 $27,218.43 $60,657.42 $50,395.71 $42,640.83 $59,785.41 $46,253.90 $33,996.87 $57,713.78 $38,282.20 $22,093.01 
p75 $63,543.09 $40,681.23 $19,593.47 $71,128.57 $62,702.24 $56,422.60 $70,356.34 $58,757.55 $51,501.02 $68,497.06 $54,631.54 $45,900.53 
p95 $80,394.23 $65,483.99 $55,071.08 $86,540.99 $79,519.34 $74,732.31 $85,774.01 $76,895.08 $71,652.18 $84,567.77 $73,384.25 $68,565.32 
bortezomib 
mean $146,752.36 $144,241.65 $143,880.83 $143,225.22 $126,707.33 $112,066.26 $143,182.74 $126,289.59 $111,836.71 $143,898.71 $129,879.22 $118,286.45 




p25 $120,116.88 $119,013.94 $117,543.10 $116,459.23 $100,562.05 $84,879.04 $116,504.01 $101,204.66 $86,061.47 $117,088.15 $104,739.53 $92,613.84 
p50 $145,319.12 $141,109.89 $141,280.06 $141,645.20 $123,926.05 $109,921.95 $141,668.59 $123,415.56 $109,458.20 $142,341.83 $126,806.87 $115,917.34 
p75 $171,052.33 $167,810.71 $167,493.17 $166,826.59 $150,376.05 $137,975.00 $167,361.62 $149,411.97 $136,052.57 $168,096.97 $153,092.86 $142,602.82 
p95 $207,595.23 $208,692.14 $206,670.11 $203,778.17 $193,084.55 $180,529.81 $204,113.49 $190,730.22 $175,710.16 $204,825.82 $193,778.49 $181,226.22 
cabazitaxel 
mean . . . $49,659.15 $27,907.70 $5,353.15 $47,655.43 $17,823.01 $-13,206.10 $45,109.72 $5,455.43 $-35,556.76 
p5 . . . $27,637.59 $-14,003.99 $-69,174.52 $24,522.90 $-38,468.96 $-111,736.36 $20,502.43 $-66,201.30 $-164,956.57 
p25 . . . $39,993.42 $14,446.10 $-15,557.46 $37,602.11 $1,880.54 $-39,672.83 $34,539.14 $-15,091.93 $-70,946.50 
p50 . . . $49,062.97 $30,525.85 $12,369.42 $47,081.37 $22,365.70 $-2,257.58 $44,598.55 $12,867.48 $-22,378.03 
p75 . . . $59,157.31 $44,344.64 $32,145.14 $57,526.08 $38,987.14 $23,816.74 $55,418.22 $32,866.41 $13,039.73 
p95 . . . $72,629.52 $61,105.14 $54,049.80 $71,221.24 $58,098.82 $48,857.74 $69,626.20 $54,207.91 $43,988.52 
cabozantinib 
mean . . . . . . $-11,072.90 $-56,527.56 $-99,093.49 . . . 
p5 . . . . . . $-28,076.20 $-139,544.71 $-251,180.48 . . . 
p25 . . . . . . $-15,435.94 $-79,569.16 $-137,633.14 . . . 
p50 . . . . . . $-9,103.86 $-45,997.19 $-78,924.00 . . . 
p75 . . . . . . $-4,587.77 $-23,655.70 $-43,225.41 . . . 
p95 . . . . . . $-1,361.99 $-6,690.50 $-12,903.11 . . . 
catumaxomab 
mean . . . . . . $-2,116.09 $-10,583.09 $-19,095.58 . . . 
p5 . . . . . . $-2,450.16 $-12,250.80 $-22,051.44 . . . 
p25 . . . . . . $-2,450.16 $-12,250.80 $-22,051.44 . . . 
p50 . . . . . . $-2,450.16 $-12,250.80 $-22,051.44 . . . 
p75 . . . . . . $-2,450.16 $-12,250.80 $-22,051.44 . . . 
p95 . . . . . . $-852.23 $-4,261.15 $-7,670.06 . . . 
clofarabine 
mean $-7,376.29 $-36,726.23 $-65,600.30 $-10,990.07 $-54,624.37 $-96,354.37 $-16,639.44 $-82,421.12 $-149,763.75 $-17,243.59 $-85,915.13 $-153,027.58 
p5 $14,337.96 $73,093.96 $129,491.62 $-22,193.38 $-111,292.18 $-202,755.36 $-33,649.84 $-166,299.11 $-311,226.44 $-32,265.07 $-167,285.36 $-292,896.71 
p25 $9,693.10 $48,634.05 $86,280.84 $-14,348.27 $-72,214.04 $-124,334.30 $-21,680.69 $-108,821.77 $-196,310.08 $-22,812.32 $-112,640.02 $-201,948.58 
p50 $6,658.64 $33,225.16 $59,473.71 $-9,971.07 $-49,233.37 $-88,173.91 $-15,230.59 $-75,561.29 $-136,375.50 $-15,358.18 $-76,895.29 $-138,109.97 
p75 $3,616.15 $17,741.34 $32,186.58 $-5,987.42 $-28,757.75 $-51,734.76 $-8,883.44 $-43,339.02 $-78,311.88 $-8,096.32 $-40,077.87 $-72,666.41 
p95 $2,969.79 $14,813.65 $26,655.07 $-3,854.82 $-19,538.81 $-34,619.58 $-6,090.27 $-29,966.05 $-54,890.54 $-7,077.21 $-35,738.42 $-64,156.64 
crizotinib 
mean $54,614.96 $53,058.16 $51,374.12 $49,228.40 $26,386.64 $3,266.73 $47,689.22 $18,765.38 $-10,479.72 $46,032.59 $10,562.61 $-25,275.05 
p5 $35,954.57 $33,767.49 $32,459.15 $29,875.58 $-6,252.41 $-48,074.95 $27,871.47 $-19,311.91 $-74,115.39 $25,756.56 $-33,895.01 $-102,269.32 
p25 $46,132.00 $44,733.39 $43,413.92 $40,800.26 $13,960.78 $-14,615.94 $39,235.88 $4,531.95 $-32,672.86 $37,270.44 $-5,732.35 $-51,906.89 
p50 $54,769.64 $52,841.02 $51,349.40 $49,514.19 $27,253.10 $6,157.48 $48,184.56 $20,180.97 $-7,058.88 $46,446.14 $12,514.57 $-20,707.70 
p75 $62,920.65 $61,338.43 $59,495.40 $57,758.22 $39,706.00 $24,017.94 $56,326.15 $34,467.42 $15,370.98 $54,784.57 $29,087.48 $6,202.68 
p95 $73,104.75 $72,511.04 $69,830.37 $68,746.52 $55,748.81 $45,064.66 $67,213.42 $52,588.15 $40,222.67 $66,322.90 $49,711.88 $35,459.75 
degarelix 
mean $-206.60 $-1,037.95 $-1,860.33 $-200.99 $-1,009.76 $-1,809.80 $-239.18 $-1,201.64 $-2,153.71 $-266.48 $-1,338.76 $-2,399.47 
p5 $255.74 $1,278.68 $2,301.63 $-248.79 $-1,243.95 $-2,239.11 $-296.07 $-1,480.33 $-2,664.60 $-329.85 $-1,649.26 $-2,968.66 
p25 $221.64 $1,108.19 $1,994.75 $-215.62 $-1,078.09 $-1,940.56 $-256.59 $-1,282.96 $-2,309.32 $-285.87 $-1,429.35 $-2,572.84 
p50 $204.59 $1,022.95 $1,841.30 $-199.03 $-995.16 $-1,791.29 $-236.85 $-1,184.27 $-2,131.68 $-263.88 $-1,319.40 $-2,374.93 
p75 $187.54 $937.70 $1,687.86 $-182.45 $-912.23 $-1,642.01 $-217.12 $-1,085.58 $-1,954.04 $-241.89 $-1,209.45 $-2,177.02 
p95 $153.44 $767.21 $1,380.98 $-149.27 $-746.37 $-1,343.47 $-177.64 $-888.20 $-1,598.76 $-197.91 $-989.55 $-1,781.20 
enzalutamide 
mean $74,851.70 $63,077.56 $51,986.50 $74,465.18 $61,136.74 $48,547.01 $72,419.23 $50,863.47 $30,340.88 $69,067.28 $34,032.47 $513.21 
p5 $47,884.24 $34,760.97 $19,039.87 $47,589.79 $32,363.43 $14,099.45 $45,435.47 $16,888.26 $-15,406.09 $41,845.43 $-8,393.50 $-68,189.03 
471 
 
p25 $63,694.86 $50,785.22 $38,736.14 $63,277.77 $48,711.98 $34,632.42 $61,261.33 $37,132.45 $12,480.13 $57,800.63 $16,566.48 $-25,187.00 
p50 $75,039.42 $63,200.49 $52,710.23 $74,638.85 $61,431.72 $49,335.68 $72,501.31 $51,552.83 $31,739.60 $69,091.60 $34,682.04 $3,164.09 
p75 $85,593.77 $74,850.68 $66,023.66 $85,303.43 $73,147.83 $63,213.32 $83,394.13 $64,643.54 $49,850.53 $80,176.43 $51,343.14 $28,838.09 
p95 $101,429.95 $90,732.59 $83,553.21 $100,998.24 $89,523.53 $81,336.09 $98,865.96 $82,942.52 $72,464.70 $96,018.44 $73,793.53 $59,234.78 
eribulin 
mean . . . $41,735.54 $34,213.53 $26,758.83 $40,289.82 $26,825.97 $13,755.29 $38,485.59 $17,679.12 $-2,301.69 
p5 . . . $26,902.34 $16,347.11 $3,682.67 $25,281.61 $2,742.21 $-22,807.14 $22,901.22 $-15,698.20 $-58,201.43 
p25 . . . $35,403.79 $27,460.32 $18,196.76 $34,056.13 $18,612.77 $1,597.85 $32,125.72 $7,035.69 $-18,797.77 
p50 . . . $41,898.86 $34,580.19 $27,671.06 $40,466.81 $27,756.53 $16,039.59 $38,650.59 $19,642.45 $2,191.22 
p75 . . . $48,079.91 $41,568.16 $36,204.06 $46,723.92 $36,457.91 $28,387.60 $45,193.36 $30,808.77 $19,222.78 
p95 . . . $56,326.44 $50,946.05 $47,017.53 $55,285.35 $47,532.84 $41,625.49 $53,818.33 $44,096.05 $36,441.81 
erlotinib 
mean $31,844.13 $25,581.85 $19,548.36 $32,616.34 $29,428.65 $26,308.49 $31,702.26 $24,875.10 $18,306.37 $32,081.61 $26,764.86 $21,627.31 
p5 $20,380.84 $9,554.93 $3,355.67 $21,394.17 $17,001.55 $11,221.14 $20,206.40 $7,804.20 $-6,185.89 $20,779.59 $12,158.92 $1,408.50 
p25 $26,966.57 $19,698.72 $12,401.51 $27,749.13 $24,017.21 $20,787.40 $26,809.88 $18,950.79 $10,766.96 $27,130.78 $21,135.93 $15,002.07 
p50 $31,794.97 $25,908.63 $21,165.99 $32,607.37 $29,699.43 $26,856.78 $31,684.74 $25,239.30 $20,349.18 $32,038.34 $27,039.71 $22,886.36 
p75 $36,892.83 $32,345.59 $28,378.03 $37,563.68 $34,802.65 $32,347.40 $36,803.25 $31,893.84 $27,663.18 $37,107.70 $33,046.92 $29,649.05 
p95 $43,131.37 $39,268.84 $37,253.33 $43,864.67 $41,459.97 $39,639.56 $43,040.97 $38,862.59 $36,686.23 $43,346.57 $39,851.35 $37,905.71 
everolimus 
mean . . . $85,691.30 $81,365.37 $77,483.31 $85,674.75 $81,282.29 $77,332.05 $85,131.96 $78,558.38 $72,372.88 
p5 . . . $56,423.19 $51,144.05 $47,381.17 $56,410.91 $50,992.84 $47,170.01 $55,915.89 $48,027.43 $41,482.33 
p25 . . . $72,924.11 $68,142.05 $64,317.87 $72,904.90 $68,064.79 $64,172.85 $72,204.54 $65,191.62 $58,915.39 
p50 . . . $85,285.10 $81,172.11 $77,286.32 $85,275.89 $81,094.62 $77,168.31 $84,706.92 $78,828.74 $72,051.90 
p75 . . . $98,545.86 $94,333.24 $90,612.59 $98,540.87 $94,230.60 $90,497.09 $98,121.95 $91,714.48 $86,178.64 
p95 . . . $114,974.10 $112,384.16 $107,406.51 $114,955.12 $112,294.06 $107,316.10 $114,583.63 $109,623.15 $103,525.41 
gefitinib 
mean $-331.81 $-1,636.00 $-2,970.73 . . . $-1,084.35 $-5,346.39 $-9,708.23 $-516.12 $-2,544.73 $-4,620.85 
p5 $777.97 $3,856.21 $7,142.96 . . . $-2,542.38 $-12,601.98 $-23,342.97 $-1,210.10 $-5,998.19 $-11,110.60 
p25 $457.36 $2,264.40 $4,176.82 . . . $-1,494.65 $-7,400.00 $-13,649.70 $-711.41 $-3,522.19 $-6,496.88 
p50 $278.01 $1,390.03 $2,502.06 . . . $-908.51 $-4,542.57 $-8,176.63 $-432.43 $-2,162.14 $-3,891.85 
p75 $161.42 $762.27 $1,372.09 . . . $-527.52 $-2,491.09 $-4,483.96 $-251.09 $-1,185.69 $-2,134.24 
p95 $44.84 $246.62 $403.56 . . . $-146.53 $-805.94 $-1,318.81 $-69.75 $-383.61 $-627.72 
ipilimumab 
mean . . . $95,295.83 $95,334.24 $95,631.98 $81,942.72 $27,839.27 $-26,198.63 $81,378.06 $25,015.52 $-31,341.63 
p5 . . . $63,985.23 $63,630.22 $63,666.55 $49,046.02 $-24,145.86 $-108,582.20 $47,432.55 $-40,123.24 $-141,324.48 
p25 . . . $81,510.13 $81,473.85 $81,603.26 $67,381.79 $8,175.22 $-55,099.56 $66,813.53 $1,669.79 $-69,803.03 
p50 . . . $95,407.97 $94,841.96 $95,777.98 $82,175.40 $29,259.53 $-23,059.17 $81,108.18 $27,298.70 $-28,291.49 
p75 . . . $108,409.71 $108,833.55 $109,414.73 $96,100.10 $49,380.08 $6,213.59 $95,872.81 $51,712.70 $15,039.26 
p95 . . . $128,177.18 $128,095.78 $127,542.03 $115,292.37 $74,426.67 $46,125.12 $115,431.29 $81,680.63 $60,587.04 
lapatinib 
mean $21,155.15 $16,335.90 $11,369.71 $21,359.22 $17,377.09 $13,200.41 $21,185.60 $16,491.26 $11,642.87 $21,022.92 $15,661.25 $10,183.48 
p5 $8,066.10 $256.78 $9,786.66 $8,352.30 $1,677.38 $-5,480.36 $8,106.05 $156.54 $-9,184.53 $7,900.62 $-1,903.46 $-12,438.01 
p25 $14,680.64 $9,495.45 $4,052.39 $14,903.93 $10,621.73 $5,887.56 $14,717.24 $9,634.04 $4,254.83 $14,560.85 $8,980.65 $2,754.59 
p50 $20,312.17 $16,037.65 $12,063.32 $20,538.78 $17,079.45 $13,562.14 $20,333.09 $16,163.18 $12,283.21 $20,139.28 $15,431.05 $11,128.26 
p75 $26,715.35 $22,982.20 $19,689.63 $26,859.93 $23,774.56 $20,910.49 $26,742.89 $23,146.16 $19,866.73 $26,581.60 $22,550.93 $18,872.13 
p95 $36,908.03 $33,616.36 $30,470.72 $37,140.63 $34,348.04 $31,463.09 $36,950.69 $33,715.22 $30,648.01 $36,822.58 $32,949.55 $29,553.24 
nelarabine 
mean . . . $-2,559.73 $-12,768.42 $-22,968.91 $-3,139.44 $-15,731.52 $-28,171.93 $-3,954.37 $-19,762.89 $-35,488.56 
p5 . . . $-4,530.97 $-22,348.27 $-39,745.33 $-5,653.73 $-27,686.20 $-49,741.03 $-6,818.84 $-34,302.52 $-60,889.34 
472 
 
p25 . . . $-3,189.58 $-16,023.33 $-28,379.66 $-3,929.41 $-19,935.45 $-35,304.77 $-4,912.50 $-24,822.28 $-43,530.42 
p50 . . . $-2,460.30 $-12,490.53 $-22,399.46 $-2,934.80 $-14,979.75 $-27,126.15 $-3,997.70 $-19,980.57 $-36,171.24 
p75 . . . $-1,787.30 $-8,963.27 $-16,328.10 $-2,183.56 $-10,915.36 $-19,845.35 $-2,772.06 $-13,819.91 $-24,907.52 
p95 . . . $-915.39 $-4,536.36 $-8,234.08 $-1,122.25 $-5,389.52 $-10,171.50 $-1,412.03 $-6,928.04 $-12,445.18 
ofatumumab 
mean . . . $-5,177.81 $-26,310.75 $-47,126.35 $-7,160.37 $-36,385.01 $-65,170.81 $-11,465.04 $-58,258.94 $-104,350.17 
p5 . . . $-7,553.20 $-37,765.99 $-67,978.78 $-10,445.28 $-52,226.41 $-94,007.54 $-16,724.77 $-83,623.86 $-150,522.95 
p25 . . . $-6,485.61 $-32,428.04 $-58,370.47 $-8,968.92 $-44,844.59 $-80,720.25 $-14,360.85 $-71,804.23 $-129,247.62 
p50 . . . $-5,418.02 $-27,090.09 $-48,762.16 $-7,492.55 $-37,462.76 $-67,432.97 $-11,996.92 $-59,984.61 $-107,972.29 
p75 . . . $-3,816.63 $-21,752.14 $-39,153.86 $-5,278.00 $-30,080.94 $-54,145.69 $-8,451.03 $-48,164.98 $-86,696.96 
p95 . . . $-2,749.04 $-13,745.22 $-24,741.39 $-3,801.64 $-19,008.20 $-34,214.76 $-6,087.11 $-30,435.54 $-54,783.97 
panitumumab 
mean $46,144.32 $35,542.85 $24,069.53 $46,986.33 $39,740.97 $32,189.19 $46,216.45 $35,523.47 $24,782.12 $43,768.34 $22,718.43 $3,121.97 
p5 $29,461.70 $12,633.36 $10,025.21 $30,355.17 $20,987.14 $7,197.99 $29,463.73 $13,965.13 $-5,022.36 $26,636.57 $-14,935.98 $-57,273.96 
p25 $38,340.03 $26,794.57 $13,126.21 $39,285.53 $31,654.55 $23,318.76 $38,584.97 $26,918.25 $14,219.55 $35,742.68 $10,989.34 $-13,295.19 
p50 $46,100.22 $36,041.00 $26,252.56 $47,031.42 $39,738.23 $32,924.03 $46,220.80 $35,898.41 $26,101.43 $43,765.91 $25,233.99 $8,124.53 
p75 $53,633.31 $44,837.55 $36,631.27 $54,437.00 $48,039.49 $42,128.95 $53,625.67 $44,435.10 $36,600.06 $51,481.64 $36,782.60 $25,505.38 
p95 $62,926.43 $56,436.11 $50,651.39 $63,829.59 $58,766.04 $53,623.08 $63,021.37 $56,220.65 $50,336.60 $61,458.72 $51,173.83 $44,366.60 
pertuzumab 
mean $254,063.84 $235,267.30 $211,401.28 $253,046.02 $230,219.22 $202,497.46 $249,425.36 $212,261.89 $170,824.22 $248,579.01 $208,064.28 $163,420.45 
p5 $163,806.30 $141,591.11 $111,709.13 $162,298.87 $137,548.60 $100,145.08 $157,671.77 $114,475.70 $55,647.87 $156,481.51 $108,922.31 $43,259.03 
p25 $214,198.64 $196,143.83 $169,882.05 $213,021.72 $190,225.11 $160,975.86 $209,756.77 $171,164.26 $125,063.68 $209,067.44 $165,795.77 $116,081.93 
p50 $255,175.49 $236,376.85 $212,206.09 $254,052.63 $231,086.43 $203,652.80 $250,299.23 $213,366.82 $173,009.26 $249,569.02 $208,886.08 $165,548.68 
p75 $292,071.23 $273,655.85 $253,112.16 $291,139.85 $269,391.60 $244,570.92 $287,861.80 $253,541.84 $218,893.02 $286,987.97 $250,144.10 $213,750.18 
p95 $345,396.55 $327,651.71 $308,832.94 $344,551.66 $323,321.84 $302,098.77 $341,070.71 $308,614.50 $282,085.02 $340,502.05 $305,246.78 $278,238.33 
regorafenib 
mean $7,986.16 $-52,561.56 $-107,988.15 $21,119.12 $13,410.10 $6,207.73 $20,402.78 $9,811.68 $-21.08 $19,121.10 $3,373.29 $-11,165.82 
p5 $12,549.25 $152,790.97 $285,789.96 $13,025.47 $-1,914.95 $-18,019.03 $12,080.28 $-9,789.65 $-32,569.03 $10,305.94 $-24,973.17 $-58,707.39 
p25 $2,265.69 $82,187.93 $139,321.33 $17,499.17 $8,632.79 $-169.55 $16,777.23 $4,093.51 $-8,140.70 $15,342.73 $-4,267.16 $-22,212.85 
p50 $9,919.31 $40,274.13 $90,660.14 $21,100.03 $14,306.40 $8,409.45 $20,438.14 $11,427.68 $3,438.98 $19,251.41 $6,210.31 $-5,831.81 
p75 $15,607.35 $15,839.67 $48,944.09 $24,678.91 $19,113.85 $15,127.87 $24,013.19 $16,844.83 $11,966.80 $22,853.29 $13,382.08 $6,421.53 
p95 $22,741.02 $5,846.27 $11,745.60 $29,374.23 $25,766.59 $22,499.81 $28,837.22 $24,477.41 $20,138.78 $28,028.14 $22,005.43 $16,639.72 
temsirolimus 
mean . . . $59,436.90 $55,997.53 $51,959.00 $57,503.43 $46,628.25 $34,975.57 . . . 
p5 . . . $38,571.17 $34,554.38 $28,399.96 $36,458.73 $14,836.36 $-12,470.03 . . . 
p25 . . . $50,287.37 $46,792.02 $42,579.51 $48,379.55 $36,312.66 $22,005.23 . . . 
p50 . . . $59,233.55 $55,934.89 $52,346.59 $57,124.88 $48,058.26 $38,584.96 . . . 
p75 . . . $68,703.74 $65,397.49 $61,842.67 $67,016.59 $58,589.34 $52,176.71 . . . 
p95 . . . $80,101.75 $77,257.09 $74,305.46 $78,750.49 $72,874.08 $67,628.28 . . . 
trastuzumab 
emtansine 
mean $90,800.33 $74,622.49 $56,266.90 $89,577.93 $68,573.33 $44,165.64 $84,905.70 $45,926.93 $1,118.15 $83,521.84 $38,656.74 $-9,630.43 
p5 $57,454.01 $28,913.14 $10,031.32 $55,893.74 $15,986.91 $-36,080.83 $50,527.81 $-27,126.07 $-125,032.01 $47,552.66 $-55,196.13 $-154,622.76 
p25 $75,621.75 $57,274.97 $36,692.22 $74,311.91 $51,092.65 $21,730.31 $69,538.67 $21,926.59 $-34,960.84 $67,964.69 $12,978.32 $-51,289.94 
p50 $90,428.27 $76,749.08 $60,418.72 $89,285.18 $71,668.62 $50,031.08 $84,664.69 $50,569.04 $13,328.80 $83,498.47 $47,312.89 $7,948.67 
p75 $105,581.77 $93,305.48 $81,241.11 $104,401.78 $89,107.74 $74,010.65 $100,053.45 $75,308.06 $49,952.82 $98,974.15 $74,420.86 $47,779.70 
p95 $125,736.36 $116,129.38 $108,454.95 $125,133.22 $113,627.39 $103,437.39 $120,627.75 $105,177.13 $88,807.72 $120,115.47 $104,263.91 $87,884.28 
vorinostat 
mean . . . . . . . . . $-5,696.81 $-28,156.07 $-51,618.32 
p5 . . . . . . . . . $-10,063.74 $-49,830.15 $-89,401.16 
473 
 
p25 . . . . . . . . . $-7,295.39 $-36,314.13 $-65,951.67 
p50 . . . . . . . . . $-5,536.68 $-27,357.73 $-49,830.15 
p75 . . . . . . . . . $-3,891.96 $-19,215.55 $-35,174.23 
p95 . . . . . . . . . $-1,937.84 $-9,282.09 $-17,880.23 
ziv-aflibercept 
mean . . . $22,137.06 $17,594.28 $13,541.52 $21,085.56 $12,253.53 $4,369.94 $17,027.63 $-8,402.34 $-31,269.26 
p5 . . . $14,164.19 $6,335.22 $-3,740.68 $12,871.05 $-5,623.72 $-25,203.67 $4,563.32 $-62,352.60 $-122,372.77 
p25 . . . $18,603.83 $13,628.37 $8,807.00 $17,455.71 $6,961.40 $-3,430.63 $12,887.18 $-21,353.56 $-51,394.14 
p50 . . . $22,145.51 $18,080.37 $14,756.57 $21,158.84 $13,729.65 $7,791.32 $17,690.91 $-826.68 $-17,910.59 
p75 . . . $25,509.50 $22,151.42 $19,925.89 $24,645.47 $19,127.52 $15,235.94 $21,961.37 $10,623.78 $2,102.29 
p95 . . . $30,038.77 $27,360.41 $25,784.12 $29,519.35 $25,404.15 $23,281.17 $27,816.70 $21,647.58 $17,251.53 
 
Source: 
Authors’ analysis of data, as described Methods section. 
Notes: 
1 Currencies are given in terms of 2015 US dollars. As explained in Chapter 3, outliers where the mean drug cost per patient was >$250,000 were censored (abiraterone, FR, Y0-2; erlotinib,  
; cabazitaxel, AU, Y0; ipilimumab, AU, Y0). 
2 SD: standard deviation; p25: 25th percentile; p50: 50th percentile; p75: 75th percentile.  





eTable 10. Net Long-Term Value Generated to Society, First Year of Marketing, Assuming Treatment Duration Follows  (Million 2015 USD). 
Drug Measure 
AU FR UK US 
10% 50% 90% 10% 50% 90% 10% 50% 90% 10% 50% 90% 
abiraterone 
mean $3.684 $3.283 $2.942 . . . $26.571 $21.657 $17.185 $665.962 $538.066 $421.255 
p5 $0.770 $0.543 $0.306 . . . $5.165 $1.525 $-2.180 $128.539 $32.623 $-64.920 
p25 $1.305 $1.059 $0.810 . . . $9.096 $5.315 $1.523 $227.230 $127.787 $28.045 
p50 $1.983 $1.811 $1.514 . . . $14.076 $10.844 $6.693 $352.264 $266.595 $157.833 
p75 $3.424 $3.304 $2.864 . . . $24.666 $21.813 $16.610 $618.142 $541.989 $406.829 
p95 $9.943 $9.654 $8.552 . . . $72.555 $68.464 $58.395 $1,820.461 $1,713.219 $1,455.898 
afatinib 
mean $-0.009 $-0.046 $-0.082 $-0.120 $-0.599 $-1.077 $-0.043 $-0.217 $-0.391 $-0.700 $-3.500 $-6.300 
p5 $0.009 $0.046 $0.082 $-0.120 $-0.599 $-1.077 $-0.043 $-0.217 $-0.391 $-0.700 $-3.500 $-6.300 
p25 $0.009 $0.046 $0.082 $-0.120 $-0.599 $-1.077 $-0.043 $-0.217 $-0.391 $-0.700 $-3.500 $-6.300 
p50 $0.009 $0.046 $0.082 $-0.120 $-0.599 $-1.077 $-0.043 $-0.217 $-0.391 $-0.700 $-3.500 $-6.300 
p75 $0.009 $0.046 $0.082 $-0.120 $-0.599 $-1.077 $-0.043 $-0.217 $-0.391 $-0.700 $-3.500 $-6.300 
p95 $0.009 $0.046 $0.082 $-0.120 $-0.599 $-1.077 $-0.043 $-0.217 $-0.391 $-0.700 $-3.500 $-6.300 
azacitidine 
mean $5.340 $5.338 $5.241 $195.678 $217.327 $182.866 $15.393 $14.008 $12.469 $280.327 $269.394 $252.255 
p5 $0.517 $0.394 $0.277 $11.266 $3.456 $-5.433 $1.155 $-0.514 $-2.280 $24.348 $7.035 $-12.913 
p25 $1.287 $1.152 $0.934 $35.597 $25.613 $15.230 $3.479 $1.792 $-0.193 $65.223 $48.148 $25.015 
p50 $2.778 $2.613 $2.315 $83.824 $73.670 $60.053 $7.848 $5.929 $3.926 $145.978 $123.257 $99.803 
p75 $6.502 $6.091 $6.298 $209.814 $197.087 $194.857 $18.541 $16.419 $15.672 $338.089 $315.897 $310.656 
p95 $21.985 $23.086 $23.166 $743.122 $763.784 $753.327 $63.234 $66.939 $64.583 $1,151.461 $1,204.786 $1,178.814 
bendamustine 
mean . . . $-0.000 $-0.001 $-0.002 $-0.052 $-0.259 $-0.466 $-9.273 $-46.364 $-83.456 
p5 . . . $-0.000 $-0.001 $-0.002 $-0.052 $-0.259 $-0.466 $-9.273 $-46.364 $-83.456 
p25 . . . $-0.000 $-0.001 $-0.002 $-0.052 $-0.259 $-0.466 $-9.273 $-46.364 $-83.456 
p50 . . . $-0.000 $-0.001 $-0.002 $-0.052 $-0.259 $-0.466 $-9.273 $-46.364 $-83.456 
p75 . . . $-0.000 $-0.001 $-0.002 $-0.052 $-0.259 $-0.466 $-9.273 $-46.364 $-83.456 
p95 . . . $-0.000 $-0.001 $-0.002 $-0.052 $-0.259 $-0.466 $-9.273 $-46.364 $-83.456 
bevacizumab 
mean $1.175 $0.740 $0.336 $88.202 $76.388 $68.972 $7.097 $6.085 $5.068 $1,347.571 $1,015.531 $821.524 
p5 $0.059 $0.274 $0.591 $9.845 $3.830 $-1.147 $0.846 $0.091 $-0.516 $92.693 $-45.226 $-195.537 
p25 $0.202 $0.134 $0.450 $21.694 $15.529 $10.191 $1.837 $1.021 $0.422 $234.945 $82.122 $-57.191 
p50 $0.439 $0.108 $0.219 $41.680 $34.640 $28.391 $3.521 $2.605 $1.889 $485.167 $304.187 $176.507 
p75 $1.082 $0.707 $0.306 $88.794 $77.916 $72.297 $7.533 $6.301 $5.446 $1,084.290 $900.568 $754.389 
p95 $4.392 $3.635 $3.005 $314.148 $292.353 $256.861 $26.687 $23.617 $20.724 $4,041.768 $3,835.847 $3,650.629 
bortezomib 
mean $12.475 $12.233 $12.296 $40.489 $40.872 $41.084 $8.919 $7.849 $7.071 $927.908 $834.510 $773.418 




p25 $9.505 $9.381 $9.288 $21.484 $18.315 $14.662 $6.838 $5.788 $4.949 $710.961 $618.435 $545.222 
p50 $11.804 $11.536 $11.661 $30.180 $26.856 $23.706 $8.490 $7.364 $6.650 $886.540 $782.080 $729.105 
p75 $14.748 $14.322 $14.510 $43.671 $42.072 $37.320 $10.484 $9.407 $8.731 $1,087.221 $998.719 $949.070 
p95 $20.327 $20.178 $19.972 $92.362 $95.376 $90.331 $14.388 $13.301 $12.652 $1,510.941 $1,395.991 $1,345.148 
cabazitaxel 
mean . . . $1.206 $0.944 $0.649 $3.593 $2.493 $1.294 $125.192 $72.509 $15.447 
p5 . . . $0.195 $-0.079 $-0.366 $0.510 $-0.630 $-1.812 $14.127 $-39.513 $-95.487 
p25 . . . $0.415 $0.144 $-0.141 $1.185 $0.057 $-1.121 $38.610 $-15.649 $-70.451 
p50 . . . $0.744 $0.479 $0.193 $2.220 $1.071 $-0.115 $75.439 $22.397 $-35.418 
p75 . . . $1.412 $1.173 $0.861 $4.230 $3.203 $1.958 $147.598 $97.749 $36.804 
p95 . . . $4.106 $3.983 $3.489 $12.586 $11.733 $10.156 $436.337 $395.101 $338.195 
cabozantinib 
mean . . . . . . $-0.051 $-0.253 $-0.456 . . . 
p5 . . . . . . $-0.051 $-0.253 $-0.456 . . . 
p25 . . . . . . $-0.051 $-0.253 $-0.456 . . . 
p50 . . . . . . $-0.051 $-0.253 $-0.456 . . . 
p75 . . . . . . $-0.051 $-0.253 $-0.456 . . . 
p95 . . . . . . $-0.051 $-0.253 $-0.456 . . . 
catumaxomab 
mean . . . . . . $-0.021 $-0.107 $-0.192 . . . 
p5 . . . . . . $-0.021 $-0.107 $-0.192 . . . 
p25 . . . . . . $-0.021 $-0.107 $-0.192 . . . 
p50 . . . . . . $-0.021 $-0.107 $-0.192 . . . 
p75 . . . . . . $-0.021 $-0.107 $-0.192 . . . 
p95 . . . . . . $-0.021 $-0.107 $-0.192 . . . 
clofarabine 
mean $-0.013 $-0.063 $-0.113 $-0.085 $-0.423 $-0.761 $-0.074 $-0.372 $-0.669 $-0.281 $-1.406 $-2.530 
p5 $0.013 $0.063 $0.113 $-0.085 $-0.423 $-0.761 $-0.074 $-0.372 $-0.669 $-0.281 $-1.406 $-2.530 
p25 $0.013 $0.063 $0.113 $-0.085 $-0.423 $-0.761 $-0.074 $-0.372 $-0.669 $-0.281 $-1.406 $-2.530 
p50 $0.013 $0.063 $0.113 $-0.085 $-0.423 $-0.761 $-0.074 $-0.372 $-0.669 $-0.281 $-1.406 $-2.530 
p75 $0.013 $0.063 $0.113 $-0.085 $-0.423 $-0.761 $-0.074 $-0.372 $-0.669 $-0.281 $-1.406 $-2.530 
p95 $0.013 $0.063 $0.113 $-0.085 $-0.423 $-0.761 $-0.074 $-0.372 $-0.669 $-0.281 $-1.406 $-2.530 
crizotinib 
mean $1.118 $1.131 $1.024 $1.849 $1.381 $0.702 $0.236 $0.157 $0.050 $11.797 $6.757 $0.316 
p5 $0.313 $0.298 $0.281 $0.430 $-0.088 $-0.608 $0.051 $-0.034 $-0.120 $2.372 $-3.000 $-8.383 
p25 $0.512 $0.493 $0.477 $0.780 $0.257 $-0.263 $0.097 $0.011 $-0.075 $4.698 $-0.710 $-6.090 
p50 $0.735 $0.726 $0.709 $1.173 $0.668 $0.146 $0.148 $0.064 $-0.022 $7.308 $2.021 $-3.374 
p75 $1.181 $1.145 $1.123 $1.960 $1.406 $0.877 $0.250 $0.160 $0.073 $12.530 $6.923 $1.478 
p95 $2.894 $2.953 $2.451 $4.981 $4.596 $3.220 $0.642 $0.574 $0.377 $32.594 $28.103 $17.033 
degarelix 
mean $-0.000 $-0.002 $-0.004 $-0.199 $-0.995 $-1.790 $-0.006 $-0.029 $-0.053 $-0.588 $-2.940 $-5.293 
p5 $0.000 $0.002 $0.004 $-0.199 $-0.995 $-1.790 $-0.006 $-0.029 $-0.053 $-0.588 $-2.940 $-5.293 
p25 $0.000 $0.002 $0.004 $-0.199 $-0.995 $-1.790 $-0.006 $-0.029 $-0.053 $-0.588 $-2.940 $-5.293 
p50 $0.000 $0.002 $0.004 $-0.199 $-0.995 $-1.790 $-0.006 $-0.029 $-0.053 $-0.588 $-2.940 $-5.293 
p75 $0.000 $0.002 $0.004 $-0.199 $-0.995 $-1.790 $-0.006 $-0.029 $-0.053 $-0.588 $-2.940 $-5.293 
p95 $0.000 $0.002 $0.004 $-0.199 $-0.995 $-1.790 $-0.006 $-0.029 $-0.053 $-0.588 $-2.940 $-5.293 
enzalutamide 
mean $3.999 $3.786 $3.246 $12.152 $11.320 $9.489 $11.122 $9.435 $6.814 $32.188 $22.669 $10.355 
p5 $1.354 $0.926 $0.483 $4.084 $2.596 $1.061 $3.587 $1.287 $-1.058 $9.624 $-1.730 $-13.218 
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p25 $2.141 $1.656 $1.253 $6.485 $4.823 $3.409 $5.830 $3.366 $1.135 $16.340 $4.497 $-6.651 
p50 $3.016 $2.539 $2.168 $9.155 $7.516 $6.199 $8.323 $5.882 $3.742 $23.806 $12.029 $1.155 
p75 $4.585 $4.028 $3.695 $13.942 $12.056 $10.858 $12.794 $10.122 $8.093 $37.194 $24.727 $14.184 
p95 $9.749 $9.585 $9.217 $29.693 $29.009 $27.702 $27.506 $25.956 $23.825 $81.247 $72.141 $61.291 
eribulin 
mean . . . $22.383 $19.628 $17.458 $2.369 $1.869 $1.426 $4.217 $2.851 $1.586 
p5 . . . $5.356 $2.773 $0.646 $0.525 $0.047 $-0.388 $0.843 $-0.487 $-1.743 
p25 . . . $9.415 $7.163 $4.744 $0.968 $0.508 $0.047 $1.659 $0.346 $-0.938 
p50 . . . $15.125 $12.605 $10.237 $1.572 $1.082 $0.631 $2.796 $1.429 $0.164 
p75 . . . $26.455 $23.237 $21.639 $2.770 $2.258 $1.858 $5.030 $3.566 $2.304 
p95 . . . $63.224 $58.635 $58.387 $6.915 $6.242 $5.916 $12.764 $11.016 $10.120 
erlotinib 
mean $0.628 $0.593 $0.596 $69.123 $67.498 $70.107 $4.657 $4.363 $4.358 $59.742 $56.962 $57.863 
p5 $0.071 $0.029 $0.010 $8.365 $5.975 $4.009 $0.523 $0.178 $-0.139 $6.929 $3.485 $0.410 
p25 $0.144 $0.105 $0.066 $16.253 $14.246 $12.280 $1.060 $0.741 $0.424 $13.786 $10.674 $7.599 
p50 $0.262 $0.219 $0.184 $29.186 $26.781 $25.194 $1.940 $1.593 $1.302 $25.028 $21.570 $18.824 
p75 $0.534 $0.484 $0.456 $58.876 $55.652 $54.854 $3.959 $3.557 $3.320 $50.835 $46.665 $44.604 
p95 $1.972 $1.904 $2.097 $215.788 $210.620 $233.948 $14.634 $14.099 $15.504 $187.226 $181.367 $200.277 
everolimus 
mean . . . $5.264 $5.276 $4.902 $6.113 $6.124 $5.687 $297.386 $293.084 $266.880 
p5 . . . $1.481 $1.307 $1.173 $1.719 $1.514 $1.355 $82.765 $67.897 $55.311 
p25 . . . $2.436 $2.230 $2.041 $2.829 $2.586 $2.364 $136.974 $120.280 $104.595 
p50 . . . $3.536 $3.429 $3.243 $4.106 $3.980 $3.760 $199.362 $188.333 $172.788 
p75 . . . $5.614 $5.493 $5.455 $6.520 $6.376 $6.329 $317.241 $305.383 $298.255 
p95 . . . $13.773 $13.249 $13.517 $15.997 $15.385 $15.693 $780.181 $745.453 $755.637 
gefitinib 
mean $-0.031 $-0.157 $-0.282 . . . $-0.028 $-0.141 $-0.253 $-29.418 $-147.092 $-264.766 
p5 $0.031 $0.157 $0.282 . . . $-0.028 $-0.141 $-0.253 $-29.418 $-147.092 $-264.766 
p25 $0.031 $0.157 $0.282 . . . $-0.028 $-0.141 $-0.253 $-29.418 $-147.092 $-264.766 
p50 $0.031 $0.157 $0.282 . . . $-0.028 $-0.141 $-0.253 $-29.418 $-147.092 $-264.766 
p75 $0.031 $0.157 $0.282 . . . $-0.028 $-0.141 $-0.253 $-29.418 $-147.092 $-264.766 
p95 $0.031 $0.157 $0.282 . . . $-0.028 $-0.141 $-0.253 $-29.418 $-147.092 $-264.766 
ipilimumab 
mean . . . $68.124 $67.035 $66.704 $3.590 $1.523 $-0.389 $430.738 $205.445 $281.465 
p5 . . . $29.049 $28.968 $29.335 $1.401 $-0.621 $-2.592 $98.243 $-74.943 $-257.561 
p25 . . . $43.689 $42.109 $42.715 $2.236 $0.274 $-1.728 $181.900 $3.903 $-178.278 
p50 . . . $57.828 $56.439 $57.630 $3.098 $1.104 $-0.869 $285.339 $94.324 $-93.308 
p75 . . . $79.556 $78.458 $78.507 $4.316 $2.284 $0.301 $439.825 $246.644 $68.767 
p95 . . . $134.118 $132.509 $131.864 $7.095 $5.113 $3.347 $895.408 $682.969 $594.845 
lapatinib 
mean $0.012 $0.010 $0.009 $9.371 $8.238 $7.272 $6.421 $5.541 $4.776 $286.026 $242.475 $204.083 
p5 $0.001 $0.000 $0.001 $1.151 $0.194 $-0.565 $0.767 $0.008 $-0.615 $33.225 $-4.912 $-36.959 
p25 $0.004 $0.002 $0.001 $2.824 $1.985 $1.122 $1.917 $1.240 $0.545 $84.667 $50.178 $14.917 
p50 $0.007 $0.006 $0.004 $5.277 $4.525 $3.679 $3.605 $2.987 $2.305 $160.115 $128.300 $93.572 
p75 $0.014 $0.013 $0.011 $10.817 $10.268 $8.709 $7.415 $6.938 $5.765 $330.502 $304.924 $248.270 
p95 $0.044 $0.039 $0.038 $33.399 $30.401 $29.247 $22.949 $20.786 $19.892 $1,025.031 $924.129 $879.937 
nelarabine 
mean . . . $-0.030 $-0.152 $-0.274 $-0.008 $-0.039 $-0.071 $-0.585 $-2.927 $-5.269 
p5 . . . $-0.030 $-0.152 $-0.274 $-0.008 $-0.039 $-0.071 $-0.585 $-2.927 $-5.269 
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p25 . . . $-0.030 $-0.152 $-0.274 $-0.008 $-0.039 $-0.071 $-0.585 $-2.927 $-5.269 
p50 . . . $-0.030 $-0.152 $-0.274 $-0.008 $-0.039 $-0.071 $-0.585 $-2.927 $-5.269 
p75 . . . $-0.030 $-0.152 $-0.274 $-0.008 $-0.039 $-0.071 $-0.585 $-2.927 $-5.269 
p95 . . . $-0.030 $-0.152 $-0.274 $-0.008 $-0.039 $-0.071 $-0.585 $-2.927 $-5.269 
ofatumumab 
mean . . . $-0.039 $-0.197 $-0.354 $-0.027 $-0.135 $-0.243 $-0.302 $-1.509 $-2.716 
p5 . . . $-0.039 $-0.197 $-0.354 $-0.027 $-0.135 $-0.243 $-0.302 $-1.509 $-2.716 
p25 . . . $-0.039 $-0.197 $-0.354 $-0.027 $-0.135 $-0.243 $-0.302 $-1.509 $-2.716 
p50 . . . $-0.039 $-0.197 $-0.354 $-0.027 $-0.135 $-0.243 $-0.302 $-1.509 $-2.716 
p75 . . . $-0.039 $-0.197 $-0.354 $-0.027 $-0.135 $-0.243 $-0.302 $-1.509 $-2.716 
p95 . . . $-0.039 $-0.197 $-0.354 $-0.027 $-0.135 $-0.243 $-0.302 $-1.509 $-2.716 
panitumumab 
mean $0.275 $0.243 $0.203 $14.643 $12.904 $11.839 $1.553 $1.288 $1.072 $72.289 $61.432 $44.133 
p5 $0.062 $0.024 $0.018 $3.764 $2.254 $0.765 $0.426 $0.168 $-0.054 $13.272 $-5.893 $-23.175 
p25 $0.110 $0.072 $0.036 $6.577 $5.063 $3.866 $0.746 $0.483 $0.256 $25.428 $7.392 $-9.134 
p50 $0.172 $0.136 $0.102 $10.106 $8.511 $7.477 $1.111 $0.864 $0.640 $43.352 $24.973 $8.201 
p75 $0.299 $0.262 $0.223 $16.438 $15.144 $13.993 $1.802 $1.508 $1.329 $77.522 $56.362 $43.845 
p95 $0.698 $0.733 $0.665 $40.555 $35.532 $35.288 $4.055 $3.651 $3.386 $210.949 $186.408 $168.093 
pertuzumab 
mean $2.486 $2.340 $2.192 $1.124 $1.044 $0.964 $36.223 $32.111 $27.983 $245.204 $214.891 $184.460 
p5 $0.835 $0.705 $0.546 $0.375 $0.303 $0.218 $11.844 $7.969 $3.670 $79.770 $51.062 $19.471 
p25 $1.317 $1.181 $1.043 $0.594 $0.519 $0.443 $18.964 $14.996 $11.014 $128.087 $98.745 $69.310 
p50 $1.886 $1.785 $1.656 $0.852 $0.793 $0.721 $27.365 $23.923 $20.067 $185.093 $159.328 $130.742 
p75 $2.803 $2.808 $2.652 $1.267 $1.256 $1.173 $40.905 $39.021 $34.779 $276.977 $261.782 $230.578 
p95 $6.115 $6.000 $5.806 $2.769 $2.704 $2.603 $89.817 $86.169 $81.354 $608.898 $581.728 $546.635 
regorafenib 
mean $0.006 $-0.011 $-0.028 $11.887 $9.549 $7.042 $0.213 $0.151 $0.087 $17.523 $9.390 $0.993 
p5 $0.002 $0.019 $0.036 $2.661 $-0.275 $-2.961 $0.044 $-0.028 $-0.096 $3.056 $-6.015 $-14.692 
p25 $0.000 $0.017 $0.034 $5.274 $2.425 $-0.045 $0.092 $0.021 $-0.043 $7.153 $-1.780 $-10.120 
p50 $0.003 $0.014 $0.030 $9.071 $6.278 $3.822 $0.161 $0.091 $0.028 $13.107 $4.260 $-4.057 
p75 $0.008 $0.008 $0.025 $15.060 $13.432 $11.231 $0.271 $0.222 $0.163 $22.499 $15.479 $7.562 
p95 $0.022 $0.006 $0.012 $32.350 $30.759 $27.346 $0.587 $0.539 $0.458 $49.610 $42.648 $32.830 
temsirolimus 
mean . . . $150.076 $154.665 $157.533 $5.180 $5.088 $4.937 . . . 
p5 . . . $18.395 $14.766 $11.784 $0.580 $0.201 $-0.154 . . . 
p25 . . . $37.384 $36.309 $32.094 $1.243 $0.954 $0.555 . . . 
p50 . . . $71.865 $73.537 $65.236 $2.447 $2.254 $1.713 . . . 
p75 . . . $141.393 $152.762 $154.454 $4.876 $5.022 $4.829 . . . 
p95 . . . $563.022 $566.708 $645.863 $19.604 $19.482 $21.995 . . . 
trastuzumab 
emtansine 
mean $0.628 $0.601 $0.535 $36.573 $35.624 $41.214 $57.504 $49.744 $28.784 $503.639 $407.552 $250.324 
p5 $0.099 $0.040 $0.014 $6.186 $1.388 $-3.134 $10.375 $-4.456 $-20.312 $65.553 $-61.413 $-182.011 
p25 $0.197 $0.151 $0.098 $12.442 $8.126 $3.334 $20.240 $6.293 $-9.189 $145.443 $26.125 $-102.018 
p50 $0.355 $0.314 $0.246 $21.691 $18.258 $12.229 $35.521 $22.980 $5.640 $264.126 $159.857 $23.809 
p75 $0.659 $0.656 $0.579 $39.336 $37.782 $31.662 $62.152 $55.922 $36.368 $511.452 $463.204 $291.467 
p95 $1.988 $2.101 $1.926 $116.841 $125.858 $106.229 $177.596 $187.552 $145.593 $1,588.745 $1,602.605 $1,358.096 
vorinostat 
mean . . . . . . . . . $-0.189 $-0.943 $-1.697 
p5 . . . . . . . . . $-0.189 $-0.943 $-1.697 
478 
 
p25 . . . . . . . . . $-0.189 $-0.943 $-1.697 
p50 . . . . . . . . . $-0.189 $-0.943 $-1.697 
p75 . . . . . . . . . $-0.189 $-0.943 $-1.697 
p95 . . . . . . . . . $-0.189 $-0.943 $-1.697 
ziv-aflibercept 
mean . . . $31.210 $26.441 $25.403 $0.008 $0.006 $0.005 $39.090 $15.255 $128.831 
p5 . . . $4.364 $1.694 $-0.883 $0.001 $-0.000 $-0.002 $1.249 $-15.563 $-32.223 
p25 . . . $9.471 $6.299 $4.267 $0.002 $0.001 $-0.000 $6.831 $-10.064 $-26.252 
p50 . . . $16.921 $13.498 $12.046 $0.004 $0.003 $0.002 $16.186 $-0.743 $-16.514 
p75 . . . $33.213 $28.262 $28.643 $0.009 $0.007 $0.006 $36.931 $17.944 $3.828 
p95 . . . $111.218 $96.538 $93.203 $0.031 $0.024 $0.024 $151.669 $107.569 $97.493 
 
Source: 
Authors’ analysis of data, as described in Methods section. 
Notes: 
1 Currencies are given in terms of 2015 billion US dollars. As explained in Chapter 3, outliers where the mean drug cost per patient was >$250,000 were censored (abiraterone, FR, Y0-2; 
erlotinib, ; cabazitaxel, AU, Y0; ipilimumab, AU, Y0). 
2 SD: standard deviation; p25: 25th percentile; p50: 50th percentile; p75: 75th percentile. 





eTable 11. Incidence-Adjusted Cost, Effect and Incremental Cost-Effectiveness Ratio, Adjusted to Reflect a Maximum Expected Patient Population Equal to 1.5x the Yearly Number 




t = 2004 t = 2014 Δ t t = 2004 t = 2014 Δ t4 
Australia $11,676.36 $17,665.41 $5,989.05 4.203 3.221 0.981 $5,305.78 
France $17,067.51 $24,553.63 $7,486.11 5.248 3.837 1.411 $6,102.50 
UK $10,307.28 $21,743.14 $11,435.86 4.820 3.683 1.138 $10,050.91 
US $25,714.15 $49,279.66 $23,565.51 4.465 3.750 0.715 $32,973.07 
 
Source: 
Authors’ analysis of data, as described Methods section. 
Notes: 
1 Adjusted to reflect incidence-adjusted expenditure (cost, C) or YPLLs (effect, E), where incidence is adjusted to reflect 1.5x the expected number of incident neoplasm cases. 
2 Figures given in terms of constant 2014 US dollars. 
3 Effect is given in terms of YPLLs. 
4 For convenience, values for the change in YPLL between 2004-2014 are multiplied by -1. 
5 Country records sorted by ICER estimates. 





eTable 12. Net Value from Cancer Drug Spending, per Neoplasm and to Society, Adjusted to Reflect a Maximum Expected Patient Population Equal to 1.5x the Yearly Number of 
Incident Cases, 2004-2014 
Country 
Net Value per Neoplasm1,2 Net Value to Society3 
10% 25% 50% 75% 90% 10% 25% 50% 75% 90% 
France $6,623.23 $27,787.25 $63,060.61 $98,333.97 $119,497.99 $3.69 $15.50 $35.18 $54.85 $66.66 
UK $-57.93 $17,008.97 $45,453.80 $73,898.62 $90,965.52 -$0.03 $8.80 $23.50 $38.21 $47.04 
Australia $3,825.04 $18,546.19 $43,081.43 $67,616.67 $82,337.81 $0.74 $3.58 $8.32 $13.06 $15.90 
US $-16,418.61 $-5,698.27 $12,168.97 $30,036.21 $40,756.56 -$39.96 -$13.87 $29.61 $73.10 $99.18 
 
Source: 
Authors’ analysis of data, as described Methods section. 
Notes: 
1 Adjusted to reflect incidence-adjusted expenditure (cost, C) or YPLLs (effect, E). 
2 Figures given in terms of constant 2014 US dollars. 
3 Figures given in terms of billion, constant 2014 US dollars.  
4 Country records sorted by estimates of the net value generated per neoplasm, where the assumed percentage of health gains observed owing to cancer drug care equaled 50%. 






eTable 13. Net Value from Cancer Drug Spending, per Neoplasm and to Society, Assuming 10%-90% of Survival Gains are Attributable to Drug Development, 2004-2014 
Country 
Net Value per Neoplasm1,2 Net Value to Society3 
10% 25% 50% 75% 90% 10% 25% 50% 75% 90% 
France $9,305.05 $40,106.37 $91,441.91 $142,777.46 $173,578.78 $3.46 $14.91 $34.01 $53.10 $64.55 
UK -$748.65 $23,859.06 $64,871.91 $105,884.76 $130,492.47 -$0.26 $8.22 $22.36 $36.50 $44.98 
Australia $5,737.56 $27,819.28 $64,622.14 $101,425.00 $123,506.71 $0.74 $3.58 $8.32 $13.06 $15.90 
US -$24,253.95 -$7,612.42 $20,123.46 $47,859.34 $64,500.87 -$39.35 -$12.35 $32.65 $77.65 $104.65 
 
Source: 
Authors’ analysis of data, as described Methods section. 
Notes: 
1 Adjusted to reflect incidence-adjusted expenditure (cost, C) or YPLLs (effect, E). 
2 Figures given in terms of constant 2014 US dollars. 
3 Figures given in terms of billion, constant 2014 US dollars.  
4 Country records sorted by estimates of the net value generated per neoplasm when the percentage of long-term gains in YPLLs attributed to cancer drug innovation equals 50%.  


























eTable 14. Multivariate Linear Regression Analysis, Total Cost per Patient per  
Treatment with New Medicines and their Beneficial Impact to Health in the First Year of Drug Marketing in 
Australia, France, the UK, and the US 
Variable Model1 






















Ind. Var2 1 2 3 4 1, 2 1, 3 1, 4 1, 2, 3 1, 2, 4 

















































































































































































































































































































































































































































































































































































































































































e # FR 












e # UK 












e # US 







































































Observations 131 119 119 119 119 119 119 119 119 119 
R2 0.161 0.244 0.147 0.188 0.485 0.308 0.306 0.527 0.535 0.564 





Authors’ analysis of data, as described in Methods section. 
Notes: 
1 Sensitivity analysis with a sqrt transformation of the dependent variable, total cost per patient per  
 treatment in the first year of marketing (mean estimate  from Chapter 3), assuming treatment 
duration  Overall survival is coded as a categorical variable, as described in Methods 
section. 
2 1: Treatment descriptors (treated condition, rarity); 2: OS; 3: QoL; 4: safety. 
3 Reference categories: ascites; AU; OS: >/=3 months improvement, certain; QoL: improve; safety: improve. 







eTable 15. Multivariate Linear Regression Analysis, Total Number of Patients Completing  
 Therapy with New Medicines per 100,000 Incident Cases of Neoplasm and their Beneficial Impact 
to Health in the First Year of Drug Marketing in Australia, France, the UK, and the US 
Variable Model1 
 (A) (B) (C) (D) (E) (F) (G) (H) (I) (J) 




















Ind. Var2 1 2 3 4 1, 2 1, 3 1, 4 1, 2, 3 1, 2, 4 











































































































































































































































































4.608*   
[2.216] 
OS_>/=3 mo, 


















































































































































































































































































































2.514*   
[1.096] 











2.587*   
[1.027] 
safety_ME 












































































e # FR 












e # UK 












e # US 








































































Observations 137 125 125 125 125 125 125 125 125 125 
R2 0.101 0.445 0.33 0.325 0.478 0.418 0.409 0.555 0.577 0.647 





Authors’ analysis of data, as described in Methods section. 
Notes: 
1 Sensitivity analysis with a natural log transformation of the dependent variable, total number of patients completing  
 therapy in the first year of marketing per 100,000 incident cases of neoplasm (TPi)(mean 
estimate of distribution from Chapter 3), assuming treatment duration  Overall survival 
is coded as a categorical variable, as described in Methods section. 
2 1: Treatment descriptors (treated condition, rarity); 2: OS; 3: QoL; 4: safety. 
3 Reference categories: ascites; AU; OS: >/=3 months improvement, certain; QoL: improve; safety: improve. 











eTable 16. Multivariate Linear Regression Analysis, Total Cost per Patient per  
Treatment with New Medicines and their Beneficial Impact to Health in the Second Year of Drug Marketing 
in Australia, France, the UK, and the US 
Variable Model1 
 (A) (B) (C) (D) (E) (F) (G) (H) (I) (J) 




















Ind. Var2 1 2 3 4 1, 2 1, 3 1, 4 1, 2, 3 1, 2, 4 






















































































































































































































































   
 
 





































































































































































































e # FR 












e # UK 












e # US 









































































119 85 111 111 85 111 111 85 85 85 
R2 0.12 0.2 0.144 0.174 0.361 0.299 0.279 0.441 0.458 0.518 
Adj R2 0.056 0.127 0.029 0.043 0.222 0.133 0.088 0.255 0.201 0.205 
 
Source: 
Authors’ analysis of data, as described Methods section. 
Notes: 
1 Sensitivity analysis with a sqrt transformation of the dependent variable, total cost per patient per  
 treatment in the second year of marketing (mean estimate from Chapter 3), assuming 
treatment duration   
2 1: Treatment descriptors (treated condition, rarity); 2: OS; 3: QoL; 4: safety. 
3 Reference categories: ascites; AU; QoL: improve; safety: improve. 







eTable 17. Multivariate Linear Regression Analysis, Total Number of Patients Completing  
 Therapy with New Medicines per 100,000 Incident Cases of Neoplasm and their Beneficial Impact 
to Health in the Second Year of Drug Marketing in Australia, France, the UK, and the US 
Variable Model1 
 (A) (B) (C) (D) (E) (F) (G) (H) (I) (J) 




















Ind. Var2 1 2 3 4 1, 2 1, 3 1, 4 1, 2, 3 1, 2, 4 
























































































































































































































































   
 
 





































































































































































































e # FR 












e # UK 












e # US 









































































121 87 113 113 87 113 113 87 87 87 
R2 0.231 0.15 0.191 0.357 0.394 0.432 0.512 0.437 0.573 0.585 
Adj R2 0.176 0.074 0.085 0.257 0.265 0.301 0.386 0.255 0.378 0.327 
 
Source: 
Authors’ analysis of data, as described Methods section. 
Notes: 
1 Sensitivity analysis with a natural log transformation of the dependent variable, total number of patients completing  
 therapy in the second year of marketing per 100,000 incident cases of neoplasm (mean estimate 
of distribution from Chapter 3), assuming treatment duration   
2 1: Treatment descriptors (treated condition, rarity); 2: OS; 3: QoL; 4: safety. 
3 Reference categories: ascites; AU; QoL: improve; safety: improve. 











eTable 18. Multivariate Linear Regression Analysis, Total Cost per Patient per  
Treatment with New Medicines and their Beneficial Impact to Health in the Third Year of Drug Marketing in 
Australia, France, the UK, and the US 
Variable Model1 






















Ind. Var2 1 2 3 4 1, 2 1, 3 1, 4 1, 2, 3 1, 2, 4 


































































































































































































































   
 
 


























































































































































































e # FR 












e # UK 












e # US 









































































93 72 87 87 72 87 87 72 72 72 
R2 0.105 0.221 0.161 0.198 0.395 0.351 0.327 0.456 0.505 0.552 
Adj R2 0.031 0.135 0.025 0.028 0.259 0.166 0.096 0.257 0.253 0.224 
 
Source: 
Authors’ analysis of data, as described Methods section. 
Notes: 
1 Sensitivity analysis with a sqrt transformation of the dependent variable, total cost per patient per  
treatment (TCp) in the third year of marketing (mean estimate from Chapter 3), assuming treatment 
duration   
2 1: Treatment descriptors (treated condition, rarity); 2: OS; 3: QoL; 4: safety. 
3 Reference categories: ascites; AU; QoL: improve; safety: improve. 







eTable 19. Multivariate Linear Regression Analysis, Total Number of Patients Completing  
 Therapy with New Medicines per 100,000 Incident Cases of Neoplasm and their Beneficial Impact 
to Health in the Third Year of Drug Marketing in Australia, France, the UK, and the US 
Variable Model1 
 (A) (B) (C) (D) (E) (F) (G) (H) (I) (J) 




















Ind. Var2 1 2 3 4 1, 2 1, 3 1, 4 1, 2, 3 1, 2, 4 
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e # UK 









-3.228*   
[1.575] 
safety_reduc
e # US 









































































94 73 88 88 73 88 88 73 73 73 
R2 0.22 0.089 0.142 0.477 0.348 0.41 0.626 0.471 0.786 0.82 
Adj R2 0.156 -0.009 0.005 0.368 0.204 0.245 0.499 0.281 0.671 0.684 
 
Source: 
Authors’ analysis of data, as described Methods section. 
Notes: 
1 Sensitivity analysis with a natural log transformation of the dependent variable, total number of patients completing  
 therapy in the third year of marketing per 100,000 incident cases of neoplasm (mean estimate of 
distribution from Chapter 3), assuming treatment duration   
2 1: Treatment descriptors (treated condition, rarity); 2: OS; 3: QoL; 4: safety. 
3 Reference categories: ascites; AU; QoL: improve; safety: improve. 











eTable 20. Multivariate Linear Regression Analysis, Total Number of Patients Completing  
 Therapy with New Medicines per 100,000 Population and their Beneficial Impact to Health in the 
First Year of Drug Marketing in Australia, France, the UK, and the US 
Variable Model1 
 (A) (B) (C) (D) (E) (F) (G) (H) (I) (J) 










































































































































































































































4.312*   
[2.030] 














































   
 
 




































































































3.577*   
[1.523] 













































































































































































Observations 137 96 125 125 96 125 125 96 96 96 
R2 0.102 0.248 0.329 0.326 0.313 0.419 0.411 0.447 0.534 0.634 
Adj R2 0.039 0.189 0.25 0.233 0.174 0.293 0.27 0.27 0.339 0.421 
 
Source: 
Authors’ analysis of data, as described in Methods section. 
Notes: 
1 Sensitivity analysis with a natural log transformation of the dependent variable, total number of patients completing  
 therapy in the first year of marketing per 100,000 population (mean estimate of distribution 
from Chapter 3), assuming treatment duration   
2 1: Treatment descriptors (treated condition, rarity); 2: OS; 3: QoL; 4: safety. 
3 Reference categories: ascites; AU; QoL: improve; safety: improve. 











eTable 21. Multivariate Linear Regression Analysis, Total Cost per Patient per  
Treatment with New Medicines and their Beneficial Impact to Health in the First Year of Drug Marketing in 
Australia, France, the UK, and the US 
Variable Model1 
 (A) (B) (C) (D) (E) (F) (G) (H) (I) (J) 




















Ind. Var2 1 2 3 4 1, 2 1, 3 1, 4 1, 2, 3 1, 2, 4 







































































































































































































































































   
 
 






































































































































































































e # FR 












e # UK 












e # US 









































































131 90 119 119 90 119 119 90 90 90 
R2 0.162 0.166 0.151 0.206 0.379 0.309 0.321 0.439 0.493 0.543 
Adj R2 0.1 0.095 0.045 0.09 0.243 0.15 0.147 0.243 0.26 0.246 
 
Source: 
Authors’ analysis of data, as described in Methods section. 
Notes: 
1 Sensitivity analysis with a sqrt transformation of the dependent variable, total cost per patient per  
 treatment (TCp) in the first year of marketing (median estimate from Chapter 3), assuming treatment 
duration   
2 1: Treatment descriptors (treated condition, rarity); 2: OS; 3: QoL; 4: safety. 
3 Reference categories: ascites; AU; QoL: improve; safety: improve. 







eTable 22. Multivariate Linear Regression Analysis, Total Number of Patients Completing  
 Therapy with New Medicines per 100,000 Incident Cases of Neoplasm and their Beneficial Impact 
to Health in the First Year of Drug Marketing in Australia, France, the UK, and the US 
Variable Model1 
 (A) (B) (C) (D) (E) (F) (G) (H) (I) (J) 




















Ind. Var2 1 2 3 4 1, 2 1, 3 1, 4 1, 2, 3 1, 2, 4 
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[2.068] 





























































































































































































































































e # FR 












e # UK 












e # US 









































































137 96 125 125 96 125 125 96 96 96 
R2 0.091 0.263 0.335 0.333 0.316 0.414 0.407 0.458 0.519 0.638 
Adj R2 0.027 0.204 0.258 0.242 0.177 0.288 0.265 0.285 0.318 0.427 
 
Source: 
Authors’ analysis of data, as described in Methods section. 
Notes: 
1 Sensitivity analysis with a natural log transformation of the dependent variable, total number of patients completing  
 therapy in the first year of marketing per 100,000 incident cases of neoplasm (TPi)(median 
estimate of distribution from Chapter 3), assuming treatment duration   
2 1: Treatment descriptors (treated condition, rarity); 2: OS; 3: QoL; 4: safety. 
3 Reference categories: ascites; AU; QoL: improve; safety: improve. 











eTable 23. Multivariate Linear Regression Analysis, Total Cost per Patient per  
Treatment with New Medicines and their Beneficial Impact to Health in the First Year of Drug Marketing in 
Australia, France, the UK, and the US  
Variable Model1 






















Ind. Var2 1 2 3 4 1, 2 1, 3 1, 4 1, 2, 3 1, 2, 4 







































































































































































































































































   
 
 
























































































































-261.8*   
[107.1] 











































































e # FR 












e # UK 












e # US 









































































127 86 115 115 86 115 115 86 86 86 
R2 0.213 0.112 0.128 0.136 0.372 0.331 0.299 0.434 0.442 0.499 
Adj R2 0.153 0.032 0.016 0.005 0.226 0.171 0.112 0.224 0.168 0.149 
 
Source: 
Authors’ analysis of data, as described in Methods section. 
Notes: 
1 Sensitivity analysis with a sqrt transformation of the dependent variable, total cost per patient per  
 treatment in the first year of marketing (mean estimate from Chapter 3), assuming treatment 
duration   
2 1: Treatment descriptors (treated condition, rarity); 2: OS; 3: QoL; 4: safety. 
3 Reference categories: ascites; AU; QoL: improve; safety: improve. 







eTable 24. Multivariate Linear Regression Analysis, Total Number of Patients Completing  
 Therapy with New Medicines per 100,000 Incident Cases of Neoplasm and their Beneficial Impact 
to Health in the First Year of Drug Marketing in Australia, France, the UK, and the US 
Variable Model1 
 (A) (B) (C) (D) (E) (F) (G) (H) (I) (J) 




















Ind. Var2 1 2 3 4 1, 2 1, 3 1, 4 1, 2, 3 1, 2, 4 
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e # UK 












e # US 









































































137 96 125 125 96 125 125 96 96 96 
R2 0.159 0.224 0.33 0.299 0.35 0.453 0.448 0.469 0.559 0.653 
Adj R2 0.1 0.162 0.252 0.202 0.219 0.335 0.315 0.3 0.375 0.451 
 
Source: 
Authors’ analysis of data, as described in Methods section. 
Notes: 
1 Sensitivity analysis with a natural log transformation of the dependent variable, total number of patients completing  
 therapy in the first year of marketing per 100,000 incident cases of neoplasm (TPi)(mean 
estimate of distribution from Chapter 3), assuming treatment duration   
2 1: Treatment descriptors (treated condition, rarity); 2: OS; 3: QoL; 4: safety. 
3 Reference categories: ascites; AU; QoL: improve; safety: improve. 











eTable 25. Multivariate Linear Regression Analysis, Total Cost per Patient per  
Treatment with New Medicines and their Beneficial Impact to Health in the First Year of Drug Marketing in 
Australia, France, the UK, and the US 
Variable Model1 
 (A) (B) (C) (D) (E) (F) (G) (H) (I) (J) 




















Ind. Var2 1 2 3 4 1, 2 1, 3 1, 4 1, 2, 3 1, 2, 4 
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[108.0] 
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131 90 119 119 90 119 119 90 90 90 
R2 0.244 0.096 0.136 0.117 0.373 0.34 0.324 0.415 0.443 0.494 
Adj R2 0.188 0.019 0.029 -0.012 0.236 0.189 0.151 0.212 0.188 0.166 
 
Source: 
Authors’ analysis of data, as described in Methods section. 
Notes: 
1 Sensitivity analysis with a sqrt transformation of the dependent variable, total cost per patient per  
 treatment in the first year of marketing (mean estimate  from Chapter 3), assuming treatment 
duration   
2 1: Treatment descriptors (treated condition, rarity); 2: OS; 3: QoL; 4: safety. 
3 Reference categories: ascites; AU; QoL: improve; safety: improve. 







eTable 26. Multivariate Linear Regression Analysis, Total Number of Patients Completing  
Therapy with New Medicines per 100,000 Incident Cases of Neoplasm and their Beneficial Impact 
to Health in the First Year of Drug Marketing in Australia, France, the UK, and the US 
Variable Model1 
 (A) (B) (C) (D) (E) (F) (G) (H) (I) (J) 




















Ind. Var2 1 2 3 4 1, 2 1, 3 1, 4 1, 2, 3 1, 2, 4 
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[1.684] 













































   
 
 
























































































































3.822*   
[1.601] 











































































e # FR 












e # UK 
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137 96 125 125 96 125 125 96 96 96 
R2 0.135 0.22 0.397 0.31 0.369 0.473 0.426 0.501 0.545 0.638 
Adj R2 0.073 0.158 0.326 0.215 0.241 0.36 0.289 0.341 0.355 0.428 
 
Source: 
Authors’ analysis of data, as described in Methods section. 
Notes: 
1 Sensitivity analysis with a natural log transformation of the dependent variable, total number of patients completing  
 treatment in the first year of marketing per 100,000 incident cases of neoplasm (TPi)(mean 
estimate of distribution from Chapter 3), assuming treatment duration   
2 1: Treatment descriptors (treated condition, rarity); 2: OS; 3: QoL; 4: safety. 
3 Reference categories: ascites; AU; QoL: improve; safety: improve. 
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12 * Mac 
13 cd "/Users/salasveg/Desktop/Project Files/Cancer/Cancer Paper 1_FINAL/Comparative Study of Spending Value/Value Data/YLL 
Analysis/YLL Relationship with Generic Use" 
14 
15 
16 * Prepare Stata: 
17 set more off 
18 set trace off 
19 set maxvar 32767 
20 set segmentsize 256m 
21 
22 * Load data: 
23 use "/Users/salasveg/Desktop/Project Files/Cancer/Cancer Paper 1_FINAL/Comparative Study of Spending Value/Value Data/YLL 
Analysis/YLL Relationship with Generic Use/YLL_IHMEtotal_RelationshipwithGenericUtilization_DerivedYLLvalues.dta" 
24 
25 
26 /// Dataset preparation 
27 
28 drop if (age_group_name != "Age-standardized" | sex_name !="Both sexes" | unit !="Rate per 100,000" | cause_name != "Neoplasms") 
29 drop if (location_name == "Canada" | location_name == "Germany" | location_name == "Italy" | location_name == "Japan" | 
location_name == "Sweden") 
30 
31 gen location_id=. 
32 replace location_id = 1 if location_name=="Australia" 
33 replace location_id = 3 if location_name=="France" 
34 replace location_id = 8 if location_name=="United Kingdom" 
35 replace location_id = 9 if location_name=="United States" 
36 
37 drop if location_id == . 
38 
39 sort location_id year case_id 
40 
41 * Bring in utilization and expenditure data from "/Descriptives/UpdatedHADataset_expendConsumption_FINAL.dta" for years 2005, 
2010, and 2013. 
42 * Look at association between YLLs in each year for each indication with three variables (taking advantage of previous command 
duplicating observations by 3. These variables include: 1) country-wide utilization of cancer medicines per year per capita (given 
e.g. off-label use, we can't link drugs by ATC to YLLs by cause_name), /// 
43 * 2) country-wide proportion use of generic medicines per capita (i.e. out of all medicines used in each country in each year, what 
percentage are generics); 3) country-wide expenditure on cancer medicines per year per capita; and 4) country-wide proportion 
expenditure of generic medicines per capita (i.e. out of total expenditure for all cancer medicines /// 
44 * used in each country in each year, what percentage is spent on generics). 
45 
46 * For volume derivations, see "Figure_VolumeConsumption_AllYears.xlsx", "UpdatedHA_Descriptives_AllYears.do", 
"Figure_VolumeConsumption_AllYears.xlsx", and "Figure_VolumeConsumption_AllYears.xlsx" 
47 
48 gen double totalPerCapitaSalesSU = . 
49 replace totalPerCapitaSalesSU = 2.005030357 if location_name == "Australia" & year == 2004 
50 replace totalPerCapitaSalesSU = 2.551342059 if location_name == "France" & year == 2004 
51 replace totalPerCapitaSalesSU = 2.848168927 if location_name == "United Kingdom" & year == 2004 
52 replace totalPerCapitaSalesSU = 2.545064441 if location_name == "United States" & year == 2004 
53 
54 replace totalPerCapitaSalesSU = 2.531855571 if location_name == "Australia" & year == 2005 
55 replace totalPerCapitaSalesSU = 2.556388039 if location_name == "France" & year == 2005 
56 replace totalPerCapitaSalesSU = 2.907302745 if location_name == "United Kingdom" & year == 2005 
57 replace totalPerCapitaSalesSU = 2.513759391 if location_name == "United States" & year == 2005 
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59 replace totalPerCapitaSalesSU = 1.945269617 if location_name == "Australia" & year == 2006 
60 replace totalPerCapitaSalesSU = 2.709957861 if location_name == "France" & year == 2006 
61 replace totalPerCapitaSalesSU = 2.684843694 if location_name == "United Kingdom" & year == 2006 
62 replace totalPerCapitaSalesSU = 2.502073678 if location_name == "United States" & year == 2006 
63 
64 replace totalPerCapitaSalesSU = 2.145730233 if location_name == "Australia" & year == 2007 
65 replace totalPerCapitaSalesSU = 2.796150660 if location_name == "France" & year == 2007 
66 replace totalPerCapitaSalesSU = 2.805177199 if location_name == "United Kingdom" & year == 2007 
67 replace totalPerCapitaSalesSU = 2.519407778 if location_name == "United States" & year == 2007 
68 
69 replace totalPerCapitaSalesSU = 2.208080257 if location_name == "Australia" & year == 2008 
70 replace totalPerCapitaSalesSU = 2.748605910 if location_name == "France" & year == 2008 
71 replace totalPerCapitaSalesSU = 2.940797526 if location_name == "United Kingdom" & year == 2008 
72 replace totalPerCapitaSalesSU = 2.507241153 if location_name == "United States" & year == 2008 
73 
74 replace totalPerCapitaSalesSU = 2.288237621 if location_name == "Australia" & year == 2009 
75 replace totalPerCapitaSalesSU = 2.673152231 if location_name == "France" & year == 2009 
76 replace totalPerCapitaSalesSU = 3.085537669 if location_name == "United Kingdom" & year == 2009 
77 replace totalPerCapitaSalesSU = 2.515365710 if location_name == "United States" & year == 2009 
78 
79 replace totalPerCapitaSalesSU = 2.383934458 if location_name == "Australia" & year == 2010 
80 replace totalPerCapitaSalesSU = 2.624139441 if location_name == "France" & year == 2010 
81 replace totalPerCapitaSalesSU = 3.273018997 if location_name == "United Kingdom" & year == 2010 
82 replace totalPerCapitaSalesSU = 2.552452765 if location_name == "United States" & year == 2010 
83 
84 replace totalPerCapitaSalesSU = 2.386668430 if location_name == "Australia" & year == 2011 
85 replace totalPerCapitaSalesSU = 2.581171865 if location_name == "France" & year == 2011 
86 replace totalPerCapitaSalesSU = 3.305106720 if location_name == "United Kingdom" & year == 2011 
87 replace totalPerCapitaSalesSU = 2.621787826 if location_name == "United States" & year == 2011 
88 
89 replace totalPerCapitaSalesSU = 2.356708747 if location_name == "Australia" & year == 2012 
90 replace totalPerCapitaSalesSU = 2.602557862 if location_name == "France" & year == 2012 
91 replace totalPerCapitaSalesSU = 3.413042607 if location_name == "United Kingdom" & year == 2012 
92 replace totalPerCapitaSalesSU = 2.595261256 if location_name == "United States" & year == 2012 
93 
94 replace totalPerCapitaSalesSU = 2.374399093 if location_name == "Australia" & year == 2013 
95 replace totalPerCapitaSalesSU = 2.635270332 if location_name == "France" & year == 2013 
96 replace totalPerCapitaSalesSU = 3.544536452 if location_name == "United Kingdom" & year == 2013 
97 replace totalPerCapitaSalesSU = 2.643948123 if location_name == "United States" & year == 2013 
98 
99 replace totalPerCapitaSalesSU = 2.529025783 if location_name == "Australia" & year == 2014 
100 replace totalPerCapitaSalesSU = 2.680253291 if location_name == "France" & year == 2014 
101 replace totalPerCapitaSalesSU = 3.761700707 if location_name == "United Kingdom" & year == 2014 
102 replace totalPerCapitaSalesSU = 2.690603629 if location_name == "United States" & year == 2014 
103 
104 label variable totalPerCapitaSalesSU "Total drug sales (SU) per capita, by location_name in each year" 
105 format totalPerCapitaSalesSU %12.0g 
106 
107 gen double prop_Sales_generic = . 
108 replace prop_Sales_generic = 0.318938467 if location_name == "Australia" & year == 2004 
109 replace prop_Sales_generic = 0.151408400 if location_name == "France" & year == 2004 
110 replace prop_Sales_generic = 0.349434545 if location_name == "United Kingdom" & year == 2004 
111 replace prop_Sales_generic = 0.488183604 if location_name == "United States" & year == 2004 
112 
113 replace prop_Sales_generic = 0.416042970 if location_name == "Australia" & year == 2005 
114 replace prop_Sales_generic = 0.145246739 if location_name == "France" & year == 2005 
115 replace prop_Sales_generic = 0.349914158 if location_name == "United Kingdom" & year == 2005 
116 replace prop_Sales_generic = 0.524453324 if location_name == "United States" & year == 2005 
117 
118 replace prop_Sales_generic = 0.337018569 if location_name == "Australia" & year == 2006 
119 replace prop_Sales_generic = 0.144576308 if location_name == "France" & year == 2006 
120 replace prop_Sales_generic = 0.352311133 if location_name == "United Kingdom" & year == 2006 
121 replace prop_Sales_generic = 0.527513273 if location_name == "United States" & year == 2006 
122 
123 replace prop_Sales_generic = 0.343799431 if location_name == "Australia" & year == 2007 
124 replace prop_Sales_generic = 0.154081218 if location_name == "France" & year == 2007 
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125 replace prop_Sales_generic = 0.399629905 if location_name == "United Kingdom" & year == 2007 
126 replace prop_Sales_generic = 0.531156961 if location_name == "United States" & year == 2007 
127 
128 replace prop_Sales_generic = 0.344337842 if location_name == "Australia" & year == 2008 
129 replace prop_Sales_generic = 0.176172289 if location_name == "France" & year == 2008 
130 replace prop_Sales_generic = 0.435169081 if location_name == "United Kingdom" & year == 2008 
131 replace prop_Sales_generic = 0.546965005 if location_name == "United States" & year == 2008 
132 
133 replace prop_Sales_generic = 0.344555320 if location_name == "Australia" & year == 2009 
134 replace prop_Sales_generic = 0.197950464 if location_name == "France" & year == 2009 
135 replace prop_Sales_generic = 0.440116812 if location_name == "United Kingdom" & year == 2009 
136 replace prop_Sales_generic = 0.566830950 if location_name == "United States" & year == 2009 
137 
138 replace prop_Sales_generic = 0.350587298 if location_name == "Australia" & year == 2010 
139 replace prop_Sales_generic = 0.214908438 if location_name == "France" & year == 2010 
140 replace prop_Sales_generic = 0.462174331 if location_name == "United Kingdom" & year == 2010 
141 replace prop_Sales_generic = 0.611057497 if location_name == "United States" & year == 2010 
142 
143 replace prop_Sales_generic = 0.358383295 if location_name == "Australia" & year == 2011 
144 replace prop_Sales_generic = 0.243114008 if location_name == "France" & year == 2011 
145 replace prop_Sales_generic = 0.531450226 if location_name == "United Kingdom" & year == 2011 
146 replace prop_Sales_generic = 0.632835289 if location_name == "United States" & year == 2011 
147 
148 replace prop_Sales_generic = 0.369021091 if location_name == "Australia" & year == 2012 
149 replace prop_Sales_generic = 0.260276730 if location_name == "France" & year == 2012 
150 replace prop_Sales_generic = 0.551391407 if location_name == "United Kingdom" & year == 2012 
151 replace prop_Sales_generic = 0.661197142 if location_name == "United States" & year == 2012 
152 
153 replace prop_Sales_generic = 0.371904669 if location_name == "Australia" & year == 2013 
154 replace prop_Sales_generic = 0.270129408 if location_name == "France" & year == 2013 
155 replace prop_Sales_generic = 0.557098470 if location_name == "United Kingdom" & year == 2013 
156 replace prop_Sales_generic = 0.689145529 if location_name == "United States" & year == 2013 
157 
158 replace prop_Sales_generic = 0.415767745 if location_name == "Australia" & year == 2014 
159 replace prop_Sales_generic = 0.288525472 if location_name == "France" & year == 2014 
160 replace prop_Sales_generic = 0.574276997 if location_name == "United Kingdom" & year == 2014 
161 replace prop_Sales_generic = 0.711754930 if location_name == "United States" & year == 2014 
162 label variable prop_Sales_generic "Proportion of total drug sales sold as generics, by location_name in each year" 
163 format prop_Sales_generic %12.0g 
164 
165 gen double prop_Sales_genericMG = . 
166 replace prop_Sales_genericMG = 0.298928202 if location_name == "Australia" & year == 2004 
167 replace prop_Sales_genericMG = 0.166081296 if location_name == "France" & year == 2004 
168 replace prop_Sales_genericMG = 0.322215670 if location_name == "United Kingdom" & year == 2004 
169 replace prop_Sales_genericMG = 0.499346964 if location_name == "United States" & year == 2004 
170 
171 replace prop_Sales_genericMG = 0.297418662 if location_name == "Australia" & year == 2005 
172 replace prop_Sales_genericMG = 0.171799331 if location_name == "France" & year == 2005 
173 replace prop_Sales_genericMG = 0.325372987 if location_name == "United Kingdom" & year == 2005 
174 replace prop_Sales_genericMG = 0.545300607 if location_name == "United States" & year == 2005 
175 
176 replace prop_Sales_genericMG = 0.328818017 if location_name == "Australia" & year == 2006 
177 replace prop_Sales_genericMG = 0.175239886 if location_name == "France" & year == 2006 
178 replace prop_Sales_genericMG = 0.338529012 if location_name == "United Kingdom" & year == 2006 
179 replace prop_Sales_genericMG = 0.552920134 if location_name == "United States" & year == 2006 
180 
181 replace prop_Sales_genericMG = 0.367141923 if location_name == "Australia" & year == 2007 
182 replace prop_Sales_genericMG = 0.187936048 if location_name == "France" & year == 2007 
183 replace prop_Sales_genericMG = 0.393261749 if location_name == "United Kingdom" & year == 2007 
184 replace prop_Sales_genericMG = 0.560345864 if location_name == "United States" & year == 2007 
185 
186 replace prop_Sales_genericMG = 0.373580000 if location_name == "Australia" & year == 2008 
187 replace prop_Sales_genericMG = 0.229880894 if location_name == "France" & year == 2008 
188 replace prop_Sales_genericMG = 0.432742529 if location_name == "United Kingdom" & year == 2008 
189 replace prop_Sales_genericMG = 0.584150608 if location_name == "United States" & year == 2008 
190 
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191 replace prop_Sales_genericMG = 0.369227657 if location_name == "Australia" & year == 2009 
192 replace prop_Sales_genericMG = 0.258419834 if location_name == "France" & year == 2009 
193 replace prop_Sales_genericMG = 0.446392379 if location_name == "United Kingdom" & year == 2009 
194 replace prop_Sales_genericMG = 0.621300932 if location_name == "United States" & year == 2009 
195 
196 replace prop_Sales_genericMG = 0.389109696 if location_name == "Australia" & year == 2010 
197 replace prop_Sales_genericMG = 0.297150245 if location_name == "France" & year == 2010 
198 replace prop_Sales_genericMG = 0.455077569 if location_name == "United Kingdom" & year == 2010 
199 replace prop_Sales_genericMG = 0.643511521 if location_name == "United States" & year == 2010 
200 
201 replace prop_Sales_genericMG = 0.387003541 if location_name == "Australia" & year == 2011 
202 replace prop_Sales_genericMG = 0.322674125 if location_name == "France" & year == 2011 
203 replace prop_Sales_genericMG = 0.517660701 if location_name == "United Kingdom" & year == 2011 
204 replace prop_Sales_genericMG = 0.636476581 if location_name == "United States" & year == 2011 
205 
206 replace prop_Sales_genericMG = 0.273154116 if location_name == "Australia" & year == 2012 
207 replace prop_Sales_genericMG = 0.318978963 if location_name == "France" & year == 2012 
208 replace prop_Sales_genericMG = 0.509967521 if location_name == "United Kingdom" & year == 2012 
209 replace prop_Sales_genericMG = 0.634116085 if location_name == "United States" & year == 2012 
210 
211 replace prop_Sales_genericMG = 0.391276901 if location_name == "Australia" & year == 2013 
212 replace prop_Sales_genericMG = 0.318300382 if location_name == "France" & year == 2013 
213 replace prop_Sales_genericMG = 0.514184231 if location_name == "United Kingdom" & year == 2013 
214 replace prop_Sales_genericMG = 0.638734740 if location_name == "United States" & year == 2013 
215 
216 replace prop_Sales_genericMG = 0.410989933 if location_name == "Australia" & year == 2014 
217 replace prop_Sales_genericMG = 0.343220525 if location_name == "France" & year == 2014 
218 replace prop_Sales_genericMG = 0.567959785 if location_name == "United Kingdom" & year == 2014 
219 replace prop_Sales_genericMG = 0.679999359 if location_name == "United States" & year == 2014 
220 label variable prop_Sales_genericMG "Proportion of total drug sales sold as generics (MG), by location_name in each year" 
221 format prop_Sales_genericMG %12.0g 
222 
223 gen double prop_Sales_branded = . 
224 replace prop_Sales_branded = 0.681061533 if location_name == "Australia" & year == 2004 
225 replace prop_Sales_branded = 0.848591600 if location_name == "France" & year == 2004 
226 replace prop_Sales_branded = 0.650565455 if location_name == "United Kingdom" & year == 2004 
227 replace prop_Sales_branded = 0.511816396 if location_name == "United States" & year == 2004 
228 
229 replace prop_Sales_branded = 0.583957030 if location_name == "Australia" & year == 2005 
230 replace prop_Sales_branded = 0.854753261 if location_name == "France" & year == 2005 
231 replace prop_Sales_branded = 0.650085842 if location_name == "United Kingdom" & year == 2005 
232 replace prop_Sales_branded = 0.475546676 if location_name == "United States" & year == 2005 
233 
234 replace prop_Sales_branded = 0.662981431 if location_name == "Australia" & year == 2006 
235 replace prop_Sales_branded = 0.855423692 if location_name == "France" & year == 2006 
236 replace prop_Sales_branded = 0.647688867 if location_name == "United Kingdom" & year == 2006 
237 replace prop_Sales_branded = 0.472486727 if location_name == "United States" & year == 2006 
238 
239 replace prop_Sales_branded = 0.656200569 if location_name == "Australia" & year == 2007 
240 replace prop_Sales_branded = 0.845918782 if location_name == "France" & year == 2007 
241 replace prop_Sales_branded = 0.600370095 if location_name == "United Kingdom" & year == 2007 
242 replace prop_Sales_branded = 0.468843039 if location_name == "United States" & year == 2007 
243 
244 replace prop_Sales_branded = 0.655662158 if location_name == "Australia" & year == 2008 
245 replace prop_Sales_branded = 0.823827711 if location_name == "France" & year == 2008 
246 replace prop_Sales_branded = 0.564830919 if location_name == "United Kingdom" & year == 2008 
247 replace prop_Sales_branded = 0.453034995 if location_name == "United States" & year == 2008 
248 
249 replace prop_Sales_branded = 0.655444680 if location_name == "Australia" & year == 2009 
250 replace prop_Sales_branded = 0.802049536 if location_name == "France" & year == 2009 
251 replace prop_Sales_branded = 0.559883188 if location_name == "United Kingdom" & year == 2009 
252 replace prop_Sales_branded = 0.433169050 if location_name == "United States" & year == 2009 
253 
254 replace prop_Sales_branded = 0.649412702 if location_name == "Australia" & year == 2010 
255 replace prop_Sales_branded = 0.785091562 if location_name == "France" & year == 2010 
256 replace prop_Sales_branded = 0.537825669 if location_name == "United Kingdom" & year == 2010 
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257 replace prop_Sales_branded = 0.388942503 if location_name == "United States" & year == 2010 
258 
259 replace prop_Sales_branded = 0.641616705 if location_name == "Australia" & year == 2011 
260 replace prop_Sales_branded = 0.756885992 if location_name == "France" & year == 2011 
261 replace prop_Sales_branded = 0.468549774 if location_name == "United Kingdom" & year == 2011 
262 replace prop_Sales_branded = 0.367164711 if location_name == "United States" & year == 2011 
263 
264 replace prop_Sales_branded = 0.630978909 if location_name == "Australia" & year == 2012 
265 replace prop_Sales_branded = 0.739723270 if location_name == "France" & year == 2012 
266 replace prop_Sales_branded = 0.448608593 if location_name == "United Kingdom" & year == 2012 
267 replace prop_Sales_branded = 0.338802858 if location_name == "United States" & year == 2012 
268 
269 replace prop_Sales_branded = 0.628095331 if location_name == "Australia" & year == 2013 
270 replace prop_Sales_branded = 0.729870592 if location_name == "France" & year == 2013 
271 replace prop_Sales_branded = 0.442901530 if location_name == "United Kingdom" & year == 2013 
272 replace prop_Sales_branded = 0.310854471 if location_name == "United States" & year == 2013 
273 
274 replace prop_Sales_branded = 0.584232255 if location_name == "Australia" & year == 2014 
275 replace prop_Sales_branded = 0.711474528 if location_name == "France" & year == 2014 
276 replace prop_Sales_branded = 0.425723003 if location_name == "United Kingdom" & year == 2014 
277 replace prop_Sales_branded = 0.288245070 if location_name == "United States" & year == 2014 
278 label variable prop_Sales_branded "Proportion of total drug sales sold as generics, by location_name in each year" 
279 format prop_Sales_branded %12.0g 
280 
281 * The following two variables adjust for cancer incidence, rather than population. Data is derived from OECD & CDC data. See 
"LinReg_CancerIncidence.xlsx", "Figures_VolumeConsumption_AllYears.xlsx", & "UpdatedHA_Descriptives_AllYears.do". 
282 
283 gen double totalPerNeoplasmSalesSU = . 
284 replace totalPerNeoplasmSalesSU = 432.545489967 if location_name == "Australia" & year == 2004 
285 replace totalPerNeoplasmSalesSU = 552.292197753 if location_name == "France" & year == 2004 
286 replace totalPerNeoplasmSalesSU = 607.544978967 if location_name == "United Kingdom" & year == 2004 
287 replace totalPerNeoplasmSalesSU = 539.674430777 if location_name == "United States" & year == 2004 
288 
289 replace totalPerNeoplasmSalesSU = 533.188659683 if location_name == "Australia" & year == 2005 
290 replace totalPerNeoplasmSalesSU = 542.182826225 if location_name == "France" & year == 2005 
291 replace totalPerNeoplasmSalesSU = 610.643138747 if location_name == "United Kingdom" & year == 2005 
292 replace totalPerNeoplasmSalesSU = 528.723447955 if location_name == "United States" & year == 2005 
293 
294 replace totalPerNeoplasmSalesSU = 401.061198770 if location_name == "Australia" & year == 2006 
295 replace totalPerNeoplasmSalesSU = 563.229451150 if location_name == "France" & year == 2006 
296 replace totalPerNeoplasmSalesSU = 555.805621555 if location_name == "United Kingdom" & year == 2006 
297 replace totalPerNeoplasmSalesSU = 522.384031076 if location_name == "United States" & year == 2006 
298 
299 replace totalPerNeoplasmSalesSU = 429.974944284 if location_name == "Australia" & year == 2007 
300 replace totalPerNeoplasmSalesSU = 569.455505290 if location_name == "France" & year == 2007 
301 replace totalPerNeoplasmSalesSU = 572.879283803 if location_name == "United Kingdom" & year == 2007 
302 replace totalPerNeoplasmSalesSU = 522.203704106 if location_name == "United States" & year == 2007 
303 
304 replace totalPerNeoplasmSalesSU = 436.532214171 if location_name == "Australia" & year == 2008 
305 replace totalPerNeoplasmSalesSU = 548.561582965 if location_name == "France" & year == 2008 
306 replace totalPerNeoplasmSalesSU = 592.785315781 if location_name == "United Kingdom" & year == 2008 
307 replace totalPerNeoplasmSalesSU = 516.043979601 if location_name == "United States" & year == 2008 
308 
309 replace totalPerNeoplasmSalesSU = 447.050520656 if location_name == "Australia" & year == 2009 
310 replace totalPerNeoplasmSalesSU = 522.925530244 if location_name == "France" & year == 2009 
311 replace totalPerNeoplasmSalesSU = 613.968217253 if location_name == "United Kingdom" & year == 2009 
312 replace totalPerNeoplasmSalesSU = 513.873672647 if location_name == "United States" & year == 2009 
313 
314 replace totalPerNeoplasmSalesSU = 458.407236858 if location_name == "Australia" & year == 2010 
315 replace totalPerNeoplasmSalesSU = 503.368330543 if location_name == "France" & year == 2010 
316 replace totalPerNeoplasmSalesSU = 643.345887794 if location_name == "United Kingdom" & year == 2010 
317 replace totalPerNeoplasmSalesSU = 517.503919511 if location_name == "United States" & year == 2010 
318 
319 replace totalPerNeoplasmSalesSU = 451.384201435 if location_name == "Australia" & year == 2011 
320 replace totalPerNeoplasmSalesSU = 485.745877190 if location_name == "France" & year == 2011 
321 replace totalPerNeoplasmSalesSU = 641.984629783 if location_name == "United Kingdom" & year == 2011 
322 replace totalPerNeoplasmSalesSU = 527.294254523 if location_name == "United States" & year == 2011 
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324 replace totalPerNeoplasmSalesSU = 440.247269492 if location_name == "Australia" & year == 2012 
325 replace totalPerNeoplasmSalesSU = 480.617706462 if location_name == "France" & year == 2012 
326 replace totalPerNeoplasmSalesSU = 654.808144954 if location_name == "United Kingdom" & year == 2012 
327 replace totalPerNeoplasmSalesSU = 517.891014978 if location_name == "United States" & year == 2012 
328 
329 replace totalPerNeoplasmSalesSU = 438.530267250 if location_name == "Australia" & year == 2013 
330 replace totalPerNeoplasmSalesSU = 477.725398626 if location_name == "France" & year == 2013 
331 replace totalPerNeoplasmSalesSU = 671.531942501 if location_name == "United Kingdom" & year == 2013 
332 replace totalPerNeoplasmSalesSU = 523.579084986 if location_name == "United States" & year == 2013 
333 
334 replace totalPerNeoplasmSalesSU = 461.391177667 if location_name == "Australia" & year == 2014 
335 replace totalPerNeoplasmSalesSU = 477.166378997 if location_name == "France" & year == 2014 
336 replace totalPerNeoplasmSalesSU = 703.951027155 if location_name == "United Kingdom" & year == 2014 
337 replace totalPerNeoplasmSalesSU = 528.798691910 if location_name == "United States" & year == 2014 
338 label variable totalPerNeoplasmSalesSU "Total drug sales (SU) per incident neoplasm, by location_name in each year" 
339 format totalPerNeoplasmSalesSU %12.0g 
340 
341 gen double totalPerNeoplasmSalesMG = . 
342 replace totalPerNeoplasmSalesMG = 43290.939500000 if location_name == "Australia" & year == 2004 
343 replace totalPerNeoplasmSalesMG = 60645.190200000 if location_name == "France" & year == 2004 
344 replace totalPerNeoplasmSalesMG = 48189.496700000 if location_name == "United Kingdom" & year == 2004 
345 replace totalPerNeoplasmSalesMG = 50350.944300000 if location_name == "United States" & year == 2004 
346 
347 replace totalPerNeoplasmSalesMG = 42542.180100000 if location_name == "Australia" & year == 2005 
348 replace totalPerNeoplasmSalesMG = 61542.810300000 if location_name == "France" & year == 2005 
349 replace totalPerNeoplasmSalesMG = 50049.868400000 if location_name == "United Kingdom" & year == 2005 
350 replace totalPerNeoplasmSalesMG = 52140.842500000 if location_name == "United States" & year == 2005 
351 
352 replace totalPerNeoplasmSalesMG = 44715.095700000 if location_name == "Australia" & year == 2006 
353 replace totalPerNeoplasmSalesMG = 66893.834400000 if location_name == "France" & year == 2006 
354 replace totalPerNeoplasmSalesMG = 55014.359800000 if location_name == "United Kingdom" & year == 2006 
355 replace totalPerNeoplasmSalesMG = 53455.308100000 if location_name == "United States" & year == 2006 
356 
357 replace totalPerNeoplasmSalesMG = 46460.727290000 if location_name == "Australia" & year == 2007 
358 replace totalPerNeoplasmSalesMG = 69893.887600000 if location_name == "France" & year == 2007 
359 replace totalPerNeoplasmSalesMG = 59409.204000000 if location_name == "United Kingdom" & year == 2007 
360 replace totalPerNeoplasmSalesMG = 55544.900500000 if location_name == "United States" & year == 2007 
361 
362 replace totalPerNeoplasmSalesMG = 47039.849570000 if location_name == "Australia" & year == 2008 
363 replace totalPerNeoplasmSalesMG = 70177.100900000 if location_name == "France" & year == 2008 
364 replace totalPerNeoplasmSalesMG = 62102.237000000 if location_name == "United Kingdom" & year == 2008 
365 replace totalPerNeoplasmSalesMG = 56443.977600000 if location_name == "United States" & year == 2008 
366 
367 replace totalPerNeoplasmSalesMG = 46303.039100000 if location_name == "Australia" & year == 2009 
368 replace totalPerNeoplasmSalesMG = 68296.751800000 if location_name == "France" & year == 2009 
369 replace totalPerNeoplasmSalesMG = 64235.472100000 if location_name == "United Kingdom" & year == 2009 
370 replace totalPerNeoplasmSalesMG = 56385.799200000 if location_name == "United States" & year == 2009 
371 
372 replace totalPerNeoplasmSalesMG = 46650.453300000 if location_name == "Australia" & year == 2010 
373 replace totalPerNeoplasmSalesMG = 67094.633300000 if location_name == "France" & year == 2010 
374 replace totalPerNeoplasmSalesMG = 71357.088100000 if location_name == "United Kingdom" & year == 2010 
375 replace totalPerNeoplasmSalesMG = 56990.767000000 if location_name == "United States" & year == 2010 
376 
377 replace totalPerNeoplasmSalesMG = 47781.264100000 if location_name == "Australia" & year == 2011 
378 replace totalPerNeoplasmSalesMG = 65298.560500000 if location_name == "France" & year == 2011 
379 replace totalPerNeoplasmSalesMG = 61604.616300000 if location_name == "United Kingdom" & year == 2011 
380 replace totalPerNeoplasmSalesMG = 58249.813200000 if location_name == "United States" & year == 2011 
381 
382 replace totalPerNeoplasmSalesMG = 48640.680710000 if location_name == "Australia" & year == 2012 
383 replace totalPerNeoplasmSalesMG = 66640.926500000 if location_name == "France" & year == 2012 
384 replace totalPerNeoplasmSalesMG = 63248.492700000 if location_name == "United Kingdom" & year == 2012 
385 replace totalPerNeoplasmSalesMG = 56458.940700000 if location_name == "United States" & year == 2012 
386 
387 replace totalPerNeoplasmSalesMG = 50457.698340000 if location_name == "Australia" & year == 2013 
388 replace totalPerNeoplasmSalesMG = 66968.418100000 if location_name == "France" & year == 2013 
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389 replace totalPerNeoplasmSalesMG = 65217.815300000 if location_name == "United Kingdom" & year == 2013 
390 replace totalPerNeoplasmSalesMG = 55185.835200000 if location_name == "United States" & year == 2013 
391 
392 replace totalPerNeoplasmSalesMG = 53564.817600000 if location_name == "Australia" & year == 2014 
393 replace totalPerNeoplasmSalesMG = 67577.219600000 if location_name == "France" & year == 2014 
394 replace totalPerNeoplasmSalesMG = 67018.856300000 if location_name == "United Kingdom" & year == 2014 
395 replace totalPerNeoplasmSalesMG = 54109.046000000 if location_name == "United States" & year == 2014 
396 label variable totalPerNeoplasmSalesMG "Total drug sales (MG) per incident neoplasm, by location_name in each year" 
397 format totalPerNeoplasmSalesMG %12.0g 
398 
399 * For expenditure derivations, see "Figure_Expenditure_AllYears.xlsx" & "UpdatedHA_Descriptives_AllYears.do". 
400 
401 gen double totalPerCapitaExpendcUSD = . 
402 replace totalPerCapitaExpendcUSD = 81.187264396 if location_name == "Australia" & year == 2004 
403 replace totalPerCapitaExpendcUSD = 118.266379249 if location_name == "France" & year == 2004 
404 replace totalPerCapitaExpendcUSD = 72.480729490 if location_name == "United Kingdom" & year == 2004 
405 replace totalPerCapitaExpendcUSD = 181.899055074 if location_name == "United States" & year == 2004 
406 
407 replace totalPerCapitaExpendcUSD = 94.071870473 if location_name == "Australia" & year == 2005 
408 replace totalPerCapitaExpendcUSD = 145.977897890 if location_name == "France" & year == 2005 
409 replace totalPerCapitaExpendcUSD = 75.246040616 if location_name == "United Kingdom" & year == 2005 
410 replace totalPerCapitaExpendcUSD = 205.513781898 if location_name == "United States" & year == 2005 
411 
412 replace totalPerCapitaExpendcUSD = 95.913764138 if location_name == "Australia" & year == 2006 
413 replace totalPerCapitaExpendcUSD = 177.967278175 if location_name == "France" & year == 2006 
414 replace totalPerCapitaExpendcUSD = 93.289306559 if location_name == "United Kingdom" & year == 2006 
415 replace totalPerCapitaExpendcUSD = 251.045869234 if location_name == "United States" & year == 2006 
416 
417 replace totalPerCapitaExpendcUSD = 108.818357245 if location_name == "Australia" & year == 2007 
418 replace totalPerCapitaExpendcUSD = 213.324404210 if location_name == "France" & year == 2007 
419 replace totalPerCapitaExpendcUSD = 108.030546839 if location_name == "United Kingdom" & year == 2007 
420 replace totalPerCapitaExpendcUSD = 280.720837981 if location_name == "United States" & year == 2007 
421 
422 replace totalPerCapitaExpendcUSD = 112.397252960 if location_name == "Australia" & year == 2008 
423 replace totalPerCapitaExpendcUSD = 236.401051239 if location_name == "France" & year == 2008 
424 replace totalPerCapitaExpendcUSD = 120.207686939 if location_name == "United Kingdom" & year == 2008 
425 replace totalPerCapitaExpendcUSD = 285.264937292 if location_name == "United States" & year == 2008 
426 
427 replace totalPerCapitaExpendcUSD = 117.411007958 if location_name == "Australia" & year == 2009 
428 replace totalPerCapitaExpendcUSD = 224.523634636 if location_name == "France" & year == 2009 
429 replace totalPerCapitaExpendcUSD = 126.739632966 if location_name == "United Kingdom" & year == 2009 
430 replace totalPerCapitaExpendcUSD = 304.003266190 if location_name == "United States" & year == 2009 
431 
432 replace totalPerCapitaExpendcUSD = 127.315192164 if location_name == "Australia" & year == 2010 
433 replace totalPerCapitaExpendcUSD = 214.854515573 if location_name == "France" & year == 2010 
434 replace totalPerCapitaExpendcUSD = 129.519135317 if location_name == "United Kingdom" & year == 2010 
435 replace totalPerCapitaExpendcUSD = 305.754817357 if location_name == "United States" & year == 2010 
436 
437 replace totalPerCapitaExpendcUSD = 130.062387966 if location_name == "Australia" & year == 2011 
438 replace totalPerCapitaExpendcUSD = 199.728687794 if location_name == "France" & year == 2011 
439 replace totalPerCapitaExpendcUSD = 128.045712135 if location_name == "United Kingdom" & year == 2011 
440 replace totalPerCapitaExpendcUSD = 300.122366184 if location_name == "United States" & year == 2011 
441 
442 replace totalPerCapitaExpendcUSD = 129.984045414 if location_name == "Australia" & year == 2012 
443 replace totalPerCapitaExpendcUSD = 185.532529470 if location_name == "France" & year == 2012 
444 replace totalPerCapitaExpendcUSD = 133.859713501 if location_name == "United Kingdom" & year == 2012 
445 replace totalPerCapitaExpendcUSD = 310.239349280 if location_name == "United States" & year == 2012 
446 
447 replace totalPerCapitaExpendcUSD = 137.852952073 if location_name == "Australia" & year == 2013 
448 replace totalPerCapitaExpendcUSD = 197.230431233 if location_name == "France" & year == 2013 
449 replace totalPerCapitaExpendcUSD = 149.664435583 if location_name == "United Kingdom" & year == 2013 
450 replace totalPerCapitaExpendcUSD = 324.453540512 if location_name == "United States" & year == 2013 
451 
452 replace totalPerCapitaExpendcUSD = 145.244274815 if location_name == "Australia" & year == 2014 
453 replace totalPerCapitaExpendcUSD = 206.877344740 if location_name == "France" & year == 2014 
454 replace totalPerCapitaExpendcUSD = 174.283105966 if location_name == "United Kingdom" & year == 2014 
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455 replace totalPerCapitaExpendcUSD = 376.112972620 if location_name == "United States" & year == 2014 
456 label variable totalPerCapitaExpendcUSD "Total drug expenditure (2014 USD) per capita, by location_name in each year" 
457 format totalPerCapitaExpendcUSD %12.0g 
458 
459 gen double prop_Expend_generic = . 
460 replace prop_Expend_generic = 0.179896267 if location_name == "Australia" & year == 2004 
461 replace prop_Expend_generic = 0.056763393 if location_name == "France" & year == 2004 
462 replace prop_Expend_generic = 0.171088554 if location_name == "United Kingdom" & year == 2004 
463 replace prop_Expend_generic = 0.083603761 if location_name == "United States" & year == 2004 
464 
465 replace prop_Expend_generic = 0.231000016 if location_name == "Australia" & year == 2005 
466 replace prop_Expend_generic = 0.055387123 if location_name == "France" & year == 2005 
467 replace prop_Expend_generic = 0.168299613 if location_name == "United Kingdom" & year == 2005 
468 replace prop_Expend_generic = 0.076030259 if location_name == "United States" & year == 2005 
469 
470 replace prop_Expend_generic = 0.196902329 if location_name == "Australia" & year == 2006 
471 replace prop_Expend_generic = 0.056138275 if location_name == "France" & year == 2006 
472 replace prop_Expend_generic = 0.167190426 if location_name == "United Kingdom" & year == 2006 
473 replace prop_Expend_generic = 0.072563095 if location_name == "United States" & year == 2006 
474 
475 replace prop_Expend_generic = 0.226689500 if location_name == "Australia" & year == 2007 
476 replace prop_Expend_generic = 0.067375368 if location_name == "France" & year == 2007 
477 replace prop_Expend_generic = 0.215554509 if location_name == "United Kingdom" & year == 2007 
478 replace prop_Expend_generic = 0.072407163 if location_name == "United States" & year == 2007 
479 
480 replace prop_Expend_generic = 0.243427300 if location_name == "Australia" & year == 2008 
481 replace prop_Expend_generic = 0.091738002 if location_name == "France" & year == 2008 
482 replace prop_Expend_generic = 0.250469230 if location_name == "United Kingdom" & year == 2008 
483 replace prop_Expend_generic = 0.067727315 if location_name == "United States" & year == 2008 
484 
485 replace prop_Expend_generic = 0.243009314 if location_name == "Australia" & year == 2009 
486 replace prop_Expend_generic = 0.103774703 if location_name == "France" & year == 2009 
487 replace prop_Expend_generic = 0.273296392 if location_name == "United Kingdom" & year == 2009 
488 replace prop_Expend_generic = 0.086281317 if location_name == "United States" & year == 2009 
489 
490 replace prop_Expend_generic = 0.247678271 if location_name == "Australia" & year == 2010 
491 replace prop_Expend_generic = 0.128770452 if location_name == "France" & year == 2010 
492 replace prop_Expend_generic = 0.303227431 if location_name == "United Kingdom" & year == 2010 
493 replace prop_Expend_generic = 0.134388905 if location_name == "United States" & year == 2010 
494 
495 replace prop_Expend_generic = 0.272982512 if location_name == "Australia" & year == 2011 
496 replace prop_Expend_generic = 0.211824533 if location_name == "France" & year == 2011 
497 replace prop_Expend_generic = 0.365832163 if location_name == "United Kingdom" & year == 2011 
498 replace prop_Expend_generic = 0.149396715 if location_name == "United States" & year == 2011 
499 
500 replace prop_Expend_generic = 0.326145524 if location_name == "Australia" & year == 2012 
501 replace prop_Expend_generic = 0.264179997 if location_name == "France" & year == 2012 
502 replace prop_Expend_generic = 0.354548110 if location_name == "United Kingdom" & year == 2012 
503 replace prop_Expend_generic = 0.187615570 if location_name == "United States" & year == 2012 
504 
505 replace prop_Expend_generic = 0.334643073 if location_name == "Australia" & year == 2013 
506 replace prop_Expend_generic = 0.257387072 if location_name == "France" & year == 2013 
507 replace prop_Expend_generic = 0.330761712 if location_name == "United Kingdom" & year == 2013 
508 replace prop_Expend_generic = 0.250575906 if location_name == "United States" & year == 2013 
509 
510 replace prop_Expend_generic = 0.342387285 if location_name == "Australia" & year == 2014 
511 replace prop_Expend_generic = 0.267124006 if location_name == "France" & year == 2014 
512 replace prop_Expend_generic = 0.337765726 if location_name == "United Kingdom" & year == 2014 
513 replace prop_Expend_generic = 0.305568658 if location_name == "United States" & year == 2014 
514 label variable prop_Expend_generic "Proportion of total drug expenditure associated with generic drug sales, by location_name in 
each year" 
515 format prop_Expend_generic %12.0g 
516 
517 gen double prop_Expend_branded = . 
518 replace prop_Expend_branded = 0.820103733 if location_name == "Australia" & year == 2004 
519 replace prop_Expend_branded = 0.943236607 if location_name == "France" & year == 2004 
520 replace prop_Expend_branded = 0.828911446 if location_name == "United Kingdom" & year == 2004 
YLL_IHMEtotal_AllNeoplasms3 26/04/2017, 18:41 






521 replace prop_Expend_branded = 0.916396239 if location_name == "United States" & year == 2004 
522 
523 replace prop_Expend_branded = 0.768999984 if location_name == "Australia" & year == 2005 
524 replace prop_Expend_branded = 0.944612877 if location_name == "France" & year == 2005 
525 replace prop_Expend_branded = 0.831700387 if location_name == "United Kingdom" & year == 2005 
526 replace prop_Expend_branded = 0.923969741 if location_name == "United States" & year == 2005 
527 
528 replace prop_Expend_branded = 0.803097671 if location_name == "Australia" & year == 2006 
529 replace prop_Expend_branded = 0.943861725 if location_name == "France" & year == 2006 
530 replace prop_Expend_branded = 0.832809574 if location_name == "United Kingdom" & year == 2006 
531 replace prop_Expend_branded = 0.927436905 if location_name == "United States" & year == 2006 
532 
533 replace prop_Expend_branded = 0.773310500 if location_name == "Australia" & year == 2007 
534 replace prop_Expend_branded = 0.932624632 if location_name == "France" & year == 2007 
535 replace prop_Expend_branded = 0.784445491 if location_name == "United Kingdom" & year == 2007 
536 replace prop_Expend_branded = 0.927592750 if location_name == "United States" & year == 2007 
537 
538 replace prop_Expend_branded = 0.756572700 if location_name == "Australia" & year == 2008 
539 replace prop_Expend_branded = 0.908261998 if location_name == "France" & year == 2008 
540 replace prop_Expend_branded = 0.749530770 if location_name == "United Kingdom" & year == 2008 
541 replace prop_Expend_branded = 0.932272411 if location_name == "United States" & year == 2008 
542 
543 replace prop_Expend_branded = 0.756990686 if location_name == "Australia" & year == 2009 
544 replace prop_Expend_branded = 0.896225297 if location_name == "France" & year == 2009 
545 replace prop_Expend_branded = 0.726703608 if location_name == "United Kingdom" & year == 2009 
546 replace prop_Expend_branded = 0.913719226 if location_name == "United States" & year == 2009 
547 
548 replace prop_Expend_branded = 0.752321729 if location_name == "Australia" & year == 2010 
549 replace prop_Expend_branded = 0.871229548 if location_name == "France" & year == 2010 
550 replace prop_Expend_branded = 0.696772569 if location_name == "United Kingdom" & year == 2010 
551 replace prop_Expend_branded = 0.865610811 if location_name == "United States" & year == 2010 
552 
553 replace prop_Expend_branded = 0.727017488 if location_name == "Australia" & year == 2011 
554 replace prop_Expend_branded = 0.788175467 if location_name == "France" & year == 2011 
555 replace prop_Expend_branded = 0.634167837 if location_name == "United Kingdom" & year == 2011 
556 replace prop_Expend_branded = 0.850603413 if location_name == "United States" & year == 2011 
557 
558 replace prop_Expend_branded = 0.673854476 if location_name == "Australia" & year == 2012 
559 replace prop_Expend_branded = 0.735820003 if location_name == "France" & year == 2012 
560 replace prop_Expend_branded = 0.645451890 if location_name == "United Kingdom" & year == 2012 
561 replace prop_Expend_branded = 0.812383903 if location_name == "United States" & year == 2012 
562 
563 replace prop_Expend_branded = 0.665356927 if location_name == "Australia" & year == 2013 
564 replace prop_Expend_branded = 0.742612927 if location_name == "France" & year == 2013 
565 replace prop_Expend_branded = 0.669238287 if location_name == "United Kingdom" & year == 2013 
566 replace prop_Expend_branded = 0.749424267 if location_name == "United States" & year == 2013 
567 
568 replace prop_Expend_branded = 0.657612715 if location_name == "Australia" & year == 2014 
569 replace prop_Expend_branded = 0.732875994 if location_name == "France" & year == 2014 
570 replace prop_Expend_branded = 0.662234274 if location_name == "United Kingdom" & year == 2014 
571 replace prop_Expend_branded = 0.694431651 if location_name == "United States" & year == 2014 
572 label variable prop_Expend_branded "Proportion of total drug expenditure associated with branded drug sales, by location_name in 
each year" 
573 format prop_Expend_branded %12.0g 
574 
575 * The following two variables adjust for cancer incidence, rather than population. Data is derived from OECD & CDC data. See 
"LinReg_CancerIncidence.xlsx", "Figures_VolumeConsumption_AllYears.xlsx", & "UpdatedHA_Descriptives_AllYears.do". 
576 
577 gen double totalPerNeoplasmExpendcUSD = . 
578 replace totalPerNeoplasmExpendcUSD = 17514.540337860 if location_name == "Australia" & year == 2004 
579 replace totalPerNeoplasmExpendcUSD = 25601.270633100 if location_name == "France" & year == 2004 
580 replace totalPerNeoplasmExpendcUSD = 15460.916964400 if location_name == "United Kingdom" & year == 2004 
581 replace totalPerNeoplasmExpendcUSD = 38571.210844700 if location_name == "United States" & year == 2004 
582 
583 replace totalPerNeoplasmExpendcUSD = 19810.788222930 if location_name == "Australia" & year == 2005 
584 replace totalPerNeoplasmExpendcUSD = 30960.365970500 if location_name == "France" & year == 2005 
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585 replace totalPerNeoplasmExpendcUSD = 15804.504192900 if location_name == "United Kingdom" & year == 2005 
586 replace totalPerNeoplasmExpendcUSD = 43226.061893700 if location_name == "United States" & year == 2005 
587 
588 replace totalPerNeoplasmExpendcUSD = 19774.785400670 if location_name == "Australia" & year == 2006 
589 replace totalPerNeoplasmExpendcUSD = 36988.181201400 if location_name == "France" & year == 2006 
590 replace totalPerNeoplasmExpendcUSD = 19312.379760300 if location_name == "United Kingdom" & year == 2006 
591 replace totalPerNeoplasmExpendcUSD = 52413.454805000 if location_name == "United States" & year == 2006 
592 
593 replace totalPerNeoplasmExpendcUSD = 21805.708088400 if location_name == "Australia" & year == 2007 
594 replace totalPerNeoplasmExpendcUSD = 43444.996759000 if location_name == "France" & year == 2007 
595 replace totalPerNeoplasmExpendcUSD = 22062.229199300 if location_name == "United Kingdom" & year == 2007 
596 replace totalPerNeoplasmExpendcUSD = 58185.661443000 if location_name == "United States" & year == 2007 
597 
598 replace totalPerNeoplasmExpendcUSD = 22220.669536000 if location_name == "Australia" & year == 2008 
599 replace totalPerNeoplasmExpendcUSD = 47180.475887000 if location_name == "France" & year == 2008 
600 replace totalPerNeoplasmExpendcUSD = 24230.621463300 if location_name == "United Kingdom" & year == 2008 
601 replace totalPerNeoplasmExpendcUSD = 58713.643874000 if location_name == "United States" & year == 2008 
602 
603 replace totalPerNeoplasmExpendcUSD = 22938.462231000 if location_name == "Australia" & year == 2009 
604 replace totalPerNeoplasmExpendcUSD = 43921.606613900 if location_name == "France" & year == 2009 
605 replace totalPerNeoplasmExpendcUSD = 25218.977968300 if location_name == "United Kingdom" & year == 2009 
606 replace totalPerNeoplasmExpendcUSD = 62106.012202900 if location_name == "United States" & year == 2009 
607 
608 replace totalPerNeoplasmExpendcUSD = 24481.463932600 if location_name == "Australia" & year == 2010 
609 replace totalPerNeoplasmExpendcUSD = 41213.876488400 if location_name == "France" & year == 2010 
610 replace totalPerNeoplasmExpendcUSD = 25458.331647600 if location_name == "United Kingdom" & year == 2010 
611 replace totalPerNeoplasmExpendcUSD = 61991.061914700 if location_name == "United States" & year == 2010 
612 
613 replace totalPerNeoplasmExpendcUSD = 24598.350737200 if location_name == "Australia" & year == 2011 
614 replace totalPerNeoplasmExpendcUSD = 37586.565999500 if location_name == "France" & year == 2011 
615 replace totalPerNeoplasmExpendcUSD = 24871.626262800 if location_name == "United Kingdom" & year == 2011 
616 replace totalPerNeoplasmExpendcUSD = 60360.646746900 if location_name == "United States" & year == 2011 
617 
618 replace totalPerNeoplasmExpendcUSD = 24281.796023000 if location_name == "Australia" & year == 2012 
619 replace totalPerNeoplasmExpendcUSD = 34262.530753300 if location_name == "France" & year == 2012 
620 replace totalPerNeoplasmExpendcUSD = 25681.610444600 if location_name == "United Kingdom" & year == 2012 
621 replace totalPerNeoplasmExpendcUSD = 61908.976827500 if location_name == "United States" & year == 2012 
622 
623 replace totalPerNeoplasmExpendcUSD = 25460.206793600 if location_name == "Australia" & year == 2013 
624 replace totalPerNeoplasmExpendcUSD = 35754.201464500 if location_name == "France" & year == 2013 
625 replace totalPerNeoplasmExpendcUSD = 28354.751177800 if location_name == "United Kingdom" & year == 2013 
626 replace totalPerNeoplasmExpendcUSD = 64251.313508800 if location_name == "United States" & year == 2013 
627 
628 replace totalPerNeoplasmExpendcUSD = 26498.119337700 if location_name == "Australia" & year == 2014 
629 replace totalPerNeoplasmExpendcUSD = 36830.442044800 if location_name == "France" & year == 2014 
630 replace totalPerNeoplasmExpendcUSD = 32614.708346900 if location_name == "United Kingdom" & year == 2014 
631 replace totalPerNeoplasmExpendcUSD = 73919.508473500 if location_name == "United States" & year == 2014 
632 label variable totalPerNeoplasmExpendcUSD "Total drug expenditure (2014 USD) per incident neoplasm, by location_name in each year" 
633 format totalPerNeoplasmExpendcUSD %12.0g 
634 
635 * Incidence data was obtained from OECD and CDC (for US). YLLs (neoplasms) / 100,000 data was obtained from the IHME (above) for 
2000, 2005, 2010, and 2013. Simple linear regression against year used to derive estimates of yearly YLL (all neoplasms) / 100,000 
population (provided here). These figures, alongside population estimates from the World Bank, /// 
636 * were also used to derive age-adjusted YLLs (neoplasms) / inicident neoplasm (country-level average), which are used as an 
alternative depedent variable below. Refer to "YLLtrends_Expenditure_ValueAssessment.xlsx" and "LinReg_YLLtrends.xlsx" for 
information on how these values were derived. 
637 
638 gen double meanYLL_per100000 = . 
639 replace meanYLL_per100000 = 2922.292880000 if location_name == "Australia" & year==2004 
640 replace meanYLL_per100000 = 3636.453288000 if location_name == "France" & year==2004 
641 replace meanYLL_per100000 = 3389.739904000 if location_name == "United Kingdom" & year==2004 
642 replace meanYLL_per100000 = 3158.622756000 if location_name == "United States" & year==2004 
643 
644 replace meanYLL_per100000 = 2894.928600000 if location_name == "Australia" & year==2005 
645 replace meanYLL_per100000 = 3596.094110000 if location_name == "France" & year==2005 
646 replace meanYLL_per100000 = 3345.951130000 if location_name == "United Kingdom" & year==2005 
647 
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replace meanYLL_per100000 = 3129.006445000 if location_name == "United States" & year==2005 
649 replace meanYLL_per100000 = 2867.564320000 if location_name == "Australia" & year==2006 
650 replace meanYLL_per100000 = 3555.734932000 if location_name == "France" & year==2006 
651 replace meanYLL_per100000 = 3302.162356000 if location_name == "United Kingdom" & year==2006 
652 replace meanYLL_per100000 = 3099.390134000 if location_name == "United States" & year==2006 
653 
654 replace meanYLL_per100000 = 2840.200040000 if location_name == "Australia" & year==2007 
655 replace meanYLL_per100000 = 3515.375754000 if location_name == "France" & year==2007 
656 replace meanYLL_per100000 = 3258.373582000 if location_name == "United Kingdom" & year==2007 
657 replace meanYLL_per100000 = 3069.773823000 if location_name == "United States" & year==2007 
658 
659 replace meanYLL_per100000 = 2812.835760000 if location_name == "Australia" & year==2008 
660 replace meanYLL_per100000 = 3475.016576000 if location_name == "France" & year==2008 
661 replace meanYLL_per100000 = 3214.584808000 if location_name == "United Kingdom" & year==2008 
662 replace meanYLL_per100000 = 3040.157512000 if location_name == "United States" & year==2008 
663 
664 replace meanYLL_per100000 = 2785.471480000 if location_name == "Australia" & year==2009 
665 replace meanYLL_per100000 = 3434.657398000 if location_name == "France" & year==2009 
666 replace meanYLL_per100000 = 3170.796034000 if location_name == "United Kingdom" & year==2009 
667 replace meanYLL_per100000 = 3010.541201000 if location_name == "United States" & year==2009 
668 
669 replace meanYLL_per100000 = 2758.107200000 if location_name == "Australia" & year==2010 
670 replace meanYLL_per100000 = 3394.298220000 if location_name == "France" & year==2010 
671 replace meanYLL_per100000 = 3127.007260000 if location_name == "United Kingdom" & year==2010 
672 replace meanYLL_per100000 = 2980.924890000 if location_name == "United States" & year==2010 
673 
674 replace meanYLL_per100000 = 2730.742920000 if location_name == "Australia" & year==2011 
675 replace meanYLL_per100000 = 3353.939042000 if location_name == "France" & year==2011 
676 replace meanYLL_per100000 = 3083.218486000 if location_name == "United Kingdom" & year==2011 
677 replace meanYLL_per100000 = 2951.308579000 if location_name == "United States" & year==2011 
678 
679 replace meanYLL_per100000 = 2703.378640000 if location_name == "Australia" & year==2012 
680 replace meanYLL_per100000 = 3313.579864000 if location_name == "France" & year==2012 
681 replace meanYLL_per100000 = 3039.429712000 if location_name == "United Kingdom" & year==2012 
682 replace meanYLL_per100000 = 2921.692268000 if location_name == "United States" & year==2012 
683 
684 replace meanYLL_per100000 = 2676.014360000 if location_name == "Australia" & year==2013 
685 replace meanYLL_per100000 = 3273.220686000 if location_name == "France" & year==2013 
686 replace meanYLL_per100000 = 2995.640938000 if location_name == "United Kingdom" & year==2013 
687 replace meanYLL_per100000 = 2892.075957000 if location_name == "United States" & year==2013 
688 
689 replace meanYLL_per100000 = 2648.650080000 if location_name == "Australia" & year==2014 
690 replace meanYLL_per100000 = 3232.861508000 if location_name == "France" & year==2014 
691 replace meanYLL_per100000 = 2951.852164000 if location_name == "United Kingdom" & year==2014 
692 replace meanYLL_per100000 = 2862.459646000 if location_name == "United States" & year==2014 
693 label variable meanYLL_per100000 "Mean YLL (neoplasm) per 100,000 population, age-standard, derived from OECD & CDC data" 
694 format meanYLL_per100000 %12.0g 
695 
696 gen double meanYLL_perIncNeoplasm = . 
697 replace meanYLL_perIncNeoplasm = 6.304266673 if location_name == "Australia" & year==2004 
698 replace meanYLL_perIncNeoplasm = 7.834663166 if location_name == "France" & year==2004 
699 replace meanYLL_perIncNeoplasm = 7.193054542 if location_name == "United Kingdom" & year==2004 
700 replace meanYLL_perIncNeoplasm = 6.719641297 if location_name == "United States" & year==2004 
701 
702 replace meanYLL_perIncNeoplasm = 6.096489538 if location_name == "Australia" & year==2005 
703 replace meanYLL_perIncNeoplasm = 7.599573487 if location_name == "France" & year==2005 
704 replace meanYLL_perIncNeoplasm = 6.999848343 if location_name == "United Kingdom" & year==2005 
705 replace meanYLL_perIncNeoplasm = 6.598172373 if location_name == "United States" & year==2005 
706 
707 replace meanYLL_perIncNeoplasm = 5.912130502 if location_name == "Australia" & year==2006 
708 replace meanYLL_perIncNeoplasm = 7.371609173 if location_name == "France" & year==2006 
709 replace meanYLL_perIncNeoplasm = 6.816934013 if location_name == "United Kingdom" & year==2006 
710 replace meanYLL_perIncNeoplasm = 6.483147197 if location_name == "United States" & year==2006 
711 
712 replace meanYLL_perIncNeoplasm = 5.691371801 if location_name == "Australia" & year==2007 
713 replace meanYLL_perIncNeoplasm = 7.148712621 if location_name == "France" & year==2007 
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714 replace meanYLL_perIncNeoplasm = 6.643304414 if location_name == "United Kingdom" & year==2007 
715 replace meanYLL_perIncNeoplasm = 6.370670035 if location_name == "United States" & year==2007 
716 
717 replace meanYLL_perIncNeoplasm = 5.560909385 if location_name == "Australia" & year==2008 
718 replace meanYLL_perIncNeoplasm = 6.931880308 if location_name == "France" & year==2008 
719 replace meanYLL_perIncNeoplasm = 6.476068865 if location_name == "United Kingdom" & year==2008 
720 replace meanYLL_perIncNeoplasm = 6.261101902 if location_name == "United States" & year==2008 
721 
722 replace meanYLL_perIncNeoplasm = 5.441945645 if location_name == "Australia" & year==2009 
723 replace meanYLL_perIncNeoplasm = 6.721783622 if location_name == "France" & year==2009 
724 replace meanYLL_perIncNeoplasm = 6.312373084 if location_name == "United Kingdom" & year==2009 
725 replace meanYLL_perIncNeoplasm = 6.150347650 if location_name == "United States" & year==2009 
726 
727 replace meanYLL_perIncNeoplasm = 5.303569888 if location_name == "Australia" & year==2010 
728 replace meanYLL_perIncNeoplasm = 6.519561471 if location_name == "France" & year==2010 
729 replace meanYLL_perIncNeoplasm = 6.155617383 if location_name == "United Kingdom" & year==2010 
730 replace meanYLL_perIncNeoplasm = 6.040197224 if location_name == "United States" & year==2010 
731 
732 replace meanYLL_perIncNeoplasm = 5.164580873 if location_name == "Australia" & year==2011 
733 replace meanYLL_perIncNeoplasm = 6.325332233 if location_name == "France" & year==2011 
734 replace meanYLL_perIncNeoplasm = 6.003588757 if location_name == "United Kingdom" & year==2011 
735 replace meanYLL_perIncNeoplasm = 5.928798425 if location_name == "United States" & year==2011 
736 
737 replace meanYLL_perIncNeoplasm = 5.050072761 if location_name == "Australia" & year==2012 
738 replace meanYLL_perIncNeoplasm = 6.137375408 if location_name == "France" & year==2012 
739 replace meanYLL_perIncNeoplasm = 5.851093197 if location_name == "United Kingdom" & year==2012 
740 replace meanYLL_perIncNeoplasm = 5.820341635 if location_name == "United States" & year==2012 
741 
742 replace meanYLL_perIncNeoplasm = 4.942359084 if location_name == "Australia" & year==2013 
743 replace meanYLL_perIncNeoplasm = 5.955917310 if location_name == "France" & year==2013 
744 replace meanYLL_perIncNeoplasm = 5.699801675 if location_name == "United Kingdom" & year==2013 
745 replace meanYLL_perIncNeoplasm = 5.714303315 if location_name == "United States" & year==2013 
746 
747 replace meanYLL_perIncNeoplasm = 4.832152317 if location_name == "Australia" & year==2014 
748 replace meanYLL_perIncNeoplasm = 5.781241472 if location_name == "France" & year==2014 
749 replace meanYLL_perIncNeoplasm = 5.552540534 if location_name == "United Kingdom" & year==2014 
750 replace meanYLL_perIncNeoplasm = 5.610206117 if location_name == "United States" & year==2014 
751 label variable meanYLL_perIncNeoplasm "Mean YLL (neoplasm) per incident neoplasm, age-standard, derived from OECD & CDC data" 
752 format meanYLL_perIncNeoplasm %12.0g 
753 
754 gen totalPerNeoplasmSalesKG = totalPerNeoplasmSalesMG/1000000 
755 format totalPerNeoplasmSalesKG %12.0g 
756 
757 * To help with interpretation, convert prop_Sales_generic to non-proportion form: 
758 
759 gen prop_Sales_genericNP = prop_Sales_generic * 100 
760 format prop_Sales_genericNP %12.0g 
761 
762 gen prop_Sales_brandedNP = prop_Sales_branded * 100 
763 format prop_Sales_brandedNP %12.0g 
764 
765 gen prop_Expend_genericNP = prop_Expend_generic * 100 
766 format prop_Expend_genericNP %12.0g 
767 
768 gen prop_Expend_brandedNP = prop_Expend_branded * 100 
769 format prop_Expend_brandedNP %12.0g 
770 
771 * To help with interpretation, convert prop_Sales_generic to non-proportion form (KG): 
772 
773 gen prop_Sales_genericNPMG = prop_Sales_genericMG * 100 
774 format prop_Sales_genericNPMG %12.0g 
775 
776 * Generate a log transformed value of YLLs, given the large positive skew. 
777 
778 histogram mean 
779 
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780 histogram meanYLL_per100000 
781 
782 histogram meanYLL_perIncNeoplasm 
783 
784 * Tests for normality of dependent variables. 
785 
786 swilk meanYLL_per100000 
787 * meanYLL_per100000 is normally distributed. 
788 
789 sfrancia meanYLL_per100000 
790 * meanYLL_per100000 is normally distributed. 
791 
792 swilk meanYLL_perIncNeoplasm 
793 * meanYLL_per100000 is normally distributed. 
794 
795 sfrancia meanYLL_perIncNeoplasm 
796 * meanYLL_per100000 is normally distributed. 
797 
798 * Run specifications with and one without a log-transformed 'mean' variable. The reason for this is that there appears to be 
somewhat a rightward skew in the YLLs across neoplasm incidence profile observed in each country. We don't report these variables 
because above tests for normality indicate that dependent variables are normally distributed (p > 0.05) -- these are nevertheless 
created because there is a trend towards non normality (e.g. p = 0.2). 
799 
800 gen ln_YLLper10000 = ln(meanYLL_per100000) 
801 histogram ln_YLLper10000 
802 
803 gen ln_YLLperNeoplasm = ln(meanYLL_perIncNeoplasm) 
804 histogram ln_YLLperNeoplasm 
805 
806 * Create panel_id variable for location_id clusters 
807 
808 egen panel_id = group(location_id) 
809 
810 gen LOGtotalPerNeoplasmSalesMG = ln(totalPerNeoplasmSalesMG) 
811 format LOGtotalPerNeoplasmSalesMG %12.0g 
812 
813 gen LOGtotalPerNeoplasmSalesKG = ln(totalPerNeoplasmSalesKG) 
814 format LOGtotalPerNeoplasmSalesKG %12.0g 
815 
816 * Create a lag variable for independent variables. 
817 
818 sort location_name year 
819 bysort location_name: gen prop_Sales_genericNP_1lag = . 
820 replace prop_Sales_genericNP_1lag = prop_Sales_genericNP[_n-1] 
821 replace prop_Sales_genericNP_1lag =. if year == 2004 
822 
823 sort location_name year 
824 bysort location_name: gen totalPerNeoplasmSalesSU_1lag = . 
825 replace totalPerNeoplasmSalesSU_1lag = totalPerNeoplasmSalesSU[_n-1] 
826 replace totalPerNeoplasmSalesSU_1lag =. if year == 2004 
827 
828 * Create a lag variable for independent variables (KG) 
829 
830 sort location_name year 
831 bysort location_name: gen prop_Sales_genericNPMG_1lag = . 
832 replace prop_Sales_genericNPMG_1lag = prop_Sales_genericNPMG[_n-1] 
833 replace prop_Sales_genericNPMG_1lag =. if year == 2004 
834 
835 sort location_name year 
836 bysort location_name: gen totalPerNeoplasmSalesMG_1lag = . 
837 replace totalPerNeoplasmSalesMG_1lag = totalPerNeoplasmSalesMG[_n-1] 
838 replace totalPerNeoplasmSalesMG_1lag =. if year == 2004 
839 
840 sort location_name year 
841 bysort location_name: gen LOGtotalPerNeoplasmSalesMG_1lag = . 
842 replace LOGtotalPerNeoplasmSalesMG_1lag = LOGtotalPerNeoplasmSalesMG[_n-1] 
843 replace LOGtotalPerNeoplasmSalesMG_1lag =. if year == 2004 
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845 sort location_name year 
846 bysort location_name: gen totalPerNeoplasmSalesKG_1lag = . 
847 replace totalPerNeoplasmSalesKG_1lag = totalPerNeoplasmSalesKG[_n-1] 
848 replace totalPerNeoplasmSalesKG_1lag =. if year == 2004 
849 
850 sort location_name year 
851 bysort location_name: gen LOGtotalPerNeoplasmSalesKG_1lag = . 
852 replace LOGtotalPerNeoplasmSalesKG_1lag = LOGtotalPerNeoplasmSalesKG[_n-1] 
853 replace LOGtotalPerNeoplasmSalesKG_1lag =. if year == 2004 
854 
855 * Create time trend variable 
856 bysort panel_id (year): gen timetrend3 = 1 if year == 2004  
857 bysort panel_id (year): replace timetrend3 = 2 if year == 2005 
858 bysort panel_id (year): replace timetrend3 = 3 if year == 2006 
859 bysort panel_id (year): replace timetrend3 = 4 if year == 2007 
860 bysort panel_id (year): replace timetrend3 = 5 if year == 2008 
861 bysort panel_id (year): replace timetrend3 = 6 if year == 2009 
862 bysort panel_id (year): replace timetrend3 = 7 if year == 2010 
863 bysort panel_id (year): replace timetrend3 = 8 if year == 2011 
864 bysort panel_id (year): replace timetrend3 = 9 if year == 2012 
865 bysort panel_id (year): replace timetrend3 = 10 if year == 2013 
866 bysort panel_id (year): replace timetrend3 = 11 if year == 2014 
867 
868 
869 /// Analysis: 
870 * Above incidence data is derived from OECD & US CDC incidence data. Refer to "LinReg_CancerIncidence.xlsx" and 
"YLLtrends_Expenditure_ValueAssessment.xlsx" for information on how these were derived. 
871 
872 * Age-standardized YLL rates per 100,000 across each country in each available year 
873 
874 by location_id: table cause_name year, contents(mean meanYLL_per100000) 
875 
876 scatter meanYLL_per100000 year 
877 
878 separate meanYLL_per100000, by(location_id) 
879 twoway (scatter meanYLL_per1000001 year) (scatter meanYLL_per1000002 year) (scatter meanYLL_per1000003 year) (scatter 
meanYLL_per1000004 year) (scatter meanYLL_per1000005 year) (scatter meanYLL_per1000006 year) (scatter meanYLL_per1000007 year) ( 
scatter meanYLL_per1000008 year) (scatter meanYLL_per1000009 year), /// 
880 ytitle(YLL / 100000) legend(order(1 "Australia" 2 "Canada" 3 "France" 4 "Germany" 5 "Italy" 6 "Japan" 7 "Sweden" 8 "UK" 9 "USA")) 
881 
882 * Age-standardized YLL rates per incident neoplasm across each country in each available year 
883 
884 by location_id: table cause_name year, contents(mean meanYLL_perIncNeoplasm) 
885 
886 scatter meanYLL_perIncNeoplasm year 
887 
888 separate meanYLL_perIncNeoplasm, by(location_id) 
889 twoway (scatter meanYLL_perIncNeoplasm1 year) (scatter meanYLL_perIncNeoplasm2 year) (scatter meanYLL_perIncNeoplasm3 year) ( 
scatter meanYLL_perIncNeoplasm4 year) (scatter meanYLL_perIncNeoplasm5 year) (scatter meanYLL_perIncNeoplasm6 year) (scatter 
meanYLL_perIncNeoplasm7 year) (scatter meanYLL_perIncNeoplasm8 year) (scatter meanYLL_perIncNeoplasm9 year), /// 
890  ytitle(YLL / Inc Neoplasm) legend(order(1 "Australia" 2 "Canada" 3 "France" 4 "Germany" 5 "Italy" 6 "Japan" 7 "Sweden" 8 "UK" 9 
"USA")) 
891 
892 *** YLL / country 
893 
894 separate meanYLL_perIncNeoplasm, by(location_id) 
895 separate prop_Sales_brandedNP, by(location_id) 
896 twoway (scatter meanYLL_perIncNeoplasm1 prop_Sales_brandedNP1) (scatter meanYLL_perIncNeoplasm2 prop_Sales_brandedNP2) (scatter 
meanYLL_perIncNeoplasm3 prop_Sales_brandedNP3) (scatter meanYLL_perIncNeoplasm4 prop_Sales_brandedNP4) (scatter 
meanYLL_perIncNeoplasm5 prop_Sales_brandedNP5) (scatter meanYLL_perIncNeoplasm6 prop_Sales_brandedNP6) (scatter 
meanYLL_perIncNeoplasm7 prop_Sales_brandedNP7) (scatter meanYLL_perIncNeoplasm8 prop_Sales_brandedNP8) (scatter 
meanYLL_perIncNeoplasm9 prop_Sales_brandedNP9), /// 
897 ytitle(meanYLL_perIncNeoplasm1) xtitle(prop_Sales_brandedNP) legend(order(1 "Australia" 2 "Canada" 3 "France" 4 "Germany" 5 
"Italy" 6 "Japan" 7 "Sweden" 8 "UK" 9 "USA")) 
898 
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899 * Model specification 1 -- non-log transformed mean variable (based on swilk, sfrancia) 
900 
901 global id panel_id 
902 global t year 
903 global ylist meanYLL_perIncNeoplasm 
904 global xlist LOGtotalPerNeoplasmSalesKG 
905 
906 describe $id $t $ylist $xlist 
907 summarize $id $t $ylist $xlist 
908 
909 * Set data as panel data. 
910 sort $id $t 
911 xtset $id $t 
912 xtdescribe 
913 xtsum $id $t $ylist $xlist 
914 
915 * Fixed effects or within estimator 
916 xtreg $ylist $xlist, fe robust 
917  est sto m1 
918 
919 * Model specification 2 -- non-log transformed mean variable (based on swilk, sfrancia) 
920 
921 global id panel_id 
922 global t year 
923 global ylist meanYLL_perIncNeoplasm 
924 global xlist LOGtotalPerNeoplasmSalesKG prop_Sales_genericNPMG 
925 
926 describe $id $t $ylist $xlist 
927 summarize $id $t $ylist $xlist 
928 
929 * Set data as panel data. 
930 sort $id $t 
931 xtset $id $t 
932 xtdescribe 
933 xtsum $id $t $ylist $xlist 
934 
935 * Fixed effects or within estimator 
936 xtreg $ylist $xlist , fe robust 
937  est sto m2 
938 
939 * Model specification 3 -- non-log transformed mean variable (based on swilk, sfrancia) 
940 
941 global id panel_id 
942 global t year 
943 global ylist meanYLL_perIncNeoplasm 
944 global xlist LOGtotalPerNeoplasmSalesKG 
945 
946 describe $id $t $ylist $xlist 
947 summarize $id $t $ylist $xlist 
948 
949 * Set data as panel data. 
950 sort $id $t 
951 xtset $id $t 
952 xtdescribe 
953 xtsum $id $t $ylist $xlist 
954 
955 * Fixed effects or within estimator 
956 xtreg $ylist $xlist i.year, fe robust 
957  est sto m3 
958 
959 * Model specification 4 -- non-log transformed mean variable (based on swilk, sfrancia) 
960 
961 global id panel_id 
962 global t year 
963 global ylist meanYLL_perIncNeoplasm 
964 global xlist LOGtotalPerNeoplasmSalesKG prop_Sales_genericNPMG 
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966 describe $id $t $ylist $xlist 
967 summarize $id $t $ylist $xlist 
968 
969 * Set data as panel data. 
970 sort $id $t 
971 xtset $id $t 
972 xtdescribe 
973 xtsum $id $t $ylist $xlist 
974 
975 * Fixed effects or within estimator 
976 xtreg $ylist $xlist i.year, fe robust 
977  est sto m4 
978 
979 * Model specification 5 -- non-log transformed mean variable (based on swilk, sfrancia) 
980 
981 global id panel_id 
982 global t year 
983 global ylist meanYLL_perIncNeoplasm 
984 global xlist LOGtotalPerNeoplasmSalesKG 
985 
986 describe $id $t $ylist $xlist 
987 summarize $id $t $ylist $xlist 
988 
989 * Set data as panel data. 
990 sort $id $t 
991 xtset $id $t 
992 xtdescribe 
993 xtsum $id $t $ylist $xlist 
994 
995 * Fixed effects or within estimator 
996 xtreg $ylist $xlist l.LOGtotalPerNeoplasmSalesKG, fe robust 
997 est sto m5 
998 
999 * Model specification 6 -- non-log transformed mean variable (based on swilk, sfrancia) 
1000 
1001 global id panel_id 
1002 global t year 
1003 global ylist meanYLL_perIncNeoplasm 
1004 global xlist LOGtotalPerNeoplasmSalesKG prop_Sales_genericNPMG 
1005 
1006 describe $id $t $ylist $xlist 
1007 summarize $id $t $ylist $xlist 
1008 
1009 * Set data as panel data. 
1010 sort $id $t 
1011 xtset $id $t 
1012 xtdescribe 
1013 xtsum $id $t $ylist $xlist 
1014 
1015 * Fixed effects or within estimator 
1016 xtreg $ylist $xlist l.LOGtotalPerNeoplasmSalesKG, fe robust 
1017 est sto m6 
1018 
1019 * Model specification 7 -- non-log transformed mean variable (based on swilk, sfrancia) 
1020 
1021 global id panel_id 
1022 global t year 
1023 global ylist meanYLL_perIncNeoplasm 
1024 global xlist LOGtotalPerNeoplasmSalesKG prop_Sales_genericNPMG 
1025 
1026 describe $id $t $ylist $xlist 
1027 summarize $id $t $ylist $xlist 
1028 
1029 * Set data as panel data. 
1030 sort $id $t 
1031 xtset $id $t 
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1033 xtsum $id $t $ylist $xlist 
1034 
1035 * Fixed effects or within estimator 
1036 xtreg $ylist $xlist l.LOGtotalPerNeoplasmSalesKG l.prop_Sales_genericNPMG, fe robust 
1037 est sto m7 
1038 
1039 * Model specification 8 -- non-log transformed mean variable (based on swilk, sfrancia) 
1040 
1041 global id panel_id 
1042 global t year 
1043 global ylist meanYLL_perIncNeoplasm 
1044 global xlist LOGtotalPerNeoplasmSalesKG prop_Sales_genericNPMG 
1045 
1046 describe $id $t $ylist $xlist 
1047 summarize $id $t $ylist $xlist 
1048 
1049 * Set data as panel data. 
1050 sort $id $t 
1051 xtset $id $t 
1052 xtdescribe 
1053 xtsum $id $t $ylist $xlist 
1054 
1055 * Fixed effects or within estimator 
1056 xtreg $ylist $xlist l.LOGtotalPerNeoplasmSalesKG l.prop_Sales_genericNPMG i.year, fe robust 
1057 est sto m8 
1058 
1059 esttab m1 m2 m3 m4 m5 m6 m7 m8, ar2 r2 brackets label 
1060 
1061 esttab m1 m2 m3 m4 m5 m6 m7 m8, p ar2 r2 brackets label 
1062 
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